{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "structural-bible",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[34mApplications\u001b[m\u001b[m           \u001b[34mLibrary\u001b[m\u001b[m                US8080243.pdf\r\n",
     ]
    }
   ],
   "source": [
    "!ls"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "owned-necklace",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pdfminer.high_level"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "incorporated-patient",
   "metadata": {},
   "outputs": [],
   "source": [
    "text = pdfminer.high_level.extract_text('US8080243.pdf')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "first-trigger",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "'IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII\\nUS008080243B2\\n\\n(») United States Patent\\n\\nLiang et al.\\n\\n(io) Patent No.:\\n(4s) Date of Patent:\\n\\nUS 8,080,243 $2\\nDec. 20, 2011\\n\\n(54)\\n\\n(73)\\n\\nISOLATI(D ANTIBODY WHIC\\'H\\nSPEC\\'ii\\'ICALLY BINDS TO PCSK9\\n\\nIuva&iorsz Hung I.iang, Snu Francisco. C\\'A (IJS).\\nYasmina Noubia Abdiche, Mountain\\nY&ew, CA (US); Javier Fernando\\nChaparro Riggers. Sau Mateo, CA\\n(IJS): Bruce C\\'buries Onmes,\\nAshburuimm. iVLA (LIS): Juiie Jia Li\\nHawhins. Old Lyme, Ci\\'(US): Jaume\\nPons, Sau Bruno, CA (IJS), Yuii Wang,\\nSan 1)iego, (\\'A (US)\\n\\n(73) Assignees. Riuut Neuruscience Corp.. Swah Sau\\nFrancisco, CA (US). Pfizer Inc« New\\nYork, NY (US)\\n\\n(\\n\\n) Notice\\n\\nSubject to any d&sclsuuer. the teuu oi\\'this\\npatent is exmuded or adjusted under 35\\nU.S.(2 154(b) by 0 days.\\n\\n(21) Appl. No. 12/558,312\\n\\n(22)\\n\\nFiled:\\n\\nSep. II& 2009\\n\\nPrior Publication Data\\n\\nIJS 2010/0068199 A I\\n\\nMar. 18. 2010\\n\\nRelated U.S. Appiicstiou Data\\n\\n(65)\\n\\n(60)\\n\\nProv&s&ouai apphcauou No. 61(235.643, filed on Aug.\\n20, 2009, provisional application No. 61/232,161,\\nIiied on Aug. 7. 200\\'I, provisional application No.\\n61/096.716, iiled on Sep 12, 2008.\\n\\n(5 1\\n\\n)\\n\\nInt. CI.\\nd 6IIC 392395\\n\\n(2006.01)\\n\\n(52) U.S. C:I..................... 424/130.1; 424/133.1\\n(58) Field of Classification Search............ None\\nSec application file Ii&r complete search history\\n\\n(56)\\n\\nReferenws Cited\\n\\nI J S PATleNT DOC\\'UMFNTS\\n\\n7,261,893 02 &\\n7,456,264 B2\\'12008 Kclcretel\\n\\n8 2007 Veldman et al\\n\\n2009 014»352 A I\\n\\nC&\\'2009\\n\\nJackson et al\\n\\n424 145 I\\n530 3884\\n\\nWO\\nWO\\nWO\\nWO\\nWO\\nIVO\\n\\nWOOI&57081 A2\\n\\nIVO 2008 0(7457\\nWO 2008&057458 A2\\nIVO 2008 057459 A2\\nW(J 2008&lÃ647 A2\\nWO 2009 0557&B A2\\n\\n8(2001\\nI\\'&008\\n5 2008\\n5 2008\\n11\\'2008\\n4 2009\\n\\nOTHF.R PUBLICATIONS\\n\\nAlbornet el., C1&n Chem 53. 1814-1819,2007P\\nC\"ham&«and Ashkana(i, T&bterh 14 52-60, 1979(i\\n\\n\"\\'ud&koffet sl., Proc. Natl, Aced Sc& 79 1979-1983, 1982.»\\n\\nd&ct&on, pp 492-495. 1994 \"\\nBottomlcy. M . et al . \"Stnictuiel and B&ochanical C\\'hmactcnzat&on\\nof ihe Vyild Iype PC.\\'SK&J-L(\\'1(AB) Complex and Natural I mrulial\\n\\nWells, 1990. B&ochanistiy 29 8509-8517\\'goet al . The Protein Folding Problem and Tenisry Stn&cture Pi e-\\n\\nIlypercholesterolemia Mutantsy ihe Journo/ of Bioiog&r&d C\\'(ie«u»-\\n(ri; 2009, 1311-1321, vol 284, Vo 2\\nC\\'han. J, et al, \"A Propiotein Convcrtase Subtilisin Kes&n Type 9\\ni&eat&ah(&n AntibodykeducesSerum(holesteiolinM&cean&IVon-\\nhuman P«matesy Prmeedi&i os of(he ¹uonai I cudemi of Sa nrei\\nof iiie Lyin &ed S(o(e» ofrtiseiiru, 2009, &(8209825, sot 106, No 24\\nC:unninghanx D „et al. \"Structural and Biophysical Studies of\\nPCSK9 and &ts Mu&ants L&nked to I mrul&al Hypercholeste&olem&sy\\nVonire,S&rurrvrni a .Volecsisr Bio iogi\\n. 2007, 413-419, vol 14. Vo\\n\\\\\\nGrefhorst 5, e& al. \"Plasma PCSK9 P&eferent&ally Reduces I ner\\nLDL Recepiois m M&cey dos«in/ &i/\\'Lipid krieoi&/i, 2008, 1303-\\n1311, vol 49\\nKwon. H, ct al, \"Molecular Basis ioi I.DI. Racptoi Rsvognit&on by\\nPCSK\\'JP I\\'rocee&iisg& of (h» Nvuonsi.&cad& mi oi\\'Science» of B&r\\nL\\'m(ed S(oies ofdsiemra, 2008. 1820-I 825, vol. 10(. No. 6\\nPandit. S., et al, \"I unctional Analysis of Sites wuhin P(\\'SK9\\nRmponuble fo& Hypacholesterolemisy,hi«rani o//»pid Reseoirh,\\n2008, 17&1-1343 &ol 49\\nPeter~on, A ei al, \"P(\\'SK9 I unction and Physiologyy Journo/ of\\nLipid /(eseorcii, 2008. 1595-1599, vol 49\\n\\'*St«&ct&ual Rcqu&remen&a t\\'or PCSK9-Mcd&ated\\nLhang, D, ct al .\\nDegradat&on of the I ow-Density I ipop&otein Receptor,*\\'mreed\\n\\n&sgi of (/ie.V&(iona/.(eadem& o/\\'Sae&ice» of (he (I«ied S(ore&o/\\'Imemco.2008, 13045-13050, vol 105, No 35\\n\\n\\'*Iherapeut&c RVA& target&ng P(\\'SK9\\nlrank-Kmnenetsky, et al..\\nacutely lowers plasma choleste&ol &n rodents and I.DL choleste&ol &n\\nnonhuman pmnatesy Pioceed&ngs of the Nat&onal Aciulemy of Sc&-\\nences of the L\\'mted States, Aug 2008. Pp 119i 5-11920, vol 105,\\nNo 13\\nGrab&un, \"Anusense mh&b&&&on of prop«&te&n convertase subt&l&s&n\\nkex&n type 9 reduces semm LDL in hyperl&pidem&c nu cep Joamia i of\\nLipid Research, Apr 2007. pp 763-767, vol 48, No 4\\nHorton et al, \"Molcculm biolo yof PCSK9 its role in I DI mctabo-\\nl&smy Trend» iii Bia hem&(oi Srien(er, 2007, pp 71-77, sot 32\\nInrcrnational P&el&mmmy Fxaminat&on Repo&t issued Jun 30, 2010,\\nfor Inte&national Patent Apphcat&on No PC:7\\'IB2009 053990\\nInta national Prclnn&na&y Fxam&nation Rcpoit &ssucd Dcc 15, 2010,\\nfor Inte&na&ional Patent Apphcat&on No PC\\'T 102009\\'053990\\nInternational Search Report mailed Jun I, 2010, for International\\nPatent Spphcat ion No PC.\\'7\\'102009 051990\\nI opcz. D, lnlub&t&on of PC\\'SK9 as a novel stiatcgy foi thc ticatmcnt\\nofhipar/m/e&(em/esne, Dm Vev s g Perspectives, 2008, pp 321-\\n330, vol. 21\\n\\n((\\'outinued)\\n\\nPrim«O Emminer\\n(74) .Ikorue&, »Igeu(, or F/rm Pfizer iuc.\\n\\nCiyau Chm&drn\\n\\nThe prmseut &us& i&i&ut& pu&sides autugo&uiing m&t&bod&es. m&ti-\\ngen-binding portions thereof. und aptumem that bind tu pro-\\npmiein convertmsc subtilisiu kcxin type \\'I (PC\\'.SK9). Also\\nprovided ure ant&bodies d&rected to peptides, in v;hich the\\nantibodies bind tu P(JSK9. Tim invention further provides a\\nmethod of obtain&ug such m&t&bodies aud aut&body-encod&u\\nnucleic acid. The invention f&irther relates to therapeutic\\nnwthods for use of thesv. antibodies und antigen-binding por-\\nuous thereof to reduce LDL-chuiesteml levels aud/or for the\\ntreatment mtd/or prevention of cardiovascular diseuse,\\nu&cludmg treatment of hypercholesterolemia\\n\\n3 Claims, 30 i)rawing Sheets\\n\\nFORFIGN PATI\\'.NT DO( UMI:,NTS\\n\\n(57)\\n\\n&&BSTR,ACT\\n\\n\\x0cUS 8,080,243 $2\\nPage 2\\n\\nOTHER PUB LIOATI 01&IS\\nI open, D, \"pCSK9\\'n enig&natic piotcimscy Siorhemirc oil&i\\nBivphy&iin.tcm. 200S, pp 194-191, vol. 170 I\\nMcKutt M C, ct al., \\'*Antagonism of sccicted PCSK9 increases lorn\\ndensity lipoprotein rcccptor exp& cssion in HcpO2 cellsigiouruai of\\nII&olog&col i\\'ii&morrlv 2009,pp. 10561-10570, vol 2S4\\n\\nOtfic&al Conunun&cat&on issued h ov. I(, 2010, m connection volh\\nInternalmnal Pateni Application Vo Pi \"I \\'IB 2009,\\'053990\\n((\\'«nen Opinion of thc ISA issued Slay 2 (, 2010. for Intenmtional\\nPatent Application go, PC\\'I IB2009&tl(3990,\\n\\'ited bv cxanllllcr\\n\\n\\x0cU.S. Patent\\n\\nDec.20,2011\\n\\nSheet I of30\\n\\nUS 8,080,243 B2\\n\\nA mPCSK9\\n(100nM)\\n\\nmAb(nM)\\n\\n800 40Q200100 50 25\\n\\n0\\n\\n0\\n\\n6F6.G10.3 Q W rt@.-::,:.,\\'.=:::-:.;.::,,::::;:;:: ~4\\n»44 WM4~+~4\\n\\n8\\n\\nhPCSK9\\n(100nM)\\nmAb(nM)\\n\\n6F6.G10.3\\n\\n800 4002001QQ 50 25\\n\\n0\\n\\n0\\n\\n4A5G3 M@NeWuN\\n\\n4A5.G3\\n\\n5A10 88\\n\\nFigure 1\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 2 of 30\\n\\nUS 8,080,243 B2\\n\\nHuman PGSK9{0.4nM}- human LDLR Binding\\npH7.5\\n\\no I\\n\\n0\\nO 0.5\\n\\n0\\n\\no\\n\\n0\\n\\n2.5\\n\\n2\\n\\n1.5\\n\\n0.5\\n\\n0\\n\\n1.0E-03\\n\\n1.0E-02 1.0E-01\\n\\n1.0E+00 1.0E+01 1.0Et02 1.0Ee03\\n\\nmAb Concentration (nM)\\n\\nMouse PGSK9 {0.8nM)- human LDLR Binding\\npH7.5\\n\\n1.0E 03\\n\\n1.0E 02\\n\\n1.0E 01\\n\\n1.0E+00\\n\\n1.0E+01\\n\\n1.0E+02\\n\\n1.0E+03\\n\\nmAb Concentration {nM)\\n\\nFigure 2\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 3 of 30\\n\\nUS 8,080,243 B2\\n\\n40\\n\\n30\\n\\n20\\n\\n10\\n\\nCI\\n\\n0\\n\\n0.1\\n\\n+ 4,i\\',\\n\\nIC50=\\'?.I nM\\n\\n1\\n\\n10\\nrnAb concentration (nM)\\n\\n100\\n\\n1000\\n\\nFigure 3\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 4 of 30\\n\\nUS 8,080,243 B2\\n\\nA\\n\\nB Normahxed binding by premixed 29.70M hPCSK9 and rgG\\n\\nU~ Fcx-6F6 G10 3\\n\\n9 l c 3= 641 0 36\\nBl c2=4A6643\\n\\nNPCGIIO\\n\\n8 F6 010 3\\n\\n704 4\\n\\n5410 08\\n\\n4AF C3\\n\\nGEI C4\\n\\n\\'IF\" FG\\n\\nc6 HI 0\\n\\nGl 5 HI I\\n\\n41.1 0 I\\n\\n56 610\\n\\n%5 C4 41\\n\\n40121 8\\n\\n4E4 010\\n\\nFigure 4\\n\\n0\\n\\n20\\n\\n40\\n\\n0\\n\\nPO\\n\\n103\\n\\n120\\n\\nNcr mzlizcd hlnding\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 5 of 30\\n\\nUS 8,080,243 B2\\n\\n4A5 5A10 6F6\\n\\n6G7 7D4 42H7\\n\\n~ PCSK9\\n\\nPCS K9\\n\\nPCSK9\\n\\nHuman\\n\\nCyno Monkey\\n\\nMouse\\n\\nRat\\n\\nFigure 5\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 6 of 30\\n\\nUS 8,080,243 B2\\n\\nESI Control mAb {30rng/kg/day)\\n\\ng/kg/day)\\n\\n150\\n\\n0 &oo\\nO\\nttt\\nO\\n0\\no 5o\\n\\npre total post total pre HDL post HDL\\n\\nFigure 6\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 7 of 30\\n\\nUS 8,080,243 B2\\n\\nPCSK9 {6ug/ml)\\nCRN6 pAb (100ug/ml)\\n\\n—\\n\\n—\\n\\nHu Hu\\n\\n— Mu Mu\\n\\n—\\n\\n+\\n\\n—\\n\\n—\\n\\n+\\n\\nB B\\n\\nI Control mAb (30mg/kg/day)\\n\\n/kg/day\\n\\n150\\n\\no 100\\n\\nsr\\no\\nV 50\\n\\n0\\n\\npratotal post total pre HDL postHDL\\n\\nFigure 7\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 8 of 30\\n\\nUS 8,080,243 B2\\n\\nC3 7D4 (10mg/kg i v)\\nR Saline\\n\\nA=\\'a\\n\\n100\\n\\nVl\\nE\\n\\n0\\nCl\\n\\nVle\\n0\\nU\\nC\\n0I-\\n\\nB\\n\\n0\\n\\n60\\n\\n40\\n\\n20\\n\\n0\\n\\n80\\n\\n60\\n\\n40\\n\\n20\\n\\n1day 2 day 4day 7 day 14day21day\\n\\n1 day 2 day 4 day 7 day 14 day 21 day\\n\\nFigure 8\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 9 of 30\\n\\nUS 8,080,243 B2\\n\\nta\\n\\n0\\net\\nIee \\'U\\nsots 5\\no E\\no\\n\\n2\\n\\n60\\n\\nst Sa\\n\\nE aa\\n\\ncr 20X\\n\\n\"la\\n\\nI 0 1mg/kg/day (n=at\\n\\nt((()t)t 0 3mg/kglday (n =8)\\n%31mg/kg/day (n=8)\\nEZI 3mg/kgfday (ne8)\\nE310mg/kg/day (ne8)\\nIZB 30ntgfkgfday (n=8)\\n\\npre dosing\\n\\npost dosing\\n\\n10.0\\n\\n7.5\\n\\not\\nE 5.0\\ncr\\n\\n2.5\\n\\n0,0\\n\\nFigure g\\n\\npre dostng\\n\\npost dosing\\n\\npre dosing\\n\\npost dosing\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 10 of 30\\n\\nUS 8,080,243 B2\\n\\n\"liijiii} 0.1\\n%30.3\\nE31\\n[ZD3\\nIZ310\\nEZI saline\\n\\nEE90.3\\nEKI1\\nE33\\nIZZI10\\nKZZI Sahne\\n\\nI-I\\n\\nA\\n\\n80\\n\\n70\\n\\n60\\n\\no\\nL~~50\\nN ot\\nr\\n0\\n\\n30\\n\\n20\\n\\n10\\n\\n0\\n\\nI\\n\\nt=\\n\\n0\\nCl\\n\\n— E\\n\\nD\\n\\n110\\n100\\n90\\n80\\n70\\n60\\n50\\n\\n30\\n20\\n10\\n0\\n\\n~o\\n\\noe\\n\\nDose (mg/kg/day, 4x)\\n\\n0.3\\n\\n1\\n\\n3\\n10\\nDose (mg/kg, 1x)\\n\\nSaline\\n\\nFigure 10\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 11 of 30\\n\\nUS 8,080,243 B2\\n\\n4A5\\n\\nml0.3\\nER91\\nE33\\nCZ310\\nEZ3 Saline\\n\\nII0.3\\n%31\\nE33\\n62310\\nEZ3Saline\\n\\n100\\n\\n75\\n\\n50\\n\\n\\'g\\nVl\\nE\\n\\nC\\nQ\\nC\\n0\\n4\\ni\\nttj\\n\\nttt\\n\\n0\\nV\\nt5\\n\\n0I-\\n\\n90\\n\\n80\\n\\n70\\n\\n30\\n\\n20\\n\\n10\\n\\n0\\n\\n60\\nOU50\\n\\no\\nV\\n\\n0I-\\n\\n0.3\\n\\n1\\n\\n10\\n\\n3\\nDose (mglkg, i.v. on Day 0)\\n6F6\\n\\nSaline\\n\\n0.3\\n\\n3\\nDose (mg/kg, i.v. on Day 0)\\n\\n10\\n\\nSaline\\n\\nFigure 11\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 12 of 30\\n\\nUS 8,080,243 B2\\n\\n4A5\\n\\n5A10\\n\\nGF6\\n\\n7D4\\n\\nPBS\\n\\nLDLR ~ ~~~~yeae rtrrrrtrewee~~ ews~ eww \"\"»\\nGAPDH ~\\n\\nFigure 12\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 13 of 30\\n\\nUS 8,080,243 B2\\n\\n300\\n\\n200\\n\\n100\\n\\nTotal\\n\\nHDL\\n\\nLDL\\n\\nFigure 13\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 14 of 30\\n\\nUS 8,080,243 B2\\n\\nC3 PBs\\n53 4A5\\nE3 5A10\\n[PD 6F6\\nIZ3 7I34\\n\\n100\\n\\n80\\n\\n\\'V\\n\\nE\\n\\n60\\n\\nI\\n-\\'00\\n\\n0\\n\\n20\\n\\n0\\n\\n1mg/kg\\n\\n10mg/kg\\n\\nFigure 14\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 15 of 30\\n\\nUS 8,080,243 B2\\n\\nA\\n\\n$ 4\\n0J 2\\n\\n1\\n\\n9 1\\nI 1\\n0\\n8\\nN\\n\\n8\\n0\\n\\nE\\n\\nthb\\ntJ\\n\\nc\\nO.\\n\\ncI\\nZ\\n\\n30\\n\\n28\\n\\n10\\n\\n0\\n\\nG\\n\\nE\\nOl\\n\\na\\ncC\\nE\\n\\nm\\'3\\n\\nZ\\n\\nD\\n\\nIIIera\\n\\nIII\\nO.\\n\\nrc\\n\\nTll\\n0\\n\\n88\\n\\n7\\n\\n2\\n\\nF\\n\\n4\\n\\nUl 3\\nE\\ne\\n;2\\n\\n01\\n\\n3800\\n\\n2000\\n\\nOlc\\n\\nY\\nor 1800\\n47\\nc.\\n\\nDO D2 D7 D9 D11 D14 D21 D28\\n\\nDO D2 Dr D9 D11 D14 D21 D28\\n\\nDO D2 D7 D9 D11 914 D21 D28\\n\\n0% 0S 08\\n\\n0%\\n\\nbb\\nb+\\n0 0 0\\n\\n0\\n\\n00\\n\\n0%\\n\\n0& 04\\n\\nwb\\n0\\nmhb Concentrations in Plasma\\n\\nbb\\n0\\n\\n0\\n\\n0\\n\\nDO D2 D7 D9 D11 D14 D21 D28\\n\\nH\\n\\nPCSK9 Concentrations in Plasma\\n\\nDO D2 Dr D9 D11 D14 D21 D28\\n\\nDO D2 D7 D9 D11 D14 D21 D28\\n\\nFigure 15\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 16 of 30\\n\\nUS 8,080,243 B2\\n\\n20 mg/kg TD4\\n\\n3 mg/kg 7D4\\n\\n\\'0\\n\\nE\\n\\nd\\n\\nUl\\nE\\n\\nd\\n\\nVl\\nE\\nd\\n\\nOt\\nE\\n\\nd\\n\\n00\\n\\n02 D7 DS\\n\\n011 D14 D21 D28\\n\\n00 D2 D7\\n\\n09 D11 D14 D21 028\\n\\n1 mg/kg 7D4\\n\\n0.3 mg/kg 7D4\\n\\nDO D2 D7 DS D11 D14 D21 D28\\n\\nDO D2 D7\\n\\nDS D11 D14 D21 D28\\n\\nFigure 16\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 17 of 30\\n\\nUS 8,080,243 B2\\n\\n100\\n\\n62~ 60\\n\\n1\\n\\nCI\\n\\n100\\n\\ncr~ 60\\n\\n1\\n\\ng\\n\\nCI\\n\\no\\'\\'e O\\'~ O\\'e Oe o\\n\\n6F6\\n\\nD-2 Do D1\\n\\nD2 D4 D6 D9 D1 4\\n\\n7D4\\n\\nD-2 Do\\n\\nD1\\n\\nD2 D4 D6 D9 D14\\n\\nD-2 D0\\n\\nD1\\n\\nD2 D4 D6 D9 D1 4\\n\\nFigure 17\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet IS of 30\\n\\nUS 8,080,243 B2\\n\\n33.4% Keel fat, 0.1% cholesterol diet\\n\\n~ saline\\n~ 7D4\\n\\nN=3\\n\\n225\\n\\n200\\no 175\\nI= 150\\ns 125\\ng 100\\n75\\n\\n50\\n\\n25\\n\\n0\\n\\no~ o~ c~ oooo oooo oooooooo oooooooooooo oooo\\no o o o o o o o o \\'o o o o o o o o o\\n\\ns nx nx+nx+n)+nx+nxo\\n\\nDate\\n\\nFigure 18\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 19 of 30\\n\\nUS 8,080,243 B2\\n\\n+ + + +\\n\\n+\\n\\n+ +\\n\\n400 200100 50 25 12.5\\n\\n0\\n\\n0\\n\\n(100nM)\\nmAb (nM)\\n\\nHuman PCSK9\\n\\nMouse PCSK9\\n\\nFigure 19\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 20 of 30\\n\\nUS 8,080,243 B2\\n\\n0,36nM Human PGSK9 pH7,5\\n\\nOL1L3~ 5A10\\n\\n* 42H7\\n\\noo. I„s\\'% so\\n\\n0.35nM Human PCSK9 pH 5.3\\n\\nB\\n\\n1.5\\n\\n0Is\\'b !b\\n\\no\\n\\ne 4\\'\\'\\n\\nb\\n\\nb\\'\\n\\n0.31nM Mouse PGSK9 pH 7.5\\n\\nC\\n\\n1.5\\n\\n0.5\\n\\n1.5\\n\\n0.5\\n\\n0.31 nM Mouse PGSK9 pH 5.3\\n\\nso\\'p\\'o o\\'\\'\\'\\'\\'\\'\\n\\no~ y oA\\n\\noo\\n\\ns~\\n\\nPo\\n\\npo\\n\\noA\\n\\no&\\n\\noo\\n\\noo\\n\\nFigure 20\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 21 of 30\\n\\nUS 8,080,243 B2\\n\\n0\\n01 26 \\'Z$\\no\\noE\\n\\nCS\\n\\n90\\n\\n60\\n\\n45\\n\\n30\\n\\n15\\n\\n2-dBys\\n\\n4-days\\n\\n7-days\\n\\nFigure 21\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 22 of 30\\n\\nUS 8,080,243 B2\\n\\nHDL\\n\\nLDL\\n\\n~ 5A10\\n\\nLIL3\\n\\nII\\ncs\\n8 100\\n\\nII\\n\\nCI\\nZ\\n\\n50\\n\\n0\\n\\n10\\n\\n20\\n\\n30\\n\\nDays\\n\\n8\\n\\n18\\n\\n28\\n\\nDays\\n\\n150\\n\\nCl\\n\\nISs 100\\n8\\nV\\n\\ng\\n\\nCI\\n\\n50\\n\\n0\\n\\n-2\\n\\nFigure 22\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 23 of 30\\n\\nUS 8,080,243 B2\\n\\nL1L3 F\\n\\nLOLR-EGF\\n\\nPCSK9\\n\\nPCSK9\\n\\nPCSK9\\n\\nPCSK9\\n\\np\\n\\nL1L3 Epitoper\\n\\nLDLR EGF Epitopo\\n\\nFigure 23\\n\\n\\x0cU.S. Patent\\n\\nDec. 20, 2011\\n\\nSheet 24 of 30\\n\\nUS 8,080,243 B2\\n\\no\\nX\\n\\nO\\n\\nO\\n\\nO o o O\\nY\\n(0\\n\\nm\\n\\nCQ\\n\\n(C\\n\\n0.\\n\\nUJ\\n\\n(A\\n\\nCj6\\n\\nIZ\\nUJ\\n\\nCj\\n\\n0\\nCC\\nIJJ\\n\\ncj\\nIK\\n\\nCL\\n\\nUJ\\n\\ncj\\nY\\n(C\\n\\n0.\\n(0\\n~J\\n\\ncj\\n0.\\n\\n0.\\n\\nUJ\\n\\ncj\\ntll\\n\\nIL\\nIZ\\nQI\\n\\nCj\\n\\nCl\\n\\nCj\\n\\nIL\\nCC\\nIU\\n\\n0\\n\\nO\\n\\nQ.\\n\\nLL\\n\\nm\\n\\nCJx\\n\\nQ.\\nZ\\nIJJ\\n\\n\\'0\\n\\nN\\n\\nLU\\n\\nZ\\nZ\\n\\nCQ\\nUI\\nN\\n(L\\nZ\\nUJ\\n\\nN\\n\\nUJZ\\nZ\\n(0\\n(7\\n(0\\n(0\\nQ.\\nZ\\nIU\\n\\nCQ\\nY\\nY\\n\\nUJZ)ZI-\\n\\nCC\\n(7\\nVj\\n0\\nZ\\nUJ\\n\\n(0\\n\\nUJ\\nZ\\nZ\\n\\nVlo\\nN\\n0.\\nZ\\nUJ\\n\\nIL\\nZ\\nZ\\n\\nC\"\\n\\n0\",\\nQ.\\nZ\\nIL\\n\\nIQ\\n\\nN\\n\\nU.\\n\\nIU\\nZ\\nZ\\n\\nCC\\n\\nZ\\nCQ\\nN\\n0.\\nZ\\nIU\\n\\nCQ\\n\\nIL\\n\\nIU\\nZ\\nZ\\n\\nN\\nVt\\nN\\nQ.\\nZ\\nUJ\\n\\nCU\\n\\nUJ\\nIL\\'\\n\\n0\\n\\nCJ\\nCl\\n\\nO\\n(7o\\n(0\\n\\nVI\\n\\nI(\\n\\nm\\nZ\\n\\nCj\\n\\nCL\\n\\nUJ\\n\\nVjv\\n\\nUJ\\nZ\\nZ\\n\\nCC\\n\\nY\\nN\\nCL\\nZ\\nUJ\\n\\nVJ\\n\\nIL\\n\\nCL\\n\\nVj\\n\\nCj\\ncj\\n\\nCC\\n\\nN\\nN\\n\\nO\\n\\nN\\n\\nCj\\nc(\\nVj\\n\\n)\\n\\nN\\n\\nCQ\\nCV\\n\\nN)\\n\\nC!\\nc(\\n\\nCJ\\n\\nIL\\n\\nLJ\\n\\nN\\nO\\n\\nZ\\nZ\\n\\nC7\\n\\n0\\'I\\n0.\\nZ\\nLJ\\n\\nN\\n\\nQ.\\n\\nVj\\n\\nCI\\nCj\\n\\n0(\\n\\nZ\\n\\nVj\\n\\nVj\\n\\no\\nm\\n\\nN\\n\\nCj\\nci\\n\\nVf\\n\\nCj\\n\\nCL\\nCC\\nIU\\n\\nN\\nY\\nIL\\n\\nUJ\\nZ\\nZ\\n(0\\nU\\nN\\nILZ\\n\\nUJ\\n\\nZ\\n\\nN\\n\\n(7\\n\\n(0\\nN\\nN\\n\\n(7\\n\\nN\\n\\nCj\\n\\n\\x0cU.S. Patent\\n\\nDec. 20, 2011\\n\\nSheet 25 of 30\\n\\nUS 8,080,243 B2\\n\\nO\\nI!\\nN\\n\\nC\\nX\\nLl\\n\\n\\'Io\\n\\nif\\n\\n7\\nO o\\nI!\\n\\n\\'!o\\n\\nI!\\n\\nC\\nX\\n\\nO\\nIfo\\n\\no\\nif\\nIA\\n\\nK\\n\\nCIJ\\n\\nK0\\'\\n\\nC\\n\\nIIJ\\nIL\\n\\nC.0\\n\\nCf\\n\\nDi\\n\\nK\\n0\\n\\nN\\n\\nCC\\n\\nf/i\\n\\nCC0\\nI3\\n\\nK\\n\\nK\\n0\\n0\\n\\n\\'JJ\\n\\nT\\n3\\n\\'3 00\\n\\nK\\'\\n\\nIJJ\\n\\nK0\\n0\\n\\n0\\n\\nK0\\n0\\n\\nK\\n\\nfo\\n\\nCL\\'\\n\\nK\\n\\nIJJ\\n\\nK0\\n\\nCI\\n\\nK\\n\\nIL\\'IJ\\n\\nK\\n0\\n0\\n\\nffi\\n\\nK0\\n\\nf3\\n\\nK\\n\\nK00\\n\\nC!f!\\n\\nfL\\nCf\\n\\nIII\\n\\nK\\nCI\\nCI\\n\\nK\\nill\\nIJJ\\nIIJ\\n\\n0\\'\\n\\no\\n\\nK\\n\\n0\\n\\nCE\\nCJ\\n\\nO\\n\\nK\\nc(0\\n\\nffi\\n\\nCC0\\nf3\\n\\nCIJ\\n\\nI3\\n\\nO3\\n\\nCff\\n\\nCU\\n\\n0\\n\\nY\\'K\\n\\nO\\nI!\\nN\\n\\nn\\n\\nCL\\nK\\nlij\\n\\no\\n\\nnI-\\n\\nCL\\n\\nlli\\n\\nN\\nX\\n\\nN\\n\\nQ\\n\\nK\\nIIJ\\n\\nIG\\nY\\nI!\\nY\\nllJZ\\nZ\\n\\nffi\\nZ\\ntli\\n\\nIL\\n\\nfCJ\\n\\nCC\\n\\nN\\n\\nK\\n\\nflJ\\nÃ\\n\\n)0\\n\\nÃ\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 26 of 30\\n\\nUS 8,080,243 B2\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 27 of 30\\n\\nUS 8,080,243 B2\\n\\nO\\nX\\n\\nI\\n\\nIC\\n\\nO\\nX\\n\\nO\\nX\\n\\n7\\nO\\nX\\nO\\n\\nO\\n\\nCC\\n\\nI\\n\\nO\\n\\nX\\n\\nX\\n\\nO\\n\\nCQ\\n\\nCQ\\n\\nN\\n\\nLUZ\\nZ\\n\\nCC\\nN\\n\\nrO\\n\\nei\\nLU\\n\\nVJ\\n\\nIL\\n\\nIU\\nZ\\nZ\\n\\nCQ\\n\\nQ.2\\n\\nUJ\\n\\nU\\n\\nUJ\\nZ\\nZ\\n\\nIC\\n\\nCO\\nY\\nIL\\n\\nLUZ\\nZ\\n\\nCC\\nCI\\nCO\\nIL\\nCL\\nCO\\n\\nUJ\\n\\nVf\\nCO\\n\\nVl\\nY\\nIL\\n\\nIU\\nZ\\nZ\\nZ\\n\\nCQ\\n\\nQ\\nIO\\n\\nLU\\n\\nO\\n\\nN\\nY\\n\\nUJ\\nZ\\nY\\nZ\\n\\nCC\\nfQ\\n\\nCQ\\nICJ\\nUI\\nCI\\n\\nLU\\n\\nLL\\n\\nUJZ\\nZ\\n\\nCL\\'Q\\n\\nCQ\\n\\nCL\\nVI\\nIU\\n\\nCC\\n\\nN\\n\\nIL\\n\\nLU\\n\\nZ\\nZ\\n\\nfQ\\nZ\\nIU\\nQ.\\nZ\\nUj\\n\\nCO\\nY\\nIL\\n\\nIU\\nZ\\nZ\\nZ\\nN\\nUI\\nIO\\nQ.\\nZ\\n\\nLU\\n\\nN\\n\\nUJZ\\nZ\\nIC\\nCQ\\nZ\\n\\nZ\\nUJ\\n\\nN\\nY\\nY\\nIJJ\\nZ\\nZ\\n\\nIC\\nCQ\\n\\nCO\\n\\ncf\\nfL\\nY\\nUl\\n\\nUJ\\nZ\\nZ\\n\\nCC\\n\\nCQ\\nY\\n\\nQ.\\nZ\\nIU\\n\\nN\\n\\nUJZ\\nZ\\n\\nCC\\n\\nCQ\\nIQ\\n\\nfO\\nUJ\\n\\nK\\n\\nIL\\nZ\\nZ\\n\\nU.\\n\\nOC\\nI\\n\\nVi\\n\\nIL\\n\\nUl\\nZ\\nZ\\n\\nCQ\\nCJ\\nrO\\n\\nCf\\nIU\\n\\nQ\\n\\nCIJ\\n\\nJJJ\\n\\n0\\n\\nCCZ\\n\\nCC\\n\\nZ\\n\\nCQ\\n\\nO\\n\\nCL\\'/J\\n\\nN\\n\\nCf\\nCf\\n\\nCC\\n\\nCO\\nN\\n\\nCC\\nC1\\nCJ\\n\\nV&\\n\\nCC\\nCJ\\n\\nCC\\n\\nCCZ\\n\\nU0\\n\\nCQ\\nIL\\nN\\n\\nCC\\nCf\\nl3\\n\\nI-\\nIC\\nQ\\n\\ncf0\\n\\nCC\\nCJ\\nCJ\\n\\nCJ\\n\\nQ.\\nIU\\nUJ\\n\\nCO\\nN\\nY\\nLL\\n\\nUJ\\nZ\\nZ\\n\\nCQ\\n\\nN\\nQ.\\n\\nLU\\n\\nZ\\n\\nVJ\\n\\nCO\\n\\nIC\\nQ.\\n\\nCO\\n\\nIU0\\n\\nCJ\\n\\nN\\n\\nO\\n\\nCO\\n\\nCJ\\nCJ\\nVJ\\n\\n\\x0cU.S. Patent\\n\\nDec. 20, 2011\\n\\nSheet 2S of 30\\n\\nUS 8,080,243 B2\\n\\nO\\n\\n0\\nZ\\n\\nQ.\\nE\\nUJ\\n\\nO\\n\\nIO\\n\\n0\\nZ\\n\\nCL\\nIC\\nUJ\\n\\nO\\n\\nIC\\nt\\n\\n0\\nN\\n\\nQ.\\nIC\\nIU\\n\\nIC\\nCt\\n\\nIQ\\n\\nIL\\'\\n\\nIL\\n\\ntri\\n\\n0\\n2\\n\\nIL\\nfL\\nLU\\n\\nJj\\n\\nIQ\\n\\nM\\n\\nX\\nJJ\\n\\n0\\nM\\n\\nQ\\nCC\\nUJ\\n\\nO O\\n\\nCC\\n\\nCC\\nCO\\n\\nO\\nX\\nCO\\n\\nCO\\nCO\\n\\n0\\nZ\\n\\nQ\\nCC\\nUl\\n\\n0\\nM\\n\\nI\\nQ.\\nCC\\nIU\\n\\n0\\n\\nQ.\\n\\nUl\\n\\ncf0\\nN\\n*C\\n\\nQ\\nIZ\\nLU\\n\\nN0\\nZ\\n\\nQ.\\nIC\\nLU\\n\\nN0 0I- M\\n\\nQ.\\n\\nIU\\n\\nCL\\n\\nIU\\n\\nIA\\nCO\\n\\n0\\nZ\\n\\nC\\n\\nUJ\\n\\nIVI\\n\\n0\\nx\\n\\ncC\\n\\nQ.\\nfL\\nUJ\\n\\nCO\\n\\n0\\nN\\n\\nQ.\\nIC\\nIU\\n\\n0\\nZ\\n\\nCL\\n\\nE\\nUl\\n\\n0\\nM\\n\\nL0\\n\\nN\\n\\nQ\\nIC\\nIJJ\\n\\nUJ\\n\\ntJJ\\n\\n6\\n\\nLL\\n\\nO\\nX\\nCO\\n\\nCJ\\n\\nM\\n\\nLLZ\\nLll\\nZ\\nZ\\n\\nICI-\\n00\\n\\nQ.\\nZ\\nITI\\n\\nZ\\n\\nOt\\nZ\\n\\nZ\\n\\nCt\\n\\n0\\n\\nCL\\nIC\\nUl\\n\\nICI\\n\\nN\\n\\nIL\\n\\nIU\\nZ\\nZ\\n\\nCC0\\n\\nLO\\nM\\nQ.\\nZ\\nUJ\\n\\nN\\n\\nLO\\n\\nCC\\nCL\\n\\nN\\n\\nCf\\n\\n0\\n\\nOt\\n\\nN\\nCl\\nN\\n\\nO\\n\\nN)0\\n0\\nN\\n\\nO\\n\\nLU\\n\\nN\\nV\\nLL\\n\\nUJZ\\nZ\\n\\nCC\\n\\nCjt\\nQ.\\nZ\\nIJJ\\n\\nZ\\n\\nI \\'I\\n\\nCC\\nQ\\n\\n\\'Jl\\n\\n0\\n\\nCC\\n\\nM\\n\\nCri\\n\\nO\\n\\nCri\\n\\nLj\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 29 of 30\\n\\nUS 8,080,243 B2\\n\\nCh\\nN\\nN\\n\\nff Li\\nP I\\n\\nIh\\nI\\n\\np\\nIh\\n\\nQ.\\nE\\nIU\\n\\np\\nth\\n\\nQ.\\nIU\\nLU\\n\\np\\nih\\n\\nQ.\\n\\nUJ\\n\\nih\\n\\nIL\\n\\nUJ\\n\\nZ\\nIL\\nIQ\\nIg\\nIL\\nQ\\nIh\\nUJ\\n\\np\\nIh\\n\\nQ.\\nIU\\nUJ\\n\\nIh\\n\\nIL\\n\\nUl\\nZ\\nZ\\n\\nLL\\n\\np\\nQ.\\nIh\\nUl\\n\\nLL\\n\\nUl\\nZ\\nZ\\n\\nLL\\n\\nLQ\\n\\nQ.\\nih\\nUl\\n\\nC\\\\\\n\\nI-\\nx\\n\\nV,\\n7.\\nIU\\n\\nIU\\n\\n0\\'\\n\\nK\\n\\nIU\\n\\np\\n\\nN\\n\\n6\\nIh\\nE\\n\\nIII\\nih\\nIh\\n\\n8\\n\\no\\n\\np\\nx\\n\\nQ\\nLL\\nUJ\\n\\nN\\n\\np\\nX\\n\\nQ.\\nIU\\nUJ\\n\\nZh\\'\\n\\nJJ\\n\\nI\\nIh\\n\\nJJ\\n\\nIh\\nY\\nU.\\nY\\nLUZ\\n\\nIL0\\n\\nCf\\n\\nZ\\n\\nLLI\\n\\nIh\\nY\\n\\n~J\\nZ\\nZ\\n00\\nZ\\n~J\\n\\nfh\\nY\\nIL\\n\\nUJ\\nZ\\nZ\\n\\np\\n0\\nQ.\\nlh\\nUJ\\n\\nIh\\n\\nZ\\nZ\\n\\nIL\\n\\nQ.\\nfh\\n\\n(C\\n\\nLL\\n\\nZ\\nZ\\n\\nIZ\\n\\nfQ\\n\\nLL\\n\\nZ\\n\\nN\\n\\n\\x0cU.S. Patent\\n\\nDec. 20,2011\\n\\nSheet 30 of 30\\n\\nUS 8,080,243 B2\\n\\n0\\n\\nIll\\n\\nD\\n0\\n\\nCD\\n\\nCDo\\n\\nCCD\\nCD\\n\\nN\\nZ\\n\\nN\\n0\\n\\nZ\\nN\\n\\nCj\\n\\no\\n\\n0\\n\\nE\\nUJ\\n\\nLL\\n\\nUJ\\nZ\\nZ\\nt-\\nE\\n0\\n0\\n\\nLL\\n\\nUJ\\n\\nN\\n\\n0\\n\\nE\\n\\nUj\\n\\nUj\\n\\n0 o o\\n\\nC5\\nUt\\n\\nt1\\nE\\nIU\\n\\nCI\\nN\\n\\nLL\\nIU\\nLU\\n\\nIA\\n\\nCCI\\n\\n0\\nUj\\n\\nE\\nUl\\n\\nUj\\n\\nLL\\n\\nUJ\\nZ\\nZ\\nE\\n0\\n0\\n\\nQ\\ntlj\\nUJ\\n\\nE\\nUj\\nIL\\'\\n\\nCt0\\n\\n0\\nN\\n\\nQ\\n\\nE\\nIU\\n\\nN\\n\\nIL\\n\\nLUZ\\nZ\\nIU0\\n0\\nIL\\nQ.\\nN\\nUJ\\n\\n0\\nUj\\n\\nQ\\nE\\nUl\\n\\nUj\\n\\njL\\'L\\'J\\n\\nZ\\nZ\\nE\\n0\\n0\\nIL\\nQ.\\n\\nLLI\\n\\nCt0\\n\\nF\\nQt o\\n\\nI\\n\\nCt\\n\\nD\\n\\nCj\\n\\no\\n\\nCI\\n\\nt1\\n\\nUJ\\n\\nICI\\n\\nZ\\n\\nZ\\n\\nCCC\\n\\nCj\\n\\nQ.\\nE\\nUJ\\n\\nN\\n\\nLL\\n\\nUJ\\nZ\\nZ\\nI-\\nE\\n0\\n0\\n\\nLL\\n\\nZ\\nIU\\n\\n0\\n\\ntZ\\nQ\\nN\\nZ\\nCt0\\n\\nN\\nCj0\\nN\\n\\n\\x0ctjs 8,080,243 B2\\n\\n1\\nISOI.ATKH ANTIBODY YVHIC.\\'H\\nSPEC\\'IFICALLY Rl ~ HS TO PCSK9\\n\\nin individuals with mitosomal dominmu hypercholcster-\\nolemia, v,bile other \"loss-of-function\" (LOF) nmtations are\\nlinked with reduced plasma cholesterol. Morbidity and mor-\\nialiiy studio~ in Ibis group clearly dcmnnstratext thai riducing\\nPCSK9 I\\'unction significmltly diminished thc risk of cardio-\\nvascular disease.\\n\\nfiled\\n\\nThis applicatmn claims priority, ulxler 35 IJSC\\'5119fc), to\\nilm liillou ing US provisional applications, IJ.S Appl No\\n61/096,716, filed Sep. 12, 200K U.S. Appl. No. 61/232.161,\\nAu. 7. 2009, and U S. Appl. No. 61/235 643, filed Aug.\\n\\n20. 2009.\\n\\nOf sigiuficant importance to the treatment of CVD. a LOF\\nmutation may sensitize humans to statins, allouing for efii-\\ncacy nt a lower dose fhcncc, improving risks associatixI with\\nsafety and tolerance) and potentially achieving lower plasma\\ncholesterol levels than with current therapies.\\n\\nRFFFRI\\',NC\\'I\\'. TO SFQIJFN(\\'I\\'. I,ISTIN(i\\n\\ntocytes. Cienetic modulation of PCSK9 in miceconfimled\\n\\n\\'Elis application is being filed electronically via EFSHVeb\\nand includes nn elcctrmiically submitted scqucncc listing\\nin ixi fomiat Thc.ixt lile contains a sequence listing entitled\\n\"PC33713 A SequenceListing.txt\" created on Sep 10, 2009\\nand having a size of 51 KB The scqucncc listing mmtaiimd in\\nthis .txt file Is part of the spe ulication and is herein incorpo-\\nrated by reference in its entirety.\\n\\nPC\\'SK 9 Is secreted into ilm plasma predomuinnilv by hei(a-\\nth\\nability of PCSK9 to regulate blood lipids, and suoogested tint\\nlishedd.\\nit acts to dou.n-regulate hepatic LDLR protein levels.\\n\\nln\\n\\nFfiil D OF THI\\', INVEN1 ION\\n\\n\"o\\n\\nThe present invention relates to antibodies. e.g.. full lenbuh\\nantibodies or antioen-binding portions thereof, pcptides, and\\naptamers that anta onize the activity of extracellular propro-\\nteln convertase subtilisin kexin type 9 ft\\'CSK9), including its\\n\\n\"-\\'nieractionwith die lou density lipoprotein (I,DI.) receptor\\n\\n(LDLR). More specifically. the invention relates to compos&-\\ntions comprising antagonist PC\\'SK9 antibodie~, peptides,\\nand/or aptamers uid methods of using these uitibodies and/or\\npeptldes and/or aptamers as n medicament. 1he antagonist \"\"\\nPC\\'SK9 mitibodicx peptides, aml aptamers can bc used thera-\\npeutlmilly to lover I Dlocholesterol levels in blood, and can\\nbc used in tfm prevention and/or treatment of cholesterol and\\nlipoprotmn metabolism disorders, including fninilial hyperc-\\nholesterolemim athemgenlc dyslipidenum atherosclerosis,\\nmid. more generally, cardiovascular disease (C\\'VD).\\n\\n\"\"\\n\\nBA(\\'K(iROI JND OF THF, INVFNTION\\n\\nMillions of people in tile U.S. are at risk for heart disease so\\n\\ntmd resulting cardiac events (JV D and underlying atheroscle-\\nrosis Is the leading cause of death among all demograpluc\\ngroups, despite the availability of themspies directed at its\\nmultiple risk lactors Atherosclerosis is a disease of the niter-\\nIes and Is responsible for coronary heart disease associated 4.\\nwith many deaths in industrialized countries. Several risk\\nfactors for comnary heari disease have nov, been identified:\\ndysllpldemias. h)pertension, diabete~. snxiking, poor diet.\\nuiaciivity and straws. The most clinically relevmit and com-\\nmon dyslipldenuas are clmractenzed by an increase in beta-\\nlipopmtmns (very low density lipoprotein (VLDL) and LDL)\\nunh hypercholcsterolemia in theabsence or preselxe\\n\\no\\n\\nol\\'ypeitnglyceridemta(Frednckson et al.. 1967, N L\\'ngl 1 Med.\\n276 34-42. 94-10\\'3, 143-1 56, 215-225. and 273-2g I ). I\\'here is\\na long-I\\'elt sigmficmu unmet oined with respect to CVD with\\n60-70Ao of cardiovascular events. heart attacks and strokes\\noccimillg despite illc ircaiirlcllt u itll staiiils (tlm cllrrcrli si ul-\\ndard of care in atherosclerosis). Moreover, neiv guidelines\\nsuggest that even loiver LDI, levels should be achieved in\\norder to pmtect hi h risk patients from prmnature C.\\'VD [Na- mi\\ntional (\\'holesterol 1.\\'ducation I\\'rogram fNCEP). 2004].\\n\\n1\\n\\nPCS K9, also known ns NAR(u I, was idenrified as a pmtcin\\nwltll a gcilcilc illa t\\'Itloll 111 soillc forllls of filluillal hl\\'pci\\'cho-\\nlestemlemia. I\\'(\\'SK9 Is synthesized as a zymogen that under-\\ngoes mitocatalytic processing at tlm niotif LVFAQ in the (\\nendoplasnuc reticulum. Population studies have shown tlmt\\nsome PCSK9 mutations are \"gain-of-function\\'* and are found\\n\\nThc mechanism by which. and the site ai which, P( SK9\\ndown-regulates I DI,R protein has not been clmlrly estab-\\n(Vien over expressed. PCSK9 may act both witlun the\\nhapatecyse and as a secreted ligaud for I,DI.R. There is strong\\nevidence that extracellular PC:SK9 binds io cell surface\\nI,DLR and promotes LDLR degmdation at an intmcellular\\nsite. I lou ever, It Is also possible that PCSK9 could uiteract\\nwith the LDLR when the two proteins are translated witlun\\nthe endoplasmic reticulum fER) and traffic tlu\\'ough endoso-\\nmal compartnienms iimnrds the cell membrane Maxwell et\\nul., 2005. Ciur. Opin. Lipidol. 16;167-172. showed that\\nP( SKI)-midiaticd I DI,R cndocytosis tmd degradation v;as\\nnot altered by proteosome inhibitors nor was it modulatesf by\\ndifferent classes of lysosomal and nonlysosomal proteases.\\nTwo naturally occurring familial hypcrcholesterolmnia nuita-\\ntions, S127R mid D I 29CJ, have beeo reported to be defective\\nin mitoprocessing and secretion as levels of tlmse nmtant\\npmteins u erc greatly reduccxt or undetectable in lhe media of\\ntrutsfectwf cells. Yet\\nthese mutants demonstrated an\\nenhanced ability to doiin-regulate I.DI,R, consistent widi\\ntheir identilicaiion ui\\nindividuals with high pissant I.DI.\\nfHomer et al., 200g, Athemsclerosis 196:659-(166: Cameron\\nct al, 2006 Hummi Molecular Cienctics 15 1551-155g, I.am-\\nbert et al., 200 Cx TRENDS in Lndocnno logy and Metabolism\\n17 79-31. Since these mutants apparently do not get secreted\\nextracdlularly, and ivt do downregulate I DI R, this strongly\\nsuggests that an intracellufar site of action Is physiologically\\nimponant.\\n\\nFrom the inliirmauon available in the ari, and prior to the\\npresent Imention, it renmined unclear whether the Introduc-\\ntion of\\'i antibody-, peptide-, or apiamcr-based PC\\'SK9\\nantagoiust into the blood circulation to selectively antagonize\\nextracellular PCSK9 would be effective to reduce hypercho-\\nlesierolenun and the associnicd incidence of C\\'VD and. if so,\\nuhat properties of a PCSK9 mit Igonist are needed for such In\\nvive cffcctlvcniss\\n\\nSUMIVIARY OF THI, INVFNTION\\n\\nThis invention relates to antagonist antibodies. peptides,\\nand apiamers thm solcctivcly intcmcl with and inhibit P( SK9\\nfuncuon. It is demonstrated for the first time that certaui\\nP(:SK9 antagonists are effective in vivo to loumr blood cho-\\nlesterol\\n\\nIn one embodiment.\\n\\nthe invention provides an isolated\\nantagonist of P( SK9 which comprises nn antibody. a peptide,\\nor an aptamer, which interacts v, ith PCSK9 and when achnin-\\nistered to a subject lowers the LDL-cholesterol level in blood\\nof said subject. Tlm antagonist can be an antibody, for\\nexample, a monoclonal antibody or human. Iuunaiuzed, or\\nchimeric antibody.\\n\\n\\x0cUS 8,080,243 B2\\n\\nIn another mrbodinwnt, the invm&tion provides an isolated\\nant&-PCS K9 antibody tvluch specifically binds to PCS K 9 and\\nwluch is a full antagonist of the PCSK9-mediated etTect on\\nI BI,R le&mls when nwasurcd in vitro using the 13)I,R down\\nregulat&on assay &n lluh7 cells d&sclosed here&n.\\n\\nIn yet another embodiment, the invention prov ides an iso-\\nlated an rhody &v hich antagonizes the extracellular interact &on\\nof PCS K9 with the LDLR. as measured by PCS K9 bu&du&g to\\nthe I BI.R in vitro. mxi. &vien administcrcdl to a subject,\\nlouers the LDL-cholesterol level &n blood of sa&d subiect.\\nPreferably. the antibody recoyuzes an epitope on luunan\\nPC\\'SK9 that overlaps &vith tuore &ban about 75\",z& of the surface\\non PCSK9 that u&temcts with the EGF\\'-hke dommn of the\\nI,BI.R as described in Kwon et nl., 2008, PNAS, 105. 1820-\\n1825\\n\\nIn yet another embodiment. the invent&on provides an anti-\\nbody that recognizes a tirst epitopo of PC\\'SK9 that overlaps\\nw&th a second epitope that is recoguzed by a monoclonal\\nm&tibody selected from the group consisting of 5A10, which\\nline dcpositcdi with thc\\nis producod by a hybridoma cell\\nAmerican Type Culn&re Collection and assigned accession\\nnumber IzIA-8986; 4A5. which is produced by u hybridoma\\ncell l&ne deposited u ith the Amertc ul Type Culture Collect&on\\nand assim&ed accession number I\\'TA-8985; C&F6, which is\\nproduced by a hybridoma cell linc dcpositcd u ith tl&o Ameri-\\ncan Type Culture Collect&on and assigned access&on number\\nPTA-8984, and 7D4. wlfich is produced by a hybridoma cell\\nlinedcpositedwiththeAmericm& TypeCultureCofiect&onand\\nass&y&ed accession number PIA-8983.\\n\\nhl anothcr clnbodiment, thc invention pmvidcs nn antibody\\nto humm& PCSK9, ~herein the antibody recognwes an\\nepitope on luunan PCSK9 comprising anuno acid residues\\n153-1 &5, 194, 195, 197, 237-239, 367, 369, 374-379 nnd 381\\nof the PCSK9 amu&o ac&d sequence ol\\'EQ ID NO: 53.\\nPreferably. the m&tibodv cpitopc on human PCSK9 does not\\ncomprise one or morc oi\\'amino acid rcsiducs 71. 72, 150-152.\\n187-192, 198-202. 212, 214-217, 220-226, 243. 255-258,\\n317, 318, 347-351, 372, 373, 380, 382, and 383.\\n\\nIn still unotber embodu&mnt, dw.\\n\\ninvent&on prov&des un\\nant&body which specifically binds PCSK9 comprising a VH\\ncon&pten&cntary detem&ining region one (( BR I) having thc\\nanuno acid sequence shown in SL&Q ID NO:8 (SYYNIII). a\\nVH C\\'DRZ having the amino acid sequence shou n in SLQ ID\\nNO 9 (IIISPF(i(iRTNYNFKFKS), and/or VH CBR3 having\\nthe anuno acid sequence shown u& SL\\'Q ID NO:10 (ERI\\'L-\\nYASi)1 ), or a variant therm&f having one or more conserva-\\ntrte mn&no acid substitutions in said sequences of CDRI,\\nCDR2, and/or CDR3, wherein the variant retains essentially\\nthc same binding specitimty as the CBR defined by said\\nsequences. Preferably. the vanant comprtses up to about ten\\nanuno acid substitut&ons and, more preferably, up to about\\nI\\'our mnino ac&d substituuons.\\n\\nant &body\\n\\nThe invention &s further d&rected to an\\n\\ncomprt s&ng\\na VI, C\\'BR I having the an&inn acid svqucncc six&w n in S I\\',Q IB\\nNO 11 (RASQCiISSAI,A). a C\\'DR2 hav&ng the am&no amd\\nsequence shown in SFQ ID NO:12 (SASYRYTk and&or\\nCBR3 having thc mnino acid sequence shown in SFQ IB\\nNO.13 (QQRYSI.WRT). or a vartant thereof lmvmg m&e or\\nmore conservative muino acid substitutions in said sequences\\noi\\'(. DRI. C\\'.DR2. and.\\'or CBRS, uhclehl thc varimlt retains\\nessent&ally the same binding specitic&ty as the CDRI defined\\nby said sequences. Prefembly, the variant comprises up to\\nabout ten mnino ac&d subst&tut&ons and, more preferably. up to\\nabout four amino ac&d subst&tutions.\\n\\nIn another embodiment, the invention pmvides an m&tibody\\ncomprisu&g specific VL CDRI. CDR2. and/or CDIL)\\nsequences, or a variant thereof lmving one or more conserva-\\n\\ns\\n\\ntive amino acid substitutions in ( DR I, ( BR2, and/or C\\'BR3\\nund further compris&ng a VH complementary detenmiun\\nregion CDRI having the amino acid sequence shown in Sk.Q\\nID NO:59, 60, or 8, a VH C:DR2 having the an&ino acid\\nsequence shown in SEQ ID NO:61 or 9. and/or VH CDR3\\nhaving the amino acid sequence shown in SFQ ID NO:10, or\\na variant thereof lmv it&8 one or nulre conserve t&ve amino ac&d\\nsubst&tutions in said sequences of CDRI, CDR2. und/or\\nC\\'DR\\'3. u herein thc variant retains essentially the sanlc bind-\\nnl u&g specitic&ty as the CDRI. CDR2. u&d/or CDR3 defined by\\nsaid sequences. Preferably. the variant comprises up to about\\ntwenty mnino acid substitutions and, morc prclbrably. up to\\nabout e&J&t amu&o acid subst&tutions. In another preferred\\nembodinwnt, the antibody of the invention h&ms n variable\\nheavy clmu& sequence con&prts&ng or consistu&g of SI.Q ID\\nNO: 54 and u variable fi&J&t chain sequence comprising or\\nciulsisting of SEIQ IB NO: 53\\n\\nThe invention also pmvides a humanized m&tibody mnu-\\nprising polypeptides selected from the groups consisting of\\no SFQ ID NO 14. SFQ IB NO.15, or both SFQ ID NO 14 nnd\\nSFQ ID NO:IS, or a vanant thereof having one or more\\nconservative amino acid substitutions in said sequences,\\nwhere&nthevanantreta&nsessenuallythesamebind&n spec&-\\ntic&ty as the ant&body defined by said sequence(s). It also\\nincludes an antibody lacking a terminal lysinc on the heavy\\nchain, as tlus &s normally lost in a proportion of ant&bodies\\nduring manufacture.\\n\\nlo amino acid substitution~. Prefi.rably,\\n\\nPreferably. the variant compnses up to about turn&ty amu&o\\nacid subst&tut&ons and more preferably. up to about eight\\nthc antibody furtlwr\\ncomprtses an unmunolog&cally u&ert constant re ion, and/or\\nthe antibody has an &sotype that &s selected fmm the youp\\nconsisting of\\'gC»,,\\nlgCis. 18CI&aw 18CI«s, Ig(iszc IgCis\\nS228 P. IgG«s S228P and IRCis „S22 8P. In another preferred\\n\\n\"» embodiment, the constant region is aglycosylatcd Fc.\\n\\nIn onc mnboduncnk the invention provides a n&cthod for\\nreducu&g a level ol LDL. LDL-cholesterol, or total cholesterol\\nin blood, serum, or plasmn of a subject\\nin need thereof,\\ncomprisuig adininistcring to the subjcmt a therapeutically\\n\\nso efibctive amount of an antagonist of the invention.\\n\\nIn ime embodinwnt, the invention provides a therapeuti-\\ncally effect&ve amount of an antagonist of the invention for\\nuse in reducing a level of I.DL, LDI.-cholesterol, or total\\ncholostcrol in blood, serum, or plasma of a subjoct in need\\nthereof. The u&venuon further provides the use of a therapeu-\\ntically etTective amount of an antagonist of the invention in\\nthe manufacture ofa medicament for reduc&ng a level ofLDI.,\\nLDL-cholesterol, or total cholesterol\\nin blood, sertuu, or\\nplasma of a sub)cct in need thereof.\\nIn yet another embod&ment,\\n\\nthe invent&on provides a\\nmetlald of preparing an ant&body wluch specifically binds\\nPCSK9. which comprises: a) prtlviding a PCSK9-negative\\nhost aiumal: b) imnuuuzu&g sa&d P( SK9-ne at&ve host a&u-\\nn&al with P(\\'SK9; and c) obtaining an tmtibody An m&tibody-\\ns pmducmg cell, or an anubody-encodu&g nucleic amd from\\namid p( SK9 negative host animal. and preparing an antibody\\nfrom said antibody-producing cell or said antibody-cnm&ding\\nnucleic ac&d.\\n\\nu\\n\\nThe invention also comprises a method t\\'or reducing the\\nm& level of I.BI, in bk&od ofa subject in nccd thcreol\\'. comprismg\\nadnunistering to the subject a therapeutically effective\\namount of the m&tibody prepnrcd according to tl&o invention.\\nThe sub&act can be further treated by arhuimsteru& a stern. In\\na preferred embodiment, the subject is a lorn&an subject.\\n\\nIn onc cmbodimem. thc antibody is adn&inistcred in u for-\\nmulation as a sterile aqueous solution lmving a pit that ranges\\nfrom about S.O to about 6.5 m&d compris&ng from about I\\n\\n\\x0cDRI \\n\\nIn uiother embodunent, the invention pmvides a thempeu-\\ntically elTective unount ol\\'the antibody prepared accorduig to\\nthe invention for use in reducing thc leiml of I DI in blood of\\na subfect in need thereof. The invention further provides the\\nuse of a thempeutically effective amount of the antibody\\nprepared uccording to the invention in the mmiuiacture ol\\'a\\nin blood of a\\nmedicament for rixfucing the level of LDI\\nsubject in need thereof. \\'fhe thempeutically effective amount\\ncan optionally be combuied ivith a thempeuncally effective\\naniount of a suitin.\\n\\n5\\nmg/nil to nbout 200 nig/ml of antibody. front about I milli-\\nmolar to about 100 mill imo far of histidine buffer, from nbout\\n0.01 mg/ml to about 10 mg/ml of polysorbate 80, from about\\n100 nli I limo far ur aboui 400 m ill i molar of treha lose. and I\\'rom\\nabout 0.01 millumilar to about I 0 millimolm ol\\'disodmm\\nEDIA dihydrate.\\n\\n111 aliothcr clnbilifilnclit, tlm inventioll provides a hybri-\\ndoma cell line that produces a I\\'CSK9-specific antibody or an\\nanti en-bmding portion theresrf. wherem the hybridomn cell\\n\\n1 (1\\n\\nUS 8,080,243 B2\\n\\nline is selected from the group consistingol\\'AShaving an AT(\\'(: Accession No. of PTA-8985:\\n\\n5A10 lmving an ATCC Accession No. of PTA-8986:\\n61\\'6 having ml ATCC Accession No of PTA-8984; and\\n7D4 havuig an ATCC Accession No. of PTA-8983.\\nIn miother emboduuent, the invenuon promdes cell luis\\ntluit recombulantly pmduces an mitibody wluch specifically\\nbinds to P(\\'SK9 mid comprises a heavy chain variable region\\n(VI I) complementary d el ann i lung region one (C\\n) havulg\\nthe amino acid sequence shown ui SFQ ID NO;8. 5\\'&, or 60, a \"\"\\nVH CDR2 having the mnino ncid sequence shown in SFQ ID\\nNO 9 or 61. and/or VH CDR3 having the amino amd\\nsequence shown in Sk Q ID NO.10. or a variant therixif hav-\\niilg. Cnc or iliore cotlsurvativc amiil&1 acid substitutions iil\\nCDRI, CDR2. mid/or CDR3, ulrpor compnses a light chain \"\"\\nvariable region (Vf,) (\\'DR I Imving the amino acid scxfuence\\nshown in SFQ ID NO I l. a VI CDR2 having the mnino acid\\nsequence shown in SEQ ID NO:12. and/or VL (.\\'DR3 having\\nthe mnino acid sequence shown in SFQ ID NO:13, or a\\nvanant thereof havulg one or more conservative amino acid sn\\nsubstitutions in Cf&RI, (\\'DR2, anipor CDR3. Preferably, the\\nline riecimibinmitly produces an antibody comprising\\ncell\\nSF Q ID NO: 53 anChor 54, and, more preferably, SF Q ID NO;\\n14 and/or 15\\n\\nBRIkl\\'l\\'.S(.\\'RIPTION OF 1HE\\nFIGLIRES!DRsrWINGS\\n\\nFKr\\'\\n\\nillustratms the efTect ol\\'nti-PC\\'SK9 antagonistic\\nmonoclonal antibodies 7D4.4. 4AS.C13. 61\\'6.G103 and\\nSAIO.BS on the ability of mouse PCSK9 (A) and lnunan\\nPCSK9 (B) to down regulate I,DI R ui cultured 1luh7 cells\\n61\\'CxG10,3 is a subclone of 6F6, 7D4.4 is a subclone of 7D4.\\n4AS (13 is a subclone of 4AS, and SA10 BS is n subclone of\\n5A10.\\n\\nu\\n\\n:r\\n\\nFKi. 2 if lastmtes the dose-response of anti-P( SK9 antago-\\nnist mmioclonal antibodies 6F6(il03. 7D44. 4AS C13.\\nSA I 0.BS, negative control antibody 421 17. and PBS to block\\nthe binding of recombinant biotinylated Inunan P(\\'SK9 (A)\\nand nxrusm PC:SK9 (B) to immobilixml ricombinmit I,DI.R ai\\nextracellular domain in vitro.\\n\\nFKi. 3 illustrates the dose-response of anti-P(\\'SK9 mono-\\nclonal antagonist antibodies 61\\'6.G10.3. 7D4.4. 4AS.G3 and\\nSAIO.BS to block binding of recombinant biotinyfated\\nhumnn PC\\'SK9 (30 nM) to Furopium labeled rccombinmit\\nLDLR extmcellular domain (10 CM) ui solution at neutral pH\\nin vitro.\\n\\n(\\n\\nFKi. 4 illustrates comparative cpitope binding of anti-\\n\\nPCSK9 antibodies.\\n\\nFICi. 5 illustrates Western blots of binding of anti-I\\'(\\'SK9\\n\\nantibodies to scnim P(\\'SK9 front diffi:rent species\\n\\n11Cr. 6 illustrates the effect of anti-PCSK9 monoclonal\\n\\nantibody 7D4 on blood clxilesterol levels in mice.\\n\\nFICi. 7 illustrates (A) the effect of a pariuil anuigonist\\npolyclonal anti-PCSK9 mAb CRN6 on LDLR doivn regula-\\nuon mid (B) the lack of\\'clif:ct mi cholestcnil levels in micm\\nFICi. 8 illustrates the time course of the cholesterol lower-\\ning effect obtained using anti-PCSK9 antagonist antibody\\n7D4 ill nliCe\\n\\nFIG. 9 illustrates the dose dependence of the anti-PCSK9\\nantagonist mAb 7D4 on the reduction of serum total choles-\\nteml. IIDI, and LDI, in mice.\\n\\nFKi. 10 illustrates the dose dependence of the cftofesterof\\nlowering etTi.ct of anti-PC\\'SK9 antagonist mitibody 5A10 in\\ntutee.\\n\\nFICi. 11 illustrates the dose dependence of the cholesterol\\nloss cring cfli:ct of\\'anti-PCSK9 nntagmiist mltibixlies (A) 4AS\\nand (B) 6F6 in nuce.\\n\\nFICi. 12 depicts Western blots of anti-P(\\'SK9 antagonist\\n\\natuibodies etl\\'ect on liver LDLR levels.\\n\\nFBI. 13 illustrates the lack ofeffect of anti-I\\'C SK9 antago-\\n\\nnist antibody 4A5 in an I.DI,R-/- mouse model\\n\\nFIG. 14 illustrates the effect on total serum cholesteml of\\nnuiltiple administrations of anti-PCSK9& antagonist mitibod-\\nies ul nues over a longer tune course tlmu seen is ah a single\\ndose.\\n\\nFKi. 15 illustrate the tinw. course. of the elTimts of mlti-\\nPCSK9 autagomstic mubodv 7D4 on lipid parameters in a\\ncynomolgus monkey model.\\n\\nFICi. 16 illustrates lhe dose- and time-response of anti-\\nPCSK9 mltagonistic auubody 7D4 on serum cholestenil lev-\\nels in thc cynomolgus monkey\\n\\nFICi. 17 illustrates a compmison of anti-PC SK9 antagonis-\\nuc antibodies 4AS, SA10. 6F6 and 7D4 on serum cholesterol\\nlcimks in the cynomolgus monkey.\\n\\nFICi. 18 illustrates thc time course oi\\'he sfl\\'ecl of\\'ui-\\nI\\'(\\'SK9 mitagonist antibody 7D4 on plasma cholesterol liw els\\nof cynomolgus monkeys fed a 33A% kcal fat diet suppli-\\nmented with 0.1% cholesterol.\\n\\nFICi. 19 illustmtes the effect of LIL3 (lnunanized anti-\\nP(\\'SK9 monoclonal antibody) on down regulation of IJ&I,R\\nin Huh7 cells.\\n\\nFICf. 20 illustrates the dose-response of LIL3 fnimanived\\nantibody. the mouse precursor SA10, and negative control\\nantibody 42H7 on b le ckuig the binding of recombinant bioti-\\nnylated human PCSK9 (A and B) and mouse PCSK9 (C\\'nd\\nD) to immobilized recombinmit LDLR extnscellulur domain\\nin vitro at pll 7.5 (A and C) and pH 5.3 (B and D).\\n\\nFICr. 21 illustrates the elTiect on serum cholesterol of trmit-\\n\\nment ofmicewith 10mg/k LIL3.\\n\\nFKi. 22 illustrates the elTimt ol\\'dministration of 5A10\\nantibody or L11,3 to cynomolgus monkeys and measurement\\nof changes in serum HDL (A) and serum L1&1. (B) as a\\nfunction of liam.\\n\\nI\\'ICI. 23A depic(s the crystal structure of the PC\\'SK9 (hght\\ngmy surface representation) bound to the LH 3 antibody\\n(black caruion rcqrrcscntatton) FKi 23B depicts ihc crystnl\\nstnicnire of the I\\'CSK9 (light pay surface representation)\\nbound to the fkil\\'-like domnin ol\\'lm I.DI,R (black cartoon\\nrepresentation) (Kwon et al., PNAS, 105, 1820-1S25, 2008).\\nFICi. 23(\\'hoivs tile surface area representation of PCSK9\\nwith the f,l I 3 cpitopc shown in dark gray. FKi 23D shows\\nthe surface area representation of PCSK9 with the LDLR\\nECrp-like domain epitope sluiwn in dark gvray.\\n\\n\\x0cUS 8,080,243 B2\\n\\nI\\'1(IS 24 A-(i dh7ict the substitutiims made in the ( DRs of\\nantibody 5A10 in thc course of affinity maturation and opti-\\nmization and to aclu eve particular properties. PCS K9 bu&du&\\nassocmted w&th antibi&dies having these C\\'DR substitutions is\\nalso reprcsvnted The number following each svqucnce is thc\\nSL\\'Q ID NO desi~a&ed for each sequence.\\n\\nDETAILED DESCRIPTION OF TIIE INVL\\'NTION\\n\\nia\\n\\nThe present invention relates to antibodies, pep&ides, anil\\naptamers that antagonize the iiu&ct&on of extracellulm PCS K9\\nincluding its interaction with tlm IJ&I,R. More specifically.\\nthe invi:ntion relates to methixis oi nmking nnta onist PC\\'SK9\\nant&bodies, peptides, and aptamers, compositions comprising\\ntlmsc m&tibodies, peptidcs, and/or aptamers. and nwthods of la\\nus&ng these antibodies, peptides. and/or nplamers as a med&-\\n11&e antagonist VCSK9 antibodies and peptides can\\ncament\\nbc usod to lower blood I DI -clx&lcstcrol levels, and cm& bc\\nused in the prevent&on and/or treatment of cholesteml and\\nlipopmtein metabolism disordem, including familial hyperc- zc\\nholesterolemi\\nand. more generally, (\\'VD.\\nCienc& sl Teclmiquas\\n\\n&, athemgen&c dyshpidem&a. atheroscleros&s.\\n\\nThe pract&ce of the present invent&on w&11 employ, unless\\n\\n\"\"\\n\\nothenvise ind&cated, conventional techniques of molecular\"-\\'iology(including recombinant techniques). m&crobiology,\\n\\ncel I biology, biochenu stry and inuuuno logy, winch are witlun\\ntlm ~kill of the art Such tcchniqucs nre explained fully in thc\\nliterature. such as, Molecular C\\'loning A I.abomtory Manual.\\nsecond ediuon (Sambrook et al., 1989) Cold Spnn llarbor \"\"\\nPress, Oligom&cleotide Syntlmsis (M. J. Ciait, ed, 1984),\\nMethods &n Molecular B&ology, I lumana Press, C\\'ell B&ology:\\nA I aboratory Notebook (J. I\\'I Ccllis, ed., 1998) Academic\\nPress, Animal Cell C\\'ulture (R I Frcshncy, ed . 1987), Intro-\\nducuon to Cell and Tissue Culture (J. P. Mather m&d P. Ls\\nRobert~. 1998) Vien&un Press: (.\\'ill and Tissue (\\'ulture I.abo-\\nI dtory Procedures (A. Doyle .I B. C&\\'rifiiths. and D. C& New&all.\\neds.. 1993-1998) J. Wilev and Sons; Methods in Enzvmology\\n(Acadmnic Press. Inc ): Handbook of Fxperimcntal Immu-\\nnology (D. M. We&r and C. C. Bluckv ell, eds.); C&ene Transfer sc\\nVectors for Mammalian (.\\'ella (J. M. Miller and M. P. (\\'alos.\\ncds.. 1987), ( urrent Protocols in Molecular Biology (F M\\nAusubel et al., eds., I\\')87); PCR: The Polymerase Chain\\nReaction, (Mullis et al.. eds., 1994); (\\'urrent Protocols in\\nImmunolo y(J E Col&gauetel.. eds..1991): ShortProtocols ss\\n&n Molecular Biology (Wiley and Sons, 1999): Inumu&obiol-\\nogy (C\\'. A. Jancway and P. Travers, 1997), .Antiboilics (P\\nFu&ch, 1997): Annbodies; a pnsctical approach (D. Catty.. ed.,\\nIRL Vress. 1988-1989); Monoclonal antibodies: a practical\\napprmich (P. Shepherd and C De m, eds, Oxli&rd IJni&vrs&ty su\\nPress, 2000); Using antibodies. a laboratory manual (E. Ihu-\\nlow and D. Lm&c ((\\'old Spring Harbor Laboratory Press,\\n1999), The Anubodics (M. Panetu and J. D Capra. cxls.\\nHa&wood Academic Vublishers, 1995).\\n\\nl&EVINI1IONS\\n\\nAn \\'*ant&body\" is an inm&umiglobulu& inolecule capable of\\nspecific binding to a target, such as a carbohydrate. poly-\\nnucisx&tide. lipid. polypcptickx ctc, thmugh at least onc ant&- m&\\ngen recognit&on site, located in the vanable region of the\\nimmunoglobulin molecule As used herein. the tenn encim&-\\npasses not only u&tact polyclonal or monoclonal ant&bodies,\\nbut also fragments thereof (such as Fab, Fabk F(ab\\')s. Fv),\\nsingle chain (ScFv) m&d domain antibodies), and fusion pro-\\nte&ns comprising an antibody portion, and any other mod&fied\\nconfiguration of the inununooJobufin molecule that com-\\n\\n(\\n\\nprises an nnrigen recognition site. An antibody includes m&\\nannbody of any class, such as IgO. IgA. or IgM (or sub-class\\nthereof) and the antibody need not be of any part&cular class.\\nDepending on the antibody amino acid sequm&ce of the con-\\nstant doma&n of &ts heavy cha&ns. immunoglobulins can be\\nassigned to difTerent classes. There are five major classes of\\nu&ununoglobuln&s: IgA, IgD. IgE. IgCI. m&d lgM. u&d several\\nof these may be further div&ded into subclasses (iso&&T&es),\\nc.g, IgCil. IgC12, Ig()3, Ig(14. IgAI and ISA2 Thc lmavy-\\nchain constant domau&s that correspond to the difierent\\nclasses of &nununoglobulins are called alplm, delta, eps&ion,\\ngamma and im&, respcctivcly. The auburn& structures a&xl\\ntluee-dimensional conti urat&ons of diferent classes of\\n&&ainu&&ogl(lbu1ins are well known\\n\\nAs usvd hereu&. \\'*monoclonal anl&body*\\'eli:rs to an mui-\\nbody obtained from a population of substantially homoge-\\nncoms antibodiew i c., tlm individual antibodies comprising\\nthe population are identimd except lor possible naturally-\\noccurring mutations that may be present in minor amounts.\\nMonockmal antibodies nre highly spccilic., being directed\\nagainst a single m&tigenic site. Furthermore. &n contrast to\\npolyclonal antibody prepamtions, which typically include\\nd&fferent antibod&es directed s ainst d&fferent detenn&nants\\n(ep&topes). each monoclonal antibody is d&rected against a\\n\\'11&e modifier \"mono-\\nsingle determinant on the nntigcn.\\nclonal\" u&d&cates\\nthe character of the anubody as be&n\\nobtmned from a substantially homogeneous populat&on of\\na&uibodics, m&d &s nol to be coustrucxI as requ&ring producuon\\nof the ant&bodv by any particular method. 1&or example, the\\nmonoclonal antibodies to be uscxI in accordmlcc with thc\\npresent invention nuiy be made by the hybridoma method lira&\\ndescribed by Kohier and Milste&n, 1975, Nature 25Cx495, or\\nmay bc m&xle by r&vombinant DNA methods such as\\ndescribed u& U S. Pat No. 4.816.567. The monoclonal anti-\\nbodies may also be isolatscd from phage libraries genernted\\nusing thc techniquca dcscribcd in McCaiTerly cl al, 1990.\\nNature 348. 552-554. for example.\\n\\nAs used herein, \"lnunanized\\'ntibody refers to filnns of\\nnon-lummn (e g, im&rine) mitibodies ihal are chuu eric immu-\\nnoglobulins, inununoglobulin clm&ns, or fraynents thereof\\n(such as Fv. Fab. Fab\\'. F(ab\\')s or other antigen-binding sub-\\nsequences of ant&bod&es)\\nthat contain m»umnl sequence\\nderived from non-human inununoglobulin. Preferably,\\nhumnnizcd antibodies me humnn immunoglobulins (recipi-\\nent ant&body) in wluch res&dues from a complementary deter-\\nmining region (CI&R) ofthe recipim&t are replacsxl by residues\\nfrom a CDR ofa non-human spec&es (donor ant&body) such as\\nmouse, mt. or rabbit hav&ng the des&red specific&ty, affinity,\\nand capacity. In some instiu&ces, F& I\\'ramev\\'ork reg&mt (FR)\\nresidues of the hmnan inununoglobulu& are replaced by cor-\\nrespond&ng non-human res&dues. Furthermore, the human-\\nized m&t&body may comprise residues thai are found neither u&\\nthe recipient antibody nor in the imported C DR or framework\\nsequcnccs, but arc included to furtlmr refine and optimize\\nantibody perfonnance. In general. the humanized antibody\\nwill comprise substantially all of at least one, and typically\\ntwo. variable dmnains. in && hich all or substantially all oi\\'he\\nCDR reg&ons correspi&nd lo those o I\\'a non-human unnn&no-\\nglobulin and all or substantially all ofthe FR regions are those\\nof a human immunoglobulin consensus sequence The\\nhuman&zed antibody optimally also w&11 comprise at least a\\nportion of an imnnu&oglobulin consmnt region or domain\\n(Fc), typically that ofa luunan immunoglobulin. Preferred are\\nantibodies having Vc regions mod&fied as described u& WO\\n99/58572. Othm fonna of hmnanizixI nntibodics have one or\\nmore CDRs (CDR L i. CDR L2, CDR L3. CDR I I I. CDR 1 12.\\nand/or CDR H3) which are altersxI w ith respect to the original\\n\\n\\x0cUS 8,080,243 B2\\n\\nmitibody. which are also termed one or morc Cl&Rs \"derived\\nfrom\" one or more CDRs from the oriynal antibody.\\n\\nAs used herein, \"human antibody\" means an antibody hav-\\ning an mnino acid scqucncc corresponding to tlu&t of an anti-\\nbody that can be produced by a human and/or which has been s\\nmade using any ofthe teclmiques for making Inunan antibod-\\nies known to those sloiled in the an or disclosed herein. This\\ndefinition of a lnunan antibody includes antibodies compos-\\ning at least one human hcavy chain polypeptide or at least onc\\nhunt ut light chain polypepude. One such example is an anti- ui\\nbody comprismg nninne light chain and human heavv clmin\\npolypcptidcs I lumen mitibodies can bc pmduccd using ven-\\nous teciuuques intown in the art. In one embodiment, the\\nlnunmi antibody is scicctcd from a phage library, where tlmt\\nphage library expresses human mitibodies (Mmighan et nl .\\n1996. Nature B iotechnoloay. 14: 309-314; Sheets et al., 19(J8,\\n(IJSA) 95:6157-6162: Hoogcnboom\\nProc. Natl Acad. Sci\\nand Winter, 1991, .1. Mol. Bml,, 227:381: Mnrks et al.. 1991.\\nJ. Mol. Biol., 222 581). Human antibodies cmi also be made\\nby immunira1ion of aninials into which bun(an immunoglo-\\nbulin loci have been trmisgenically introduced in place of the\\nendogmiom loci, e.g., mice in which the endogenous inumi-\\nnoglobulin enes have been partially or completely uiacti-\\nvated. This approach is des cubed in U.S. Pat. N os. 5,545,807;\\n5,545,80(i: 5,569,825, 5,(i25,126; 5,633.425; and 5,661,016&\\nthe lnunan antibody &nay be prepared by\\nAlternatively,\\nimmortalizing lmnmn B lymphocytes that produce an anti-\\nbody (irected against a tar et antigen (such B lymphocytes\\nmay be recovered from an individual or may have been immu-\\nniz(d in vitro) Scc, e g, Cole et al Monoclonal Antibodies io\\nand Cancer Therapy Alan R. I isa, p. 77, 1985. Boerner et al,\\n1991. J. Inuuunol., 147 (I):86-95: and U.S. Pat. No. 5,750,\\n373\\n\\nio\\n\\nA \\'*vanable region\" of an antibody refers to the vera&hie\\nregion ofthe antibody light chain or the variable region ofthe \"»\\nantlb(xlv heavv\\'fraul, el&be( alone or u1 co&nbinatlon As\\nknown ut the a&t. the venable regions of the heavy and light\\nchain each consist of f(iur fmmework regions (FR) connected\\nby three complementarity determining regions (C\\'DRs) tlmt\\ncontain hypervariable regions. The ( DRs in each chain are so\\nlmld togetlmr in close proximity by tlm FRs and, with thc\\nCDRs from the other chain, contribute to the fomiation ofthe\\nantigen-binding site of antibodies. There are at least two\\ntechniques for determining CDRs: (I) an approach based on\\ncross-species\\nSequences of Vroteins of Immunological Interest, (5th ed.,\\n1991. National Institutes of I iealth. Bethesda Md.)k and (2)\\nan approach based on c&ystalloyaphic studies of antigen-\\nantibody complexes (Al-lazikani ei al, 1997, I Molec Biol\\n273:927-948). As used herein. a CDR may refer to CDRs\\ndefined by either approach or by a combination of both\\napproaches\\n\\nsequence vanability (i.e., Kabat\\n\\nal. 4.\\n\\net\\n\\no\\n\\nAs known in the art u \"constmit re@on\" of an antibody\\nrefers to dw. constant region of the antibody light chain or tlm\\nconstant region ol\\'the mtibody heavy cluiin, either alone or in\\ncolllbination.\\n\\n1\\n\\nAs used herein. thc tcmi \"PCSK9\" refers to any formoi\\'CSK9and vanants thereol\\'hat retaui ai least part of the\\n\\nactivity of PCSK9 Unless indicated differently, such as by\\nspccilic refcrmicc to human PCSK9. P(\\'SK9 includes all ni\\nmanunaiian species of native sequence PCSK9, e.g., human.\\ncanine, feline, equiim, mid bovine. Onc exemplary human\\nPCSK9 is found as Un&prot Accession Number QSNBP7\\n(SLQ ID NO:16().\\n\\nAs used lmrein, a \"PCSK9 mitagonist\" refers to an anti-\\nbody. pepude. or aptamer that is able to inlubit PCSK9 bio-\\nlogical activity and(or downstremn patlnvay(sj mediated by\\n\\n&\\n\\n10\\nV( SK9 signaling, including PCSK9-mediated down-regula-\\ntion of the LDLI&, and PCSK9-mediated decrease ui LDL\\nblood clearance. A VCSK9 antagonist antibody encompasses\\nantibodies that block, antagonize, suppress or reduce (to any\\ndree including significantly) PCSK9 biological activity,\\nincluding downstream pathways mediated by PCSK9 signal-\\nuig. such as I,DI R uiteraction andior elicitation of a cellular\\nresponse to PCSK9. For purpose of the present uivention. &t\\nwill be explicitly understood that the tern& \"PCSK9 antago-\\nmst antibody\" encompasses all\\nthe previously identified\\nstates and clmracteristics\\nterms.\\nv, hereby the PCSK9 imvli. a PCSK9 biological act&Cloy (in-\\ncluding but not hmited to its ability to mediate any aspect of\\ninteraction with the I JJI.R, down regulation of I DI.R, and\\ndcmrexsed blood LDI. clearance). or the conscxluences ol\\'he\\nbiological activity, are substantially nullified, decreased, or\\nneutralized in any nieaningful degree In some embodiments,\\na PCSK9 uttag(mist mitibody buids PCSK9 and preven1s\\ninteraction with the LDLR. 1)xampfes of VCSK9 antagonist\\nalulbodlLs are provided bc&el&1\\n\\ntitles, and functional\\n\\nAsusedhereina\\n\\n\"fullanta onist\"isanantagonistwhich,at\\nan eifective concentmtion, essentially completely blocks a\\nmeasurable effect of PCSK9. By a partial mits omst is meant\\nan antagonist tltat is capable of partmlly blocking a measur-\\nable eifect, but that, even at a hivhest concentration is not a\\nii&11 antagomst. By essentially completely is meant at least\\nabout 80%. preferably, at least about ()0(%(s more preferably, at\\nleast about 95%, and most preferablv, at least about 98% or\\n99% of the measurable effect is blocked. The relevant \"mea-\\nsurable cfii:cts\" arc dcsscribmi hcrcin mid include down regu-\\nlation of I.DI.R by a PCSK9 antagomst as assayed in Huh7\\ncells in vitro, in vivo decrease in blood (or plasma) levels of\\ntotal cholcsn.\\'rol and ill vlvo dcclcasc ln I.DI, ICYLL( ill blood\\n(or plasma).\\n\\nAs usLVI herein. tlm term \"clinically meaningful\\'* means at\\nleast a 15% rcdiuction in bio&xi I,DI,-cholesterol levels in\\nh&unans or at least a 15% reduction ui total blood cholesterol\\nin mice It is clear that mcasurcmcnts in plasina or senim can\\nserve m surrogates I\\'or nicasuremmit of levels in blood\\n\\nAs usLVI herein, the term \"PCSK9 antagonist peptide\" or\\n\\'PCSK9 antagonist aptamer\" includes any conventional pep-\\nnde or polypeptide or aptamer that blocks, antagonizes, sup-\\npresses or reduces (to any degree including sigotificantly)\\nPCSK9 biological activity, including downstrcnm pathways\\nmediated by VCSK9 sig(&Cling, such as LDLR interaction\\nand(or elicitation of a cellular response to i(CSKO. IK\\'SK9\\nantagoiust peptides or polypeptides include I c fusions com-\\nprising the LDLR and soluble portions of the LDLR, or\\nmutants thereol\\'with higher ailimty to P( SK9\\n\\nThe terms \"polypeptide\". \"ohgopeptide\", \"peptide\" and\\n\"protein\" are used intercliangeabiy herein to refer to elmins of\\namino acids of any length. preferably, relatively short (e.g,\\n10-100 iuruno acids). 11&e clmin may be linear or branched. &t\\nniay comprise modified aniino acids, and/or may bc inter-\\nrupted by non-amino acids The terms also encompass an\\namino acid chain that has been modified naturally or by\\nintcrvmition, for example, disuliide bond liinnation, glyco-\\nlip&dation. acetylatmn. phosphorylation. or uiy\\nsylation.\\nother manipulation or modification, such as conjugation with\\na labeling component Also inc iud(d withui thc dclinition arc,\\nfor example, pc l)3(Opt&des containing one or more ana logs of\\nan amino acid (including, for exnmple, unnatural amino\\nacids. etc ), as well as other modiiications known in the an. It\\nis understood tlmt the polypeptides can occur as single chains\\nor associated chains\\n\\nAs loiov;n in the art, \"polynucleotide,\" or \"nucleic acid,\" as\\nused interchangeably herein, refer to chains of nucleotides of\\n\\n\\x0cUS 8,080,243 B2\\n\\nI\\n\\nwly length. and include DNA and RNA The nucleotides can\\nbe deoxyribohhuclcothdes, ribonucleotldes, modified nucle-\\notides or bases. and/or their ana logs. or any substrate that can\\nbc incorporatcxl into a chain by DNA or RNA polymcrase. A\\npolynucleotide may compnse modified nucleotldes, such as\\nmethylated nucleotides and their analogs. If present. modifi-\\ncation to the nucleotide structure may be imparted before or\\nafter assembly of the chain. The sequence ofnucleotldes may\\nbe uucmipted by non-nucleotide components A polynucle-\\notlde may be further modified after polymerization, such as ni\\nby conjugation with a labeling component. Other types of\\nnllxiificmiOns inClude. for example. *\\'caps\\'*. substiuition ol\\none or more of the naturally occurnng mlcleotides uith an\\nwlalog, intcrnuclcotide modificarions such as. I\\'or example,\\nthose 111th uncharged hnkages (e g.. methyl plmsphonates.\\nplmsphotriesters, phosphoamidates. carbamates, etc.) and\\nwith charged linkages (e g., phosphorothioates, phospho-\\nroditlnoates, etc ). those contauung peudmit moieties, such\\nas, for example, proteins (e.g., nucleases, toxins, antibodies.\\ns~gnal PePtidcs. Polv-l.-lyslnL. i\\'Ic ), Ihosi: with lillLlcilliltol\\'s so\\nthose containing chelators\\n(e.g., acridine, psoralen, etc.).\\n(c.g.. metals, mdioactive metals, boron. Oxidative metal~,\\netc.), those contaimn alkylators. those with modified luik-\\nages (e.g.. alpha anomeric nucleic acids, etc.). as well as\\numnodified fonna of tlm polynucleotide(s). Further, any of \"\\nthe hydmxyl youps ordlnartly present in the sugars may be\\nreplaced. for exmnple, by phosphonate woups, phosptmte\\ngrolips, prohccIPLI by sIBlxlald prtllcctnlg gl\\'oops, oh\\'lctlvaIPd\\nto prepare additional hnkages to additional nucleotides. or\\nmay bc conjugated to solid supports. Thc 5\\'nd 3\\'erminal\\nOII can be phosphorylated or substitutsxl 111th amiues or\\norgaruc capping group moieties offrom I to 20 carbon atoms.\\nOther hydroxyls may also bc derivatil,cd to standard protect-\\nuig groups. Polynucleotides can also contain analogous\\nfortns of ribose or deoxyribose sugars that nre gmlemliy \"»\\nknou n in Ihc arL including„ for example, 2n0-methyl-. 2u0-\\nallyl. 2uthioro- or 2uazido-ribose. carbocychc sugar uialogs,\\nalpha- or beta-anonmric sugars, epinwric sugars such as am-\\nbuiosc, xyloscs or lyxoscs. pyr Bio st.\\'ugal s. fwalulsc sugals,\\nsedoheptuloses, acyclic analogs and abasic nuclsmiside ana- sc\\nlogs such as methyl riboside. One or morc phosphodiester\\nlinkages may be replaced by alternative linking aroups. These\\nalternative linking groups include, but are not limited to,\\nembodiments lvhcrein phosphate is replaced by P(0)S(\"tbio-\\nate\"). I\\'(S)S (\"dkthioate\"), (0)NRi (\"anudate\"). V(0)R, P(0) 4.\\nOR\\'. (.\\'0 or CHC (\"fonnacetal\\'). in which each R or R\\'s\\nuidependently I I or substituted or luisubstltuted alkvl (1-20\\n(:) optionally containin an ether ( 0 ) hnkage, aryl, alk-\\nenyl. cycloalkyl. cycloalkenyl or araldyl. Not all hnkages in a\\npolynucleotide need be identical. The preceding descnptlon c\\napplies to all polynucleotides referred to herein. including\\nRNA and DNA\\n\\nso\\n\\nA \"PCSK9ants onlstaptamer,\"wluchcomprisesamicleic\\nacid or pmtein sequence. is, for example, selected from a\\nlarge pool of rwidom sequences and specifically binds\\nVt SK9. I\\'he nucleic acid of the aptamer is double-stranded\\nDNA or single-strmid RNA Nucleic acid aptwncrs can\\nuiclude moditied bases or functional groups, uicluding but\\nnot limited to 2ufluorine nucleotides and 2LO-methyl nucle-\\notidcs Aptamcrs can include hydrophilic polymers.\\nexample, polyethylene glycol. Aptamers may be made by\\nmethods known in the art and selected for Vt SK9 antagonist\\nacuvity by routine modification of the methods ihsclosed in\\nthe Examples.\\n\\nI\\n\\nfor ai\\n\\nAs hhssxf herein, an mltibody, peptide, or aptahucr \"interacts\\nwith\" PCSK9 when the equilibrium dissociation constant ls\\nequal to or less titan 20 BM, preferably less than about 6 BM,\\n\\nr\\n\\n12\\nmorc prefcmbly less than about 1 nM, most prcti.rably less\\nthan about 0.2 nM, as measured by the methods disclosed\\nherein in Example 2.\\n\\nAn epitope that \"prefcrcntially binds\" or \"specifically\\nbuids\" (used ulterchangeably herein) to an antibody or a\\npolypeptide is a tenn ii el 1 understood in the art. and methods\\nto deiernune such specdic or preterentud binding are also\\nwell known ln the art. A molecule is said to exlublt \"speci bc\\nbinding.\\'r *\\'pret\\'Lrential binding*\\'t\\'t reacts or associates\\nmore frequently. more rapidly, uith greater duration and/or\\nwith yester affiiuty with a particular cell or substance than it\\ndoes with altcrnatilw cells or substances An antibody \"spe-\\ncifically bulds\" or \"preferential ly binds\" to a target lf it buids\\nwith greater atfinity, avidity, more readily, mid/or with greater\\nduration Ihnn il binds to other substnnces. For ex uuple. Wi\\nantibody that specificallv or preferential ly binds to a I\\'(.\\'SK9\\nepitopc is an antibody that binds this epitope with greater\\nafiimty, avidity. more readily, and/or lvith grwiter duration\\nthan it binds to other V( SK9 epitopes or non-p(.\\'SK9\\nepitopcs. It is also understood by reading this definitiml that,\\nfor example, an antibody (or moiety or epltope) that specif-\\nicall or preferentially binlLS to a first target may or may not\\nspecifically or preferentially bind to a second target. As such,\\n\"specific binding\" or \"preferential binding\" does not neces-\\nsarily require (although it can include) exclusive binding.\\nGenerally. but not necessartly. reference to binding means\\npreferential binding.\\nAs usexf lmrein,\\n\\n\\'*substantially pure*\\'efi:rs to matertnl\\nuhich is at least 50% pure (i.e.. free from contaminants),\\nmorc preferably, at least 90% pure„morc prefi:rably. at least\\n95% pure. yet more preferably, at least 98% pure. and most\\npreferably, at least 99% pure.\\n\\nA \"host cell\" includes an individiwl cell or cell culture Ihat\\nc m be or has been a recipient for vector(s) for incorporation\\nof polynucleotide inserts. Host cells include progeny of a\\nsingle host cell mid the progeny may not necessartly be\\ncompletely identical (in morpholog) or ui genonuc DNA\\ncomplement) to thc original parent cell due to natural. acci-\\ndental. or deliberate mutation A host cell mcludes celL~ trwis-\\nfected in vivo with a polynucleotide(s) of tllis invention.\\n\\nlnstlmtes of\\n\\nAs know n in the art. rim term \"Fc region\" is used to dctinc\\na C-ternunal region of an utuuunoglobulin heavy clmsln. The\\n\\'Fc region\" may bee native scsquence Fc region ore variant Fc\\nfcgl 011. Although hie boundaries ofthe Fc region ofan imnni-\\nnoglobulul heavy chain might vary, the human IgCh heaiq\\nchain Fc region is usually defined to snatch from ml amino\\nacid residue at position Cys226, or from Pro230. io the car-\\nboxyl-terminus thereof. The numbering of the residues in the\\nFc region is that of Ihc FIJ index as in Kabat Kabai et al,\\nSequences of Proteuis of Immunological Interest, 5th Ed.\\nI\\'ublic Ifealth Service. National\\nlfealth,\\nBethesda Md, 1991 The Fc region of an immunoglobului\\nenemslly comprises two constant domains. CI12 and CII3.\\nAs used in tlw art, \\'Fc receptor\" and \"FcR\\'* describe a\\nreceptor that binds to the Fc re ion ol an uitibody. The pre-\\nferred FcR is a native sequence lnuuml FcR Moreover, a\\nprcfcrrel FcR is onc which hinds an I (i antibody (a gmnma\\nreceptor) and includes receptors of the Fcyki, FcyRII. aod\\nFc/RIII subclasses. including allelic variants and altcma-\\ntivcly spfhCLXI Iorms of thisC reCeptnr. FcyRH recLPIors\\ninclude FcykllA (an \"activating receptor\") and FcykllB (an\\n\\'itdfibiting receptor*\\'). which have similar amino acid\\nsequences that hhtfer prunarily in the cysoplashuic domains\\nthereof. Fcks are reviewed in Ravetch and Kinet. 1991, Ami.\\nRcv. hnnuinol.. 9457-92,\\nImnni-\\nnomethods. 4:25-34: and de 1 lass et ul.. 1995. J. Lab. Clin.\\nMed.. 126:330-41. \"Fck*\\'lso includes the neonatal receptor,\\n\\nI apcl et al..\\n\\n1994.\\n\\n\\x0cUS 8,080,243 B2\\n\\n13\\nFcRn, which is responsible for the transfer of mnternal IgCis\\nto the fetus (Ciuyer et al.. 1976 I. Inuminol., 117: SS7; and K&m\\net al.. 1994, .l. Inununol.. 24:249).\\n\\nn&\\n\\nThe term *\\'compete*h as used hcrcin with regard to an\\nant&body. means that a first antibody. or an antigen-buid&ng s\\nponion thereof, binds to an epitope in a manner sufficiently\\nsinular to the b&nd&ng of a second antibody. or a» u&ugen-\\nb&ndm portion thereof. such tlmt the result of binduig of the\\nfirsl m&nbody u ilh ics cognate epitopc is dclcclnbly do:re&i&md\\n&a the presence of the second ant&body compared to the buid-\\n&ng ofthe first antibody in the absence ofthe second antibody.\\nThe altcmative. where thc binding ol the second anlibixly n&\\n&ts epitope &s also detectably decreased in the presence of the\\ntirst antibody, cnn, but need not be the case Thnr is, a tirst\\nanl&body can udiibil lhe binding of a svcond antibody lo ils\\nepitope u:ithout that second antibody inhibiting the binding of\\nthe first antibody to its respective cpitopc. However, where\\neach antibody detectably inlnb&ts the binding of the other\\nm&tibody with its cognate epitope or ligand, whether to the\\nsame, grcalcr. or lesser oxtcnh tlm antibodies are snid to sc\\n\"cross-compete\" v;ith each other for bind&ng of their respec-\\ntive epitope(s). Both competing and cross-competing anti-\\nbodies are encompassed by the present invent&on. Regardless\\nof the meclianism by &vhich such competition or cross-com-\\nsteric hindrance, confonnational\\npetition occurs\\nchange, or bind&n to a conunon ep&tope. or port&on thermA,\\nthe skilled art& san would appreciate, based upon the teachings\\nprovided here&n. that such compeung and/or cmss-competing\\nant&bodies are encompassed and can be useful for the meth-\\nods disclosed hcrcin.\\n\\n(e.g,\\n\\n\"(1\\n\\n\"\\n\\nBy an mu&body with an c7&tope that *\\'overlaps*\\'v&th\\nanother (second) ep&tope or iv&th a surface on PCSK9 tlmt\\ninteracts with the FCiF-bkc donuiin of the I.DI,R is meant lhc\\nshanng of space in tern&a of the PCSK9 residues that are\\ninteractcd with. To calculate the percm&t of overlap. for \"»\\ntlm percvnt overlap of ibe claimed m&t&body*a\\nexample,\\nPCSK9 ep&tope w&th the surface of PCSK9 uhich interacts\\nwith thc HiF-like domain of tfm I,DI R, thc surface area of\\nPC\\'SK9 buried when in complex u ith the I DI R is calculated\\non a per-residue basis. \\'Bie buried area is also calculated for sc\\nthese residues in the PCSK9 nntibody complex To prevent\\nmore than 100% poss&ble overlap. surface area for residues\\nthat i&ave hind&er buried surface area in the FCSK9:antibody\\ncomplex thm& in I,DLR PC\\'SK9 con&plex is sel to values from\\nthe LDLR:PCSK9 complex (100%). Percent surface overlap 4.\\nis calcu latcxl by sununing over aff of thc LDI,R:PC\\'SK9 inter-\\nact&ng residues u&d is v, eig&ed by the uiteraction ares.\\n\\nA \"functional Iic region\" possesses at least one effector\\nI\\'unction ol\\'a native sequence Fc region Fxen&phuy \"elT&wtor\\nfiu&ctions*\\'include Clq hindu&g,complement dependent cyto-\\ntoxicity; Fc receptor binding; ant&body-dependent cell-medi-\\nated cytoloxicity: pluigocytosis, down-regulation of cell sur-\\nface receptors (e.g., B cell receptor), etc. Such effector\\nfunctions genernl ly rcquirc thc Fc region to bc combined with\\na bindn&g domai»(e.g, ananubody vnriabledomau&) andean\\nbe assessed using vnrious assays kno&vn in the art for evalu-\\nating such antibody effi.ctor functions\\n\\nu\\n\\ns\\n\\nA \\'native sequence Tc region*\\'ompnses mi amu&o amd\\nsequence idm&tical to tlm amino acid scequm&cc ofan Fc region\\n1\\'om&d in imturc A \"vanmu Fc region\" comprises ail a&stille s&1\\nacid sequence wh&ch differs from that of a native sequence Fc\\nregion by virtue of at least one nmino acid moditication, yet\\nretains at least one effector h&ncnon ofthe native sequence Fc\\nrey\\'on. I\\'referably. the variant Fc region has at least one amino\\nacid substitution con&pared to a native sequence Fc region or r\\nto the I\\'c reg&on of a parent polypeptide. e.g.. from about one\\nto about ten amino acid substin&tions, m&d preferably, from\\n\\n14\\nabout one to about five mnino acid substitutions in a native\\nsequence Fc region or in the Fc region of the parent polypep-\\nt&de. The vanant I\\'c reg&on herein w&ll prefemsbly possess at\\nlmcst abiiul g0\\'is sequence identity u ilk a native svquence Fc\\nregion mid/or with mi Fc region ol\\'a parent polypepiidc, and\\nmost preferablv. at least about 90% sequence identity there-\\nu&tin more prefemsbly. at least about &95%. at least about 96%,\\nat least about 97\"!u at lemst about 9g%. at least about 99bv\\nsequence identity therewith.\\n\\nAs used herein. \"treatment\" is an approach for obtai&ung\\nI&or purposes of this\\nbenefic&al or desired ch&ucal results.\\ninvent&on. bencticial or desired clu&ical resulcs include, but\\nare not limited to, one or more ofthe folio&& ing: enhancement\\nof LDL clearance and reducing incidence or mnelioration of\\naberr uit cholesterol and/or lipoprotein levels resultu&g from\\nmetabolic m&d/or cating disorders. or including I\\'amilial\\nhypcrcholesterolemia, athcrogenic dyslipidemia, atlmrosclc-\\nrosis, and, naire generally. cardiovascular disease (CMD).\\n\\n**Reducu&g mmdence\" means any of reducuig severity\\n(which can utclude reducing iuwd for and/or ammmt of (e g.,\\nexposure to) other drugs and/or therapies generally used tiir\\ntlus condition. As &s understood by those skilled u& the art,\\nind&viduals may vary in terms of their response to treatment,\\nand, as such, for example. a \"nmthod of reducing\\n\\nincidence*\\'etlectsadmuustenng the PCSK9 ants onist annbody, pep-\\n\\nt&de. or aptamer based on a reasonable expectat&on that such\\naihmni ~ t ration may l&kely unuse such a reduction in me&dence\\nui that part&cular ind&vidual.\\n\\nlo ilol\\n\\n*\\'Ameliorating*\\'eans a lcsscning or improvement of onc\\niir nlore sv\\'&lip&ellis as co&i&pareil\\na\\nPCS K9 antagon&st antibody. peptide. or ap tamer. \"Amel&orat-\\ning\\'* also includes shortening, or rnluction in duration of a\\nsymptom.\\n\\nail&i&i&i&slat&i&\\n\\nAs used herein, an \"effi:ctive dosage*\\'r \"cffi:ctive\\namoum\" ol\\'drug. compound, or pharmaceutical compositmn\\n&s an amount sutlic&ent to effect uiy one or more beneficial or\\ndcsircxf results. For prophylactic use, bencticial or desired\\nresults u&elude eliminating or reducing tbc nsh, lessening thc\\nseverity, or delaying the outset of tl&e disease. including bio-\\nclmmical, histological ancUor behavioral symptoms ul\\'lm\\nd&sense, its compl&cat&ons and &ntermedmte pathological phe-\\nnotypes presenting during development of the disease. For\\ntherapeutic use, beneficial or dcaimd results include clinical\\nresults such as reducing hypercholesterolemia or one or more\\nsymptoms of dyslipidemia, atherosclerosis. I\\'irlk or coro-\\nnary heart disease, decrees&ng the dose of other med&cations\\nrequired to treat the disease, enhancing the efTect of another\\nmed&cat&on, and/or delaying lhe progression of&he disease\\n\\nol\\'atients.An effective dosage cmi be ad&u&mater&xf &n one or\\n\\nmore administmtions. For purposes of this invention, an\\neffeclive dosage of dn&g. compound, or pharmaceutical com-\\nposiuon is iu& amount sufficient to accomplish prophylact&c or\\nthempeutic treatment either directly or indirectly As isundcr-\\neffect &ve\\nu& eti\\'ective dosage of a drug,\\nstood in the clinical context.\\ncompound. or pharmaceutical composition may or may not\\nbe achieved in cmfilunction u i&h m&other drug, compomid. or\\nphannaceutimd composition. Thun ui \"ell\\'ecuve dosage\"\\nmay be considered in the context of administering one or\\nmorc therapeutic agents. and a smgle agent may be consid-\\nered to be g&ven in an\\namoiuit & f, in conjunct&on with\\nonc or more other ngents. a desirable result may be or is\\nachieved.\\n\\nAn \"individual\" or a \"subject\" is a manunal, more prefer-\\nably. a luunan Mnnm&als also include, but are not limited to,\\nfarm an&mals. sport anunals. pets, pnmates, horses, dogs.\\ncats. mice and rats.\\n\\n\\x0cUS 8,080,243 B2\\n\\n15\\n\\n16\\n\\nAs uscxI\\n\\nlmrcin, \"&veto&\" nwans n construct, which is\\ncapuble of del&venng. and. preferably. expressing, one or\\nmore gene(s) or sequence(s) of interest\\nin a la&st cell.\\nFxan&ples of vsictors include, but arc not limited to, viral\\nvectors. ooked DNA or RNA expression vectors. plasmid,\\ncosmid or phage vectors. DNA or RNA expression vectors\\nassocuued with cationic condensing a ants. DNA or RNA\\nexpression ~actors encapsulated in liposomes. and certain\\neukaryotic cells, such as producer cells\\n\\nAs used herein. \"expression control sequence\" means a\\nnucleic acid sequence that directs transcnption of a m&cleic\\nacid An expression control svqumiee can bc a promoter. such\\nas a constitutive orat& inducible pmmoter. or an enhancer. The\\nexpression control sequence is opembly linked to the nucleic\\nacid svquence to be transcribed\\n\\nsubject \\'s\\n\\nAs used herein. \"plmrmaceutically occeptable carrier\" or\\n*\\'phanuaccutical acceptable excipient\\'* includes any n&aterial\\nwinch. &shen comb used with mi active &ngredi ant, allows the\\ningredient to retain biological activity and is non-reactive\\nwith the\\nin&mune systmn. Fxamp les include, but orc\\nnot limited to, any of the standard pharmaceutical carriers\\nsuch as a phosphate bufferixI saline solution. water. emulsions\\nsuch as o&l/water emulsion, and various types of &vettut\\nagents. Preferred d&luents for aemsol or parenteral adnunis-\\ntration ore phosphate buffered saltlm (PI)S) or normal (0 9%n)\\nsaline. Compositions comprising such carriers are fornn&lated\\nby well known conventional methods (see. for example. Rem-\\nuigto&i\\'s Pharmaceutimd Sciences. 18th edition. A Gem&aro.\\ned., Mack Pubhslung Co.. L\\'aston. Pa.. 1990: and Remington,\\nThe Science m&d Pmctice of Plmrmacy, 20th Fd „Mack Pub-\\nlisluog. 2000)\\n\\nTl&e tenn \"K„„\". as used herein, refers to the rate constant\\nI\\'or association of an muibndy to on \\'mtigen Specilicnlly, thc\\nrate constants (k„, and k.y) md eq&ulibuum dissociation con-\\nstants are measured using~ Fab antibody fmgmmits (i.e, uni-\\nvoiel&t) aud P( SK9.\\n\\nThe term \"k,f\\'2 as used herein. refers to the rate constmtt\\nfor dissociation of an m&tibody fron& the antibody/antigen\\ncol&&plex\\n\\n\\'lite tern& \"Kr\", as used herein. refers to the eqmlibrnuu\\n\\ndissociation constant of m& antibody-antigen interaction\\n,A. Methods for Preventing or Treating Disorders Associated\\nwith Hypercholesterolemia\\n\\nIn one aspect. the invention provides a nmthod for treating\\nor preventing hypercholesterolenna. and/or at\\nleast one\\nsymptom of dyslipidemio. atherosclerosis. (\\'VD or coronary\\nheart disease. u& an u&dividual comprising adnunistering to\\nthe individual an effective amount of a PCSK9 antagonist\\nantibody nr peptide or aptmucr tlvu antagonizes circuloiing\\nPCSK9.\\n\\nIn a t\\'urther aspect, the imention provides an effective\\namnunt of a PCSK9 antagonist antibody. peptide. or apiamer\\nthat ants oiuzes c&rculat&n PCSK9 for use in treatin or\\npreventing hypercholestcrolemia, and/or at least one symp-\\ntom of dysl&p&demia, athemsclerosis, CVD or coronary heart\\ndisease. in an individual. The invention further provides the\\nosv. ol\\'an e(Tcetive muoont of a P(.SK9 antagonist antibody.\\npepude. or ap tamer that antagomzes extracellular or circulat-\\ning PCS K 9 in the manufacture ofa medicament fnr treating or\\nprevm&ting hyperchnlcsterolemi i, and/nr at lmist nnc symp-\\ntom of dyslipidemia, atherosclerosis, CVD or coronary heart\\ndisease. in an individual.\\n\\nAdvantageously, therapeuuc odmuustration of the ann-\\nbody. peptide. or optamer results in lower blood cholesterol\\nm&d/or lower blond I,DI Preferably, blrxid cholesterol mid&or\\nblood LDL &s ot least about 10% or 16%a lower than befnre\\nadministration. More preferably, blood cholesterol andcir\\n\\nis at least about 20% lower than bcf&ire adminis-\\nblood I,I/I\\ntration ofthe antibody Yct more preferably, blood cholesterol\\nand/or blood LDL is at least 30% lower than befnre a&hnin-\\nistration of ibe &u&tibndy. Advantageously. blood cholesterol\\nand/or blood I,DI is a& lmist 80% lower than be(i&re o&huin-\\nistration of tine antibody. More advantageously, blood cho1es-\\nteml and/or blood LDL is at least 60% lower than before\\nadm&mstration of the antibody. Very preferably, blood cho-\\nlesterol ond/or blood LDL is ot least 60% le&vcr tlmn betiirc\\nadm&nistmntion of the antibody. Most preferably. blood cho-\\nlesterol ond/or blood LDL &s at least 70&/8 lower than before\\nad&a&ala&ration of the mtibody\\n\\n&&1\\n\\nWith respect to all methods described herein, reference to\\n, PCSK9 antagonist antibodies, peptides, and aptamers also\\nuiclude compositions compris&n one or more additional\\nagents Tlmsc compositim&s moy fintlmr comprise suitable\\nexcipients, such os plmrmaceutically acceptable excipients\\nincluding buffers, wluch are well knov;n ui the ait. The\\nn present invention ran be used alone or &n combi&rntion with\\n\\nother conventional methods of treatment\\n\\nThe P(JSK9 antagonist antibody. peptide, or aptamcr can\\nbe a&bnimstered to an u&C&vidual via any suitable route. It\\nshould be apparent to a person skilled in the on tint the\\nexamples Ccscribcd herein are not intended to be limiting but\\nto be illustrative of the tecluuques ac ulable. Accordingly. ui\\nsome embodiments, the I\\'(\\'SK9 antagonist antibody, peptide,\\nor optamer &s adm&ni ~tered to an individual ui accord &&ith\\nknown methods. such as &ntmvenous a&hn&n&stration. e... as a\\nsn holus or by mmtinunus inl\\'usion over a period of tinm, by\\n&nuamuscular. mtraperitoneal, &ntracerobrospu&al. uansder-\\nintrasyn-\\nmal, subcutaneous. &ntmn-articular, subhnguolly,\\novial. via insufflation, intmthccal, &mil, inhalatim& or &opicol\\nmutes. Ad&ouzo&rat&on can be systemic, e.g., us&ravenous\\n\"» administration, or localized. Conuneiciolly available nebu-\\nhzee\\'or bquid fom&ulations, including jct ncbuli!ers and\\nultrasonic nebul&zers are usefi&1 for admimstmnt&on. Liquid\\nf&irmulations can be directly nebulized and lynphilizcd pow-\\nder cun bc nebuli!ed alter reconstitutim& Alternatively,\\nsn I\\'(\\'SK9 antagonist antibody. peptide. oraptamer con be aero-\\nsnli!ed using a fluorocarbon fnnnulation and a metered dose\\nuihaler. or uilialed as a lyophilized and nulled powder.\\n\\nIn one embodiment, o P(\\'SK9 antagonist antibody, pep-\\ntiCe. or aptan&ur is administered via site-spccilic or targeted\\nlocal delivery techniques. Examples of site-specific or tor-\\ngetixI local delivery techniques include varinus implontable\\ndepot sources of the PCSK9 antago&ust antibody. peptide. or\\naptamer or local delivery catheter~. such as mfu sion catheters,\\nindwelling catheters. or ncvdle catheters. syntheuc grafts„\\nn advennt&al wraps. shunts and stents or other &mplontable\\ndevices, site specific carriem, direct in)ection, or direct appli-\\ncation See c g., PCT Publ No. W000/63211 andi).S Pot.\\nNo. 5.981,668.\\n\\nVarious liinnulotions nf a PCSK9 antagonist antibody,\\ns peptide. or optamer may be used for administration In some\\nembodiments, the P(\\'SK9 antagonist antibody. peptide, or\\nIn sonw. embodiments,\\naptamcr nt 9 bc administered neat\\nPCSK9 antagonist u&tilxidy, peptide. or apt uner mtd a phar-\\nmaceutically acceptable cxcipient may be in various formu-\\nro latmns Pharnraceutically acceptable cxcipients are known m\\nthe a&t. and are relatively inert substances tint facihtate\\nadministration of a pharmacologically effective substance.\\nI\\'or exmnple, an exc&pient can give fomi or consi stency. or act\\nas o diluent. Suitable excipients include but are not hmited to\\nstabilizing agents, wcuing and emulsifying agm&ts, salts f&ir\\nvarying os&nolo&sty, encapsulating agents. butTers. and skin\\npenetmtion enhancers. Fxcipients as well as formulations for\\n\\n\\x0cUS 8,080,243 B2\\n\\n17\\nparenteral and nm&parcnteral dnig delivery are set le&th in\\nRmuington, The Science and Vmctice of Phamiacy, 20th L\\'d.,\\nMack Pubhshing (2000).\\n\\nThese agents can be cou&bh&e»I\\n\\nivith phannaccuiically\\nacceptable vi:hiclcs such as saline, Ringer\\'s solution, dex-\\ntrose solution. and the like. I\\'he particular dosage regimen,\\n&.e.. dose„ t&m&ng and repetit&on, w&ll depend on the part&euler\\nnuliv&dual and thnt u&div&dual\\'s med&cal lustory.\\n\\nPCSK9 antibodies can also bc adn&inistered via inhalation,\\nas descnbed hereu&. Generally, for administration of PCSK9\\nant&bodies. an iiutial candidate dosage can be about 2 mg/kg.\\nFor the purpose ol\\'the present invention, a typical daily dos-\\nage mice range from about any of about 3 gg/kg to 30 gg/kg\\nto 300 Pg/kg to 3 mg/kg. to 30 u&gvkg, to 100 mg/kg or nlole\\ndepend&ng on the factors ment&oned above. For example.\\ndosave of about I mg/kg. about 2 5 mg/kg, about 5 mg/kg,\\nabout 10 mg/kg, and about 25 mg/kg may bc used. For\\nrepeated admin&strations over several days or longer. depend-\\ning on &he condition. the treatment is sustnu&ed unt&l a desirtnl\\nsuppression of symptoms occurs or until suifiment thernpeu-\\ntic levels are achieved, for example. to reduce blood LDI.\\nlevels. An exemplary dosing regimen comprises adnunister-\\n&ng an iiutial dose of about 2 mgkg, folloiied by a v,eekly\\nmaintenance dose of about I ing!kg of thc PCSK9) antibody,\\nor folio&red by a ma&ntenance dose of about I &ugkg every\\nother week. However, other dosage reg&mens may be useful.\\ndependu&g on the pauern of phanuacok&netic decay &hnt the\\npmctitioner wishes to ac lu eve. I\\'or example, in some embod&-\\nmcntx dosing fmm oim to liiur times a week is conte&»plate»I\\nIn other emboduuents dosu&g once a month or ooce every\\nother month or every three months is contemplated. The\\nprogress of this tlmrapy is easily monitored by conventional\\nteclm&ques and essays The dosu&g rein&en (including the\\nP( SK9 antagonist(s) used) can vary over tinm.\\n\\n&(1\\n\\no\\n\\n\"\\n\\n\"o\\n\\nFor the purpose ol\\'hc pit.\\'Ni:l&t &I&vcl&&101&, tlm appfoplla&c\\ndosage of a PCSK9 antago&ust ant&body. peptide, or aptamer\\nwill depend on tlm PF\\'SK9 m&tagonist m&tibody, peptide, or\\naptamer (or compos&tin&&s the&L00 en&ployexI, &bc type and\\nseverity of symptoms to be treated, ivhether the agent is 4o\\nadministered fitr preventive or themapeuti c purposes, pres ious\\ntherapy. the patient\\'s eh»ical history and response to the\\nagent, the patient\\'s blood V(\\'SK9 levels. the patient\\'s synthe-\\nsis and clearance rate fiir Pf\\'SKR the patient\\'s clem ance rate\\nfor the admin&stered agent, and the discretion ofthe attending 4.\\nphysician I\\'ypically the clinician will administer a V( SK9\\nan&agon&st antibody, pep&&de. or aptamer unt&l a dosage is\\nreached tlmt achieves the desired result. Dose and/or fre-\\nquency ciui vary oivr course ol\\'treauuent I.mpirical consid-\\nemtions. such as the half-l&fe. genemlly v;ill contribute to tire\\ndetermination of the dosage. For example, antibodies that are\\ncompatible with thc human inununc system, such as human-\\nized m&t&bodies or fiilly luunan antibodies, iuay be used to\\nprolong half-life of thc antibody m&d to prevent the antibody\\nbeutg attncked by the host\\'s imnuu&e system. Frequency ol\\'\\nadministration may be determined and adjusted over the\\ncourse el\\'herapy. m&d is generally, but not accessarily, based\\non treatment and/or suppress&on and/or amehoration aud/or\\ndelay of symptoms, e.g., hypcrcholesterolemia. Alterna-\\nlively. sustained contmuous relcasi: fiinuulations of PCSK9 ui\\nantagon&st ant&bodies may be appropriate. 3/ai&ous formula-\\ntions and devices fiir achieving suits inc»I release are known in\\nthe art.\\n\\no\\n\\nIn one embodiment. dosages for an antagonist antibody,\\npeptide, or aptamer may be detcm&ined empirically in indi-\\nv&duels who have been g&ven one or more adnun&stmt ion(s ) of\\nan antagonist antibody, peptide, or aptamer. Individuals are\\n\\n4\\n\\ngiven incremm&tal dosages of a PCSK9 antagonist antibody,\\npepnde. or aptamer. To assess eiiicacy. an &nd&cator of the\\ndisease can be follow ed.\\n\\nAdministration of a P(.\\'SK9 antagomst antibody, peptide,\\nor aptmuer &n accordance w&th the method in the present\\ninvention can be continuous or intermittent, depending, for\\nexample. upon the recip&ent\\'s phys&clog&cal cond&tion,\\nwhether the purpose of the administrat&on is therapeut&c or\\npmphy lactic, and otlier fee airs known to ski l lcd prueutioncrs.\\nThe xhnin&strat&on of a PCSK9 antagoiust anubody„peptide„\\nor aptamer may be essent&ally cont&nuous over a presefected\\nper»id of tmw. or may be in a si:ries ol\\'paced dose~\\n\\nIn some embod&ments. more than one antagoiust antibody,\\npcq&tide, or aptamcr may bc present. At lcasr onc. at least two,\\nat less& three. at least four. at least live dilferenk or more\\nantagonist antibodies nnd/or peptides can be present. (Iener-\\nally, those PC\\'SK9 antagonist nntibodies orpcptidcs n&ay have\\ncomplementary activities that do not adversely alfcct each\\notlmr A VCSK9 m&tagonist antibody, peptide, or aptamer can\\nalso bc used in conjunction with otlmr PCSK9 anuigonisis or\\nVCSK9receptoranta on&sts.forexample.oneormoreofthe\\nfollowing P(JSK9 antagonists may be used: mi ant i sense mol-\\necule directed to a PCSK9 (&nclud&ng mi anti-sense molecule\\ndirected to a nucleic acid encoding P(\\'SK9), a PCSK9 inhibi-\\ntory compound. and a PCSK&J stnicmral analog A P(\\'SK9\\nantagoiust antibody, peptide, or aptamer can also be used &n\\nconjunct&on with other agents that serve to enl&ance and/or\\ncomplement the elfect&veness of the ngents.\\n\\nAcceptable camera. exc&picots, or smb&1&zers are nontox&c\\nto rivipiems a»hc dos~gas and concentrations mnploycd, ilflil\\nmav a»npnse bulIers such as plmsphate, citrate. and other\\norganic acids; salts such as sod&um chloride: ant&oxidants\\nincluding ascorbic acid and methim&inc, prese&vatives (such\\nas octadecyldnnethylbenzyl mnmonium chloride: hexam-\\nethonium chloride: benzalkonium chloride, benzethonium\\nchloride, plmnol. butyl or bcnzyl alwihol, alkyl parabcns.\\nsuch as methyl or propyl paraben: ca tee hob resorcinol: cyclo-\\nhcxanol, 3-pentanol, and m-cresol), low molecular weight\\n(less than about 10 residues) polypeptides, pro&el&&s. si&ch tls\\nsenun albumin. gelatin, or inuuunoglobulins: hydrophilic\\npolymers such as polyvinylpyrrolidone, amino acids such as\\nglyc&ne. glutamu&e. asparagine, lustidu&e, arg&n&ne, or lys&ne;\\nmonosaccharides. disaccharides. and other carbohydrates\\nincluding glucose. mannosc, or dcxtrins, chelating agents\\nsuch as L&DTA: sugars such as sucrose, mann&tol, trehalose or\\nsorbitok salt-fern&ing counter-iona such as sodium; metal\\ncomplexes (e.g.. Zn-prote&n complexes): and/or non-&on&c\\nsurfactants such as T)&/L&LN&», PLL&RONICS\\'u or polyeth-\\nylene lycol (PFG)\\n\\nLiposomes containing the PCSK9 antagon&st ant&body,\\npept&de, or aptamer are prepared by metliods lo&own in the am\\nsuch as described iu Epsteu&. et al.. 1985, Proc Natl. Amid.\\nSc&. IJSA 82:3688; I hvang, et al.. 1980, Pmc. Natl. Aced. Sci.\\nIJSA 77:4030. and IJ.S. Pat Nos 4.485,045 and 4.544.545.\\nI.&posomes with enhanced circulat&on tnne are d&sclosed in\\nI I S. Pat No. 5 013 556. Particularly useful liposomes can be\\ngcneratedi by the reverse plxisc evaporat»m nwthod with a\\nl&pid compos&t&on ci&mpnsu&g phiisphatidylchohne, chiiles-\\nterol and VF,(i-dcrivatizcxI phosphatidylethanolaminc (PHJ-\\nPF) I,iposomes are extruded through tiltcrc ol\\'defini:d pore\\nsize to yield liposomes with the desired d&ameter.\\n\\nThe active ingr&xlicnts may nlso be entrapped in microcap-\\nsules prepared. for example, by coacervat&on teclm&ques or by\\ninterfacial polymenzation. for example, hydroxymethylcel-\\nlulosc or gelatin-microcapsules and poly-(methyhnethacry-\\nlate) microcapsules. respectively. &n collouk»1 drug dehvery\\nsystems (for example. Iiposomes. albumin microspheres,\\n\\n\\x0cUS 8,080,243 B2\\n\\n19\\nmicrommds iims, nano-particles and nano capsules) or in mnc-\\nroemulsinns. Such tecluiiques are disclosed in Remington,\\nThe Science and Pmicuce of Pharmacy. 20th Ld.. Mack Pub-\\nlishmg (2000)\\n\\nSllstan«XI\"IclcBSC pl\\'ipali&110&IS mal\\'li pl\\'i.\"Pitied Sultablc\\nexamples of sustained-release prepamtions include semiper-\\nmeable matnces of sohd hydmphobic polymers containing\\nthe antibody, winch matnces are in fiie form ol shaped\\narticlcx e g.. film~. or microcapsules Fxamplcs of sustaiiwd-\\nrelease niatrices include polyesters, hydrogels (for example,\\npoly(2-hydroxyethyl-methacrylate), or \\'poly(vinylalcohol)),\\npolylamides\\n\\n3,77\\'3,919), copolvmers\\n\\n(IJ.S Pat No\\n\\nol\\'-glutamicacid and 7 ethyl-L-glutanmte, non-degradable\\n\\nethylene-vinyl acetate, degradable lactic acid-glycolic acid „\\ncopolymers such as the LIJPRON DFPOTI\" (uijectable\\nmicrosplmrcs composed of lactic acid-glycolic acid copoly-\\nmer and leupmlidc acetate), sue«isa acetate isobutyrate. Bnd\\npoly-D-(-)-3-hydroxybutyric acid.\\n\\n\"\\n\\no\\n\\nThe fonuulations to be used lorin vivo administration must\\nbe stemle, This is readily accomptisticxt by. I\\'or example, fil-\\ntration through sterile filtration membmnes. Therapeutic\\nPCSK9 antagonist antibody, peptide. or aptamer compos&-\\ntions are generally placed into a container having a sterile\\naccess port, for example, an intmvenous solution bag or vial\\nhavingsstopperpierceableby ahypoderm&c intecuonneedle.\\nSuitable emulsions may be prepared using commercially\\nBvailiiblc fal clil&llsloilm such Bs IBIIBtlp&d™. I,lposynru.\\nInfonutrol\\'\", Lipohuidinru and Llpiphysani\", The active\\ningredient may be cilhcr dissolved in a prc-mixed cmutsion io\\ncomposition or alternatively ll may be dissolved &n an o&1\\n(e.g.. soybean oil, saftloiver oil, cottonseed o&l. sesame oil,\\ncorn oil or almond oil) Bnd an emulsion fiirmcd upon mixing\\nivlth a phospholip&d (e.g.. egg phosphohp&ds, soybean phos-\\npholipids or soybean limithin) nnd water. It will bc appreci-\\natcdt that other ingredients may be aifdcd, for cxmuple glyc-\\nlucose. to adlust fiie toiucity ofthe ennilslon. Suitable\\nerol or\\nennilsions will lypically contain up to 20%v oil, for cxaniple,\\nbelween 5 and 20%. Thc I\\'at emulsion can cmnprise fat drop-\\nlets between 0.1 and 1.0 um, particularly 0.l and 0.5 pm, and sr&\\nluive a PH in tlm range of 5 5 to 8 0.\\n\\n\"»\\n\\nThe emulsion compositions can be those prepared by mix-\\ning B P( SK9 antagonist antibody. peptide, or aptamer with\\nIntralipidr\" or the componmils thereof (soybean oil, egg\\nphospholipids. CPycerol and water).\\n\\nCmmpositions for inhalation or insuffiation include solu-\\ntions and suspensions ui pharmaceut&cally acceptable. aque-\\nous or organic solvent~. or mixtures thereof, and powders.\\nThc liquid or solid composit&mis may contain suitable phar-\\nmaceutlcally acceptable excipients as set out above. In some\\nembodiments, the compositions are Bdmmistered by the oral\\nor nasal respiratory route fiir local or systemic e fleet. Com-\\npositions in prefembly stenle pharmaceut&cally acceptable\\nsolvent~ may be ncbuliscd by usc of gases Nebulised solu-\\ntions may be breathed directly I\\'rom the nebulising device or\\nthe nebulising device may be attached to a face mask, twit or\\nintcrmiltcnt positive pre«sure breathing machine. Solution.\\nsuspens«in or poivder compositions may be administered,\\nprefembly orally or nasally, from devices which deliver the\\nformulation in an appropriate manner\\nIL PCSK9 Antagonists\\n\\n11m methods of the invention use a P(\\'SK9 antag(mist\\nantibody. peptide. or aptamer. w tuch refers to miy peptide or\\nnucleic acid molecule tlmt blocks, suppres sea or reduces (in-\\ncluding significantly reduces) P(.SK9 biologimil nctivity.\\n&ncluduig doivnstream patt«vays mediated by PCSK9 signal-\\ninc, such as elicitation of a cellular response to PCSK9.\\n\\no\\n\\n1\\n\\nso\\n\\n(\\n\\n20\\nA P(\\'SK9 nntagonist antibody, PCS&tide, or aptmner should\\nexlub&t Bny one or more of the folloiv&n clmractenstics: (a)\\nbind to PCSK9; (b) block PCSK9 interaction with the LDLR;\\n(c) block or decrease P( SK9-mcdiatcd doivn-regulation of\\nthe LDLR; (d) inlublt the PCSK9-mediated decrease ui LDL\\nblood clearance, (e) increase LDL clearance in mcxfia by\\ncultured hepalocytea, (0 increase blood I,DI. clearance by the\\nliver ui v&vo, (\\n) sensiuze to statins, and (ti) block PCSK9\\ninhibi-\\nin&cree&ion with other yei to bc identified ihctors.\\n\\n&o\\n\\nFor purposes of llus nivent&on, the milibody. peptide. or\\n\\naptamer preferably reacts with I\\'C\\'SK 9 in a maiuier that\\ntss P(. SK9 signaling functmn and I,DI,R mtcraction In some\\nembodiments. the PCSK9 antagomst antibody specitically\\nrecognizi:s prllnate P(.\\'SK9\\nthe\\nPCSK9 uitagonist antibody binds primate and rodent\\nI\\'CSKOJ.\\n\\nIn sonw. embodiments.\\n\\nThc antibodies useful in the present invention can encom-\\npass monoclonal md&bodies. polycloiml mtibodies, mitibody\\nfragments (e.g., Fab, Fab\\', F(ab\\')„Fv, Fc. etc.), chimeric\\nantibodies, bispccific mitibodics. hctcroconjugate antibodies,\\nsm~JC chain (ScFv), nu&tants thereol\\'. i&sion proteins com-\\nprising an antibody portion (e.g., a dnmain antibody), Inunan\\natuibodies, hunmn&zed antibodies, and any other modified\\nconfig&umtion of the inmuinoglobulin molecule that com-\\nprises an antigen recognition site of the required speciticity,\\nuicludin glycosylat&on variants of antibodies. amino acid\\n8\\'Ill&la&&Clog&call-\\nsequence variants of antibodies. and covalently moditied\\na&uibodica. The uitibod&es may be murine, rat. hummi. or any\\nother ofigtn (including ctumenc or humanized antibodies).\\n\\nIn some embodiments. the P(.\\'SK9 antagonist antibody is a\\nmonoclonnl anubody The PCSK9 muagonist antibody can\\nalso be lnunanized. In other embodiments, the aimbody is\\nhuman\\n\\nIn some emboduuents, the antibody composes a moditied\\n\\nc oils tant ri\\'glori, sllcli Bs a cons&alit regin&1 &liat Is\\nyally inert, that is, havulga reduced pomntia1 iiir provoking an\\nuunnuie response. In some embodiments, the constant region\\nis modified as described in I ur .1. Inummoi.. 1999. 29:2613-\\n2(124, PC:T Publ. No WO99/58572: anti\\'or UK Pulent Appli-\\ncation No. 98099S1.8. \\'the I\\'c can be human lg()2 or hilluain\\nIgCis The Fc can be human lgCi2 contain&flu thc nlillaltlol\\'I\\nA330P331 to S330S331 (Idiom), in which the Bnuno acid\\nresidues are munbered with reference to the wild type IgCi2\\nsequence Iiur J Inununol. 1999. 29 2613-2624. In some\\nemboduuents. the antibody comprises B constant region of\\nIg(14 comprising the following nu&tations (Armour et al.,\\n2003. Molemdar Inununology 40 585-s93): 0233F234L235\\nto P233M234A23S (Igni«). in which the numbering &s with\\nrel\\'erence to wild type tg(i4 In yet another embodiment. the\\nis human IgCJ4 02331\\'234L235 to P233V234A235 with\\ndeletion C&236 (tgOB „,). In another embodiment the Fc is any\\nlnunan IgC14 Fc (Ig(is. IgCI«s or Ig(i«,.) contaimng hinge\\nstabihzuig mutation S228 to P228 (Aalberse et al., 2002,\\nImmunology 105, 9-19) In anotlmr cmbodimmit. Iho Fc cmi\\nbe aglycosylnted I c\\n\\nthe constant\\n\\nIn some embodiments, the constant region is ag lycosyl ated\\nby mutating lhc oligosaccharide attaclmmnt rcsiduc (such as\\nAsn297) aod,\\'or itankuig residues tlrat are pan of the glyco-\\nsylation recognition sequence in the constant region. In some\\nregion is aglycosylatcd Ior\\ncmb&idimcnts.\\nN-linked glycosylation enzymatically. The constant region\\nmay be aglycosylatixl for N-linked glycosylation cnzymati-\\ncally or by expression in a glycosylat&on deficient host cell.\\nThe binding BSnity (Kol of a PCSK9 antagonist antibody\\nto P(.SK&J (such as Inunmi P(.\\'SK9)) can be about 0 002 to\\nabout 200 BM. In some embodiments, the buiding affinity is\\nany of about 200 nM. about 100 nM, about 50 nM, about 10\\n\\n\\x0cUS 8,080,243 B2\\n\\n21\\nnM, about I nlVL about 500 pM, about 100 pM, about 60 pM,\\nabout 50 pM, about 20 pM. about 15 pM, ubout 10 pM, about\\n5 pM, or about 2 pM. In some embodiments, the binding\\naffinity is less than any ofabout 250 nM. about 200 nM, about\\n100 nM. about 50 nM, about 10 nM, about I nM, about 500 s\\npM, about 100 pM, about 50 pM. about 20 pM, about 10 pM.\\nabout 5 pM. or about 2 pM.\\n\\na\\n\\nOne way of deternuiung binding ailimty of antibodies to\\nP(\\'SK9 is by n&easunng. binding aginity ol\\'monofunctiwml\\nFab fmgments of the antibody. To obtain monofunct&otu&1 I\\'ab 8&\\nfragments, an antibody (for example, IgCI) can be cleaved\\nw&th papaii& i&r expressel recombu&ni&tlv Thc affit&ify of a\\nPCSK9 I\\'ab fmyuent of an at&tibody can be deternuned by\\nsari\\'ace plasmon resonance (Biacore3000™ surface plasmon\\nresonance (SPR) svstcm. B&score, INC, P&scatav ay NI\\n)\\nequipped &vith pre-inunobilized streptavidin sensor chips\\n(SA) using HBS-FP nmning buffi.r (0.01M HFPFS. pH 7 4,\\n0.15 NaCI. 3 mM EDTA. 0,005% v/v Suriacxaut P20). Riot&-\\nnylated luunan VCSK9 (or any other VCSK9) cm& be diluted\\ninto HBS-FP butferus a conccntmtion ol\\'less tlum 0.5 pg/mi\\nand injected across the u&dividual clup channels usu&vg van-\\nable contact times, to achieve tvvo ranges of m&tigen density,\\ne&ther 50 200 response umts (RU) for data&led kmet&c studies\\nor 800-1,000 RU for screenmg assay&. Regenerat&on studies\\nhave shown tlrat 25 mM NaOH in 25% v/v ethanol ctfi:ctively \"\\nremoves the bound I\\'ab wlule keep&ng the actwity of PCSK9\\non the clup for over 200 injections. Typically, serial d&lutions\\n(spin&&ln&g conceal&i&t&(ii&s iif 0 I-10x est&mated Ko) ol\\'un-\\nfied I\\'ab samples are injected for I min at 100 I&L/n&inute and\\ndissociation times of up to 2 bo&lrs alc allo\\'wcvf. Thc c(incor. &(i\\n&rations of the Fab prole&ns are determined by ELISA and/or\\nSDS-PAUL elec trophores is using a Iinb of lo&own concentra-\\ntion (ns dcti:rtnincd by amiw& acid analysis) as a standard\\nK&netic assoc&anon rates (k,„) u&d d&ssociation rates (k,z) are\\nobmined simultaimously by titting the data globally to a I: I\\nI,angmuir bindin inodcl (Karla&a&n, R Roos, H Fagerstmn.\\nL. Petersson. B, 1994 Methods Enzymology 6. 99-110)\\nusing tlm BL&.evaluation program. I;quilibrium dissociation\\nconstant (K„) vului:s are calculated i&s k.~\\'k„,. This protocol\\nis suitable for use in detem&ining bind&ng affinity of an anti- sr&\\nbody to any PCSK9, including human Pt SK9. PCSK9 of\\nanother mammahan (such as mouse PCSK9. rat PCSK9,\\nprimate I&CSK9). as &veil as different forms of I&CSK9 (such\\nas o and $& fom&) Binding nliinity of an antibody is gencmlly\\nmeasured at 25\" C., but can also be measured at 37\\'.\\n\\n11&e V(:SK9 antagonist antibodies may be made by any\\nmethod known in. the ait uicludu&g the method as prov&ded &n\\nExample l. \\'I\\'he rome and schedule of immun&zat&on of the\\nhost animal are generally in keeping with es&abi&shcxl and\\nconvennonal techmques for ant&body stimulat&on and pro-\\nduct&on, as further described here&n. Oeneral techniques for\\nproduct&on ol\\'human md mouse ant&bodies are known in thc\\nait and/or are described herein. A currently preferred method\\nof n&ak&ng the antibodies con&prises tlm immuniwition of\\nPCSK9 knockout (P(\\'SK9-/-) annuals as disclosed herein\\nIt is contemplated that any manunalian subject including\\nhumnns or muibody pmducing cells thercl\\'rom can bc\\nman&pulated to serve as the basis for producuon ol\\'mamnui-\\nlian, including human. hybridoma cell lines Typically, the\\nlliisi animal is inoculated intrapcritoneally, intra&miscularly,\\nintraplantar, and/or u&tradennally\\norally, subcutaneously,\\nwith an amount of in&munogen, including as described herein\\nHybndomas cm& be prepared from the lymphocytes and\\ninunortalized myeloma cells using the geneml somat&c cell\\nhybridizatiw& technique of Kolder. B. m&d Milstcin, C . 1975.\\nNature 256:495-497 or as mod&fied by Buck, D. W.. et al..\\nI&982, In Vitro. 18:377-381. Available myeloma lines, includ-\\n\\nu\\n\\ns\\n\\nR&\\n\\nr\\n\\n22\\ning but not lin&ited to X63-Agg 6&53 m&d those from the Salk\\nInstitute. (\\'ell 1)isuibution (Jcnter, San Diego. I alif.. i ISA,\\nmay be used in the hybrtd&zat&on. (Ienerally. the teclm&que\\ninvolves fusing n&yeloma cells and lymphoid cells us&ng a\\nfusogcn such as polyethylcnc glycol, or by elcmtrical means\\nwell knot&n to those skilled in the art. After the fiision. the\\ncells are separated from the fus&on medium and gn&wn in a\\nselective growth mednun, such rwv hypoxanth&ne-uninop-\\ntcrin-thymidiim (HAT) medium, to eliminate unhybridized\\nparent cells. Any of the media described herein. supple-\\nmented w&th or &vithout serum, can be used for cultunnv\\nhybridomas lira& secrete monoclonal untibodies. As miother\\naltcmative to the cell fiision technique, EB&/ immortalized B\\ncells may be used to produce the PCSK9 monoclonal anti-\\nbod&es ofthe subject invention. The hybrtdomas are expanded\\nand subcloned. if desired. and supcrnatants are assayed for\\naf&t&.in&n&un(igen act&vlrt\\'lv\\'iinvcntun&al immunoassay pro-\\ncedures (e.g., rad&oimmunoassay, enzyme inununoassay, or\\nlluorescence &m&mmoassay)\\n\\nHybridomas that may be used as a source of nnt&bodies\\nencompass all derivatives, progeny cells of the parent hybri-\\ndomas tlmt produce nionoclonal ant&bodies specilic for\\nI\\'C SK9. or a portion thereof.\\n\\nHybrido mes that produce such antibodies may be grown in\\nv&tro or in vwo usia known procedures. The monocku&al\\nantibodies may be isolated from the culture media or body\\nlluids. by coinvent&oral immunoglobului purilication proce-\\ndures such as anunon&wn sulfate precipitation, gel electro-\\nphorcsis, dialysis. chromatography. m&d ultrafiltration, if\\ndesired. IJndesired aciivity, &f present, can be rmnoved. for\\nexample, by rnm&u&g the preparation over adsorbent s made of\\nthe immunogcn attachedto asolidphascandclutingorrclcas-\\nu&g the des&red m&tibodies off the immunogen. Inunumrtit&on\\nof a host animal with a human PCSK9, or a fragment con-\\n&ainuig the target amino acid scquencc conjugated to a protmn\\nthat &s &numu&o eric in the spec&es to be immumzed. e.g.,\\nkeyhole limpet lmmocyanin, serum albumin, bovine thyro-\\nglobulin, or soybean tryp sin inhibitor usu&g a b&li mctional or\\ndertvat&z&ng agent, for example, maleinudobenzoyl sul fosu-\\nccinimi  ester (conjugation through cysmine residues), N-hy-\\ndroxysuccin&mide (thmugh lysine residues), glutaraldehyde,\\n\\nsuccinic anhydride, SOLq„or R\\'N I\\'R, where R and\\nR\\'re dilferent alk31 groups. can yield n population oi\\'anti-\\nbod&es (e.g., monoclonal antibod&es).\\n\\nIf desired, the V(.\\'SK9 antagonist antibody (monoclonal or\\npolyclonal) ol interest may be sequenced and the polym&cle-\\not&de sequence n&ay then be cloned u&to a vector fiir expres-\\n\\nsion or propagation Tbe sequence encoding tbe &mubodyol\\'&terestmay be mau&tau&ed u& vector &n a host eel I and the host\\n\\ncell can then be expanded and frozen for future use. Produc-\\nt&on ofrecombu&mu n&wuiclonal antibod&es in cell culture can\\nbe cerned out tlu ough c luring ofant&body enes from B cells\\nby means knmvn in thc art. See, e g., Tiller ct al.. 2008, .I.\\nImnuu&ol Methods 329. 112: US Pat. No 7,314,622.\\n\\nIn an alten&ative. the polyoucleotide sequence may be used\\nfor genetic nianipulation to \"humanize\" tlm antibody or to\\nimprove the aiffimty. or other charactertst&cs of the antibody.\\nFor example, the constam rey\\'on may bc engineered to more\\nnearly resemble human constant regions hi avoid immune\\nresponse if the ant&body is used in cl&nical trtals and treat-\\nments in hunuins. It mny be desirable to genetically manipu-\\nlate the ant&body sequence to obtain greater aiiimty to PC SK9\\nand greater efficacy u& inlubiting PCSK9). It will be apparent\\nto one of skill\\nin tlm art that one or more polynuchx&tide\\nchanges can be made to the PCSK9 antagonist ant&body and\\nstill maintain its binding ability to VCSK9.\\n\\n\\x0cUS 8,080,243 B2\\n\\n23\\n\\'IJmre are filar general steps to humanize n n&onoclonal\\nanubody. \\'Ihese are: (I) determuung the nucleotide mid pre-\\nd&cted amino acid sequence of the starting antibody li Jv&t and\\nhcavy variable domains, (2) designing tlm Inimanizcd anti-\\nbody, i.e.. decidu&g v;hich mit&body frmnessork reg&on to use s\\nduring the humanizing process; (3) the actual luunanizing\\nIllelllodologlesl tech&i&clues:\\ntile trail&feet&(ill alltl\\niilltl\\nexpression ofthe humaruzed antibody. See. for example. U S.\\nPa( N(is. 4816,5C&7, 5.80771 3; 5,86C&692, 6331 415, 5„530,\\n101: 5.693,761: 5.693.762; 5,585.08&J; and CI.180.370\\n\\n(4)\\n\\nui\\n\\niklmallls Sl:e,\\n\\nA number of\"humanized\" antibody molacu les compr&sing\\nml at&ligen-binding sile dcrivcd fret&& n i&on-1&im& nl itlunuilo-\\nglobul&n have been descnbed. &ncludin clumenc antibod&es\\nhaving rodent or modified rodent V regions and their associ-\\nated CDRs fles&xi\\nfol\\nttl hill&lail et&list&lilt\\nexample, Winter et al., IWI. Namre 349:293-299: Lobuglio\\nct al., 1989. Proc Nat Aced Sci. USA 86 4220-4224. Shat&\\nei al . 1987. 1 Immiu&ol 138 4534-4538, and Brown et al..\\n1987. (\\'sneer Res. 47:3577-3583. Other references describe\\nrodent C\\'DRs grnfted into a humm& supporting framcvork n\\nre@\\'on (FR) prior to fissio with mi appropriate human ant&-\\nbody constant domain See, for example, Ricechmann et ai.,\\n1988. Nature 332.323-327, Verhoeyen et al.. 1988. Sc&ence\\n23&J&1534-153 G: and Jones et al.. 1986, Nature 321:522-52 S.\\nAnother refi:rcncc describes rodent\\nrecombinantly eng&neared rodent fmmework reg&ons. See,\\nfor example, European Patent Publ. No. OS1959G. These\\n\"humalllzetf ill(ilecllles are designed ni mlllltlllli: nllwiillletl\\n&mmunolog&cal response tou ard mdent anti-human ant&body\\nmolt:culcs which limits thc duration and efTcvtiivncss of lo\\ntherapeutic applm mons ol\\'hose moiet&es in hunuin rec&pi-\\ncots. I\\'or example. the ant&body constant reg&on can be eng&-\\n. docs not\\nncercd such that u is immunologically inert (e\\ntrigger complement lysis). See. e.g., PCT Publ. No WO99/\\n&8572; I.&K I\\'atm&t Application No. 98099&1.8. Other meth-\\nods of In&manizing antibodies that may also be utilized arc\\nd&sclosed by Dmigherty et al.. 1991. Nucl. Ac&ds Res.\\n19.2471-2476 and in U S. Pat. Nos. 6,180377; Ci,054,297;\\n5.997 867: & 866 692. 6 210 671: and 6 350 861: and in PC\\'\\nPubl. No. WO 0 1i27160.\\n\\n( DRs supponcxl by \"\\n\\nst t\\n\\n\"»\\n\\nIn yet another alternative. fully hill&la&& alltibodies mny bc\\nobta&ned by us&ng commerc&ally available m&ce that have\\nbecca engineered to express specific human inununoglobulin\\nproteins Transgonic m&imnls tlrat are designed to produce a\\nmore des&rable or more robust &nunune response may also be 4.\\nused for generation of humanized or human antibodies.\\nEx unples of such technology are Xenomousel&\\'mm\\nAbgen&x, lnc. (I\\'reniont, Calif.), lfuIVL&b-Mouseic and \\'I\\'C\\nMouseru iron& Medarex,\\nimd the\\nInc.\\nVeloclnunune*\\'k mouse from Regeneron Phannaceuticals,\\nInc. Cfanytown. N.Y).\\n\\n(Princeton, N Jl),\\n\\no\\n\\ns\\n\\nIn nn nltcrimtivc. antibodies may be made rcwomb&nantly\\nand expressed usuig any method known in the art. In another\\naltcrnativc. antibodies may bc made rccombinantly by phage\\nd&splay leclu&ology See, for example. U.S. Pnt. Nos. 5,565,\\n332: 5,580.717; S,733,743; and t&,265,150: and Winter et al.,\\n12 433-455 Alternativelv thc\\n1994. Annu Rev lmmunol\\nphage display teclmology (McCalTerty et al.. 1990, Nature\\n348:552-553) can be used to produce human antibndics and\\nant&body frag&neat& in v&tro, I\\'rom immunoglobulin vnriable ai\\n(V) dommn gene repertoires from un&mmunized donors.\\nAccording to this tecluiique, mitibody V domain genes nre\\ncloned in-frame into e&ther n major or conor coat prole&n gene\\nof a filamentous bacteriophage. such as M13 or fd, and dis-\\nplnycxl as fiinctional antibody fmgments on thc surface ofthe r\\nphage particle. Because the filamentous part&cle contains a\\nsingle-stranded DNA copy of the phage genome, selections\\n\\n24\\nbased on the functiimal prope&ties of thc m&tibody also result\\nui selection of the\\nene encoding the antibody exlub&un\\nthose properties. Thus, the plmge mimics some of the prop-\\ncnies of thc B cell Phage display can bc pcrfornwd in n\\nvanety of formats; see, e.g.. Joluison, Kevin S. and Cluswell,\\nl&avid J., 1993, (\\'urrent Opinion in Stnicnira1 Bioloht) 3:5(i4-\\n571. Several sources of V- ene segments can be used for\\nphage display. Clackson et al., IWI. Nature 352;624-628\\nisolated a diverse. array of nit&i-oxazt&lo&tc ant&bodies froin a\\nsmall nsndom combuuttonal hbrary ofV enes derived from\\nthe spleens of umnunized mice. A repertoire ofV genes f\\'rom\\nunimnnmi ted Iunuan dm&or, can bc constntctcxf and antibod-\\nies to a d&verse array of ant&gens (including self ant&gens) can\\nbe isolated cairn&tially follow:ing tlm teclmiqucs described by\\nMark et al.. 1991, I Mol B&ol 222:581-597, or Ciriffith et nl.,\\nIW3. L\\'MBO J. 12:725-734. In a natural inunune response,\\nantibody genes accuimilate mutations at a high rate (somntic\\nhypenmnat&on). Some of the ch mges introduced w&ll confer\\nhigher afhnity, mid B cells displaying high-affmity surface\\nimmunoglobulin are prefercntially replicated and diffi:rm&ti-\\nated dunng subsequent antigen challenge. Tlus natural pro-\\ncess can be mimicked by employing tl&e teclmique known as\\n\"chain shufiiingy (Marks et al.. 1992, Bio/Teclmol. 10:779-\\n783). In this method, the affinity of \"primary\\'* lmman anti-\\nbodies ohtaiiwd by phage display can be improved by sequen-\\ntially replac&ng the heavy and 1&ght chain V region enes w&th\\nrepertoires of naturally occu&ring variants (repertoires) of V\\ndomaui genes obtained from unimnnm&zed donors This lceeh-\\nmque allow s the pmduction of ant&bodies nnd antibody frag-\\nments with affinities in the pM-nM ange A stmtcgy for\\nmaku& very large phage au&&body reperto&res (also knoivn as\\n\"the mother-of-sll 1&branes\") has been described by Water-\\nhouse et al, 1993, Nucl Acids Res 21.22C&5-2266. (ienc\\nshulf1&ng can also be used to derive luuu m antibodies from\\nmdent antibodies, where the human antibody has similar\\nafiimtics aml spccilicities to tlm sinrting mdent antibody.\\nAccorduig to tlus method, uluch is also referred to as\\n\"epitopc imprinting\", the hcavy or fight chain V donmin cene\\nof rodent muibodics obtuini:d by phage display technique is\\nreplaced v;ith a repertoire ofInunan V domain genes, creating\\nrodent-human chimeras Selection on antigen results in iso-\\nlat&on of human vanable regions capable of restoring a func-\\ntional antigen-binding site. i.e, the epitope governs (im-\\nprints) thc choice of panner Whmi thc process is repeated in\\norder to replace the remaining rodent V domain, a luunan\\nantibody is obtained (see PCT Publ. No. WO 93i06213).\\nUnl&ke traditional hiunanizat&on of rodent antibodies by CDR\\ngmfting. this tecluuque provides completely luunan antibod-\\n&~es, uhich have no I\\'rameuork or C\\'DR residues of rodent\\n0&I gill.\\n\\nant \\n\\nIt &s apparent that al thous+ the above discussion pertains to\\nlnunau&zed nnubodies. the general principles d&scusssed ime\\nnppl&cable to custom&zuig ant&bodies for use. ftir exmnple, &n\\ndogs, cats, primate, equi&ms m&d bovines. It is furiher apparent\\nthat one or more aspects of human&zuig an\\n&body des cn bed\\nherein may be con&bine&I, e g.. (\\'DR grafting. framesvork\\nnuitation and C\\'DR mutation\\n\\nAnt&bodies may be made recoinb&n u&tly by first &solauog\\nthe antibodies and antibody producing cells from host ani-\\nmals, obtaining tlm gene sequence. and usia\\nihe gene\\nsequence to express the antibody recombinantly in host cells\\n(e g., ( HO cells) Another method which mny bc employcxl is\\nlti express the antibody sequence &n plants (e.g.. tobacco) or\\ntrm&sgenic milk. Methods for expressing antibodies recombi-\\nnantly in plams or milk lmvc been disclosed. Sox for\\nexample, Peeters, 2001. et al. Vaccine 19:2756: Lonberg, N.\\nand D. Huszar, IW5, Int. Rev. Inununol 13:6S: and I\\'ollock,\\n\\n\\x0c(js 8,080,243 B2\\n\\n25\\net al, 1999, I Immunol Merhods 231:147. Methods for mak-\\ning derivatives of antibodies. e g., humanized, single chain,\\netc. are known in the art.\\n\\nhnmunoassays m&d liow cytomctry sorting techniques such\\nas fiuorcscencc acti&a&ed cell sorting (FA(\\'8) can also bc\\nemployed to isolate antibodies that are specific for PCSK9.\\nThe antibod&es can be bound to many d&fferent camera.\\nCarriers can be acnve and/or u&ert I.xamples of well-known\\ncarriers include polypropylcne, polystyrene, pe)yeti&\\')cue,\\ndextran, nylon, amylases, glass, nan»al and modified cellu-\\nloses, polyacrylmnides. Sgaroses and magnet&te. \\'Il&e nature\\noithcc uriercanbeeitlmrsolubleoruisolublcforpurposesol\\'he\\n\\ninvention. fhose skillcxI in the an will know of other\\nsuitable carriers for binding antibodies. or &vill be able to\\nascertain such, usu&g rounne experuuenlation.\\nIn some\\nen&bodimcnts, tlm carrier comprises a moiety that targets the\\nmyocnrdnun\\n\\nIa\\n\\nc\\n\\nDNA encoding the monoclonal ant&bodies is readily iso-\\nla&ceil and sequenced using convent&onal procedures (e g.. by\\nusing oligonucleotide probes that are m&pable ol\\'bind&ng spe-\\nciiically to genes encoding the heavy and light chnins of the\\nmonoclonal m&tibodies). The hybndoma cells serve as a pre-\\nferred source of such DNA. Once isolated, the DNA may be\\nplaced u&to express&on vectors (such as expression vectors \"\\nd&sclosed &n PCT Publ. No. WO 87/04462). v,hich are then\\ntransfected into host cells such as E. co/i cells, simian COS\\ncells, (.hinese hains&er oven (CIIO) cells. or myeloma cells\\nthat do not otherwise produce immunoglobuhn protein, to\\nobtain tlm syntlmsis oi\\'nxmoclonal antibodies in the rccmn- &a\\nbn&anthost cells See.e.g.. PCTPubl No WO87/04462. The\\nDNA also may be modified. for example. by substitut&ng the\\ncoding scqum&cc filr human heavv aml light ch&un constant\\ndomains in place ol\\'&he homologous murine sequences, Mor-\\nrison ct al.. 1984, Proc Nat Aced. Sci. 81:6861, or by \"»\\ncovalently joining to the immunogkibubn wlding scxiucncc\\nall or part of the coding sequence for a non-&nununoglobulin\\npolypeptide. In that manner. \"chinmric\" or \"hybrid\" antibod-\\nies are prepared thut have the binding spec ifimty o I\\'a PCSK9\\nmonoclonal antibody herein.\\n\\nst &\\n\\nP( SK9 antagonist m&tibodies and polypcptides dcrivcd\\nfrom m&tibodies can be Identifie or clmracterized us&ng\\nmethods known in the art. whereby reduction, amelioration,\\nor ncutrali&ation of P(\\'SK9 biologicnl nctivity is detected\\nand/or measured. In some embodiments. a PCSK9 antagonist ss\\nantibody or polypeptide is identificxI by incubating a cm&di-\\ndate agent w&th PCSK9 and mon&tonng bu&ding &&n&L\\'or atten-\\ndm&t reduction or neutral&zation of a biological activity of\\nP(\\'SK9. The binding assay may be performed with puniied\\nPCSK9 polypepude(s). or w&th cells naturally expressing, or\\nI\\'CSK9 polypeptide(s).\\ntransfected to express,\\nIn one\\nthe binding assay is a compet&tive binding\\nemb&xliment,\\nassay, where the abihty of a cund&date ant&body to compete\\nwith a known P(\\'SK9 antagonist for P(\\'.SK9 binding is evalu-\\nated The aswiy may be performed in venous formats, inc iud-\\nIn other embodiments, a P(\\'SK9\\ning the L\\'LISA fern&at.\\nm&tagonist antibody is identified by incubating a mmdidatc\\nagent w&th P( SK9 and nu&nitoru&g bn&du&g aud attendant\\ninhibition of LDI,R expression and/or blood cholesterol\\nclmirm&ce\\n\\n1\\n\\nsa\\n\\nc\\n\\nI&ollov, ing initial identificat&on. the activity of a candidate\\nP(\\'SK9 antagonist antibody can be further confinncxI and\\nrefined by b&oassays that are known to test the targeted b&o-\\nlogical activities. Alternatively. bioassays can be used to\\nscreen candidates directly Some of thc methods for identify-\\n&ng and characterizing PCSK9 antagonist antibodies. pep-\\ntides, or aptamers are descnbcxl in detail in the Examples.\\n\\nI\\n\\n26\\nP( SK9 antagonist antibodies nu&y bc characterized using\\nmethods weil knovn u& the art. I or example, one method is to\\n\\nident&fy the epitope to which it binds, or \"epitopemapping.*\\'lmrearc many methods known in thc a&t for mapping nnd\\n\\ncharactenzu&g the location of epitopes on pmte&ns, includ&ng\\nsolving the crysta I structure of an m&tibody-antigen complex,\\ncon&pent&on assavs, gene fragulcirt cxprcsslon &&ss&&vs. &&&xi\\nsynthetic peptide-based assays, as descnbed, for example, &n\\n(\\'haptcr 11 ol\\'liar)on a&xi I,anc, Using Antibodies, a I.abo-\\nmtory Manual, (Cold Sprmg Ilarbor Labomtory Pres~. Cold\\nSpring I h&rbor N Y., 1999). In an add&tione 1 example, ep&tope\\nmappuig cm& bc used to determine the sequence to wluch a\\nerlands \\nPCSK9 antago&ust ant&body b&nds. Ep&tope mappu&g is com-\\nmercinlly avnilnblc from various sources, filr example, Pcp-\\nscan Systems (Lie)her&wc 15. 8219 PH l,elystad, The Neth-\\n). \\'II&e epitope can be a linear epito pe, i e., contained in\\na single stretch of amino acids, or a confimnational epitopc\\nfonncxl by a tinea-din&ensional interactmn of muino wids 01st\\nmay not necessarily be contained in a single stretch. Peptides\\nof var) ing lengths (c.g, at least 4-(i mnino acids king) cm& bc\\nisolated or synthesized (e... recombinantly) and used for\\nbinding essays with a P(\\'SK9 antagonist antibody In another\\nexample. the epitope to wh&ch the PCSK9 ants onist m&t&-\\nbody bu&ds can be detem&ined in a systematic screening by\\nusing overlapping pcptides derived from the P(\\'SK9\\nsequence and detennu&u& binding by the PCSK9 antagon&st\\nantibody. According to the gene fragment expression assays,\\nthe open reading frame encod&ng PCSK9 is fragmented either\\nmndomly or by spec&fic genetic construct&ons and the reac-\\ntivity of thc express&cd I\\'ragmcn&s ol\\'PCSK9 with tlm antibody\\nto be tested &s detennu&ed. The gene ikagmen(s n&ay. for\\nexample, be produced by PCR and then tmnsc rib ed and trans-\\nlated into protein in &\\'itro, in thc presence o fradioactivc amino\\nacids. The bu&du& * ofthe u&tibody to the radioactively labeled\\nPCSK9 fragments is then determined by inummoprecipita-\\ntion and gel clectroplxlresi&. (\\'crtain epitopes can also be\\n&dent&fied by using large 1&bm&nes of random pept&de\\nsequences displayed on tlm surface of phage particles (phage\\nhbraries) Alten&atively, a defined hbrary of overlapping pep-\\nt&de frag&neo&a can be tested for binding to the test antibody in\\nsimple binding essays. In nn additional example. mutagenesis\\nofan ant&gen bu&d&ng domau&. domain swapp&ng experiments\\nand alanine scaiufing nuitagenesis can be perfonucxI to iden-\\nti6 residues required, sufficient, and/or nocessary for cpitope\\nbinding. For exmnple, domain swapping expenments can be\\nperformed using a mutant P(\\'SK9 in u hich various fragments\\nof the PCSK9 polypept&de have been replaced (swapped)\\nwith sequences from VCSK9 from another species, or a\\nclosely related, but antigenicnlly distinct pmtein (such as\\nanother member of the proprote&n convertase fanuly). I)y\\nassess&ng binding of the m&tibody to the mutant I\\'CSK9. the\\nin&portance of tbe p aticular P(:SK9 I\\'ragment to antibody\\nbindino can be assessed.\\n\\nYet snot)mr nlcthod wl\\'lich can bc &ised to chamcterize a\\nPCSK9 &Intagonist ant&body is &o use competit&ou essays with\\nother nntibodies known to bind to the same antigen, i.e.,\\nvtmlous hagnlcn(s on PCSK9, to dctcm&inc if thc P( SK9\\nan&agoms& ant&body bu&ds to the same ep&tope as other mti-\\nbodies. Competition essays are well known to those of sl ill in\\nth&. art\\n\\nI\\'he crystal structure of the ant&body and antibody:ant&gen\\ncomplex cm& also be nsed to chamacterize the m&tibody \\'II&c\\nresidues are identiiied by calculating the d&fierence &n acces-\\nsible surface area between the LI L3:I\\'(\\'SK9 crystal strucnire\\nand P(.SK9 stn&cturc alone. PCSK9 residues that show buried\\nsurface area upon complex formation w&th Li L3 ant&body are\\n\\'I\\'he solvent accessible\\nincluded as a part of the cpitope.\\n\\n\\x0cUS 8,080,243 B2\\n\\n27\\nsurf\\'ace of a protein is defined as tlm Incus of the emit re ul\\'\\nprobe sphere (represennng a solvent molecule of 1.4 A\\nradius j as it rolls over the Van der Waafs surface ofthe protein.\\nThc solvent accessible surface area is calculated by gcncrat-\\nuig surface points on an extended sphere about each atom (at\\nequival-\\na distance from the atom centre equal to the smn of the atom\\nand probe nldli). and eliminating those that he 11 ithin\\nentt spheres associated with neighboring atoms as imple-\\nmented in pnrgram ARBAIMOI (Brings, P J., 2000, CC\\'P4\\nNewsletter No. 3R CCLRC, Daresbury).\\n\\n5\\n\\n1(1\\n\\nAn expression vector can be used to direct expression of a\\nPC\\'SK9 antagonist mitibody Oiw. skilled in the art is fmlihnr\\nwith administration of expression vectors to obtain expres-\\nsionofmlexogenousprotcin invivo. Sec, e g,US Pat.Nos.\\n6.436.908: 6,413,942, nnd 6,376.471 Administration ol\\'.\\nexpression vectors includes local or systemic administration,\\nincludino injoction, oral adtninistration. pnrticle gun or cath-\\neierized adnumstration, and topical admuuslration\\nIn\\nmiother embodiment, the expression vector is acbninistered\\ndirectly to thc sympathetic tnmk or angfion. or into a coro-\\nnary artery, atrium, ventrical, or pericardium.\\n\\no\\n\\n\"\\n\\nTargeted delivery of therapeutic compositions containing\\nan expression vector, or subgenomic polynucleotides c ui also\\nbe used. Receptor-mediated DNA dehvery techniques are\\ndescribed in, for exmnplc, I\\'indeis ct aln 1993, Trends Bio-\\nil;202, Cluou et al., 1994. Gene liierapeutics:\\nteclmol.\\nMethods And Applications Of Direct (iene Transfer (J. A.\\nWolff.ed 8 Wuetal..1988..1 Biol C\\'hem. 263:621,Wuetal..\\n1994, .f. Biol. Chem. 269:542; Zenke et ale 1990. Proc. Natl.\\nAced Sci. IJSA 873655; Wu cl al, 1991. I Biol Clmm so\\n266:338. Therapeutic coinpositions containing a polynucle-\\notide are admiiu stered in a range of about 100 ng to about 200\\nmg of DNA f\\'or local administration in a gene therapy proto-\\ncol Concentration ranges of about &00 ng to about &0 mg,\\nabout I pg to about 2 mg, about 5 pg to about &00 pg. and \"»\\nabout 20 pg lo about 100 pg of\\'DNA can also bc use&I during\\na gene thenspy protocol. The therapeutic polynucleotides and\\npolypeptides can be dclivcrcd using gene delivery velgcles\\nThe gene delivery vducle cml bc ol\\'iral or non-viral ongin\\n(see generally, Jolly, 1994, Cancer (rene Therapy I;Sl;\\nKimura, 1994, Hunmn (icne Therapy 5 845: (\\'onnellyi 1995,\\nlhunan Gene 111erapy I:185; and Kaplitt, 1994, Nature\\n(ieneti ca 6: 148j. L\\'xp ress i on of such coding sequences can be\\ninduced using endogenous mmmnalian or heterologous pro-\\nmoters. Lixpresslon of the coding sequence can be either 4.\\nconstitutive or regulated.\\n\\nso\\n\\nViral-based veciors for delivery of a desired polynncle-\\notide mid expression in a desired cell are well know n in the art.\\nBxemplmy viral-based vehicles include bnl are nol limited\\nto. recombuiant retroviruses (see. e.g. PCT Publ. Nos. WO o\\nc90/07936; WO 94/03622; WO 93/256198; WO 93/25234: WO\\n93/11230, WO 93/10218. WO 91/02805, US Pat. Nos\\n5.219.740 and 4.777,127; CiB Patent No. 2.200.6Si: and L\\'P\\n\\n28\\nPntent No 0 345 242), alphavinis-bswsed vectors (e g., Sindbis\\nvirus vectors. Semhlo forest vinls (ATCC VR-67; ATCC\\n(ATCVC VR-373: ATCC\\nVR-1247), Ross River virus\\nVR-1246) and Venerniclmi equine encephalitis vinis (ATCC\\nVR-923; ATCC V R-1250: ATCIC VR 1249: ATCC VR-532)),\\nand adeno-associated virus (AAV) vectors (see, e.g., PCT\\nPubl. Nos. WO 94/12649, WO 93/03769; WO 93i\\'19191, WO\\n94/2893K WO 95/11984 and WO 95/00655) Achniiustration\\nol\\'DNA linked to kifftxf adenovirus as dcscnbcd in C:uriel,\\n1992. Ihun. Ciene liter. 3:147. can also be employed.\\n\\nNoll-viral delivery vehicles and methods can also be\\nemployed. includmg. bul not limited lo. polycationic con-\\ndensed DNA linked or unlinked to killed adenovirus alone\\n(sce, c g., (\\'uriel, 1992, Hum. (iene Ther 3:147),\\nligand-\\nlmked DNA (sep, eg, Wu..l.. 1989, Biol C\\'liam 264.16985),\\neukaryotic cell dehvery vehicles cells (see, e.g., U.S. I\\'at. No.\\n5,814,482, PC:T Publ. Nos. WO 95/07994, WO 96/17072,\\nWO 95/30763: mul WO 97/42338) and nucleic charge neu-\\ntmiizmtion or fusion with cell membranes Naked DNA can\\nalso be employcdl Pxmnp fary naked DNA introduction ml th-\\nods are descnbed ln PCT Publ. No. WO 90/11092 and U.S.\\nPat. No. 5.580,859. Liposomes tliat cmi act as gene delivery\\nvelucles are described in U.S. Pat. No. 5,422,120; PCT Publ.\\nNos. WO 95/13796; WO 94/23(i97; WO 91/1444S: and BP\\n0524968. Additional nppmaches are described in I\\'hilip,\\n1994. Mol. Cell. Biol o 14. 2411, and in Wolfendin, 1994 Proc.\\nNatl. Aced. Sci. 91:1&81.\\n\\nThis invention encompasses compositions, lncludui phar-\\nmaceutical compositions. comprising antibodies descnbed\\niwrcin or made by lhc nwt bode and hnv ing the chmaclcri sties\\ndescribed hereui. As used herein, compositions comprise one\\nor more antibodies, peptides, or aptamers that antagonize the\\ninlernction of PCSK9 v,ith tlm I,DI.R, nnd/or onc or morc\\npolynucleotldes composing sequences encoding one or more\\nthese antibodies or peptides Illese compositions may further\\nsuitable excipicnts. Such as phannaceutically\\ncomprise.\\nlvluch are lvell\\nacceptable excipients lncludin\\nkl iowa lu thl\\'. Rift\\n\\nThe PCSK9 antagonist antibodies and peptidcs ol\\'hc\\ninvention are cliaracterized by any (one or more) of the fol-\\nlowing characteristics (a) bind to PCSK9: (b) block P(\\'SK9\\nuiteraction with the LDLR; (c) decrease PCSK9-mediated\\ndown-regulation of the Lf&LR: and (d) inhibit P(\\'SK9-medi-\\nated inhibition of I.DI, blood clearance. Prcfi.rably. PCSK9\\nantibodies have two or more of these features. More prefer-\\nably, the antibodies have three or more of the features. Most\\nprefensbly, the antibodies have all four charactensucs.\\n\\nbuffers,\\n\\nAccordingly, the invennon pmvides any of the follow ing,\\nor compositions (ulcluding pharnulccuiical compositions)\\ncompnslng any antibody havurg a partial light chain sequence\\nand a partial hery clmin sequence as found in \\'Iable l. The\\nunderluicd sequences are CDR sequences according to Knbnl\\nand in bold according to Chothia.\\n\\nTABLE I\\n\\nmAb Light Chatn Vattable Regton Heavy Chain Variable Regton\\n\\nSIS DIVI\\'ITQSQKPNSTSVGDRV\\n\\nEVQ\\'QQSGPELVKPGASVKISCKAS\\n\\nSVTCKASIINIIGTNVAICIQ\\n\\nGYTFTDYYININVKQSHGKSLRNIG\\n\\nQKPGQSPIGILIYSASYRYSG\\n\\nVPDRPTGSGSGTDPTLTISN\\n\\nYSTKCHELR LTSED A\\'1YYCARNL\\n\\nVLSEDLAEYPCQQFYSYPYT\\n\\nLPAYtIGQGTLVTVSA ISEQ ID\\n\\nPGGGTKLEIK lsEQ ID No\\n\\nI\\n\\nI\\n\\nNo\\n\\nEcl\\n\\n\\x0c29\\n\\nTABLE I-continued\\n\\nUS 8,080,243 B2\\n\\n30\\n\\nWAb Light Claarn Variable Regron Heavy Chain Variable Pegion\\n\\n5AZO DIVI6TQSHKFNSTSVGDRVS\\n\\nQVQLQQPGAELVKPGASVKLSCKAS\\n\\nITC~KAS DVSTAVAIvYQQK\\n\\nGYTPTSYWMHtmKQRPGQGLEWIG\\n\\nPGQSPKLLZYSASYRYTGVP\\n\\nEINPSNGRTNYNEKFKSKATLTVDKS\\n\\nDRPTGSGSGTDFTPTISSVQ\\n\\nS S TRY) )QL S 5 LT 5 5 D 5 AVYYCARER\\n\\nAEDLAVYYCQQRYSTPRTF\\n\\nPLYAMDY)GQGTSVTVSS\\n\\nGGGTKLEIK )SEQ ID No\\n\\n17)\\n\\n)SEQ ZD HO\\n\\n21)\\n\\n6P6 DIQHTQTTSSLSASLGDRVTZ\\n\\nEVQLQQSGPELl.\\'KPGASVKISCKAS\\n\\nSC~SAS\\n\\nZSNYlbclYQQKP\\n\\nGYTFTDYYMNlh)KQSHGKSLKWIG\\n\\nDGTVFLLIYTrssLHsGVPs\\n\\nRFSGSGSGTDYSLTISNLEP\\n\\nSSSTAYMELPSLTSEDSAVYYCAGG\\n\\nEDIPTYYCQQYSKLPPTPGS\\n\\nGIYYRYDRNYPDYWGQGTTLTVSS\\n\\nGTKLEIK lsEQ ID No\\n\\n15)\\n\\n)SEQ ZD HO\\n\\n22l\\n\\n7D6 DIVI\\'ITQSHKPNSTSFGDRVS\\n\\nEVKLVESEGGLVQPGSSHKLSCTAS\\n\\nITCHESDVSNALMiYQQK\\n\\nGFTPSDYYIDÃVRQVPEKGLEWVA\\n\\nPGHSPKLLI5\\'SASYRYTGVP\\n\\nNINYDGSMTSYLDSLKSRFIISRDNAK\\n\\nDRFTGSGSGTDPTFTISSVQ\\n\\nNILYLQMSSLKSEDTATYYCPPEKPA\\n\\nAEDLIVYYCQQHYSTPNTF\\n\\nAMD1WGQGTSVTVSS\\n\\nGGGTKLEIK lsEQ ID No\\n\\n19)\\n\\nISEQ ZD NO\\n\\n23)\\n\\nLZL3 DIQHTQSPSSLSASVGDRVT\\n\\nQVQLVQSGAEVKKPGASVKVSCKAS\\n\\nITC~RAS GZSSALAIvYQQKP\\n\\nGYTPTSYYMHtmRQAPGQGLEWM\\n\\nGKAPKLLIYSASYRYTGVPS\\n\\nGEISPPGGRTNYNEKFKSRVTHTRD\\n\\nRFSGSGSGTDFTFTISSLQP\\n\\nTSTSTVYHELSSLRSEDTAVYYCARE\\n\\nEDZATYYCQQRYSLWRTFG\\n\\nRPIYASDLWGQGTTVTVSS\\n\\nQGTKLEIK )SEQ ID No\\n\\n531\\n\\n(SEQ ID Ho 56)\\n\\nThe unention aiso provides CDR portions of\\'lmtibodies to as\\n\\nV( SK9 (including I\\'.hothia and Kabat (\\'DRs). Dctcnnination\\nol\\'F.\\'DR reg«ms is lvell within thc skill of thc art It is under-\\nstoodthatinsomeembodimonta( DRscanbeacombination\\nol\\'he Kabnt lmd Chothia CDR (also termed \"colnbined\\nCDRs\" or \"extended CDRs\"). In some embodiments, the\\nCDRs are the Ka bat CDRs. In other embodiments, the b \\'DR s\\nare the Chothia CDRs In other ~ords. ul embodiments la 1th\\nmore tlmn one CDIL the CDRS may be any ofKabat, Chotlua.\\nconlbination CDRs, or combinations thereof\\n\\n5\\n\\nThe ulventlon also prov)des methods of making mly ol\\'\\nthese antibodies or polypeptides. The antibodies ofthis inven-\\nlion can bc made by procedures known in tlm ar) Thc\\npolypeptides cml be produced by proteolytic or other degra-\\ndation of the mltibodics, by rccombinmlt methods (i.e, sinoJe\\nor fusion polypcplidcs) Rs described above or by chmnical N)\\nsynthesis. Volypeptides of the antibodies, especially shorter\\npolypeptides up to about 50 amino acida are conveniently\\nmade by chenucal synthesis. 37lethods of chemical synthesis\\nare known in the art and are commercially available. For\\nexample, an antibody could bc produced by an mltomated 6\\npolypeptide synthesizer employing the sohd phase method.\\nSee also, U S. Vat. Nos. 5 g07 715; 4 g16 567: and 6 331,415.\\n\\nIn another alternatilja the antibodies and peptides cml be\\nmade recombinantly using procedures tlmt are well known in\\nthe art. In one embodiment, a polynuclcotlde compnses a\\nsequence encoding the heavy chain and/or the I)pit chain\\nvmiablc regions of antibody 4A5, 5A10, 6F6. 7D4 or 1.11 3.\\nThe sequence encoding the antibody ofinterest may be main-\\ntained in a vector in a host cell and the host cell can then be\\nexpanded and froyen for future use VLT)ors (including\\nexpression vectors) and host cells are fluther described\\nherein.\\n\\nThe im ention also encompasses scl\\'v of ant)bod)ca of this\\ninvcnnon Single chain vanablc region fragments al\\'6 njadc\\nby linking light and)or heavy chain variable regions by using\\na short linking peptide. Bird et al.. 19gg, Science 242:423-\\n426. An example of a lulking pcqltide is (Cifif)C)S), (SIIQ ID\\nNO.24), which budges appmximately 3.5 nm bet~can the\\ncarboxy terminus of onc variable region and the amino ter-\\nm)Due ofthe other variable region. L uikers ofother sequences\\nhave been designed and used. Bird et el., 193 g, supra. Linkers\\nshould be short, tlexible polypeptidcs and prcfbrably com-\\np)Ised of less than about 20 anuno acid residues. Llnkers can\\nin turn be modified for additional functions. such as attach-\\n\\n\\x0c(js 8,080,243 B2\\n\\n31\\nment of drugs or attachment to solid supports Tlm single\\nchaui vanants can be produced either recombinantly or syn-\\nthetically. For syntlietic production of scFv, an mitomated\\nsynthesizer can be used For rccombinmit production of scFv,\\na suitable plasnud contauungpolymicleotide that encodes the 1\\nscpv can be introduced into a suitable host cell. either eukary-\\notic. such as yeast, plant. uisect or mammalian cells. or\\nprokaryotic. such as Fd co/i. Polynucleotides encodmg the\\nscF v o fintcrcst cnn be made by routine manipulations such as\\nligitionofpolynucleotides. Theresultantscl\\'vcanbeisolated lo\\nusing standard protein purification techniques known In the\\n\\'irt\\n\\nOther forms of sin le chain antibodies. such as diabodies\\nare also encompassed Dinbodics are bivalent. bispeci tie miti-\\nbodicsinwhtchVIlandVl.domainsareexpressedonasin le\\npolypeptide chain. but using a linker that is too short to allow\\nfor pairing bct(recon the two domains on the same chain,\\nthereby Rircing the donuuns Io pnir (vith cmuplementary\\ndomains of another chain and creating nvo antigen binding\\nsites (sce e g.. Holligcr. P. ct al . 1993, Proc Natl Acnd Sci\\nUSA \\')0:6444-6448; Poljak, R..l., et al., 1994. Structure\\n2:1121-1123).\\n\\no\\n\\nFor example, bispeciiic antibodies, monoclonal mttibodies\\nthat have binding specificities for at least t(vo different anti-\\ngens, m n be prepmed using thc antibodies disclosed imrein\\nMethods for nmkuig bi specific antibodies are known In the art\\n(see, e.g., Suresh et al.. 198&x Methods in Enzymology 121:\\n210). Traditnmnlly, the reeombuinnt production of bispemiic\\nantibodies was based on the coexpression oftwo Inuuunoglo-\\nbulin hcavy chain-light chain pairr, (1 ith the two hcavy chains io\\nhaving dilperent specifimties (Millstein and Cuello. 1983,\\nNanire 305. 537-539).\\n\\nAccording to one npproach to mnking bispecilic SIItibod-\\nIes, antibody venable dom nns with the desired b uiding speci-\\niicities (mitibody-antigmi combining sites) are fused to \"»\\nuumunoglobulin constant domaut scqumices. The liision\\npreferably is with an immunoglobulut hery ch un constmtt\\ndomain, coniprising at least part of the hinge. CH2 and & H3\\nregions It is prcfi.rrcd to have the iirst bca(T chaui amstmit\\nregion (&\\'H1), containing the site necessary for fight chain do\\nbindino, present in at least onc oftlm fusions l&NAS encoding\\nthe inununoglobului heavy chain fusions and, if desired. the\\ninuuunoglobulin light cliai, are insened into separate\\ncxprcssion (mciors, mid are cotmnsfi.ctcd into a suitable host\\norgarusm. Iliis pro~ides for peat fiexibility in adjusting the d.\\nmutual proportions of the three polypeptide fravgntents in\\nembodiments when unequal ratios of the three polypeptide\\nchains used in the construction provide the optinuuu yields. It\\nIs, la(waver, possible to htscn tlm coding sequences for Iwo or\\nall tluee polypeptide chains In one expression vector when tlie\\nexpression of at least two polypeptide chains in eqiml nitios\\nresults In hi h yields or when Ibc ratios are of mi particulnr\\nsigiuiicance.\\n\\no\\n\\nIn one approach, tlm bi speci bc antibodies are composed of\\na hybrid immunoglobulin heavy chain with a tirst binding\\nspecificity in one ann, and a hybrid imnnmoglobulin heavy\\nchain-light chain pair (providing a second binding. sp(wilic-\\nIty) In the otlier arm. Tlus asymmetnc structure, with an\\ninuuunoglobulin light chain in only one half of the bispecific\\nmolecule. facilitates the separation of th(. desired bispecilic mi\\ncompound from unwanted immunoglobulin chain combina-\\n\\'Iliis approach is described in P&\\'T Publ. No. WO\\ntions.\\n94/04690\\n\\n1\\n\\nHeteroconjugate antibodies. comprising two covalently\\njoined antibodies, are also within the scope of thc invention\\nSuch antibodies have been used to target utunune system cells\\nto unwanted cells (U.S. Pat. No. 4,676.980). and for treatment\\n\\n32\\nof His/ infection (P& T Publ Nos WO 91/00360 and WO\\n92i200373: EP 03089). Ileteroconjugate antibodies may be\\nmade using any convenient cross-linlong methods. Suitable\\ncross-linking agents nnd tcwiutiques are well Ioutwn in the an,\\nand are descnbed in U.S. Pat. No. 4,676.980.\\n\\nChimeric or hybrid antibodies also may be prepared in\\nvitro using kno(vn methods of synthetic protein chemistry,\\nuicluding those involving cmss-linking agents. For example,\\nintmunotoxins may bc constructed using d di sulfide cxchangc\\nreaction or by fornung a tlucether bond. Examples of suitable\\nreagents for tlfis purpose include iminotluolate mid methyl-\\n4-nIercapiobutyrimidatc\\n\\nIiumanized mtibody compnsuig one or more CDRs of\\nantibodies 5A10 or 7D4 or one or nxire & DRs derived from\\nantibodies 5A10 or 7D4 can be made. for example. using any\\nmetlmds know in the art. For example. four general steps may\\nbe used to humanize a monoclonal antibody Thcsc nre (1)\\ndetermining the mmleotide md predicted amino ncid\\nsequence of the starting antibody light and heavy variable\\nihchulniu11zLd dlltlbody. i.c, deciding\\nd(lluallls, (2) ilcsigl1i!I\\nwhich mitibody framework region ui use during the human-\\nizing process; (3) using the acmal humanizing methodolo-\\ngiesitechniques; and (4)\\ntransfecting mid expressing the\\nhumanized antibody. See, for exaniple. U.S. Pat. Nos. 4.816,\\n567, 5.807,715; 5,86&1,&i92; 6331,415; 5.530,101; 5,693,7&11,\\n5,693,762; 5.585,089: uid 6.i 80,370.\\n\\nIn the recombinant humanized antibodies, the Fc portion\\ncan be modilied to avoid interaction with Fc( receptor aud the\\ncomplement and uumune systems. The tecluiiques for prepa-\\nmtion of\\'such antibodies are dcscrib(xl in WO99/58572 For\\nthe cousIant region may be enguieered to more\\nex unple.\\nresemble human constant regions to avoid immune response\\nif thc antib(xly is uscxl in clinical trials and treatments in\\nhumans. See. for example, U.S. Pat. Nos. 5.997,867 and\\n5,86&i,692.\\n\\nHuntanizedi antibody comprising the bght or hmivy clmin\\nvariable regions or one or more CDRs of mi antibody or Its\\nvariants shown in Table I, or oiw or more & DRs derived from\\ntbc mitib(xly or its vananm sho(vn in Table 2 can be made\\nusing any methods known in the art.\\n\\nHunmnizcxl antibodies indi\\'IL Inada by any nwtbod know n\\n\\n111 tile an.\\n\\nThe invention encompasses modifications to the antibodies\\nand polypeptidcs of the invention vmiams shown in Table 1,\\nincluding functionally eqiuvalent antibodies which do not\\nsignificmitly affect their propenies and variants which have\\nenhanced or decreased activity andior afiinity, I\\'or example,\\nthe amino acid sequence may be mutated to obtain an anti-\\nbody with the desired buiding alIiuity to PCSK9 Modiiica-\\nnon ofpolypeptides is routine practice in the art and need not\\nbe described in detml herein. Modification of polypeptides is\\nexempli lied in the Fxmnples Fxamp les of modilied polypep-\\ntides include polypeptides (vith conservative substitutions of\\namino acid reaiducs. one or morc delctions or ndditions of\\namino acids which do not signilicantly deleteriouslv chmige\\nthe fiuictioim I activity. or wlfich mature (enhance) thc affinity\\nof thc polypcptidc for im ligiuid. or u(c of chemical aimlogs.\\nAlllillo IIcld scqucncc lllscltloIIs lllcludc alii(no- i(lid/ol\\ncarboxyl-mnninal fusions ranging in length from one rc»idue\\nto polypcptides contnining a hundred or more r(si(hics. Sws\\nwell as intrasequence insertions of single or multiple amino\\nacid residues. I:xamplcs of tenninnl insertions include mi\\namibody with an N-terminal metluonyl residue or the anti-\\nbody fused to an epitope tag. Other Insertional variants ofthe\\nantibody molecule include the fusion to the N- or &\\'-terminus\\nof the antibody of un enzyme or a polypepude wluch\\nincreases the half life ofthe antibody in the blood circulation.\\n\\n\\x0cUS 8,080,243 B2\\n\\n33\\nSubstitution varim&LS lmvc at 1m&st one amino acid residue\\nin tlm m&tibody molecule removed and a different residue\\ninserted in &ts place. 11&e sites of greatest &nterest for substi-\\ntutio&u&l mutagencsis include the hypervariable regions, but\\nFR alterations are also contcmplatcd C:onservative substitu-\\ntions are shown in Table 2 under the heading of\"conservative\\nsubstitutions\" If such substitunons result in a chan e &n bio-\\nlo ical activity, then more substantial chm&ges, denonunated\\n*\\'exemplary substitutions\" in Table 2, or as further described\\nhelot& In reference to amino acid classes. mny be introduced\\nand the products screened.\\n\\n1ABLF 2\\n\\nAmu)o Acid So«su&nouns\\n\\nCo)uer,un e\\nSuhs«&uuons\\n\\nEsca)plan\\nSub&&du«on)\\n\\n0«uuud\\nlies&due\\n\\nA&a (A)\\ni«)\\nAsn (8)\\nAsp (0(\\nCvs (C)\\n(\\nIt& ( Q I\\nmu! T)\\n(GI\\nGl\\nH)s IH)\\nne (Il\\nI.eu I L I\\nLrs(K)\\nMet (Ml\\nThe&pl\\nPro \\\\P)\\nSe&(S)\\nIau (I\\'1\\nTsp iu\\')\\nTv) (Y)\\nVat (V)\\n\\nVal\\n\\nL s\\n\\nOh)\\nOhl\\nScl\\nAsn\\nAsp\\nMa\\n\\nA&\\nLeu\\nHe\\n\\nA&s\\nLeu\\nT)s\\nAla\\nThr\\nS»l\\nTs\\n\\nI\\'h»\\n\\nI eu\\n\\nVa& Ia)L u*\\nL)s. Oln Asn\\nOln. H)s. Asp Lss. A&S\\nGlu. Asn\\nSe&. Al,&\\n\\n&so. G&u\\nA)P: r h)\\n\\nAsn. r\\'o. I\\n1: As,\\nIeu.xal. VI\\n& A(K Ph .Hcnennne\\n«odeucwe. He.t)l, Me& Ala Phe\\nA& & h),Asn\\nIeu. Phc, nc\\nLeu. Val. I&e Ala. Tir\\nAla\\nTh&\\n\\nse&\\nT n Phe\\nT)p Phe, Ths. See\\nne. Leu. Me&, Phe. &&s. Xodenca)e\\n\\nSubstantial modifications in the biological properties ofthe\\nantibody ue accon&phshed by sefectuig subsututions tlmt\\ndiffer significantly u& their efl\\'ect on mmntauiing (a) the struc-\\nture of tlm polypeptide backbone in the area ol\\'lm substitu-\\ntion, for example, as a sheet or helical conformation, (b) the\\nchar e or hydrophobicity of the molecule at the target site, or\\n(c) tlm bulk of the side clmui Naturally occurring residues are\\ndivided into groups based on common side-chain pmperties:\\n\\n(11 Non-polar: Norleucine, Met, Ala, Val, Leu. He;\\n(2) Polar without char e: Cys. Ser, Tlu„Asn. Gin:\\n(3) Acidic (ncgati&mly charged) Asp. Cilu,\\n(4) Basic (positively charged) I.ys, Arg,\\n(5) Residues that influence clmin orientation: Crly) Pro; and\\n(6) Aromauc Trp. Tyr, Phe, His.\\nNon-Lonscrvativc substitutions are made by exchan ing a\\n\\nmember of one of these classes for another class.\\n\\nAny cysteine residue not\\n\\ninvolved In mau&taining the\\nproper conformauon of the sin&body also may be substituted,\\ngcnernlly with scrinc, to impro«\\'. thc oxidnti&m stability of thc\\nmolecule and prevent aberrant cross-linking. Conversely.\\ncyste&ne bond(s) may be added to the antibody to impmve its\\nstability, particularlv where the antibody Ls u& antibody lrag-\\nment sucli as an Fv fcdgmenL\\n\\nAmino acid modifications can mnge from changing or\\nn&odif& In one or more amino acids to complete redesign of a\\nregion, such as the variable region. Changes &n the venable\\nrey\\'on can alter binding aflinity and/or specificit. In some\\ncn&bodimcnts. no n&orc than one to live conwrvative amino\\nacid substitutions nre made ssithin a CDR domain. In other\\nembodiments, no more than one to three conservative amino\\n\\n34\\nacid substitutions are n&ade within a CDR domain In still\\nother embodiments. the C DR domain & s CDR 1 13 and/or CDIL\\nL3.\\n\\nI\\n\\nModificstions also inch&de glycosylated and nonglycosy-\\nlated polypeptides. as well as polypeptides with other post-\\ntrnnslational modifications, such as. for example, glycosyla-\\ntion v ith different sugars, acetyla(ion, m&d phosphorylation.\\nAntibodies are glycosylated at conserved positions &n their\\nconstant regions (Iefli:ris dnd I und. 1997. (.hcm. Immunol.\\nlo 65,H1-128, Wught and Morrison. 1997, T&bTFCH 15:26-\\n32). The oligosacclmride side chains ofthe inununoglobulins\\naffect thc protcm*s tinct«m (Boyd et al, 1996. Mol Inunu-\\nnol 32:1311-1318: Wittwe and Howard. 1990, B&ochem.\\n29 4175-4180) Slid the intrmnoleculnr interaction between\\nportions of the glycoprotein. &vliich min sfli:ct Ihe conli)rma-\\ntion and presented three-dimens ione I surface ofthe glycopro-\\ntoin (.Ietferis and I.&md, supra Wyss mid Wagner, 1996. C:ur-\\nrent Opia. Biotech 7.409-416). Ohgosaccharides may also\\nserve to target a given glycoprotein to certmn molecules based\\nn i&pun spccilic recognition structures Cslycosylation of ai&ti-\\nbod&es lms also been reported to affect antibody-dependent\\ncellular cytotoxicity (AI&CC). In particular, C\\'HO cells with\\n(3(1.4) N-scetylglu-\\ntetracycline-regulated expression ol\\ncosaminyltransferase Hl\\na glycosyltransferase\\n(C/nTIH),\\ncatalyzing founation of bisecting CilcNAc, was reported to\\nhave &mproved ADCC activity (Umana et al.. 1999, Nature\\nBiotech. 17:176-180).\\n\\nGlycosylation of antibodies &s typimilly either N-linked or\\n0-linked. N-linked refers to the attaclm&ent of the carbohy-\\nsn dmte moiety «) tlm side chain of an aspmdoi&m rcsi&hm Thc\\ntupeptide sequences asparagme-X-senna. msparaguie-X-\\ntlu eonine, and nsparaooine-X-cyste&ne, where X &s nny amino\\nacid Lxccpt p«1bi&L) dr\\'L thc I ccogn&t&on scquc&iccs RII\\'u/s\\'\"\\nmetic attachment ol\\'he carbohydrate moiety to the aspar-\\n\"» agine side chain. Thus, the presmicc of citlmr of these tripep-\\na potential\\nt&de\\nglycosylauon site. 0-linked glycosylation refers to the\\nattaclnncnt of one of the sugnrs N-acctylgalactosamine,\\ngalactose, or xy lose to a hydro xyainu&o acid, most conunonly\\nnn serine or tlueonine, although 5-hydroxyproline or 5-hydroxy-\\n\\nin a polypeptide crmdcs\\n\\nSL«Inc«con\\n\\nlysiim may also be used\\n\\nAddition of glycosylation sites to the antibody &s conve-\\nniently accomplished by altering the amino acid sequence\\nit conmins one or more of the above-described\\nsuch that\\ntripeptide sequences (f&ir N-linked glycosylation sites). The\\naltemti on may also be made by the addition of, or substitution\\nby, one or more senne or tlu eon&ac residues to the sequence of\\nthe onginal antibody (for 0-linked gfycosylation sites).\\n\\nThc glycosylation pattern ofantibodies may also be altered\\nu without alteung the underlying nucleotide sequence. Glyco-\\nsylation largely depends on tlie host cell used to express the\\nantibody Since the cell type used lor expression of recombi-\\nnunt glycoproteins. e.g., antibodies, as potential therapeutics\\nis rarely the native ccfl. variations in the glycosylat ion pattern\\nI of the antibodies can be expected (s&m, e.g.. I lee et al.. 1997,\\n\\nI. Biol. Che&u. 272:9062-9070).\\n\\nIn addition to tlm choice of host cells, I)nctors that aft\\'Lmt\\nglycosylauon dunng recomb«rant producuon of nut&bodies\\ninclude growth mode, media fom&ulation, culture density,\\nai oxygenation, pH. purilicati&m schcmcs and tlm like Various\\nmethods have been proposed to alter the glyco aylati on pattern\\nachieved in a particular host organism including introducing\\nor overexpressin cer(aui enzymes uivolved &n ofi osaccha-\\nride production (U.S. Pat. Nos. 5,047,335; 5,510,2C)l and\\n5,278,299) Cilycosylation. or certain types of glycosylation,\\ncan be enzymnticully removed fmm the glycoprotein, for\\nexample. using endoglycosidase H (Fndo H). N-glycosidase\\n\\ns\\n\\n\\x0cos\\n\\nyl at &on\\n\\nUS 8,080,243 B2\\n\\n35\\nF, endoglycosidase F I, endoglycosidase F2, endoglycosidase\\nF3.1n addit&on, the recomb&nant host cell can be enetically\\nm&gineered to be defect&ve in process&ng certain types of\\nI\\'hcsc and similar techniques arc well\\npolysaccharidcs.\\nknown in the art.\\n\\nI\\n\\n\".o\\n\\nact &vste\\n\\nOther methods of moditication include using coupling\\ntechn&ques known in the arh including, but not h&uhed to.\\nenzymat&c means. oxidative substin&tion and chelation.\\nModilications can be used.\\n\\nIior cxmnplc. for attachmentol\\'abelsIi&r immunoassay. Modified polypept&des are made u&\\n\\nusing established procedures in the an and can be screened\\nusing standard asm&ys kn&&wn ui the an, some ol uhich are\\ndescnbed below and &n the Examples.\\n\\nImmumil., 1999. 29 2613-2624. PC\\'T Publ No so\\n\\nIn some en&bodinmnts of the invention, the antibody com-\\nprises a modified constant region. such ns a &xmstm&t region i.\\nthat &s inununoloy\\'cally inert or partially inert. e.g., does not\\ntrigger complenmnt mcdiatcd lysis, docs not stimulate\\nnucrogl ia: or have reduced activ&-\\nADCC, or does not\\nties (compared to the unmoditied antibody) in any one or\\nmore of the following triggering complacent n&cdiatcd lysis,\\nstuuulating ADCC. or acuvaung micmglia. Different mod&-\\nfications of the constant region may be used to achiswe opti-\\nmal level and/or comb&nat&on of effector functions. See, for\\nexample, Morgan et al.. 199S. htununology 86:319-324;\\nI.und et al., 1996, J. Imnninology 157\\'4963-9 IS7:4963-\\n4969: Idusog&e et al.. 2000..1. Inuuunolo s 164:4178-4184;\\nfao et al.. 1989, J. Immunology 143: 2595-2(&01; and Jefferis\\net al, 1998, Imnn&nological R&wicsvs 163.59-76. In some\\nembodiments, the constant reg&on is modified as descnbed in\\nFur\\nWO99!58572, and/or IJK Paten& Application No 9809951 8.\\nthe antibody compnses a luunan\\nIn other embodunents.\\nhmivy chain IgG2 constm» region comprising the li&flowing\\nnnitations: A330P331 to S330S331 ( unino ac&d munbenng\\nwnhrcterencetothew&ldtypelg()2sequm&ce) Eur.J.lnumi- \"»\\nnol. 1999, 29 2C&13-2624 In still other cinbodimm&ts, thc\\nconstant reg&on &s aglycosylated for N-l&nked glycosylation.\\nIn some embodiments, thc constant region is avlycosylatcd\\nI\\'or N-linked\\nlycosyla&ion by mutating the glycosylatcd\\nanuno acid residue or flanking residues that are part of the so\\nN-glycosylation recognition sequence in the constant region\\nsite N297 may be mutated to A,\\nFor example, N-glyc\\nQ. K. or H. See. lao et al., 1989. J. Inummolony 143: 2595-\\n2&&01. m&d.leff& ris ct al, 1998, Inununological kcvicsvs 163\\n59-76. In some embodunents. the constant reg&on &s aglyco- s.\\nsylatixI for N-linked glycosylation. fhe constant region may\\nbe aglycosylated lor N-hnked glycosylat&on enzymatically\\n(such as removing carbohydmte by enzyme I\\'NC&ase), or by\\nexpression in a glycosyla&ion delicient host cefl\\n\\nI\\n\\no\\n\\nOther antibody mod&iicntions include ant&bodies tlmt have\\nbeen modified as described in PCT I\\'ubl. No. WO 99/SSS72,\\nThese nnt&bodies comprise. u& addition to a binding domnin\\nd&rected at the target molecule. an elfector domo&n Imvu&g an\\namino acid sequence substantiafly homologous to all or part\\nof a constant domain of a humnn uumunoglobuhn heavy\\nchain These antibodies are capable of binding the target\\nmolecule without triggering signilicant complcmcnt dcpmi-\\ndent lys&s, or cell-med&ated destruct&on of fite target In soine\\nembodinmnts, the effector domain is capable of speciticafly\\nbuiding FcRn nnd/or Fc) Rllb. These arc typically ix&scd on a&\\nchimeric domains derived from nvo or more lnuuan mmui-\\nnoglobuli n hcavy c1m in (\\'n2 domains. Antibodies n&odi tied in\\nthis mmu&er are particularly suitable for use ui cluo&uc ann-\\nbody therapy, to avoid intlammatory and other adverse reac-\\ntions to conventional nntibody therapy.\\n\\nI\\n\\n6\\n\\nThe Invent&on u&eludes affinity matiued emboduuents. I\\'or\\nexmuple, aflinity n&aturisI antibodies can be produced by\\n\\n36\\npmcedures known in tlm art (Marks et al, 1992, Bio/Tech-\\nnology. 10 779-783, Barbas ct al.. 1994, Proc Nau Acad. Sci,\\nUSA 91:38(8-3813; Scluer et al., 1995, Gene. 169;147-155;\\nYeiton e& al, 1995..1. hnmunol., 155 1994-2004, Jackson et\\nal, 1995,.1 Immunol\\n. 154(7):3310-9: Hawkins et al.. 1992,\\nJ. Mol. Biol., 226&88&9-896; and PCT Publ. No. WO2004/\\n058184).\\n\\nThe fo1 low u&g n&ethods may be used 1br ad) using the aflin-\\nity of an antibody and for characterizing a (\\'DR. One v,ay of\\ncharactenz&ng a CDR of an annbody anChor altering (such as\\nunproving) the binding aflinity of a polypeptide, such as m&\\nantibody. tanned *\\'libr ay scanmng mutagenesis\" Cienerafly,\\nlibrary scanninv nn&tagenesis works as foflosvs. One or more\\namino acid positions in the Cllk are replaced v;ith tuo or\\nmore (such as 3, 4, s, 6, 7. 8, 9, 10. 11, 12, 13. 14, 15. 16. 17,\\n18. 19. or 20) amino ncids using art recognized nwthods. \\'11&is\\ngenerates smail libraries ol\\'lones (in some embodiments,\\none for every mnino acid pos&tion that is analyzed) each with\\na complex&ty el\\'wo or more members (&f tu o or more amino\\nacids are subst&tuted at e&\\'e&y pos&t&on). GeneIallv. &he hbla&1\\nalso includes a clone comprising the native (unsubstituted)\\namu&o ac&d A small number of cfones. e.g, about 20-80\\nclones (depending on the complex&ty of the libmry), fmm\\neach library arc screened for binding aftinity to tlm target\\npolypeptide (or other bind&ng tar et), and c mdidates w&th\\nincreased, the same, decreased, or no binding are identified.\\nMethods for determining b&nding nflin&ty are u all-knoss n ui\\nthe art. 1)u&ding alhmty may be deternuned us&n B&score\\nsurfncc pk&sirlo&\\'I rcsoflancc &i&\\'lalysis. which dc&oem difli.r-\\necess u& binding aflinity ol\\'about 2-fold or greater. B&score is\\npart&culnrly useful when the stoning ant&body already bu&ds\\nv ith a relatively high alTinity, li&r cxamplc a K„ol\\'about 10\\nnM or loss er. Screen&ng us&ng B&score surface plasmon reso-\\nnance is described in tlm Examples, lmrein\\n\\nBinding aflimty may bc Ccterminnl using Kinexa Biocen-\\nsor, scinnllation prox&muy essays. ELISA. ORIGEN &nunu-\\nnoa ssay (I CiI\\'), tluo re scen ca quenching, fluorescence trm&s-\\nfer, and/or yeast display. Bindmg nlfinity may also bc\\nscreened using a suitable bioassay.\\n\\nIn son&e em bc din&ants, every amino acid position in a (\\'DR\\nis replaced (in some emboC&ments. one at a time) anth all 20\\nnatural amino acids using art recognized mutagenesis meth-\\nods (some of which are described herein) This generates\\nsmall lib mries ofcl ones (in some embodunents. one for every\\namino acid position that is analyzed), each with a complexity\\nof 20 members (&f all 20 amino acids are subsututed at every\\npos&&&on).\\n\\nIn some embodmicn(s. the library tobe screened composes\\nsubst&tuuons &n two or more posit&ons, wluch may be &n the\\nsame (\\'Dk or in two or more CDks. 11&us. the library may\\ncompose substitut&ons in &uo or more posit&m&s u& one CDR.\\n\\'I he library may compose substitut&on &n tv,o or more posi-\\ntions in tuo or morc ( DRs. The librnry n&ay comprise sub-\\nstitution in 3. 4, 5, or more pos&lions, smd posiuons f&&und in\\nnvo. three, four, five or six (.\\'DRs. I\\'he substitution may be\\n\\nprcpnrcd using low redundancy codons. Swx c.g, Table 2ol\\'afiutet al . 1993. Ciene 137(l).109-18).\\n\\nThe CDR may be (\\'IJRH3 and/or C\\'1)RI.3. The «)JR may\\nbc onc or morc of C\\'DRI,I, C\\'DRI.2,\\n( DRIuk C\\'DRHI,\\nCDki12. and/or «DR113. 11&e CDR may be a Kabat (\\'Dk. a\\n«hotl&ia (\\'DR, or m& extended ( DR.\\n\\nCand&dates w&th improved bind&ng may be sequenced,\\nthereby Identify&ng a CDR substinuion mutant which results\\nin in&provixI aflinity (also termed an \"improved\" substitu-\\nt&on). Catxhdates tlmt b&ud may also be sequenced, thereby\\nident&fying a CDR substitution which retains binding.\\n\\n\\x0cUS 8,080,243 B2\\n\\n37\\nMultiple munds of screening may be conducted. For\\nexmuple. candidates (each composing an anuno acid substi-\\ntution at one or more position of one or more CDR) with\\nimproved binding are also usefiil for thc design of a second\\nlibrary containing at least the onginal and subsntuted anuno\\nacid at each improved (.\\'DR position (i.e.. amino acid position\\nui the CDR at wluch a substitution mut mt ahois ed nuproved\\nbindm ). Preparation, screenuig, and selection of this library\\nis discussed I\\'artier bekiw\\n\\nLibrary sc uuung mutagenesis also provides a memis for\\ncltamcterizing a CDR, in so far as the frequency of clones\\nwith improvexI binding. tfie same binding, decreased binding\\nor no binding also provide information relating to the impor-\\ntance of each amino acid position for the stability of the\\nantibody-antigen complex For example, if a positioii of the\\nC DR retains binding vvhen changed to all 20 nmino acids, that\\nis unlikely to bc\\nposition is identified as a position that\\nrequirediiirantigenbinding Conversely,ifapositionofCDR\\nretains binding in only a small percentage of substitutions.\\ntliat position is identified xs a positimi tliat is important ui\\nCDR fiuiction. \\'11tus. the library scanning mute enesis meth-\\nods generate information regarding positions in tlie CDRs\\nthat can be changed to many different amuio acids (includin\\nall 20 amino acids), and positions in the CDRs which cannot\\nbe changcxl or which cmi only be changcdl to n fiw mnino\\nacids.\\n\\nI\\'andidates ivith improved affinity may be combined in a\\nsecond library, which mcludes the improvixI amino amd. the\\noriynal mmno acid, and may further include additional sub-\\nstitutiolis at that positiiln. depending oil the complexity ill tlic\\nlibrary that is desired. or penm tted usia„ the desired screen-\\niilg iir selection method. In addition, if desired, and adjacent\\nmnuui acid position can be mndomized to at li ast two or nuirc\\namuio acids. Randon»zation of ad)scent amuio acids may\\npermit additional conformational tlexibility in the nuitant\\nCDR. which inay. in turn, permit or Iiacilitatc the intr&iduciion\\nof a larger number of uuproving mutations. The library may\\nnlso comprise substitution at positions that did not show\\nunproved alfinity in thc iirst round o I\\'screening\\n\\n\\'lite second I ibrary is screened or selected for library mem-\\nbers with inipmvcd nnd/or altered binding affinity using miy\\nmethod knov;n ui the art. including screening using 1)iacore\\nsurface plasmon resonance analysis, and selection using any\\nmethod known in the art for scloction. including phage dis-\\nplay. yeast display, and nbosome display.\\n\\nTiie invention also encompasses fiision proteins compris-\\nuig one or more fragments or regions from the antibodies or\\npolypeptides of this invention. In one embodinient, a fiision\\npolypeptide is provided that mmiprises at lmist 10 contiguous\\nanuno acids of a venable light cliain reyon shown ui SEQ ID\\nNOs: 53. 16, 17. I g, or 19 and/or at least 10 amino acids of a\\nvariable heavy chaui region shoivn in SFQ ID NOs 54. 20.\\n21. 22. or 23. In other embodiments, a fiision polypeptide is\\nprovided that comprises at least about 10, at least about 15, at\\nleast about 20, at least about 25, or at least about 30 contigu-\\nous amino acids of the variable light chain region and/or at\\nleast about 10, at least about 15, at least about 20, at least\\nabout 25, or at least nbout 30 ctintiguous amuio acids of the\\nvariable hcavy cltain region In another embodiment. the\\nI\\'usmn polypeptide comprises a light chain vnriable region\\nand/or a heavy chaui variable region, as shov;n in any of the\\nsequence pairs selected from among SFQ ID NOs: 53 mid 54,\\n16 and 20, 17 and 21. I g and 22, and 19 and 23. In another\\nembodiment, tlie fusion polypeptide comprises one or more\\n(\\'DR(s) In still other embodimmitg tlic fusion polypeptide\\ncomprises CDI& 113 (VI I CDR3) and/or CDR L3 (VL CDI&3).\\nFor purposes of tlus invention, a fusion protein contains one\\n\\n38\\nor more antibodies and another amino acid sequence to which\\nit is not attached in the native molecule. for example. a het-\\nerologous sequence or a homologous sequence from another\\nregion. Iixemplary hcterologous sequences include, but nre\\ns not limited to a \"tag\\'* such as a FLACi tag or a 611 is tag. Tags\\n\\nare vvell known in the art\\n\\nA liision polypeptide can be created by methods knoivn ui\\nthe art. for example. synthetically or recombinantly. Typi-\\ncally, thc fusion proteins ol\\'his invention are made by pre-\\nt(1 paring an expressing a polymicleotide encoding them usin\\nrecombinant methods described herein. altlxiiigh they may\\nalso be prepared by other means knov, n in the nn, nicluiling,\\nfor example, chemical synthesis.\\n\\nThis invention also provides compositions comprising\\nantibodies or polypeptides con)ugated (fiir example, linked)\\nto an agent tliat facilitate coupling to a solid support (such as\\nbiotin or avidin). I\\'or simplicity. refcrmice will bc made gen-\\nerally to mtibodies with the understanding that these methods\\napply to any ofthe P(.: SK 9 binding mid/or antagonist embodi-\\no mmits described herein Conjugation gcni:rally rcli;rs to link-\\ning these components as described hereui. Tire linking (winch\\nis generally fixing these components in proximate association\\nat least for administration) cmi be achieved ui any number of\\nways. For example, a direct reaction between an agent and an\\nantibody is possible whmi each possesses a substinient\\ncapable of reactin»vith the other. For example. a nucleo-\\nphilic youp, such as an amino or sulihydryl group. on one\\nmay be mipable of reacting is ith a carbonyl-conuunm griiup,\\nsuch as an anhydnde or an acid halide, or auth an alkyl youp\\nio containing a good leaving group (c.g, a halide) on tlie otlmr.\\nAn antibody or pohpep tide of tlus invention may be luiked\\nto a labeling agent such as a ihiorescent molecule, a radioac-\\ntive lliolccillc or\\'liv tithers labels knovvn in the art I,abcls arc\\nknown in the art wluch generally provide (either directly or\\n\\n\"» indirectly) a signal.\\n\\nThc invmiiain also provides compositions (including phar-\\nmaceutical compositioas) and kits compnsing. as this disclo-\\nsure makes clear, any or all of the antibodies and/or polypep-\\ntides dcscnbcd herein\\n\\n4o\\n\\nThe invention also provides isolated polynucfeotides\\nmicoding the mitibodies mid peptides of tlm invention, and\\nvectors and host cells comprising the polynucleotide.\\n\\nAccordingly, the invention provides polynucleotides (or\\ncompositions,\\nincluding pharmaceutical\\ncompositions),\\ncompnsuig polynucleotides encoduig any of the following;\\nthe antibodies 4A5, 5A10, 6FEi, 7D4. 1.11 3, or any fragment\\nor part thereof havuig the ability to antagonize PCSK9.\\n\\nIn another aspect. the invention provides polynucfeotides\\nencoding any ol\\'he mitibodies (including mitibody I\\'rag-\\na ments) and polypeptides descnbed herein, such as antibodies\\nand polypeptides lusving impaired eifector function. Poly-\\nnucleotides can be madeand expressed by procedures Drown\\nui the art.\\n\\n5\\n\\nIn another aspect, tlm invention provides compositions\\n(such as phamiaceutical compositions) composing any of the\\npolynucleotides of thc invention. In some embodiments. the\\ncomposition euniprises an expression vector comprising a\\npolynucleotide encoding the anubody as described hereui ln\\nother embodiment, the composition comprises an expression\\nro imcuir comprising a polvnuclcotide encoding any of thi: miti-\\nIn still other\\nbodies or polypeptides described herein.\\nmnbodi ments, tlm composition comprises citlmr or both ofthe\\npolynucleotides shown in SRQ ID NO.25 and SFQ ID\\nNO:26. Expression vectors. and administration of polynucle-\\notidc compositions are furtlmr described herein.\\n\\nIn another aspect, the invention provides a method ofmak-\\n\\ning any of the polynucleotides described herein.\\n\\n\\x0cUS 8,080,243 B2\\n\\n39\\nPolynucluotides complenmntary to any such sequences me\\nalso encompassed by the present invent&on. Polynucleotides\\nmay be single-stranded (coding or antisense) or double-\\ns&tended, and may bc DNA (genomic, cDNA or synthetic) or\\nRNA molecules. RNA molecules uiclude I lnRNA molecules,\\nwhich contain introns and correspond to a DNA molecule in\\na one-to-one manner, md mRNA molecules, wluch do not\\ncontmn introns. Add&tional coding or non-codin sequences\\nmay, but ixmd mib bc present within a polynuclc&itide of the\\npresent u&vention, mui a polynucleotide may, but need not, be\\nlinked to other molecules und/or support matenals.\\n\\nPolynucleotides nuit\\'o&lip&lse a &&attic scxiuencc (& e . a&1\\nendogenous sequence that encodes an ant&body or a port&on\\ntlmreofl or may comprise a variant of such n sequence. Poly-\\nnuclcioitide vanants contain one or more substitutions, add&-\\ntions. deletions an&1\\'or insertions such that the inununoreac-\\ntivi&y ofthe encoded polyp&7tidc is not diminished. relative to\\na native immunoreact&ve molecule. The elTect on the &mmu-\\nnoreactivity of the encoded polypeptide may generally be\\nassessed ns describe&I herein Variants prefemblv cxlribit at\\nleast about 70% ident&ty. more preferably. at least about 80%\\nidentity, yet more preferably, at least about 90\"/a identity, and\\nmost preferably. at least about 95% &dent&ty to a polynucle-\\notide sequence that encodes a nat&ve antibody or a portion\\nthereof\\n\\nTivo polynucleot&de or polypepude sequences are sa&d to\\nbe \"identical\" ifthe sequence ofaucleoti des or emu&o acids in\\nthe tivo scx)ounces is the same when aligned for maxinnuu\\ncorrespondence as descnbed beloiv. Compansons between\\ntwo sequences arc typically pcrfonn&.d by cianparinv thc\\nsequences over a companson windoiv to identify wid com-\\npare local reg&ons of sequence sundanty. A \"comparison\\nw indov, *\\'& used herein, rcfi rs to a &ugnmnt oi\\'at least about\\n20 conuguous posiuons, usually 30 to about 7 &, or 40 to about\\n&0, in ivhich a sex)uence may be con&par&xi to a reference\\n&mqucnce &ii\\'hc seine number ol\\'ontiguous posit&ons aficr\\nthe two sequences are opt&mally al&gned.\\n\\nOptimal alignment of sequences for comparison mny be\\nconducted using the Megaligo progrmn in the l,asergenc suite\\nof bioinformatics software (DNAS\\'IAR.\\nInc., Madison.\\nWis ), using default parwneters This progran& mnbodies scv-\\neml al&gnment schemes described in the follow&ng refer-\\nences: Dayhoff. M. O.. 1978, A model of evolutionary change\\nin proteins Mntrices fiir detecting distant relationships. In\\nDayhoff. M. O. (ed.) Atlas of Pmte&n Sequence and Structure\\n(National Biomedical Research Foundation. Washington\\nD C.). Mol. 5. Suppl 3, pp. 345-358: Heu& J.. 1990. Un&tied\\nApproach to Alig&ut&ent and Phylogenes pp. 626-645 Meth-\\n183, (Academic Press. Inc, Sun\\nods u& Furymology vol\\nD&ego. Calif.): H&gg&ns. D. Ci. w&d Sharp, P M., 1989,\\nCABIOS 5:151-153: Myers. L\\'. W. and Muller W., 1988,\\nCABIOS 4:11-17. Rob&nson. Pk D.. 1971, (\\'on&b. Theor\\n11 10&: Santou, N., Nes. M.. 1987, Mol. Biol. Lvol. 4:406-\\n425: Sneath. P. H. A and Sokal. R R.. 1973, Numerical\\nTaxonomy the Princ&plea and Practice of Numencal Tax-\\nonomy (Freeman Press, San Francisco. I\\'nlif.): Wilbur. W J.\\nmid I ipmm&. D..i . 198\\'3. Proc Natl. Aced. Sci. USA 80 726-\\n730.\\n\\nPreferably. the \"percentage of sequence identity\\'s deter-\\nmined by comparing two opt&mally aligncdi sequences over a\\nw&ndow of comparison of at least 20 positions, wherein the\\nportion of the polynuclmtide or polypeptide sequence in the\\ncomparison window may compose add&t&ons or deletions\\n(i e., gaps) of20 percent or less, usually 5 to 15 percent, or 10\\nto 12 percent, as compnrcd to thc refcrcnce sequences (w hich\\ndoes not compose addiuons or deletions) for optimal ahgn-\\nment of the two s&xpiences. \\'I\\'he percentage is calculated by\\n\\n40\\ndemrmining the number of positions at v,hich the identicnl\\nnucle&c ac&d bases or anuno ac&d res&due occurs &n both\\nsequences to yield the number of matched posit&ons. divi du&g\\ntlm number of n&atchcd positions by tlm total nun&ber of\\n(&.e. the wuidow size) and\\nnniltiplying the results by 100 to yield the percentage of\\nsequence ident&ty\\n\\ns positions in the reference sequence\\n\\nVanants may also. or alternatively, be substantially\\nlximologous to a nat&ve gcnc. or a portion or complmnm&t\\nu& thereol. Such polynucleot&de vanants are capable of hybnd-\\nizing under modemtely stnngent conditions to a naturally\\noccurring DNA &cqumicc encoding a native antibody (or a\\ncomplementary sequence).\\n\\nSuitable \"&miderately stringent conditions\" include pre-\\n&&saltu& u»I soh&&ion of &xSSC, 0 5% SDS. 1.0 mM I:DTA\\n(pH 8.0); hybridizing at 50\" ( .-(i5\" (.\\'., 5xSS(\\'. overnight;\\nfiilkiwed by washing twice ai 65\" C for 20 minutes with each\\nof 2x. 0.5x and 0.2xSSC conuiining 0.1% SDS.\\n\\nAs used herein, \"hivgly stringent conditions\\'r \"hikes\\no stringency conditions\\'* aro those lira& (I) employ low ionic\\nstrength and hi h temperature for wa slung. for example 0 01 &\\nM sodium chloride/0.0015 M sodium citmte!0 I \"/a sodium\\ndodecyl sulfate at 50\\'s (2) employ dune hybndization a\\ndenaturing agent. such as formam&de, for example. 50/8 (v/v)\\nformamidc with 0.1% bovine serum albumin/0.1\" k Ficoll/\\n0.1% polyvinylpyrrol&dot&e/50 mM sodium phosphate buffer\\nat pH 6&.5 with 750 mM sodium chloride, 75 mM sodium\\ncitrate at 42\\': or (3) employ 50\\'/& formamide. 5xSSC (0.75\\nM NaCI. 0.075 M sod&um citmte), 50 mM sod&um phosplmte\\n(pH 6 8), 0 1% sodium pyroplxisphatc, 5xDenhardt*s sulu-\\n&&&1&1. son&cared saki&on spe»\\'11 DNA (50 iighnl). 0.1% SDS,\\nand 105!a dextran sulfate at 42\\'., iv&th washes at 42\\'. &n\\n0.2xSS(\\'sod&um chloride/sodium ci&rate) and 50\\'/&& lonna-\\nn»de a& 55\\'., followed by a high-stnngency wash cons&stu&g\\n\"» of O.lxSSC containing RDIA at 55\\'\\'. Thc skilled n&tissu\\n&vill recognize how to adiust thc tempcniturc. ionic strength„\\netc. as necessary to ace onuno date factors such as probe length\\nand thc like.\\n\\n&o\\n\\nIt i&ill be appreciated by &hose ol\\'ordinary skill in the art\\nthat. as a result ofthe degeneracy ofthe genetic code, there are\\nnmny nucleotide sequences that encode a polypeptide as\\ndescribed herein. Some of these polym&cleotides bear mim-\\nma1 homology to the nucleotide sequence of any native gene.\\nNonothcless. polynucleotidcs that vary due to differcnccs in\\ncodon usage are spec&ficaily contemplated by the present\\ninvention. Further, ageles of the genes comprising the poly-\\nnucleot&de sequences prov&ded herein are w&thin the scope of\\nthe present invention. Alleles are endogenous genes that are\\naltered m& a result o I\\'one or more mutnti oui. such as deleuo ns.\\nu add&t&ons and/or subst&tut&ons of nuclco&tides. The result&ng\\nmRNA and prote&n may, but need not, l&ave nn altered stnic-\\nture or function. Alfcles may bc identilied using stmidard\\ntechniques (such as hybri&h&mt&on. &unpl&iieet&on and/or data-\\nbase sequcncc comparison).\\n\\ns\\n\\nThe polynucleotides of this invention can be obtauled\\nusing chemical synthesis, recombinant methods, or P(\\'R.\\nMethods of chemical polynuclwitide &yntlmsis arc well\\nknoivn in the art wid need not be described in detad herem.\\nOnc of skill in the art can use the sequences provided herein\\nro and a commercial DNA synthesizer to produce a desired\\n\\nDNA sequence.\\n\\nFor preparing polym&clcotides using recombinant meth-\\nods. a polynucleot&de compnsuig a des&red sequence can be\\ninserted into a suitable vector, and the vector in turn can be\\nintroduced into a suitable host cell fiir replication and ampli-\\nficauon. as further discussed here&n. Polym&cleot&des muy be\\ninserted into host cells by any means known in the a&t (\\'ella\\n\\n\\x0cUS 8,080,243 B2\\n\\n41\\nare transformed by introducing an exogenous polynucleotide\\nby direct uptake. endocitosis, tmnsfection, Ixmaung or elec-\\ntroporat&on. Once u&troduced, the exogenous polynucleotide\\ncan bc maintained witldn the cell ms a non-intcgratcd v&xtor\\n(such as a plasm&d) or &a&earn&ed into the host cell genome.\\nfhe pclynu ciao tide so amplified can be isolated from the host\\ncell by methods well knov,n w&thui the art. See. e.g, Sam-\\nbrook et al., 1989, supra.\\n\\nAllcmativelv,\\n\\nPC\\'R allows\\n\\nreprixlnclion\\n\\nof DNA\\n\\n1\\n\\nsequences. PCR teclmology &s well into&vn ui the art and ls lo\\ndescribed in U.S. Pat. Nos. 4,683,195. 4,800.159, 4.754,065\\n\\'i&id 4,683.202. Cs well cs PC\\'R The Polymcrase C\\'hain Reac-\\ntion, Mullis et al., 1994, eds. (Birkauswer Press. Boston,\\nMass ).\\n\\nRNA cau bc obta»ied by using lhe isolated DNA in an\\nappropriate vector and inserting it into a suitable host cell.\\nWhen the cell replica&as and the DNA is transcribed into\\nRNA. &he RNA m&n that& be isolaled using nielhods well\\nknown to those of skill in the art, as set forth in Sambrook et\\nal, 1989, supm, I\\'or cxaluplc.\\n\\n\"v\\n\\nSuitable cion&ng vectors may be constructed according to\\nstandard teclmiques, or may be selected from a large number\\nof clonuig vectors evadable in the art. Wlule the clo&un\\nvector selected nmy vary according to the host cell intended to\\nbe used, useful cloning vectors will generally have the ability \"\\nto self-replicate. may possess a s&ngle tar et for a part&euler\\nrestriction endo nuc lease. and/or may carry genes fora marker\\nthat can be used &n selecting clones contamin the vector.\\nSu&table examples uiclude plasnuds and bactenal v&ruses,\\nc g. pUC\\'l8, pU(\\'19, Blucscript (c g.. pBS SK+) and its &v\\nderivatives, inp lb, mp 19. pBR322. pMB9, Coll\\',I. pCR),\\nRP4. phage DNAs, and shuttle vectors such as pSA3 and\\npAT28 Tlmse nnd many othir clmung vectors are avnilablc\\nfrom conunerc&al vendors such as B&oRad. Strategene, and\\nI llv& t fr& get\\'1\\n\\nExpression vectors generally are replicablc polynucleotidc\\nconstructs that contain a polymicleot&de according to tile\\ninvm&tion. It is implied that an expression vector must be\\nreplicable in the Ix&st cells e&ther as CT&iso&ucs or cs an integral\\npart of the chron&oson&al DNA. Suitable expression vectors sv\\ninclude but arc not limimd to plasmids, viral vectorz includ-\\ning adenov&ruses. adeno-associated v&ruses,\\nretrov&ruses,\\ncosmids, and expression vector(s) disclosed in P(\\'T Publ. No.\\nWO 87/04462. & bc&or components may generally include.\\nbut are not limited to, one or more of the follow ing: a signal 4.\\nsequence: m& origin of replication; one or more marker genes;\\nsu&table transcnpt&onal contml l&ng elements (such as promot-\\ners, enhancers and termu&ator). I&or expression (&.e., transla-\\ntion), one or nmre translatu&nal controlluig elemcnm are also\\nusually required. such as nbosome b&nduig sites. translation\\ninitiation sites. and stop codons.\\n\\nc\\n\\nThe vectors containing the polynuclex&t&des of u&terest can\\nbe uitroduced into the host ceil by any of a number of appro-\\npriate nmanw including clectroporation, transfection employ-\\ning calmum chloride, nibid&um chloride, cele&um phosphate,\\nDL\\'AE-dextran. or other substances; microprojectile bom-\\nbmdment, lipofixtion, mxl in 1\\'ection (c g, v\\'lmre the vector is\\nan infect&ous agent such as vaccin&a &in&s). The choice of\\nintroducing vectors or polynucleotides will often depm&d on\\nI\\'eatures of limbos\\'ell\\n\\ns\\n\\nsa\\n\\n\\'lite invention also prov&des host cells comprising any of\\nthe polynuclcotides described herein Any la&st cells capable\\nof over-express&n hetemlogous DNAs cmi be used for tile\\npurpose of isolating the genes encoding the antibody,\\npolypeptide or protein of interest. Non-limiting exmnples of (\\nmanuualian host cells uiclude but are not l&mited to COS.\\nHeL1. NSO. and CHO cells. See also PCT Ih&bl. No. WO\\n\\n42\\n\\n87/04462. Suitable non-n&anunalim& host cells\\ninclude\\npmkaryotes (such as E co /i or R sub/i i/is) and yeast (such as\\n5\\'. Cerevisve, R pv&abc: or K. lvc/is). Preferably the host cells\\nexpress the cDNAs at a level of about 5 fold higher, more\\npreferably, 10 fold lugher. even more preferably, 20 fold\\nhiglier tinn that oftile corresponding endogenous antibody or\\npmte&n of interest, if present, m the host cells. Screen&ng the\\nhost cells for a specific binduig to PCS K9 or a lxCSK9 dome&n\\nis cl\\'ll:ctcd by an immunoassay or FACS. A cell overcxpress-\\nuig the antibody or proteui of interest can be &denuiied.\\nC. Ciimpositions\\n\\nThe composiiions used m the methods of tlm invention\\ncompnse an effective amount of a PCSK9 ant&1 onist ant&-\\nbody. a PCSK9 antagonist m&tibody dcrivcd polypeptide. or\\nother PC\\'SK9 mitagon&sts describexI herein, Iixamples of such\\ncompositions, as well as how to formulate them, are also\\ndescribed in mi oarlier sccction and below. In one embodiment,\\nthe compos&t&on lhrther compnses a PCSK9 antagonist\\nIn\\nanother embodiment, the composition comprises one or more\\nPC\\'SK9 antagonist m&libodics\\nIn other embodimen(S lhc\\nPCSK9 antagon&st antibody recoy&izes lnunan PCSK9. In\\nstill other embodiments, the P(.\\'SK9 antagonist antibody is\\nhuman&zed. In yet other embodiments, the PCSK9 antagonist\\nantibody compnses a constant region that does not trigger an\\nunwanted or undesirable imnumc response, such as antibody-\\nmed&ated lysis or ADCC. In other emboduuents, the PCSK9\\nantagoiust antibody compnses one or more (\\'DR(s) of the\\na&uibody (such as one. u&o.\\nI\\'our, live, or. m some\\nln some emboduuents. the\\nembod&ments. all\\nP(\\'SK9 m&tagonist nntibody is bim&an\\n\\ns&x CDRs),\\n\\nthree.\\n\\nIl &s understood that lhe composit&ous mui comprise more\\nthan one PCSK9 antagonist antibody (e.g.. a mixnire of\\nPC\\'SK9 antagonist antibodies\\nrecognize dilfcrm&l\\nep&topes of PCSK9) Other exemplary compos&uons com-\\nprise more than one P(\\'SK9 antagonist antibodies tlmt recog-\\nnize lhc same CT&itope(s). Cr dilfcrenl spec&es ol\\'C\\'SK9\\namagoiust antibod&es that bind to different ep&topes of\\nP()SK9\\n\\nthat\\n\\nThe composit&on used in lhe pres&ait invention can lurther\\ncomprise phannaceut&cally acceptable carriers, excipients, or\\nstabilizers (Rcmington: The Science and Practice of Phar-\\nmacy 20th Ed., 2000, Lippincott W&lliams and W&lkins. Ed.\\nK. E. Hoover), in the form of lyophilized formulations or\\naqueous solutions Acceptable carriers. excipienis. or stabi-\\n1&zers are nontox&c to recip&ents at the dosages and concen-\\nuations, and may comprise buffers such as phosphate, citrate,\\nand other organic ac&ds: ant&ox&dents &nclud&ng ascorb&c ac&d\\nand metluon&ne: preseivatives (such as octadecyldunethyl-\\nbm&zyl mnim&niun& chlonde, hexmnellmminn chloride, ben-\\nzalkoiuum cldonde. benzethoiumn cldonde; phenol. butyl or\\nbenzyl alcohol, allyl parabens such as methyl or propyl para-\\nben. catechol, resorcinol, cyclohexano1„3-pentanol, nnd\\nm-cresolk low molecular we& ht (less than about 10 res&dues)\\npolypeptides, proteinz such ns senun albun&in. gelntin, or\\n&mn&uuogobulins: hydrophil&c polymers such as polyvi-\\nnylpyrrolidone; amino acids such as glycine, glutamine,\\naspalagi»c, lustidinc. Cn ininc, or lysinm monosaccharidcs,\\nd&saccharides. aud other carbohydrates u&clud&ng glucose,\\nmannosc, or dextrm&s; chelating agents such as Vl) I\\'A: sugars\\nsuch ns sucrose. mannitol, trclmlosm or sorbilol, salt-fonnmg\\ncounter-iona such as sodium; metal complexes (e.g., Zn-pro-\\ntein complexes); and/or non-ionic surfnctm&ts\\nsuch as\\nTWEENPC, PLURONICS™ or polyethylene glycol (PECi).\\nPlmnuaceutically acceptable excipients are further descnbed\\nherein.\\n\\nIn one embodiment. the antibody &s achnimstered ui a for-\\nnui lation as a sterile aqueous solution Imv ing a pH t1&at ranges\\n\\n\\x0c(js 8,080,243 B2\\n\\n43\\nfrom about 5.0 to about 6 5 and comprising from about\\nI\\nm /ml to about 200 mg/ml of antibody. from about I milli-\\nmolar to about 100 mtllimolar of histidine buffer, from about\\n0 01 mg&ml to about 10 mg/ml of polysorbatc80, from nbout\\n100millimolarto about400millimolaroftrehalose,and from 1\\nabout 0.01 millimolar to about 1.0 millimolar of disodium\\nI,DTA dihydrate.\\n\\nThe PCSK9 antagonist antibody Und compositions thereof\\ncan olso be used ui ConjunCuon with other agents tlmt serve tO\\nenhance and\\'or complement the efiectiveness of the &gents.\\nD. Kits\\n\\nThc invention also provides kits liir use in the instant meth-\\nods. Kits of the invention include one or more contauiers\\ncomprising a P( SK9 antagonist antibody (such as n human-\\nIred mitibody) or peptide descnbed hereul alai ulstructimis\\nfor use in accordance w ith any of the methods ofthe invention\\ndcscribcd hcrcin Cicncrally, thcsc instnictions comprise a\\ndescnptmn of administratmn of the PC\\'SK9 ant ig&mist uiti-\\nbody. peptide, or aptamer for tlm above described therapeutic\\nlrcauucllni\\n\\nUi\\n\\n\"o\\n\\nIn some embodiments, the anubody is a humamzed anti-\\nbody In some embodiments, the antibody is lnunan In other\\nembodiments. the antibody Is a monoclonal antibody. The\\ninstructions relating to the use of a I\\'CSK9 antagonist anti-\\nbody generally include inf&imiation as to dosage, dosing \"\\nschedule, Und route of adnuiustration for the intended treat-\\nment. The containers may be unit doses. bulk packages (e.g..\\nnndti-dose packages) or sub-&uut doses Instructions supplied\\nill tile kIts of thc 1llvcitt1oil Bl\\'c typic all\\'&\\'\\nll(tell l its tinct lolls oil\\na label or package insert (c g.. a paper sheet includ&.d in Ihc so\\nkit), but machine-readable instructions (e... uistructious cer-\\nned on a magnetic or optical stomge disk) are also acceptable.\\nThe kits of this invent«m arc in suitabl&. packaging Suit-\\nable packaging ulcludes. but is not linuted to, vials. bottles,\\njars. flexiblc packaging (e g., sealed Mylar or plastic bags),\\nBud Ihc like Also coIUPJupl&11&xl itrc pack&&gas liir usc in com-\\nbuiation v\\'ith a specific device. such as an inhaler. nasal\\nndministrafiondks ice(P g,anatomixer)ormlinfusiondevice\\nsuch ms a niinipump A kit may have a stenle access port (I\\'or\\nexample the container may be an intravenous solution bag or So\\na vial having a stopper picrccnblc by a hypodermic injection\\nneedle). The container may also have a stenle access port (for\\nexmnple the contniner may be an intravmious solution bag or\\na vial having a stopper picrccablc by a hypodermic injection\\nneedle). At least one actne agent in the composition is a ss\\nP(\\'SK9 antagonist antibody. The container (e.g., pri-tilled\\nsyniige or autointector) may further compose a second phar-\\nmaceutically active agent.\\n\\n\"»\\n\\nKits may optionally provide additnmal componenms such\\nas buffers and interpretive information. Normally, the kit\\ncomprises a contmner and a label or package insert(s) on or\\nBssocuucd with the contmner.\\nMutations and Modificauons\\n\\nU\\n\\n1\\n\\nTo express tlm P( SK9 antibodies of tlm present invention,\\nDNA fragments encoding V» and V, regions can first be\\nobtained using any of the methods described abnvc Various\\nmodifications, c g . nuitat iona, dclctions, tind/or additions can\\nalso be intr&xluced into the DNA sequences using standard\\nmethods known to those of skill in die art. For example,\\n&UUtagcllcs&s call bc cart\\'lcd UUI uslllg staudal\\'0 lac(linda. such ui\\nas I\\'CR-mediated mutagenesis, in wluch the mutated nucle-\\notidcs nre incorporated into tlm P(\\'R primem such tluit the\\nPCR product contmns the desired mutations or site-directed\\nmutagenesis.\\n\\nOne type of substitution, fiir example. tlmt may bc made is /\\n\\nto change one or more cysteines in the antibody, which may\\nbe cliemically reactive, to another residue. such as, without\\n\\n44\\nlimitation, alaninc or serine. For exanlplc, there can be a\\nsubstitution of a non-canonical cysteine. The substitution cmi\\nbe made in U CDR or fmmew ork region of a variable domaui\\nor in the constmlt domain ol\\'n antibody. In some embodi-\\nnlents, the cvsteinc is canonical\\n\\nThe antibodies may also be modified, e.g., in the variable\\ndomauis of the heavy and/or light chains. e... to alter a\\nbinding property of the anubody I or ex unple, a mutation\\nnlay bc maCk in onc or morc of tlm C\\'DR regions to increase\\nor decrense the K» of thc mitibody I\\'or PCSK9. to increase or\\ndecrease k,C or to alter tile binding specificity ofthe antibody.\\nTechniques~in site-direcmd mutageiwsis nre v;cll-known in\\nthe art. See. e.g., Sambrook et al, and Ausubel et al., supra.\\nA modification or mutation may also be made in a frame-\\nwork region or constmlt domaul to increase the half-fife of a\\nI\\'C SK9 antibody. See, e.g., PCT Pub l. No. WO 00/09560. A\\nnnimtion in a framewnrk region or constant domain can also\\nbe made to alter the unnulnogemcity of the antibody, to\\nprovide a site for covalent or ixm-covalent binding to another\\nmolecule. or to alter such properties as cmnplement lixntion,\\nPCR bmdin and anubody-dependent cell-mediated cytotox-\\nicity. According to the uivention. a single antibody may have\\nmutations in any one or more of the CDRs or frammvork\\nregions of the venable domain or in the constant domain.\\n\\nIn a process kno&vn as \"germ lining\", certain mnino acids in\\nthe VII and Vi scqUPllccs cUll be mutated to match those iinuxl\\nnaturally in germline V,& and Vs sequences. In particular, the\\namino acid sopmnces o I\\'tlm I\\'rmnew ork rcgmns in the V» and\\nsequences can be nnitated to niatch Ihe germline\\nV,\\nsequences tn reduce the risk of inmumogenicity when the\\nantibody is adnnnistered Ciennline DNA Sequences Ior\\nhuman V» and Vc genes are known in the art (see e.g.. the\\n\\'Vbase\\'* human gernlline sequence database, siv. also Kabat,\\nlk A., et al. (1991) Sequences of Proteins of Immunolo Ical\\ninterest, Fifth Hdition, H S. Deportment of Health and Hummi\\nServices, NIH Publ No 91-3242, Tomlinson ct al.. 1992, .1.\\nMol. Biol. 227:776-798: Und Cox et al., 1994. Bur, J. Inunu-\\nnol 24:827-83ti.\\n\\nAnother type of amino acid substinluon tlrat may be made\\nis to remove potential proteolytic sites In the antibody. Such\\nsites may occur in a (\\'DR or franwwork region of n vtmiablc\\ndomaui or In the constanl dom Un of an antibody. Subslitution\\nof cysteine residues and removal of proteolytic sites may\\ndivroase thc risk ofheterogeneity in the antibody product and\\ntluls increase its homogeneity. Another type of amulo acid\\nsubstitution eliminates a~sparaginc-giycinc pairs, which form\\npotential deanudation sites. by altering one or both of the\\nresidues. In miother example. thc (utenninal lysins of the\\nhcavy chain of a P( SK9 antibody of tlm invention call bc\\nclem ed. In vanous embodiments of the ulvention. the hea&0\\nand light clu&ins of the I&CSK9 antibodies nlay optionally\\nulclude a signal sequence.\\n\\nOnce DNA fragtuents encoding the V» and Vc segtuents of\\nth&. prcsmlt in&mntion are obtainixi, these»DNA fragnwnts cnn\\nbe further manipulated by standard recombinant DNA tech-\\nniques, for example to mmvert the variable region genes ro\\nIhll-length mlt&body chain gcncs, to Fnb fra ment genes. or to\\na scfv gene. In these manipulations. a Vc- or Vr»encodutg\\nDNA fragment is opemtivcly linked to arixitber DNA fnsg-\\nment encoding another protein, such as an antibody constant\\nregion or a flexible linker. The tenn \"operatively linked*\\', as\\nused in Ibis contexk is illtelldcd Io &nevi&i tfmt the tv 0 DNA\\nfbagments are )oined such that the mnino acid sequences\\nmlcodcd by tlm t&vo DNA I\\'ragnmnts rcnlain in-I\\'rmnc\\n\\nTile isolatcd DNA encoding the V» regimi cnn be c&mvcrted\\nto a full-length heavy chmn gene by operatively linking the\\nVI/ encoding DNA to another DNA nmlecule encodmg\\nheavy chain constant regions (CIII, CH2 and CI13). The\\nsequences of human heavy chain constant region genes are\\n\\n\\x0c(js 8,080,243 B2\\n\\n45\\nknown in the art (scca ge Kabat, I..A., et al . 1991, Sequences\\nof Proteins of Inununological Interest, I\\'ifth I.dition, U S.\\nDeparunent of I lealth and Human Services, Nil I I\\'ubl. No.\\n91-3242) and DNA frag&cents encompassing these regions\\ncan be obtained by standard PC R an&plifhcatiim The hcavy\\nchain constant region can be an IgCi l. Igf)2, IgCi3, Igti4. IgA,\\nIgp.. IgM or I D constant re &on, but most preferably is an\\nigCII or 180i2 constant region. The Ig(i const&lnt\\nleg&on\\nsequence can be any ofthe various all el as or a I1otypes known\\nto occur among differm&t individual a\\nsuch as Cim(1). h im(2)\\nCim(3). and Gn&(17) These allotypes represent naturally\\noccurring amino acid substitution in the igtil constant\\nregions. Fora I\\'ab fragment heaiy chau& ene. the VI I-encod-\\n&n DNA cm& be opemt&vely linked to another DNA molecule\\nencoding only the hcavy clmin I HI constant region. The I H I\\nheavy chain const u&t reg&on may be denved from any of the\\nheavy chain genes.\\n\\nThe isola&cd DNA encoding thc Vr region inn bc converted\\nto a full-lenegth light chain gene (us well as a 1&ab light cha&n\\ngene) by operatively linking the Vr-encoding DNA to m&other\\nDNA molecule encodu&g the l&ght ch nn constant region, Cr .\".n\\nI\\'he sequences ofluunun fight cl&mn constant region scenes are\\nknoivu in the art (aei e g . KabaL F.. A . ct al . 1991, Sequences\\nof Prote&ns of Immunolo ical InteresL I\\'ifth Bdit&on, U S.\\nDepartment of Health and Ilunmn Serv&ces, NIH Publ. No.\\n91-3242) and DNA frag&name encompassing these regions \"\\ncan be obtained by standard PCR unpliiicat&on. The 1&ght\\nchain consmnt region can be a kappa or lambda cimstant\\nregion. The kappa constant region mav bc any ol\\'the vari&ms\\nalleles known to occur among different individuals, such as\\nInv(l). Inv(2), and inn(3). The lmnbda constant rcgim& nmy bc Tn\\nderived from any of the tinea lambda ence.\\n\\nTo create a scl\\'v gene, the V~ and Vr-encoding DNA\\nI\\'ragmcnts are operatively linked i(& dnothc&\\'&ugn&cnt cncoll-\\n&ng a fiexible 1&nker, e.g.. encoding the mnino acid sequence\\n(Cily4-Ser),, such that the Vu and Vi seqtmnces cm& be \"»\\nexpressed as a cont& uous su&gle-chau& prote&n, with the Ve\\nand Vav regions joined by the flexible linker (See e g., Bird et\\nal, 1988, Science 242.423-42t&, Huston et al, 1988, Proc\\nNatl. Acad. Sci. USA 85; 5879-5883: McCafferty et al., 1990,\\nNamre 348:552-554. The single chain antibody may be nn\\nmonovalenL if only a single Vu and Vn are used. b&valent, &f\\ntw 0 V» and V, are used, or polyvalent, &f more than nvo V„\\nm&d Vn are used. BisP&x:itic or Polyvalent anfibodics &nay bc\\ngenerated that bu&d specdically to PCSK9 and to another\\nmolecule.\\n\\n4.\\n\\nu\\n\\nIn m&otlmr einbodimint, a fusion antibody or immunoad-\\nhesin may be made tluit compmses all or a portion oi a PCSK9\\nm&tibody of the invention linkcxl to another polypeptide In\\nanother embodimenL only the vmiable domains ol\\'he\\nPCSK9 antibody are linked to the polypeptide. In another\\ncmbodinmnt,theVTudon&ainofaPC\\'SK9antibody islinkedto\\nafirstpolypeptidi.whilethcV, dmnainofaPCSK9antibody\\nis linked to a second polypeptide that associates with the first\\npolypeptide in a mannersuch that the VuandVr domains can\\ninteract ivith one another to form an ant&gen bind&ng s&te. In\\nanother preferred embodiment, the VH domain is separated\\nI\\'rom the Vr domain by a linker such that tlm VH mul VI,\\ndomains can interact with one another. The V„-hnker-\\'e\\',\\nantibody is then linked to the polypeptide of interest. In\\nadd&t&on, fiis&on anubodkes can be created in wh&ch tivo (or m&\\nmore) single-chain antibodies are linked to one another. \\'IKis\\n&s useihl il\\'one wanLs u& create a divalent or polyvalent ant&-\\nbody on a su&gle polypeptide cha&n. or if one wants to create\\na bispecific antibody.\\n\\n6\\n\\nIn other ambi&dimenta other umd&lied m&tibodies may be 6\\n\\nprepared us&ng PCSK9 anubody encoding nucleic ac&d mol-\\ncculcs For instance, \"Kappa bodies\" (ill ct ale 1997, Pmtcin\\n\\n46\\nI\\'ng, 10:949-57).\"Minibodies\" (Mnrtinctel..1994, FMBO I.\\n13 5303-9), \"Diabodies\\'Holliger et al, 1993, Proc. Natl.\\nAcad. Sc&. (ISA 90: 6444-6448), or \"Janu sins\" (Trm&necker et\\nal., 1991. L\\'MBO J. 10:3655-3659 and \\'Iraunecker et al.,\\n1992. Int Ji. Cancer (Suppl.) 7 51-52) nuiy be prepared usu&g\\nfollow&ng the\\nstandard molecular biolog&cal\\nteachings ol\\'he speciiimitmn.\\n\\ntechn&ques\\n\\nB&spec&iic antibod&es or ant&gen-b&nding fragments can be\\nproduced by a vanety of methods including fus&on of hybri-\\ndumas or linking of Fab\\'ragments. See, e.g, Songsivilai k\\nLaclm&mu&. 1990, C1&n. Bxp. Inununol. 79: 315-321„Kostelny\\nct al, 1 992. J. hnnnmol. 148 1547-1553. In addition, bispc-\\ncilic anubodies may be formed as \"d&ab&&dice\" or \\'*Jmiusins \\'*\\nIn some embodiments. the bispieciiic antibody binds to two\\ndiffi:rent epitopes of PC.SK&J\\nIn some mnbodiments. the\\nmodified ant&bodies duse&&bed above are prepared using one\\nor more of the variable domains or C\\'DR regions from a\\ninunan PC\\'SK9 antibodv provided herein.\\nCienerauon of Antigen-Specific Annbodies\\n\\nrecomb&nant\\n\\nMore than 500 polyclonal and monoclonal antibodies\\ncused against\\nfull-length human PCSK9,\\nrecombinm&t full length mouse PCSK9, and various synthet&c\\npi7 tides w ere evaluated for their ability to down regulate tots I\\nLDLR protein u& cultured Huh7 human liver cells. Amon\\nthese antibodies were a set of antibodies raised to and reactive\\nwith a set of 12-20 mnim& amd rcs&due polypc7uides that,\\nbased on the structure of PCSK9, were predicted to cover\\n&up&ority of the protein simfacc At thc highest conccntmtion,\\nthe best antibodies exhib&ted only about 60% block&ng activ-\\nity.\\n\\nThus, an alternntive aml hercu&fi&re unexplored approach\\nu&t&-\\n\\nwas employed, nmnely. the geneuu&on of monoclonal\\nbodies by inununizing PC\\'SK9 null mice with riccombinant\\nfuII-long&h PC\\'SK9 protein This mannir of antibody pri7a-\\nmuon y&aided antagorust anubodies that show complete\\nblocking of PC\\'SK9 binding to I.DI,R, mhmpletc blocking of\\nPCSK90&ixfiatnxiloweringol1 DI R levelsinlluh7cells,and\\nloitering of LDLc in vivo including in mice to levels compa-\\nmble to tlmt seen in PCSK9-/- mice, as shown in Fxample 7.\\nRepresentative ant&bodies (hybridomas) of the present\\ninvention were deposited in the American fype I\\'ulture Col-\\nlection (ATC\\'C\\') on Feb 28, 200K and were assigned tlm\\naccess&on numbers u& Table 3. Hybridomas were depos&ted\\nfor antibodies 4AS, 5A10. 61\\'Ci and 7D4.\\n\\nTABLL\\'\\n\\ni,n& bnd Re&&&ence\\n\\nATCC *iccesunn inn\\n\\n4A\\n\\nA&(&\\n\\n6&6\\n&un\\n\\nP&\\'Admns\\n&n&A4066\\nPTA-SS64\\nPTA Scent\\n\\nLXAMPI.DS\\n\\nFxmuplc I\\n\\nCicnerating and Screening PC\\'SK9 Antagonist\\nAntibodies\\n\\nCieneral Procedures for Immunization ofAnimals fihr Ciener-\\natu&g Monoclonal Antibodies:\\n\\nBalb/c or 12971&16 pcsk9-/- mice were injected 5 times on\\na 13 day schedule with 100 pg antigen PC:SK9-/- (tlmt is,\\nnul I or lu&ock out auca) can be obtained fmm. or as des cubed\\nby, Rashid et al.. 2005. I\\'mc Natl Acad Sci USA 102: 5374.\\n\\n\\x0cUS 8,080,243 B2\\n\\n47\\nSee also H.S Pat. No. 7.300,754. For the tirst 4 injections,\\nan«gen was prepared by nuxing the recombinant proteins\\nwith adjuvant. Inununogen was given via injection to the\\nscruff of thc nnvk.\\nthe fiiot pads and intraperitoncafly,\\napproximately every 3 days over the course of 11 (hnys. Ivith\\nthe last boost administered i.v., without adjuvmit. On Day 13.\\nihc roice uci\\'c cufliiliiizcd Iiiil ilmir splccus werc I\\'cI(iovcil.\\nLymphocytes were inunortalized by fusion with an estab-\\nlished cell liim «I make hybridoma clonimx using siimdard\\nhybridoma technology. distnbuted uito 96 well plates. Clones\\nwere allowed to gross. then selected by ELISA screenuig\\nusing the immimixing mitigen. as behuv.\\nELISA Screemng ot Antibodies:\\n\\nSupernatant medin from growing hybrid(mia cloncs were\\nscrewnnxt separately for their ability to bind the recombuinnt\\nluunan P(\\'SK9 or recombinant mouse VCSK9. The assays\\nwerc performed with i)6-well plates coated overnight with\\n100 pl of a I Vg/ml solution of ime of the an«gens Fxcess\\nreagents were washed from the wells be«veen each step with\\nPBS containing 0 05% Twnmn-20. Pintos werc then blocked\\nwith PBS containing 0.5% BSA. Supernatant was added to\\nthe plates and incubated at room temperature for 2 hours.\\nHorse radish peroxidase (IIRP) conlugnted goat-anti mouse\\nFc wos added to bind to the mouse antibodies bound to the\\nantigen. Tetrmncthyl beozidine was then ndded as substrate\\nfor HRP to detect the unount ofmouse antibody present in the\\nsupeniatant. The reaction uas stopped and the relative\\namount of uiu body was quonti lied by reading the absorbance\\nat 450 nm. I lybndoma clones that secreted antibodies that are\\ncapable of binding to ciihcr mouse or lnmian PCSK9 werc\\nselected for furflier onnlysis.\\nPCSK9-Mediated LDLR Down-Reg(«lotion in 1luh7 Cells:\\n\\nHybridoma cloncs secreting human or mouse PC\\'SK9\\nbinduig antibodies were expmided and supematants were\\nharvcstcd \\'Iotai IgCis were purihed from approximately 10\\nml of ihc supernatant using protein A bead~. diolyzedt uito\\nPBS buffer, and the tinal voliune reduced to yield solutions\\nwith 0 7-1 mg/mt ofantibodies. I\\'uri tied antibodies u crc then\\nused to test their ability to mhibit the ability ol\\'CSK9 to\\nmediate LDLR dovin-regulation in Huh7 cells. Huh7 cells\\nwere plated and aflou cd to grow to SO\\'Ao coirflu( (Icy in RPMI\\nmedia contauiing 10% IIBS. 4 mM glutomine, and penicdlin\\nand streptavidin in 96 well plates. 1he mediiun vvos chanoed\\nto onc containing 10%v dc-1 ipidatnxt F BS fiir 3-16 hra to induce\\nLDLR expression. Cells were then incubated for g-16 hours\\nwith 40 pl/well of 293 expression media supplementixt with C(\\npg/ml of Inunan (preferably) or mouse PCSK9. u 3th or with-\\nout 70-100 ug/nil oftest antibodies. The PCS K9 and antibody\\ncontmning midin were removed at ihe cnd of incubntion, and\\ncells were lysed with 17 gl lysis buffer by shakuig at 4 C for\\nan hour. 11ie lysis buffer consisted of 50 mM glycerol phos-\\nphate. 10 mM HFPES pH 7.4. 1% Tn«m X-IOO, 20 mM\\nNaCI, mid a cocktail of protease intubitors (Roche). Cell\\nlysates were cottcctnxt and analvzcd fiir I,DI R protein levels\\nvia staining o I\\'Western blots folloii ing SDS pclyacryl anode\\ngel electrophoresis Hybridoma clones producing antibodies\\nthat can partially or Iiully rose«c I,DI R level wcn. selected fiir\\nfurther mudysis By \\'*I,DLR down regt(lotion assay\" is memit\\nthe above assay using Huh7 cells.\\n\\nFICi\\n\\nI iflustratcs thc CITcct ol\\'nti-PC\\'SK9 antagonistic\\nmonoclonal antibodies 7D4.4, 4AS.C73. 6F6.(i10.3 mid\\n5AI 0.BS on the ability of In(mon and mouse V( SK9 to down\\nregulate LDLR ui cultured I iuh7 cells. 100 CM of n«Ouse or\\nluunon recombinant I\\'CSK9, and a serial dilution of 25-300\\nnM of antibodies werc used. A) mouse P(\\'SK9 B) lniman\\nPCSK9. 11ie figures are Western blots shomng that the anti-\\nbodies are in general more effective in blocking the function\\n\\n48\\nof hi(itin(i P(\\'Ski) than mouse P(\\'SK9 I\\'he several nntibodies\\nhaivgenerally similoroffinities forhumanP(\\'SK9but vary in\\ntheir affiiuty for munne PCS K 9.\\n\\n5\\n\\nFxample 2\\n\\nDetermining Antibody Binding Athnity\\n\\nI\\'he affinities of V(.:SK9 antibodies to VCSKI9 were mea-\\n\\'\" sured on a surface plasmon resonmice Biacore 3000 biosen-\\nsor cquippcd with a research-ornde sensor chip using HBS-\\nnou GF.\\nFP runnuig buller (BuicorcAB, Uppsala, Siveden\\nHealthcare). Rabbit polyclonal anti-Ms Ig(is vvere amine-\\ncouplod at saturating levels onto dm chip using a stmidard\\n\" N-lndroxysuccininude/etlnldimethylmninopropyl carbodi-\\nimide (NHS/1113(\\') chemistry. I\\'he buffer was sv;itched to\\nIIBS-EP+I mg,\\'mL BSA+I mg/mL CM-dextmn Full-length\\nPCS K 9 IgCis were diluted to about 15 Vno/niL and capnired for\\nI min at 5 ttt /min to give levels of about 500RII per flou cell,\\nleavuig one bl udi io serve as a reference chmuiel, 3.73-302\\nnM hl\\'C\\'SK9 or 2.54-206 nM ml\\'CSK9 mere injected as a\\n5-membcrnxt 3-fold series for I min at 100 VI /niin.\\n\\n\"-\"\\n\\nDissociation was monitored for 5 min. The chip was re en-\\nemted afler the last injection of each titmtion tvith tu o 30 sec\\n-\"\\'ulses ol\\'100 mM phosphoric amd Buffi:r cycles provided\\nblanks for double-referencuig the data. v, luch Ivere then tit\\nglobnlly to a simple binding nmdcl using Biacvaluation sofi-\\nu are v 4.1. Atiimties were de«laced from the quotieoi of the\\nkinetic rate constants (Ko=k„Fkox). The results of Example 2\\n\\'\" arishowninTablc4. Tficscdatashou tluitihemiubodies have\\nexcellent athmty for nninne PCSK9 or human PCSK9. as\\nindicated\\n\\nTABLL\\'\\n\\ninh(bi«on(t\\n7 DI K Pi SK9\\nbmrbng(K\\'v)\\n\\nK,„ror\\nPPSK9\\nii Mi)\\n\\nKiiini\\nPr\\'SK9\\n(3 Sl\\n\\nKnrni\\nPC~SK9\\n\\n(nMI\\n\\nI gnni\\n\\nSUUIUU\\n\\n7111(I(i(l\\n\\nh(n non\\n\\nhnn(UU\\n\\n\\',4 IIM\\n\\n0,4 UM\\n(.5 n Mi\\n\\n(UMI\\n\\nI\\n\\nUlnas(\\'(OUUO\\n\\nn(OUU\\n\\nn(UUU\\n\\n3 UM\\n\\n1 UM\\ni« UM\\nI nvt\\n\\nio\\n6.66\\nin\\n8.47\\n9 Isx in\\n(2 x(0\\nI 4( x io\\n7 x ino\\nI\\nI ii x IO\\n3 97 x IU\\n\\n(.89\\n\\nin\\n\\nin\\n\\n\\'55 io\\n.84\\n7 94 x I 0 \"\\nx in\\n4 S9 x 10 \\'\\n7\\n77 x io\\nin\\n\\n\\'.. 8\\n\\n6.4\\n64\\nI I\\n\\n177\\n\\nI 3\\n\\nnn\\n\\nmib\\n\\n445\\n3(0\\n\\n67\\'6\\n7D4\\n\\n5.4(n\\n6I16\\n\\n7D4\\n\\nL\\'xample 3\\n\\n0\\n\\nAi«slys(s of the Effect of PCSK9 Antibodies on\\nPCSK9-LDLR interaction\\n\\nPCSK9 hos been shou n to bind LDLR with un aflinity of\\n130 nM under neutral pH ((.unningham ct al. 2007, Nat\\n5 Struct Mol Biol. 14(57413-9). Recombinant mouse orhuman\\nVCSK9 protein was biotinylated using the Pierce reagents\\nfollowing tfm manul\\'UC«ire\\'S inatructiOns. F/EISA platea\\n(Corning Mixisorb) were coated u ith a solution of I t(g\\'mt\\nrecombinant LDI,R extracellular domain (Rdrt) Systems) in\\n60 each v cll at 4 C oveniighi. blocked with 2% BSA+PBS liir2\\nhrs at room tempemture, and then iva shed 5 times with wash-\\ning buffer (I xVBS+0.05%v Tween-20). Wells were incubated\\nu 3th 50 pl of indicated concentrations of bionnylated PC SK9\\nprotein for I hr Kf. LDLR-PCSKD) binding can be stabilized\\nby adding 50 td of 4% FDH+4% sucrose+PBS solution and\\nincubate for 5 min. Wells were wushed 5 tunes with wosiung\\nbutTer. incubated with I:2000 dilution of HRV conjugated\\n\\n\\x0cUS 8,080,243 B2\\n\\n49\\nStrepavidin (Invitrogen) I\\'or I hr at RT. wasJ&i&J 5 tinm& v ith\\nwashing buffer TMB substrate &has added to the v,ella. the\\nsolut&on v;ls incubated 20 to 30 min at RT, and the reaction\\nwas tern&inated using I M phosphoric acid. Signals were read\\nat 450 mu.\\n\\nmxl mouse P( SK9 HiRorno bi lixed\\n\\nFIO. 2 illustmtes the dose-response of ant&-PCSK9 antago-\\nnist monoclonal m&tibodies 6F6Ci103. 7D4.4. 4A5(i3,\\n5A I 0 Bg, negat&ve control antibody 42117. and PB S on block-\\ning the b&nding of recombinant biotinylated lnunan PCSK9\\nrceeombi&umt I DI R extra-\\ncellular dom un u& v&tro. Part A) shov;s humm& PCSK9 bu&d-\\ning, to human I.DI R extracellular domain and that 7D4, 4A5.\\n5A10. m&d 6F/1 are cll\\'ective in blocking binding, ulmreas\\n42H7 and I\\'BS are not. Part B) shov, s mouse PCSK9 binding\\nto human I.DI,R exrracellular domain\\n\\nThe interaci&on cm& also be evalun&ed ul free soluuon at\\nneutral pH. FJO. 3 illustrates the dose-response of anti-\\nP( SK9 monoclonal antagonist antibodies 6F6.(i 10 3, 7D4 4,\\n4A5.63 and 5AI0.B8 on blocking binding of recombinant\\nbiotinylated human P(\\'SK9 (30 nM) to liuropium labeled\\nrecombinant LDLR extracellular dom un (10 i&I) u& soluuon\\nat neutml pH in vitro. \\'Ilus assay measures b&nding &n free\\nsolution at neutml pH.\\n\\n50\\ninjecting human-P( SK9 at 50 nM for I min at 10 pl /min (ro\\ntether it via tlm Ig(i on the clup) and then binding an army of\\nI C&s (final 500 nM each) for 2 mine each. The &mmobil&zed\\nlg(is were regenerated with 0 mild acid (Pierce gentle elution\\nbufl\\'sr+I M NaCJ) Antibodies dirovted to known dilfercnt\\nepitopes were used as controls for positive sandhvich forma-\\ntion in th&s assay\\n\\nc. Siructure-guided muta enesis to map antibody b&nd&n\\ncpitopes. Ha&cd on the crystal stn&cture of P(.SK9 m&d thc\\n1&kely u&volvement of D374 in LDLR binding (Cunningham\\net 01., 2007. Nat Struct Mol Biol. 14(5): 413-419), nu&eteen\\nPCSK9 siaface-r&widue mutunts (F379A. 1369A, R194A,\\nl&374Y, D238R. T377R, K222A. R199A, F216A, R218A,\\nR237A Dl 92R l&367R R165 k R167 4 A443T A53V\\nI 474&r, 11449A) near or far from the posiuon of D374 were\\nchosen fbr nnitation to map the antibody binding epitopes.\\n\\n&0\\n\\n„-\\n\\nd Mutant and antibody production The 19 single point\\nmutants &here generated I\\'rom the prev&ously describe&I hh ikl-\\ntype DNA construct ((loaning&L7&n et al., 2007, supra) using\\nstandard DNA techniques. Thc mutant proteins werc\\ntransient tronsfowt&on &n HIJK293T coils and\\nexpressed usus\\nsecreted into the cell media. \\'I he mutant proteins were puri-\\nlicd v ith thc high-throughput AKTA Xprcss system ((iF,\\nllealthcare) by Ni\\'nd size-exclusion chromatography\\nsteps, using conditions similar to those described earlier Pro-\\nteu& concentrations were detenmned usu&g the LabClup\\ninstrument (Bio-Rad). The PCSK9-blocking murine antibod-\\nies 4A5, 7D4. 5A10 and fiF6 uvre expressed with transient\\n10 transfect&on &n IIL&K2931 cells and purilied &Pith 0 pn&te&n (1\\ncolumn eluted w&th 0.1 M (ilycine buffer at pH 2.8 and\\nneutralized into 1.0 M Tns at pl I 9.0.\\n\\nantibodies 5A 10 and 7D4 (preparation describe&I\\n\\ne. The reg&ons of PCSK9 that are contacted by monoclonal\\nlater herein)\\n;; were determined by proteus tomography (Sidec A B, Stock-\\nholm. Sweden). The loops at positions 186-200, 371-379,\\n176-181, 278-283. 449-45\\'3. 402-406. and 236-245 of P(\\'SK9\\nwere prox&mal to uuino ac&d residues of the ant&body. The\\nsequm&ces corresponding to tlm loops arc shown in Table 5,\\nand in a prcferrcd embodi men&„ the antagonis(h ol\\'he inven-\\ntxul bind to one or more of these sequences in PS(\\'K9.\\n\\nTABLE 5\\n\\nPCSK9 Loop\"\\n\\nSequence\\n\\nSEQ ID »0\\n\\n186-200\\n\\n236-245\\n\\nDTSIQSDHREIEGRV\\n\\nGPDAGVAKGA\\n\\n0\\n\\n371-379\\n\\nrssDcsTcp\\n\\n176-181\\n\\nGGSLVE\\n\\n278-283\\n\\n449-453\\n\\n402-406\\n\\nQPVGPL\\n\\nHGAGI&\\n\\nREPEL\\n\\nf. Biacore bu&du&g of the nu&tents to &mmobihzed I,DI R.\\nRecombinant LDLR extracellular domain protein was immo-\\nR& bili/cd onto 0 Biacore SA chip Fach nnitant protein uas\\ninlected to the Biacore-3000 M) in duplicates at 25 mM to\\n0.012 mM at five concontmtions (from I\\'\\n. v, ith a running\\nbufl\\'er of 50 mM Tns pil 7.5, 2 mM CaCls. 200 mM NaCJ,\\n0 02A01 20 and I tng/ml BS 3 All the results fit nicel)\\'o 0 I: I\\nbinding kinetics model As expected, nuitation at residues in\\ndirect contact with the L&(ilAA domau& (I\\'379A. R194A,\\n1369M \\'I\\'377R. 0238R) significantly weakens (by 10-100\\n\\nI\\')&ample 4\\n\\nJ.\\'p&tope Mapping/Binding of Ant&bodies using the\\nCrystal Structure of the LI I,3 P(\\'SK9 Complex,\\nBiacore, and Mutagenes&s\\n\\na Crystal structure ol the 1.11,3.P(\\'SK9 complex. The res&-\\ndues were &dent&fied by calculatu&g the difference &n acces-\\nsible surl\\'ace arcs bctwccn tlm1,113:P(\\'SK9 crystal stnicturc\\nand PCSK9 structure alone. PCSK9 res&dues that shov. buned\\nsurface area upon complex fonuation v,ith I,IL3 antibody\\nWore u&Cluded as apart GI\\'thi: Lpilopc Thc solvent accessible\\nsurface of a proteu& he as delined as the locus ol the centre of a\\nprobe sphere (representing a solvmu molecule of I 4 A\\nradius) as it rolls over the%ender W»RJS surlhccofthe protein\\nfhe solvent accessible surface area was calculated by gener-\\nating surface poif&ts on an cxtcndc&J sphcrc about each R&onl\\n(at a distance from the atom centre equal to the s&uu of the\\natom and probe radii), and eliminating those that lie witlfin\\ncquivalcnt sphorcs associand with neighboring atoms as\\nunplemented &n proc+\\'an& ARBAIMOL (Bnggs, P..i., 2000,\\nC(.:P4 Newsletter No. 38, C(\\'I.R(\\'. Daresbury).\\n\\nThe result of the crystal structure analys&s are shown &n\\nFICi. 23. I\\'JO. 23A shou s the crystal structure of the PCSK9\\n(light gray surface ILT&reseutafion) bound io the 111,3 mlti-\\nbody (black cartoon representat&on). The epitope for L 1L3\\nbinding to PCSK9 involves residues 1 &3-155, 194, 197, 237-\\n239. 367, 369, 374e&79 and 381 of thc P(\\'SK9 amino acid\\nsequence (SLQ ID NO:53). By companson, the epitope for\\nthe I DI.R HOF domain binding to P(\\'SK9 involves residues\\n15:)-1«, 194, 238, 367, 369, 372, 374-375, and 377-381\\n(Khvon et al.. 2008, PNAS 10&: 1820-1825).\\n\\nb (iroup antib&alice and epitopcs based mi competition in\\nP(\\'SK9 buuling. I\\'ull-length Jg(is were unine-coupled to a\\nCM5 sensorchip(three per chip at about 7000RU final), using\\na standard FDC/NHS-mcd&etc&I aminc-coupling chemistry\\nOne flow cell uas left umnodified to pmvide a reference\\nchannel Htunm&-P(.\\'SK9 (J00 nM) &has premixed with an\\narray of IgGs (final 500 RM) and these complexes were\\ninjected over the clup using I min injections at 10 PL/min.\\nAntibodies that bind to competing cpitope& will block the\\nb&nding of PCSK9 to the antibody inunob&lized on the chip.\\nAlternatively. a c la as icn I sandhv ich approach was used by tirst\\n\\n\\x0cUS 8,080,243 B2\\n\\n51\\nfold) 1.171 R binding Moreover, tinea nnirants not in contact\\nwith E(IF-A fR199A, R218A, K222A) showed weaker bind-\\nthey are\\nin\\ninvolved in hindu&8 other donuiins ol\\' DI,R Overall, Iheae\\nexperiments vahdatc thc mtcgrity and activity ol\\'thc mutants\\nfor subsequent epitope mapping experiments.\\n\\n85-15 fold). Tins new finding suggests that\\n\\ng. Buiding oi the mutants to immobilized 4A5, 7D4„5A10\\nand 6F6 uiubodies Biotuiylated uit&-PCSK9 antibodies\\nwere immobilized on SA chips using standard methods\\nMutant buiding experiments &vere perfonued using Biacore\\n3000 at 25\\'. with a running buffer of 50 mM Tn s-I ICI pl I\\n7 5, 1&0 mM Na(\\'I and 0.02\\'A P20 Mutm»s were tested at\\n333 nlVI or 111 nM concentmtions in duplicates, with the ones\\ngiving weakened hindi»su compared to the wild-type as the\\nresidues uivolved ui nugb binding /listed belov,).\\n\\nmwd\\n\\n4e«,\\n\\n6.3&u\\n696\\n134\\n\\n»u&dw Res&duce u& Dcs eudu&e 0&dc& I Mu&.ua I:ircc&s\\n\\nRZ17 F379;6&7 R&94 RI99 4 D 36\\nR&94, »337, 1369 D\\'9&, RI 99\\nIL&37, a&94, F379 D336. 1369. I\" 77. x&99\\nIL\\'I.R&94, F379 1369. R&99\\n\\nExample &\\n\\nCloning and Sequencing of Antibodies\\n\\nOne million hybridoma cells were hmnogcnircd usia tbu\\nQIAshrcddcr spin columns uml\\ntotal RNA was cxtractcd\\naccording to RNAeasy Micro kit from QIA(JL\\'N. cDNA was\\nsynthesized using SuperScript III RT lot from Invitrogen.\\nMauable ruegions from the PCSK9 antibodies were cloned\\nusing the mouse Ig(i-Primer Sets froni Novagen. which con-\\nsist of degenerate pruners for clonin mouse igC& heavy chain\\ngenes and the mouse kappa or lambda hght chains. PCR\\ncycluig conditions werc the liilkrwuigs I cycle ai 92 (\\'ior 2\\n\\nmin: two cycles at 94 (\\'or 30 sec. 44 (.\\'or 30 sec mid 72(\\'or2 min: two cycles at 94 C for 30 sec. 46 C for 30 sec and\\n\\n72 C for 2 min: two cycles at 94 C lor 30 sec, 48 C for 30 sec\\nand 72 (. for 2 ni in, tw o cycles ai 94 (.\\'or 30 scc. 50 C fir 30\\nsecand72( for2min;twocyclcsat94C for30scc,52( for\\n30 sec and 72 C for 2 min; follo&ved by 35 cycles at 9)4 C fbr\\n30 sec. 54 C for 30 sec uid 72 C for 45 scc. The resulung PCR\\nproducw& were cloned into Topo-TA clem ng veck&r I\\'rom lnvit-\\nrogen and sequenced. Jhe clo&&cxl antibody sequences were\\nconiimied by ¹ennuial sequencin of the tirst 10 anuno\\nacids of the onginal antibodies pmduced from ascites.\\n\\nI\\',xample 6\\n\\nC&cneration of Aniigcns Iior Immunization\\n\\nRecombinant human I\\'CSK9 protein was pmduced as\\nreported (.unningham ei al., 2007. Net Struct Mo I Biol, 14(5).\\n413-9. To produce recombinant mouse PCSK9 protein, the\\ncDNA of mouse P(\\'SK9 was clone&I into mammalian expres-\\nsion vector PRK& with the addition of a 6-His tag at the\\n( -temiinus by methods knov;n in the art. transiently trans-\\nfected and expressed in IIBK293 cells. Recombinant pmtein\\nwas purified from conditioned media using a Ni colunm.\\n\\nSurface peptides of human and mouse P( SK9 were\\nselected based on PCSK9 protein structure, and synthesized\\nby Elim Biopharmaceuticals.\\n\\nFxaf«\\'pic 7\\n\\nPCSK9-Specific Antibodies as PCSK9 A»taco»tats\\n\\nIdentification of P(\\'SK9-Specific Antagonist Antibodies\\n\\nI\\na. Identification of PCSK9-Blocking Antibodies\\n\\nMurine antibodies to human and/or mouse PCSK9 were\\ngenerated by uumumzing mice with 1»uuan-PCSK9 and\\nniousc-PCSK9 synthetic pcptidcs as prepared in I\\'xaniple 6\\n1» or recombinant proteins. and screening antibodies by ELISA\\nassay usinug human and\\'or mouse PCSK9 recombinant pro-\\ntein us Ilm untigens as de&cubed in Fxmnple I mid other\\nstandard hybridoma procedures. Over 500 positive clones\\n\\'&9& fe oh&ainu&I and allowed to gros& to confiuency in 6 well\\nplates with 10 ml media. Media supernatant were collected\\nand ton&1 IgG& in tlm conditioned media were purified using\\nn&Ab Selccct (Pierce) The ability ofpurifmd and concentrated\\nmouse ig(is to inhibit nuiuse and human PCSK93 function was\\n6 tested in lluh7 cells using the methods descubed in Iixample\\n1. Hybridoma clones expressing Ig(is that she&cad some\\ndegrees of blocking v ere expanded and retested. 60 promis-\\nuig clones were subcloned. expanded, and injected into either\\nBalb/c or nude nuce to produce sac&tea. Antibodies puniied\\nthorn dsmtes fiuid werc rctestcd for their ability to inhibit thc\\ndo&un rcuulation of I DI,R by human or mouso PCSK9 in\\nHuh7 cells. I&our hybridoma clones. 4A5, &A10. 6F6, and\\n7D4. were identified as being able to completely inlub&t\\nlnunan PCSK9 I\\'unction, and at least partially udiibit mouse\\nPCSK9 function. To determiiw IC39 of each of tlmse b loci ing\\nuntibodies, a senal dilution of lg(is i&ere used in the assay.\\nstamng from 100 ugml to 3.125 ug/ml, with human and\\nmouse P(\\'SK9 c&mc&.ntration being comstant at 6 pg&ml\\nb. Effect of PCSK9 Antagonists on P(\\'SK9-LDLR Binding\\nPCSK9 has been sluiwn to be co-localized with LDLR in\\ncellular compartments fl agdce et al.. 2006, .I (\\'lui lnv, 116\\n(11):2995-3005 Recombinant P(.SK9 protein also binds ro\\nI.DI R extrnccllular domain in vitm (Fislmr ct el., 2007, JBC,\\n46 282/28):20502-12. To determine the relationslup betv,een\\ninlubiiimi ofP(\\'SK9 mcuirdted do&un-regulation of I,DI.R nnd\\ninlubiti&m of P(\\'SK9-I,DI R bindmg by mitibodies, we tested\\nthe P(.\\'SK9 antibodies tliat partially or completely blocked\\nPCSK9 function on I,I)I R and representative& of antibodies\\nthat do not block. All partial antagonistic antibodies also\\npartially inhibited LDI,R extmcellular domain binding to\\nPCSK9. except one. Antagonisuc antibodies that can com-\\npletely block PCSK9 function, namely 4A5, 5A10, 6i&6 and\\n7D4 also completely inhibited LDLR cxtmcellular domam\\nu buidin to PCSK9 /fable 5). 1050 values of these four wit&-\\n\\n\"o\\n\\nbodies correlates with their binding affinity ui PCSK9.\\nc. Fpitope Dctenuination of the Blockuig Antibodies\\n\\nFI(i. 4 illustrates the epitope bi»ning of anti-PCSK9 anti-\\nbodies. Part A) shows cpitopc infornmtion ol\\'nti-P(\\'SK9\\n3 mAbs, deternuned by binduig to synthetic 13-18-mer pep-\\ntides or epitopc binding via Biacore Part B) shows the ability\\nof immobilized antibodies 6F6, 5A10 and 4A5 to bind to\\nhuman PCSK9 premixed with the mAbs mdicated on the y\\naxis by Biacore assay\\n\\nMi\\n\\nAnother monoclmufi miti-P(\\'SK9 mitibody, tcrnwd 6Ci7,\\nbinds to recombinant nuiuse I\\'CSK9 but not human PCSK9.\\nScuo Table t&. 6(i7, 4A5. &A10, 61\\'Ii, and 7D4 mutually exclude\\neach other\\'s buiding to mouse PCSK9. Chimem analysis\\nbenveen mouse and human PCSK9 reveals that 6(17 binding\\nto P(\\'SK9 require& the catalytic domain. Scc Table 6. Thus the\\nbinding sites of 4A5, 5A10, 6F6, und 7D4 overlup the cata-\\nlytic site and/or the epitope bound by 6(17.\\n\\n\\x0cUS 8,080,243 B2\\n\\n53\\n\\nTABLLI 6\\n\\nRecoiilbmslii pi\\'oieili\\n\\n607 t\\n\\niimiix\\n\\nHunt:ui Pt:5K9\\nHunmn pm 4 ffufffm estab ti 4 inousc C-temi\\nliurncn um 4 mouse catalvtic 4 mouse C-term\\nIs(oint pro + )fllfnm t ilill ifii + liiiiiiilii I ft\\'i\\'iii\\nIvlouse Pro+ inonse estab trc + hutnsn C tenn\\ntv(mise PCSK9\\n\\nho\\nho\\n1\\'cs\\nSo\\nYes\\n\\'es\\n\\nd. Deternuning Sequences Species Specificity of Anti-\\nP(\\'SK9 Antibodies\\n\\nTo determine the species sperilicity of the anti-PCSK9\\nantibodies. antibodies were incubated with plasnta from dif-\\nI\\'crcnt species and the result mt complexes were purified and\\nprobed by an independent anti PCSK9 anubody on Western\\nblots. The mltibodies 4 tt5, 5A10, 6F(i, mtd 7D4 recognized\\nhummt. cynmnolgus monkey. ntouse. Snd rat PCSK9. See\\nFI( L 5. Antibody 6(17 recogiu zed only murine PCS K9 and an\\nunrelated control antibody 42H7 did not recognize any tostcd\\nP(\\'SK9. Id.\\ne. Determining Stxfttences of Antagonist P(.\\'SK9 Antibodies\\nTfm mnino acid stx)ucnccs of the variable douuiins of\\nP(\\'SK9 antibodies 4A5. 5A10, 61\\'6. and 7D4 were deter-\\nmined using the method described in I\\',xample 5. The\\nscqucncca indicate that the mtt if udice are related but different\\nfrom each other. Table I shows the amino acid sequences of\\nthe variable regions of each antibody Table 7 shows thc CI&K\\nsequences of the 11 ht chains und heavy chuuts of Table I as\\nidentified by the Kabat and Dhotis methods.\\n\\nTABLE 7\\n\\nAnti-P(\\'SK91g(is 4A5, 5A 10 and 6 F6 were am inc coupled\\nto the Biacore chip. hl\\'(.\\'SK9 f100 nM) was mixed with 500\\nnM of 4A5, 5A10, 6F6 or 7D4 in vanous ratios and ut)ected\\nIior I min at 10 pl\\'min The fmu anubodimv nuitually blocked\\none another irrespective of the Rvmiy oriemation tested. sug-\\ngesting that they all bind to competing epitopes. In contrast,\\nthey are able to form sandwich complexes tvith other non-\\nfully-bloclung antibodies that were mapped to specific\\nregions using syntlmtic pcptides.\\n2. Effect of PCSK9 Specific Antibodies as PCSK9 Antagonist\\nlll Mlvo\\na. PCSK9AE(agonis(Antibodiesl owcrSemmC\\'holevterolin\\nMice\\n\\n)0\\n\\nTo determine if PCSKQ) antagonist monoclonal antibodies\\ncan all act cholesterol levels ut vivo by inhibit utg the l unction\\nof extmcellular P(\\'SK9, the effect of 7D4 tvas tested against\\nmouse PCSK9 ut vitro. on serum cholesterol tvhen inlcc(ed\\nulto mice. 6 to 7 week old male C57/bl6 nuce were kept on a\\n12 hr light/dnrk cycle, blcdl to colltmt approximately 70 pl\\nserum ou day -7 Antagonist PCSK9 anubody 7D4, nnd 0\\ncontrol isotype matching monoclonal antibody were injected\\ninto mule 7 wcck old (\\'57/bl6 mice via i p injections on days\\n0, l. 2, and 5 Mice v,ere saculiced on day 4 without fasting,\\n„, and senun samples were collected. All frozen sentm samples\\nwerc vun( to IDFXX laboratoues for totnl cholesterol, Irig-\\nlyceride, HDL clxllesterol and LDL cholesterol measure-\\nments. FI(i. 6 shou s Chat 7194 lowered serum cholfSterol by\\n4S%r v.bile the contml antibody did not have any sigmlicant\\naffect. Both the amount and percentage ofreduction are simi-\\n\\nSlocXtng PCSK9 Antlbodlen and Anttgen-binding CDR Sequence:\\n\\naccording t.o rabat\\n\\niundetlfnedl and chotia (bold)\\n\\nVL CDRZ\\n\\nVL CDR2\\n\\nVL CDR3\\n\\n4A5\\n\\nRASQNVGTNVA\\n(SEQ ID NQ. 27)\\n\\n5AIQ K~AS DVSTAVA\\n\\n(SEQ ID No\\n\\n30)\\n\\nSASYRYS\\n(SEQ ID NQ\\n\\nSASYRYT\\n(SEQ ID No\\n\\n28l\\n\\n12)\\n\\n6P6\\n\\n7D4\\n\\nSASizGISNYLN\\n(SEQ ID No\\n\\n32i\\n\\nYTSSLHS\\n(SEQ ZD No. 33)\\n\\nK~AS DVSNALA\\n(SEQ ID 110\\n\\nLZL3 RASQGISSALA\\n\\n(SEQ ID No\\n\\n34l\\n\\nill\\n\\naASYRYT\\nISEQ ID Nor 12)\\n\\nSASYRYT\\n(SEQ ID No\\n\\n12)\\n\\nQQFYSYFYT\\n(SEQ ID NO\\n\\nQQRYSTPRT\\n(SEQ ID No\\n\\n~YSKLPPT\\n(SEQ ID IIO\\n\\nQQRYSTFWT\\n!SEQ ID No\\n\\nQQRYSLWRT\\n(SEQ ID NO\\n\\n29l\\n\\n31)\\n\\n55)\\n\\n35)\\n\\n13)\\n\\nVH CDRZ\\n\\nVH CDR2\\n\\nVH CDR3\\n\\n4A5\\n\\nGYTFTDYYNN\\n(SEQ ID Non\\n56(vhole), 36 and 37i\\n\\n5AIQ GYTPTSYWNH\\n(SEQ ID Nos\\n57(Whole), 41 and 42l\\n\\n6F6 GYTPTDYPHtl\\n(SEQ ID Nos\\n56(vholet, 36 and 37)\\n\\n7D4\\n\\nGFTPSOYYI\\'IA\\n(SEQ ID uos\\n50(vholel, 48 and 49l\\n\\nLIL3 GYTPTSYYIIH\\n\\nSEQ ZD No\\n59(whole), 60, and 8\\n\\n(SEQ ZD No\\n\\n38 and 39)\\n\\nWLLPAY\\niSEQ ZD No\\n\\n40)\\n\\nE IMP SNGRT NINE KF KS\\n(SEQ ID NQ. 43 and 44)\\n\\nERPLYANDY\\n(SEQ ID NQ\\n\\n45)\\n\\n(SEQ ZD No\\n\\n38 and 4\\n\\nGGIYYRYDRNYPDY\\n47)\\n(SEQ ID IIO\\n\\nIIINYDGSNTSYLDSLKS\\n(SEQ ID NO\\n\\n50 and 51)\\n\\nSKFAIiNOY\\n(SEQ ID No\\n\\n52)\\n\\nEI SP PGGRTNYNE KF KS\\n(SEQ ZD NO.\\n\\n9 ard 61)\\n\\nERPLYASDL\\niSEQ ZD Iio\\n\\n10)\\n\\n\\x0cUS 8,080,243 B2\\n\\n55\\nlnr to what was reported for P( SK9-!- mice (PC\\'SK9) knock-\\nout mice). suggesting that one can actueve complete or near\\ncomplete inhibition of I\\'C\\'SK9 fiuiction tluough blocking\\nextracellular PCS K 9 only. and that intrace it u lar\\nPCS K 9 p lays\\nlittle or no role ui down-regulating LDLR under normal\\nliver LDLR levels\\nphysiological conditions. As expected.\\nwere uiduced ui mimals treated uith 7D4 compared to tlxise\\ntreated with a control antibody (FIG. 6).\\nb A P utially Blocking Antibody lied No FITiut on Blood\\nCholesterol Levels\\n\\nFI(i. 7 illustrates tlmt a partial antagonist polyclonal anti-\\nPC\\'SK9 mAb C\\'RN6 docs not alTect cholesterol Icvcls in mice\\nTuo groups of S week old C57/b16 mice (n 10 ance/youp)\\nwere blixl mid tcstixi for cholesterol levels on day -7, dosed\\nwith 15 nty&kg/day ol\\'CRN6 or a comtrol antibody by &.v.\\nacbninistration on days 0, l. 2 and 3: and then bled and tested\\nfor cholesterol levels 24 Iux after the tinal dose. FIG 7A\\nshows that CRN6 an1ibody partially blocks PCS K9 inc din&cd\\ndovvn regulation of LI&LR in Huh7 cells in vitro. I\\'l(r 7B\\nshoes that administration of C\\'RNti antibody does not alTi.ct\\nserum cholesterol levels in mice.\\nc. Prolonged I.ffect on Senun (\\'holesterol by Antagonist\\nPCSK9 mAb ui Mice.\\n\\ns\\n\\n&a\\n\\no\\n\\nA time course study was performed to determine the time\\nof onset and duration of thc cholesterol lovmring effect of \"\\nPCSK9 ants omst antibodies in mice. IvLAb 7D4 or salute\\ncontrol &vere each injected i.v. at 10 ms&kg or 3 mV1 g iu 48\\n6-week-old C57/bl6 mice Eight mice froiu each treatment\\nroup were sacrificed on days I, 2, 4. 7. 14 und 21 after\\ninjection. A single injection of 704 producod a fast and pro-\\nlmi ed lov cong etTect on senun cholesterol. A 25% reduc-\\ntion in senuu cholesterol vias seen at 24 lus after injection.\\nScc FICi. 8 Maximum drop of serum cholesterol uas\\nobserved at the 7 day tune point. At 21 days. the reduction in\\ncholesterol is no longer statistically significant. Pau B) shows \"»\\nHDI choh:sterol I.DI, cholesterol levels were very low\\n\\nso\\n\\nFIG. 9 illusimtes that the anti-PCSK9 ants omst mAb 7D4\\ndose dcpcndcntly reduces scn&m total cholesterol, HDI.. and\\nLDI. in mice Six groups ol\\'8 week old C\\'57!bl6 mice (n 8/\\ngroup) werebledandtestedforbatmlcholesteroHevelsonday so\\n-7 and administered with the indicat cat doses ofantibodies or\\nsaline on days 0, l. 2, and 3 by i. p. bolus in)ection. Senun\\nlevels 24 lus\\nsamples were collected and tested for cho les tern l\\natlcr tlm Inst dose FICi. 9A shows total cholesterol levels.\\nwluch decreased to less tlmn 60\\'!!o of control after administra- s.\\ntion of 3 to 30 mJokg/chsy. The maximal effect on total cho-\\nlesteml was seen at 10 mg\\'kg, and statist&cally signdicant\\nI nioo/kg. Iihi. 9B shows HDL levels, uluch\\nreduction at\\ndix:reused &o less &lain 70\\'fio al\\'ter &dian&latm&ion el\\'\\nui 30\\nmg!kg/day. FIG. 9C shows LDL levels, wluch decreased to\\nnearly zero at all tested doses of 0.3 my&\\'kg/day and above.\\nd Dose Response of Antagonist Antibodies Spccilic to\\nPCSK9 ut Mice\\n\\nu\\n\\n1\\n\\nFRi 10 illustrates that anti-PCSK9 mitagonist antibody\\n5A10 dose dependently lowers cholesterol levels in nues\\nFIC). 10A shows six groups of 8 vveek old (\\'57/bl(i mice\\n(n—8/group) to which werc administimcd the indicated doses\\nofantibodies or salute daily ou days 0. I, 2, and 3 by 1 v. bolus\\ninjection. Senim samples were collected and tested for cho-\\nlesterol levels 24 hrs after the last dose and shov,ed a gradu- ai\\nated decrease with increasing dose of antibody. PIC&. 10B\\nshovvs five groups of 8 week old ( 57/b16 mice (n=g!y&mp) to\\nwluch were administered the uidicated doses of antibodies or\\nsaline on day 0 by i. p. bolus injection. Senun samples were\\ncollected mid tcstcd fiir cholesmrol levels on day 7 and also (\\nshowed a graduated decrease with increasing doses of anti-\\nbody\\n\\nFI(i. 11 illustrates tlmt anti-PC\\'SK9) mitagonist antibodies\\n4A5 and 61\\'ti lower cholesterol levels in mice in a dose-\\ndependent fashion. Eight week old C57\\'b16 mice(n 8/group)\\nwere administered &bc indicated doses ol\\';m&ibodies or saline\\non uay 0 by i.p bolus injcciion Scnmi samples &vere col-\\nlected and tested for cholesterol le~ala on day 7. In FIC). I I A,\\nthe mttibody 4A5 showed a raduated decrease in total serum\\ncholesterol withincreasingdoseol\\'antibody In I\\'ICi. IIB, the\\nantibody 6F6 shinned decrcasc in toml serum cholesterol at 10\\nmg/kg/day.\\n\\nAnti-PCSK9 antagonist antibodies 4A5. 5A10, 6116 and\\n7D4 increase liver I.DI,R levels in mice as I\\'ound by Western\\nblot analysis. See FICi. 12. For 4A5, 5A10 and 6F6. 8 week\\nold C57&b16 mice were administercxt with 10 ms+8 of anti-\\nbodies or saline on day 0 by i.v, bolus us)ection. animals were\\nsacrihccd on day 7, and whole liver lysate of 3 individual\\naninud s uvre analyzcxt fitr I DI.R and (IAPDH pmtain levels\\nby Western. I!or 7D4. 8 week old B16/c57 nuce were admin-\\nistered u 1&h 10 m !kg of antibodies on days 0. I, 2, and 3 vu&\\ni p bolus injection, animals were sncrificed on day 4. and\\nwhole liver lysate of 3 individual mr&mals were mialyzcxl tiir\\nLDLR and CiAPDI I proteui levels by Westeni blot. All miti-\\nbody-treated nuce showed lu h levels of LDLR as compared\\nto tile I BS c&1&ltl\\'ol alice.\\n\\nFICi. 13 illustrates that miti-PCSK9 antagonist antibody\\nin the LDLR-!- mouse, L\\'1 ht week old\\nhas no effect\\n[,DI.R-/- mice (I,DI R KO mice) were administered 10\\nmg/kg 4A5 or sahne on day 0 by &.p. bolus in) ecuon. Serum\\nsmnples (from n 9-10 nuce) were collected mid tested for\\ncholesterol le&mls mi day 7. Administration ol\\'he antibody\\ndid not appreciably alter the levels of total serum cholesterol„\\nHI&L, or LI&I ..\\n\\nFICi. 14 illustrates that multiple treaunen(s of anti-PC\\'SK9\\nantagoiust aimbodies ui nues can substantially decrease total\\nserum cholesteml. I\\',ight u eek old (\\'57/blfi mice were admin-\\nis&eredt the indicated doses ol\\'antibodies or PBS on days 0, 7.\\n14 and 21 by i.v. bolus injection. Serum samples (n— 5-11\\nniicc) uvre collected and tcstcd for cholesterol levels on dny\\n28.\\n\\nL\\'xampfe S\\n\\nPCSK9Antagonist Antibodies lower Serum I,DI. in\\nNon-luunan Primates\\n\\nTo test the in vivo eIIect of antibodies to PCSK9. annbody\\n7D4 was tested in cynomolgus monkeys. I\\'our 3-4 year old\\ncynomo l gus ni on key is ere injected u it h vehicle (PB8 s0 01%o\\nTu een 20) on day 0, and 10 my kg 7D4 on day 7. Plasma lipid\\nprofiles were analyzed on days 0. 2, 7, 9, 11, 14. 21 and 28\\nfastin . A single injection of 10 mg/kg\\nfolkming overnight\\n7D4 Produced a drmnatic reduction in Plasma LDL (60\\'!!o)\\n(FI(i 15A) and I,DI paiticle numbers (FI(i. 15D) in all 4\\naiumals, wlufe having muiimal sfl\\'ect on their HDI\\nlevels\\n(FIG. 15B) and HDI, particle numbers (Fl(i. 15E). Iiital\\ncholcstcrol (FICi 15C:) &vas also rcdiucmd following 7D4 treat-\\nment. wlule tngfyceride level (PIC& 151\\') was uot signifi-\\ncantly affected. Total 7D4 ((I), and total PCSK9) levels (H)\\nwere also measured.\\n\\nPIC&. 16 illustrates the dose-response of miti-PCSK9 anti-\\nbody 7D4 on serum cholesterol levels in the cynomolous\\nmonkey. Two male and two female cynomolgus monkeys 3-5\\nyearn of age in each group st ere given the indicated dose of\\n7D4 on day 7 and an equal volume of saline on oay 0 by i v.\\nbolus uiiecuon. Plasma samples were taken at indicated tune\\npoints and plasma LDL levels v;ere measured.\\n\\n\\x0cUS 8,080,243 B2\\n\\n57\\nI\\'if) 17 illustrates a con&parison of anti-PCSK9 nntibodies\\n4A«, A10. 6F6 and 7D4 (&n scnun clx)lc&terol levels in thc\\ncynomolgu& monkey Tvvo male and two female cynomolgus\\nmonkeys 3-6 years of age in each gn&up werc gii cn I mg/kg\\nof the indicated antibody on day 0 by i.v bolus i»)ection\\nPlasnui 6 unplcs narc taken at indicated tnne points, plasma\\nIiDI. levels wcm measured and noi&haling to tlmt on day -2\\nFICi 18 illustmtes thc eifect ol\\'nti-PC\\'SK9 nntngonist\\nantibody 7D4 nn plasma cholesrerol levels of cynomolgus\\nmonkeys fed a 33 4% kcnl Iat dict suppicn&en&vedi w&th 0.1%\\ncholesterol. Six 3-5 yenr old cynonu&lgus monkeys (vere put\\non high-Iht dict I\\'or 16 wacke Three monkeys werc tres)cd\\nwith 10 mg/kg 7D4 and three with saline on thc indicated\\nlevels of individunl moid(eys were measured and\\ndate I.DI\\nnonnahzed to tlmt of the treatment day.\\n\\nFxan&pie 9\\n\\nHumanized Anti-PC\\'SK9 Antibody\\n\\n11&e murine monoclonal antibody 5A10 was humanized\\n\\'itld affinity matured to provide the I 113 antibody LI I 3 has\\n\\n6\\n\\nweek old 057/b16 &nice w ere do seal with 10 n&g/kg I. I I 3 or m&\\nequal volume of aalu&e by i. p, iniect&on on day 0, Serum\\nsmnples werc 00&llcctcd and nssayed for cholesterol levels on\\ndays 2. 4 and 7. LIL3 decreased total serum cholesterol by\\nabout 40% at days 2 and 4 In another study, when 10 mg/kg\\nof1,113 was affininistered as a single intrapcritonenl (IP) dose\\nto I 57BI /6 mice feed a normal dict (n=10), scn&m cholesterol\\nlevels v ere reduced by 47%0 compared to safu&e treated con-\\nn& trois. 4 days post treatment. When LIL3 was a(hnuustered as\\na s&ogle IP dose at 0„0.1, 1„10 and 80 mg(\\'kg (n 6/youp) u&\\na dose-response experiment in male Spra gue-Daw ley rats fed\\na normal diet, serum cholesterol levels were dose-depen-\\ndently reduccxI. n ith nmximum effect of 50% seen at 10 and\\n80 mg/kg. 48 hours post dosinc. The dumtion of the choles-\\nterol repression vms also dose dependent, rm&gu&g fron& I\\ntn\\n21 days\\n\\nThe un&no acid sequence of 1,11.3 fully hu&danired hea(y\\nchain (SL\\'Q ID NO\\'15) is shown in Table 8. \\'H&e sequence of\\nthe variable region is underlined (SFQ ID NO. 54).\\n\\nTABLE B\\n\\n~v&v s ae ~vkk\\n\\nasv&v scka~cf(tft ~sheer a ~&evm e ~&s\\n\\nf\\n\\nrtn\\n\\nnekfksrvtv, trdtststvy melsslrsed (tea&a(carer ~1 asdlv\\n\\ngttvtvssas\\n\\ntkgps(fpla pcsrstsest aalgclvkdy fpep (tvsvn sgaltsgvht fpavlqasgl\\n\\ny 1 svvtvp\\n\\nnfgtqtyt cnvdhkp nt kvdktverkc cvecppcpap pvagpsvflf\\n\\npp)pkdtlmi srtpevtcvv vdvshedpev qfn(yvdgve vhnakt)pre eqfn tfrvv 30o\\n\\nsvltvvhqdv lngkeykckv snkglpss&e kt&.sktkgqp repq(yt&pp sreemtknqv 360\\n\\na&tel(kgfy psd&aveses ngqpennykt.\\n\\ntppmldsdgs fflyskltvd ksrwqqgn(f\\n\\n620\\n\\nrcsvmhealh nhytqksl 1 spgk\\n\\nan affi&uty for munne PCSK9 of 200 pM and an affin&ty for\\nhummi PCSK9 ol\\'100 pM when mmisured by Biacorc 1.113\\ncompletely u&h&b&ts the PCSK9-med&ated down reyilat&on of\\n\\nThe am&no ac&d sequence of LIL3 fi&lly humanized light\\nchain (SFQ ID N(yl4) is six)wn in Table 9 Thc variable\\nreyon &s underl&ned (SBQ ID NO: 53).\\n\\nTABLE 9\\ni- ~ala&.\\n\\n~di\\n\\nt s\\n\\nI asvcidtvt ~xtcza-\\n\\ni: ~ka alii . ~a. r t\\n\\n.\\n\\n~rfs 0 s td ~ftft&ssl\\n\\n~edict\\n\\nc\\n\\n~rs&vrtf\\n\\ngtkle&krtv aapsvf&fpp\\n\\nsdeqlksgta svvcllnnfy preakvqvkv dnalq gnsq esvteqdskd styslsstlt\\n\\n1 kadyekhk (yacevthqg lsspvtksfn rgec\\n\\nLDLR &n cultured Huh7 cells when incubated w&th 100 nM\\nluunan or murine PCSK9 ant&body. See FIO. 19.\\n\\nI\\'ICi. 20 illustrates the dose-response of I I L3, mouse pre-\\nmusor 5A10. and ncSative control mti body 42117 to block the\\nbindins of recnmbinant biotinylated human P(.\\'SK9 and\\nmouse PCSK9 to inm&ob&iized recombinant LDLR extracel-\\nlular domain in v&tro. I\\'ICI. 20A shows ln&man PCSK9 b&nd&ng\\nto human I,DI.R extracellular domain at pH 7 5 FICI 20B\\nshows human PCSK9 binding to Imnmn LDLR extmcellular\\ndomain at pl I 53. 1&ICi. ZU(\\'hou s mouse P(:SK9 binding to\\nhum m I,DI,R extracellular domau& at pH 7.5.\\nI\\'ICL 20D\\nshows uu&use PC SK9 lund&ng to hiuntu& I,DI,R extracellular\\ndona&in at pH 5 3.\\n\\nI\\'IO. 21 shows the effect on serum cholesterol of treatment\\nwith 10 mg/kg LIL3 in mice. Two groups (n—8/group) of 8\\n\\n11O. ZZ shows the effect of mtravenous admimstmtion of\\nan effect&ve dose (3 n&cc/kg) of antibody 5A10 (solid circles)\\nor m&tibody L I IB (solid sqimres) to each ol\\'our cynonuil us\\n6 monkeys at day zero. \\'I he change in senm& HDI (FICI. 22A)\\nand senun LDI. (VI(i. ZZB) was n&easurcxI from -2 to +28\\ndays Both antibodies resulted in greater than about 70%0\\ndecrease in sen&m I,DL levels by about seven days, an effect\\nthat substantially persistcxI for about six more days in the\\nu& animals admmistcred I,H 3 All thc animal& slmwed nom&nl\\n1&ver and kidney function and near-normal hematocrits.\\n\\nI,H 3 dose dependently rcduccd I DI.-CL with a max innun\\neffiect observed &othe mg/k group. wh&ch mau&tained a 70%0\\nreduction u& LDL-I\\'evels uun I day 21 post-dosing. and fully\\nrecovered by day 31. HDIc(\\'evels werc not affcected by\\nL I L3 treaunent in all dose groups. The aiumals u& the 3 mg\\'kg\\ndose youp (n—4) were also given nvo add&tional IM doses nf\\n\\n60\\n\\n120\\n\\n100\\n\\n260\\n\\n60\\n\\n120\\n\\nlsc\\n\\n216\\n\\n\\x0cUS 8,080,243 B2\\n\\n59\\n3 mg/ko I 11 3 on study days 42 mid 56 (2 wucks npart). These\\nnvo additional doses again lowered LDL-C mid maintauied\\nLDL-(\\'evels belovi 50% for 4 weeks. LDL-(\\'evels remnied\\nto normnl two weeks later Senmi HDI.-C lcvcls remained\\nunchanged tlmiupout the study.\\n\\n\\'lite efficacy of LI L3 in non-human primates with hyper-\\nclxilesterolemia and pluimiacodynanuc interactions between\\nL I L3 and I IMO-CoA reductase inhibituioo statins were inves-\\ntigated Priortothcinitiationofihcstudy,thcl,DI.-C\\'Iuvclsol\\'\\ncohort of cynomolgus monkeys (n 12) were elevated to an\\naverage of 120 nig/dL. compared to the normal average levels\\nol 50 mg/dl„by fcehng with a dict contaiimi\\n35%o I\\'at\\n(wtiwt) and 600 ppm cholesterol lor over I g months. Surpris-\\ningly, no effect was observed on senun total cholesterol or\\nI.DI -C\\'levels afier the daily admutist ration ol\\'a medium-dose\\n(10 myo\\'animal) of Crestorag (msuvastatin calcium) for 6\\nweeks, and after a subsequent dnily administcition ofhigh-\\ndose (20 mg,\\'k ) for 2 weeks A single administration of 3\\nmgil 0 I,I L3 with Crestorii\\'r vehicle treatment for 2 weeks.\\nolfivtivcly lowered scntm [,DI.-C 1st\\'i.ls by 56i\\'o bv dny 5\\n\\n60\\npost treatment, and gradually recovered in 2.5 to 3 wrecks\\nwhile not afi\\'ectmg IIDL-C levels. Upon switclun the ani-\\nmals to daily administration of 50 mg/kg Zocotot (simvasta-\\ntin), their I DI,-(. Icvcls reach\\' maximal reduction of 43%\\nat day 5, and stabilized thereafter. After 3 weeks of 50 mg/kgi\\nday!ocor(tt administration, these miima Is were treated with a\\nsuigle dose ol 3 mg~kg I,11.3 ii bile still receiving 50 mg/kg/\\nday Zocorg, Administration of LIL3 resulted in another\\nadditional 65% rahictimi m I DIe(., ui addition ui the 43%\\ni(i reduction by Zocorg. by day 5. and returned to pre-dosin\\n\\nI\\n\\nlevels within 2 ii eeks.\\n\\nOther CDR amino acid substitutions welf.\\'\\'iilr\\'. 113 5A10 in\\nthr coUise iif lliiillailiEtititlil tiild afiinity maturation and to\\nachieve particulnr properties. The sequences of tlm moditied\\nCDRs and the PCSKQ buiding abiliucs ol\\'he nntibodies\\ncontaining these modifiixt (\\'DRs are listed in Fq(IS. 24 A-Ci.\\nTlm numbers following each sequence in FICIS. 24 A-(i rep-\\nresent the SRQ ID NO for that sequence.\\n\\nfhe disclosures of ail references cited herein are hereby\\n\\nincotporatuxf by rcfi:rcncc herein\\n\\nSEQUEtiCE LISTING\\n\\n160 NUNBER OP SEQ ID NOS\\n\\n167\\n\\n210\\n211\\n212\\n\\nSEQ ID No I\\nLENGTH\\nTYPE\\n\\nPRT\\n\\n15\\n\\n400\\n\\nSEQUENCE\\n\\nI\\n\\na213 ORGPNISH Homo\\n\\naPren\\n\\nasp Thr Ser Ile Gln Ser asp His Erg Glu Ile Glu Gly Rrg Val\\nI\\n15\\n\\n10\\n\\n5\\n\\nSEQ ID No 2\\nLENGTH\\nTYPE\\n\\n210\\n211\\n212\\nPRT\\n213 ORGIUIISii Homo sapiens\\n\\n10\\n\\n400\\n\\nSEQUEIICE\\n\\n2\\n\\nGly arg asp ala Gly Val Rla Lys Gly ala\\n10\\n\\n5\\n\\n210\\nSEQ ID No\\n211\\nIENGTH 0\\n212\\nPRT\\nTYPE\\n213 ORGmiISN Homo saprens\\n\\n400\\n\\nSEQUENCE\\n\\n3\\n\\nala Ser Ser ifsp Cys Ser Thr Cys Phe\\nI\\n5\\n\\nSEQ ID NO\\nLENGTH 6\\nPRT\\nTYPE\\n\\n210\\n211\\n212\\n213 ORGSIIISii Homo\\n\\n400\\n\\nSEQUENCE\\n\\n4\\n\\napreno\\n\\nGly Gly Ser Leu\\nI\\n\\nVal Glu\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID No\\nLEIIGTH\\n6\\nTYPE\\nPRT\\nORGBNISH Homo\\n\\napren\\n\\n\\x0c61\\n\\n62\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n400\\n\\nSEQUENCE\\n\\n5\\n\\nGln Pro Val Gly Pro Leu\\nI\\n\\n5\\n\\ns210\\n211\\n212\\n213\\n\\nSEQ ID NO 4\\nLEI\\'GTH 5\\nPRT\\nTYPE\\nORGANISE Homo sapzens\\n\\n400\\n\\nSEQUENCE\\n\\nHzs Gly Ala Gly Trp\\nI\\n\\n5\\n\\nSEQ ID NO 7\\nLENGTH\\n\\n5\\nPRT\\n\\n210\\n211\\n212s T\\'ZPE\\n213\\n\\n400\\n\\nSEQUENCE\\n\\n7\\n\\nAla Glu Pzo Glu Leu\\nI\\n\\n5\\n\\nORGANISE Homo sapzens\\n\\n5\\nPRT\\n\\nSEQ ID NO 8\\nLENGTH\\nTYPE\\n\\n210\\n211\\n212\\n213 ORMEISH Artzfzc\\n220\\n223\\n\\nFEATURE\\nOTHER INFORFLATION\\n\\nzal\\n\\ns400\\n\\nSEQUENCE\\n\\n8\\n\\nSer Tyr Tyr Net Hrs\\nI\\n\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 9\\nLENGTH\\nPRT\\nTYPE\\nORGAEISH Artzfzc\\nFEATURE.\\nOTHER INFORHATION\\n\\nlal\\n\\n400. SEQUENCE\\n\\n9\\n\\n5\\n\\nSer\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID EO 10\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artzfrc\\nFEATURE.\\nOTHER INFORHATION\\n\\nzal\\n\\n400\\n\\nSEQUENCE\\n\\n10\\n\\nVARIABLE HEPNY CHAIN CDR\\n\\nVARIABLE HEAVY CHAIN CDP.\\n\\nGlu Ile Ser Pro Phe Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\n\\n10\\n\\n15\\n\\nVARIABLE HEAVY CHAIN CDR\\n\\nGlu Arg Pro Leu Tyr Ala Ser Asp Leu\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n11\\n\\nSEQ ID I\\'10 11\\nLENGTH\\nPRT\\nTYPE\\nORGANISE Artzftc\\nFEZTURE\\nOTHER INFORSZATION\\n\\nzal\\n\\n400\\n\\nSEQUENCE\\n\\n11\\n\\nArg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala\\nI\\n\\n10\\n\\n5\\n\\nVARIABLE LIGHT CHAIN CDR\\n\\n\\x0c63\\n\\n64\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\nV..RIABLE LIGHT CHAIN CDR\\n\\n210\\n211\\n212\\nc213\\nc220\\n223\\n\\nSEQ ID NO 12\\nLENGTH\\n7\\nPRT\\nTYPE\\nORG.SHSN AZtzfzC\\nFEATURE:\\nOTHER 11\\'IFORNATION\\n\\nral\\n\\n400\\n\\nSEQUENCE\\n\\n12\\n\\nSer Ala Ser Tyr Arg Tyr Thr\\nI\\n\\nSEQ ID NO 13\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGWIISN Artzfzc\\n\\n210\\n211\\n212\\n213\\n220. FEATURE.\\n223\\n\\nOTHER INFORN\\'ZION\\n\\nlal\\n\\n400\\n\\nSEQUENCE\\n\\n13\\n\\nVARIABLE LIGHT CHAIN CDR\\n\\nGln Gln Azg Tyr Ser Leu Trp Azg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 14\\nLENGTH 214\\nPRT\\nTYPE\\nORG621ISH Artzfzc\\nFEATURE\\nOTHER INFORFZATION\\n\\nzal\\n\\nc400\\n\\nSEQUENCE\\n\\n14\\n\\nHUHZUZIEED LZL3 LIGHT CHTIN\\n\\nAsp Ile Gln Het Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala\\n\\n20\\n\\n25\\n\\n30\\n\\nLeu Ala Trp Tyr Gln Gln Lys Pro Gly L. Ala Pro Lys Leu Leu Ile\\n\\n35\\n\\n40\\n\\n45\\n\\nTyr Ser Ala 6\\'er Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly\\n\\n50\\n\\n55\\n\\n60\\n\\nSer Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro\\n65\\n80\\n\\n\". 5\\n\\n70\\n\\nGlu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Ser Leu Trp Arg\\n\\n85\\n\\n90\\n\\n95\\n\\nThr Phe Gly Gln Gly Thr Ly. Leu Glu Ile Lys Arg Thr Val Ala Ala\\n\\n100\\n\\n105\\n\\n110\\n\\nPro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly\\n\\n115\\n\\n12 0\\n\\n125\\n\\nThr Ala Ser Val Val Cys\\n\\n130\\n\\nLeu Leu Asn Asn\\n135\\n\\n140\\n\\nPhe Tyr Pro Arg Glu Ala\\n\\nLys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln\\n145\\n160\\nasp Ser Thr Tyr Ser \\'u Ser\\n\\nGlu Ser Val Thr Glu Gln A p Ser Ly\\n165\\n\\n170\\n\\n155\\n\\n150\\n\\n1. 7 5\\n\\nSer Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys Hzs Lys Val Tyr\\n\\n180\\n\\n185\\n\\n190\\n\\nAla Cys Glu Val Thr Hzs Gln Gly Leu Ser Ser Pro Val Thr Lys Ser\\n\\n195\\n\\n200\\n\\n205\\n\\nPhe Asn Azg Gly Glu Cy-\\n\\n210\\n\\n\\x0c65\\n\\n66\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n210\\n211\\n212\\n213\\n220\\na223\\n\\n444\\n\\nSEQ ID NO 15\\nLENGTH\\nPRT\\nTYPE\\nORGANISE Artzftc\\nFEATURE\\nOTHER INFORHATION\\n\\ntal\\n\\n400\\n\\nSEQUENCE\\n\\n15\\n\\nHUI131IZED LIL3 HEAVY CHAIN\\n\\nGln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr\\n\\n20\\n\\n25\\n\\n30\\n\\nTyr Het Hzs Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Het\\n\\n35\\n\\n40\\n\\n45\\n\\nGly Glu Ile Ser Pro Phe Gly Gly Arg Thr Asn Tyr Asn Glu Ly- Phe\\n\\n50\\n\\n55\\n\\n0\\n\\nLys Ser Irg Val Thr Het Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr\\n80\\n\\n75\\n\\n70\\n\\nHet Glu Leu Ser Ser Leu Arg Ser Glu Asp Tht Ala Val Tyr Tyz Cys\\n\\n85\\n\\n90\\n\\n95\\n\\nAla Arg Glu Arg Pro Leu Tyr Ala Ser Asp Leu Trp Gly Gln Gly Thr\\n\\n100\\n\\n105\\n\\n110\\n\\nThr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro\\n\\n115\\n\\n12 0\\n\\n125\\n\\nLeu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly\\n\\n13 0\\n\\n135\\n\\n140\\n\\nCys Leu Val Ly Arp Tyr Phe Pzo Glu Pro Val Thr Val Ser Trp Asn\\n145\\n160\\n\\n155\\n\\n150\\n\\nSer Gly Ala Leu Thr Ser Gly Val Hzs Thr Phe Pro Ala Val Leu Gln\\n\\n165\\n\\n170\\n\\nI\\n\\n5\\n\\nSer Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser\\n\\n180\\n\\n185\\n\\n190\\n\\nAsn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp Hzs Lys Pro Ser\\n\\n195\\n\\n200\\n\\n205\\n\\n4 n Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys\\n\\n210\\n\\n215\\n\\n220\\n\\nPro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe\\n240\\n225\\n\\n230\\n\\n235\\n\\nPro Pro Lys Pro Lys Asp Thr Leu Het Ile Ser Arg Thr Pro Glu Val\\n\\n245\\n\\n250\\n\\n255\\n\\nThr Cy. Val Val Val Asp Val Ser Mzs Glu Asp Pro Glu Val Gln Phe\\n\\n260\\n\\n265\\n\\n270\\n\\nAsn Trp Tyr Val Asp Gly Val Glu Val Hts Asn Ala Lys Thr Lys Pro\\n\\n275\\n\\n280\\n\\n285\\n\\nArg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr\\n\\n290\\n\\n295\\n\\n300\\n\\nVal Val Hr ~ Gln Aap Trp Leu Ann Gly Ly- Glu Tyr lys Cy. Lya Val\\n320\\n305\\n\\n310\\n\\n315\\n\\nSer Asn Ly- Gly Leu Pro Ser Ser Ile Glu Ly Thr Ile Ser Ly- Thr\\n\\n325\\n\\n330\\n\\n335\\n\\nLys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg\\n\\n340\\n\\n345\\n\\n350\\n\\nGlu Glu Het Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly\\n\\n355\\n\\n360\\n\\n365\\n\\nPhe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pzo\\n\\n370\\n\\n375\\n\\n380\\n\\n\\x0c67\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\nGlu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser\\n400\\n385\\n\\n395\\n\\n390\\n\\nPhe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln\\n\\n405\\n\\n410\\n\\n415\\n\\nGly Asn Val Phe Ser Cys Ser Val Met Mrs Glu Ala Leu Hrs Asn His\\n\\n420\\n\\n425\\n\\n430\\n\\nTyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys\\n\\n435\\n\\n440\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 16\\nLEIIGTH\\nTYPE\\nORGANISM Mu mu culus\\n\\n108\\n\\nPRT\\n\\n400. SEQUENCE\\n\\n16\\n\\nAsp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly\\n\\n5\\n\\n10\\n\\n15\\n\\nAsp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thz Asn\\n\\n20\\n\\n25\\n\\n30\\n\\nVal Ala Trp Tyr Gln Gln Lys Pro Gly Gln Set Pro Ly. Ala Leu Ile\\n\\n35\\n\\n40\\n\\n45\\n\\nTyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly\\n\\n50\\n\\n55\\n\\n60\\n\\nSer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Leu Ser\\n65\\n80\\n\\n70\\n\\n75\\n\\nGlu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Phe Tyr Ser Tyr Pro Tyz\\n\\n85\\n\\n90\\n\\n95\\n\\nThr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg\\n\\n100\\n\\n105\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 17\\nLEIIGTH\\nTYPE\\nORGANIS\\'N Mus mus«ulu\\n\\n108\\n\\nPRT\\n\\n400. SEQUENCE\\n\\n17\\n\\nAsp Ile Val liat Thr Gln Ser His Lys Phe Met. Ser Thr Ser Val Gly\\n\\n5\\n\\n10\\n\\n15\\n\\nAsp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala\\n\\n20\\n\\n25\\n\\n30\\n\\nVal Ala Trp Tyr Gln Gln Lys Pro Gly Gln Set Pro Ly. Leu Leu Ile\\n\\n35\\n\\n40\\n\\n45\\n\\nTyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly\\n\\n50\\n\\n55\\n\\n60\\n\\nSer Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala\\n65\\n80\\n\\n70\\n\\n75\\n\\nGlu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Arg Tyr Ser Thr Pro Arg\\n\\n85\\n\\n90\\n\\n95\\n\\nThr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg\\n\\n100\\n\\n105\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 18\\nLENGTH\\nTYPE\\nORGANIS\\'N Mus musculu\\n\\n107\\n\\nPRT\\n\\n400\\n\\n6\\'EQUENCE\\n\\n18\\n\\n!\\\\sp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser .Ala Ser Leu Gly\\n\\n\\x0c69\\n\\n70\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n10\\n\\n15\\n\\nAsp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr\\n\\n20\\n\\n25\\n\\n30\\n\\nLeu A n Tzp Tyr Gln Gln Lys Pzo .\\'. p Gly Thr Val Ly- Leu Leu Ile\\n\\n35\\n\\n60\\n\\n65\\n\\nTyr Tyr Thr Ser Ser Leu Hts Ser Gly Val Pro Ser Arg Phe Ser Gly\\n\\n50\\n\\n55\\n\\n60\\n\\nSer Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro\\n65\\n80\\n\\n70\\n\\n75\\n\\nGlu Acp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Phe\\n\\n85\\n\\n90\\n\\n95\\n\\nThr Phe Gly Ser Gly Thr Ly- Leu Glu Ile Ly\\n\\n100\\n\\n105\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 19\\nLENGTH\\nTYPE\\nORGANISN Nu- tsusculus\\n\\n108\\n\\nPRT\\n\\n600\\n\\nSEQUENCE\\n\\n19\\n\\nAsp Ile Val Met Thr Gln Ser His Lys Phe Net Ser Thr Ser Pits Gly\\n\\n1\\n\\n5\\n\\n10\\n\\n15\\n\\nAsp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Asn Ala\\n\\n20\\n\\n25\\n\\n30\\n\\nLeu Ala Trp Tyr Gln Gln Lys Pro Gly Hzs Ser Pro Lys Leu Leu Ile\\n\\n35\\n\\n60\\n\\n65\\n\\nPhe Ser Ala Ser Tyr Azg Tyr Thr Gly Val Pro Asp Azg Phe Thr Gly\\n\\n50\\n\\n55\\n\\n60\\n\\nSer Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala\\n65\\n80\\n\\n75\\n\\n70\\n\\nGlu Acp Leu Ala Val Tyr Tyr Cys Gln Gln Hz Tyr Ser Thr Pro Trp\\n\\n85\\n\\n90\\n\\n95\\n\\nThr Phe Gly Gly Gly Thr Lys Leu Glu Ile Ly Arg\\n\\n100\\n\\n105\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID 110 20\\nLENGTH\\nTYPE\\nORGANISE Nus musculus\\n\\n115\\n\\nPRT\\n\\n600\\n\\nSEQUENCE\\n\\n20\\n\\nGlu Val Gln Leu Gln Gln Sez Gly Pro Glu Leu Val Ly- Pro Gly Ala\\n1\\n\\n5\\n\\n15\\n\\n10\\n\\nSer Val Lys Ile Ser Cys Lys I\\\\la Ser Gly Tyr Thr Phe Thr I\\\\sp Tyr\\n\\n20\\n\\n25\\n\\n30\\n\\nTyr Net Asn Trp Val Lys Gln Ser Hzs Gly Lys Ser Leu Glu Trp Ile\\n\\n35\\n\\n40\\n\\n65\\n\\nGly Asp Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe\\n\\n50\\n\\n55\\n\\n60\\n\\nLy. Gly Ly Ala Thr Leu Thr Val Asp Ly- Ser Tyr Ser Thr Ala Tyr\\n65\\n80\\n\\n75\\n\\n70\\n\\nNet Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys\\n\\n85\\n\\n9Q\\n\\n95\\n\\nAla Arg Trp Leu Leu Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr\\n\\n100\\n\\n105\\n\\n110\\n\\nVal Ser Ala\\n115\\n\\n\\x0c71\\n\\n72\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n210\\n211\\n212\\na213\\n\\nSEQ ID NO 21\\nLENGTH\\nTYPE\\nORGANIISN Nu- musculus\\n\\n118\\n\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n21\\n\\nGln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nSer Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr\\n\\n20\\n\\n25\\n\\n30\\n\\nTrp Net Hzs Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ils\\n\\n35\\n\\n40\\n\\n45\\n\\nGly Glu Ile Asn Pro Ser Asn Gly Arg Thr Aan Tyr Asn Glu Ly- Phe\\n\\n50\\n\\n55\\n\\n0\\n\\nLys Ser Lys Tla Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr\\n80\\n\\n75\\n\\n70\\n\\nNet Gln Leu Ser Ser Leu Thz Ser Glu Asp Set Ala Val Tyr Tyz Cys\\n\\n85\\n\\n90\\n\\n95\\n\\nAla Arg Glu Arg Pro Leu Tyr Ala Net Asp Tyt Trp Gly Gln Gly Thr\\n\\n100\\n\\n105\\n\\n110\\n\\nSer Val Thr Val Ser Ser\\n\\n115\\n\\n210\\na211\\n212\\n213\\n\\nSEQ ID NO 22\\nLENGTH\\nTYPE\\nORGANIISN Nu mu culus\\n\\nPRT\\n\\n123\\n\\n400\\n\\nSEQUENCE\\n\\n22\\n\\nGlu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nSer Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arp Tyr\\n\\n20\\n\\n25\\n\\n30\\n\\nTyr Net Asn Trp Val Lys Gln Ser Hza Gly Lys Ser Leu Glu Trp Ile\\n\\n35\\n\\n40\\n\\n45\\n\\nGly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe\\n\\n50\\n\\n55\\n\\n60\\n\\nLys Gly Lys Ala Thr Leu Thr Val Asp Lys Ssr Ser Ser Thr Ala Tyr\\n65\\n80\\n\\n75\\n\\n70\\n\\ntact Glu Leu Arg Ser Leu Thr Ser Glu Asp Set Ala Val Tyr Tyr Cys\\n\\n85\\n\\n90\\n\\n95\\n\\nAla Gly Gly Gly Ile Tyr Tyr Arg Tyr Asp Arg Asn Tyr Phe Asp Tyr\\n\\n100\\n\\n105\\n\\n110\\n\\nTrp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser\\n\\n115\\n\\n12 0\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 23\\nLENGTH\\nTYPE\\nORGANISE Mu mu culus\\n\\n117\\n\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n23\\n\\nGlu Val Lys Leu Val Glu Ser Glu Gly Gly Leu Val Gln Pro Gly Ser\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nSer Net Lys Leu Ser Cy- Thz Ala Ser Gly Phe Thr Phe Ser Asp Tyr\\n\\n20\\n\\n25\\n\\n30\\n\\nTyr Het Ala Trp Val Arg Gln Val Pro Glu Lys Gly Leu Glu Trp Val\\n\\n\\x0c73\\n\\n74\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n35\\n\\n40\\n\\nAla Asn Ile Asn Tyr Asp Gly Ser Asn Tfsr Ser Tyr Leu Asp Ser Leu\\n\\n50\\n\\n55\\n\\n60\\n\\nLy. Ser Arg Pfse Ile Ile Ser Arg .\\'. p A n Ala Ly- Asn Ile Leu Tyr\\n65\\n80\\n\\n70\\n\\n75\\n\\nLeu Gln Het Ser Ser Leu Lys Ser Glu Asp Tnr Ala Tnr Tyr Tyr Cys\\n\\n85\\n\\n90\\n\\n95\\n\\nAla Arg Glu Lys Pfre Ala Ala Net Asp Tyr Trp Gly Gln Gly Tnr Ser\\n\\n100\\n\\n105\\n\\n110\\n\\nON\\n\\nLINKING PEPTIDE\\n\\nGly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nVal Thr Val Ser Ser\\n115\\n\\n15\\n\\nSEQ ID NO 24\\n\\n210\\n211s LENGTH\\n212\\n213\\n220\\n223\\n\\nPRT\\nTYPE\\nORGANISE Artrf\\nFEPTUPE\\nOTHER INFORNTTI\\n\\nrcral\\n\\n400\\n\\n6\\'EQUENCE\\n\\n24\\n\\n210\\n211\\n212\\n213\\ns220\\n223\\n\\n642\\n\\nSEQ ID NO 25\\nLENGTH\\nTYPE\\nDNA\\nORGAEISN Artrf\\nFEATURE:\\nOTHER 11\\'IFORHATI\\n\\nrcral\\n\\n400\\n\\nSEQUENCE\\n\\n25\\n\\nON\\n\\nHUILANIZED LIGHT CH..II\\'1 NUCLEOTIDE SEQUENCE\\n\\ngatatacaaa tgacacaatc tccatcctct ctttccgcat cagtcggcga ccgcgtaacc\\n\\nat.cacatgta gagcttctca aggcatctcc tccgccctcg catggtacca acaaaaacca\\n\\nggtaaagccc caaaactcct catatactca gcttcataca gatacaccgg cgtaccctca\\nagattctcag gttcaggctc tggaacagac tttactttca ccatttcatc actccaaccc\\n\\ngaagacatag ctacatatta ctgccaacaa agatacagcc t.ctggagaac att.tggccaa\\n\\nggaacaaaac tcgagatcaa acgtacggtg gctgcaccat. ctgtcttcat ctt.cccgcca\\n\\ntctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat\\n\\ncccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag\\n\\ngagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg\\n\\nctgagca\\n\\ng\\n\\ng\\n\\ng\\n\\ng\\n\\nt\\n\\ngt t\\n\\ng ct gcgaagtcac c.cat.c.agggc\\n\\nctgagctcnc ccgtcacaaa gagcttcaac aggggagagt gt\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 26\\n1332\\nLENGTH\\nTYPE\\nDNA\\nORGANHSH Artrf\\nFEATURE.\\nOTHER INFORf4ATI\\n\\nrcral\\n\\n400\\n\\nSEQUENCE\\n\\n26\\n\\nON\\n\\nHUSUUIIZED HEAV\\'I CHAIN NUCLEOTIDE SEQUENCE\\n\\ncaagttcaac tcgttcaatc tggagcagaa gtaaaaaaac ctggcgcctc tgttaaagta\\n\\nagttgtaaag catccggtta cacattcaca tcatattaca tgcattgggt aagacaagcc\\n\\ncctcgacaag cactcgaatg gatgggtgaa atctctcctt ttggcggccg aacaaactat\\n\\naatgaaaaat ttaaatcccg cgtaactatg acccgagaca catccacatc tactgtttat\\n\\n60\\n\\n120\\n\\n180\\n\\n240\\n\\n300\\n\\n3 0\\n\\n420\\n\\n480\\n\\n540\\n\\n600\\n\\n60\\n\\n120\\n\\n180\\n\\n240\\n\\n\\x0c75\\n\\n76\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\natggaacttt cctcactgcg ttctgaagac actgctgttt attactgtgc acgcgaaaga\\n\\ncctctctacg cttccgatct ctggggccaa ggaacaacgg tcaccgtctc ctcagcctcc\\n\\naccaagggcc catctgtctt cccactggcc ccatgctccc gcagcacctc cgagagcaca\\n\\ngccgccctgg gctgcctggt caaggactac ttcccagaac ctgtgaccgt. gtcctggaac\\n\\ntctggcgctc tgaccagcgg cgtgcacacc ttcccagctg tcctgcagtc ctc.aggtctc\\n\\ntactccctca gcagcgtggt gaccgtgcca tccagcaact tcggcaccca gacctacacc\\n\\ntgcaacgtag atcacaagcc aagcaacacc aaggtagata agaccgtgga gagaaagtgt\\n\\ntgtgtggagt gtccaccttg tccagcccct ccagtggccg gaccatccgt gttcctgttc\\n\\ncctccaaagc caaaggacac cctgatgatc tccagaaccc cagaggtgac ctgtgtggtg\\n\\ngtggacgtgt cccacgagga cccagaggtg cagttcaact. ggtatgtgga cggagtggag\\n\\ngtgcacaacg ccaagaccaa gccaagagag gagcagttca actccacctt cagagtggtg\\n\\nagcgtgctua ccgtggtgca ccaggactgg ctgaacggaa aggagtataa gtgtaaggtg\\n\\ntccaacaagg cactcccatc cagcatcgag aacaccatct ccaagaccaa gggacagcca\\n\\nagagaqccac agctgtatac cctgccccca tccaqagacg acatgaccaa gaaccaggtg\\n\\ntccctgacct gtctggtgaa gggattctat ccatccgaca t.cgccgtgga gtgggagtcc\\n\\naacggacagc cagagaacaa ctataagacc acccctccaa tgctggactc cgacggatcc\\n\\nttcttcctgt attccaagct gaccgtggac aagtccagat ggcagcaggg aaacgtgttc\\n\\ntcttgttccg tgatgcacga ggccctgcac aaccactata cccagaagag cctgtccctg\\n\\n300\\n\\n360\\n\\n420\\n\\n480\\n\\n540\\n\\n600\\n\\n660\\n\\n720\\n\\n780\\n\\n840\\n\\n900\\n\\n960\\n\\n1020\\n\\n1080\\n\\n1140\\n\\n1200\\n\\n1260\\n\\n1320\\n\\n1332\\n\\nLys Ala Ser Gln Asn Val Gly Thr Asn Val Ala\\n1\\n\\n10\\n\\n5\\n\\ntctccaggaa ag\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 27\\nLENGTH\\nTYPE\\nORGANISE Hus musculus\\n\\nPRT\\n\\n11\\n\\n400\\n\\nSEQUENCE\\n\\n27\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 28\\nLENGTH\\nTYPE\\nORGANISE Nus musculus\\n\\n7\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n28\\n\\nSer Ala Ser Tyr Arg Tyr Ser\\nI\\n\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 29\\nLENGTH\\nTYPE\\nORGAEISN Nus musculus\\n\\n9\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n29\\n\\nGln Gln Phe Tyr Ser Tyr Prc Tyr Thr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 30\\nLENGTH\\nTYPE\\nORGANIB\\'N Mus musculu\\n\\nPRT\\n\\n11\\n\\n400\\n\\n6\\'EQUENCE\\n\\n30\\n\\nLys Ala Ser Gln Asp Val Ser Thr Ala Val Ala\\n\\n\\x0cUS 8,080,243 B2\\n\\n-continued\\n\\n78\\n\\n77\\n\\n10\\n\\nSEQ ID NO 31\\nLENGTH\\nTYPE\\n\\n210\\n211\\ns212\\ns213 ORG.NIS14 Nu\\n\\n9\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n31\\n\\ntAll culu\\n\\nGln Gln Erg Tyr Ser Thr Pro Rrg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 32\\nLEIIGTH\\nTYPE\\nORGRNISII Mu mu culus\\n\\nPRT\\n\\n11\\n\\n400. SEQUENCE\\n\\n32\\n\\nSer Rla Ser Gln Gly Ile Ser Rsn Tyr Leu Isn\\n\\n5\\n\\n10\\n\\n210\\n211\\n212\\n213\\n\\n5\\'EQ ID NO 33\\nLENGTH\\nTYPE\\nORGRNISM Mus musculus\\n\\n7\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n33\\n\\nTyr Thr Ser Ser Leu Hrs Ser\\nI\\n\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID I\\'10 34\\nLENGTH\\nTYPE\\nORGRNISM Mus musculus\\n\\nPRT\\n\\n11\\n\\n400\\n\\nSEQUENCE\\n\\n34\\n\\nLy Rla Ser Gln Rsp Val Ser R n Rla Leu Rla\\nI\\n\\n10\\n\\n5\\n\\n210m SEQ ID NO 35\\n211m LENGTH\\n212\\n213\\n\\n9\\nPRT\\n\\nTYPE\\nORGRNISbt Mus mttscullts\\n\\n400\\n\\nSEQUENCE\\n\\n35\\n\\nGln Gln Hrs Tyr Ser Thr Pro Trp Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 36\\nLENGTH\\nTYPE\\nORGRNISN Mus musculus\\n\\n7\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n36\\n\\nGly Tyr Thr Phe Thr Rsp Tyr\\nI\\n\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID I\\'10 37\\nLENGTH\\nTYPE\\nORGRNISM Mus musculus\\n\\n5\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n37\\n\\nRsp Tyr Tvr Met Rsn\\nI\\n\\n5\\n\\n\\x0c79\\n\\n80\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n4 p Ile Aan Pro Aan Aan Gly Gly Thr Thr Tyr Aan Gln Lya Phe Ly-\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 39\\nLENGTH\\nTYPE\\nORGANISN Mus musculus\\n\\nPRT\\n\\nc400\\n\\nSEQUENCE\\n\\n39\\n\\nAan Pro Asn Aan Gly Gly\\nI\\n\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 39\\nLENGTH\\nTYPE\\nORGANISN Mus musculu\\n\\nPRT\\n\\n17\\n\\n400\\n\\nSEQUENCE\\n\\n39\\n\\nGly\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 40\\nLENGTH\\nTYPE\\nORGPAHSN Mu musculu\\n\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n40\\n\\nTrp Leu Leu Phe Als Tyr\\nI\\n\\n5\\n\\nc210\\n211\\n212\\n213\\n\\nSEQ ID NO\\nLEI\\'GTH 7\\nPRT\\nTYPE\\nORGPIIISM Mu mu culua\\n\\n400\\n\\nSEQUENCE\\n\\n41\\n\\nGly Tyr Thr Phe Thr Ser Tyr\\nI\\n\\n5\\n\\nSEQ ID NO 42\\n\\n210\\n211m LENGTH\\n212m T\\'IPE\\n213\\n\\n5\\nPRT\\n\\nORGANISM Mus musculus\\n\\n400\\n\\nSEQUENCE\\n\\n42\\n\\nSer Tyr Trp Met Hts\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 43\\nLENGTH\\nTYPE\\nORGANISM Mus musculus\\n\\n6\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n43\\n\\nA n Pro Ser Asn Gly Arg\\n\\n5\\n\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEO ID NO 44\\nLENGTH\\nTYPE\\nORGANISM Mus musculus\\n\\nPRT\\n\\n17\\n\\n400\\n\\nSEQUENCE\\n\\n44\\n\\nGlu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Lya Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nSer\\n\\n\\x0c81\\n\\n82\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n4 p Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGly Gly Ile Tyr Tyr Arg Tyr Asp Arg Asn Tyr Phe Asp Tyr\\nI\\n\\n10\\n\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID No 45\\nLEItGTH 9\\nPRT\\nTYPE\\nORGANISN Mus musculus\\n\\nssoo\\n\\nSEQUENCE\\n\\n45\\n\\nGlu Arg Pro Leu Tyr Ala tset Asp Tyr\\nI\\n5\\n\\nSEQ ID No 46\\nLENGTH\\nTYPE\\nORGAEISM Mus musculus\\n\\nPRT\\n\\n17\\n\\nsEQUENCE\\n\\n46\\n\\n210\\n211\\n212\\n213\\n\\nsoo\\n\\nGly\\n\\n210\\n211\\n212\\n213\\n\\n6\\'EQ ID No 47\\nLENGTH\\nTYPE\\nORGANISM Mus musculus\\n\\nPRT\\n\\n14\\n\\n400\\n\\nSEQUENCE\\n\\n47\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID I\\'io 48\\nLENGTH\\nTYPE\\nORGANISM Mus musculus\\n\\n7\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n48\\n\\nGly Phe Thr Phe Ser Asp Tyr\\nI\\n\\n5\\n\\n210m SEQ ID No 49\\n211m LENGTH\\n212\\n213\\n\\n5\\nPRT\\n\\nTYPE\\nORGANISbi Mus musculus\\n\\n400\\n\\nSEQUENCE\\n\\n49\\n\\nAsp Tyr Tyr Met Ala\\nI\\n\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID No 50\\nLENGTH\\nTYPE\\nORGANISN Mus musculus\\n\\n6\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n50\\n\\nAsn Tyr Asp Gly Ser Asn\\nI\\n\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID I\\'io 51\\nLENGTH\\nTYPE\\nORGANISM Mus musculus\\n\\nPRT\\n\\n16\\n\\n400\\n\\nSEQUENCE\\n\\n51\\n\\nAsn Ile Asn Tyr Asp Gly Ser Asn Thr Ser Tyt Leu Asp Ser Leu Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\n\\x0c83\\n\\n84\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 52\\nLENGTH\\nTYPE\\nORGAEISN Mus musculua\\n\\n8\\nPRT\\n\\ns400\\n\\nSEQUENCE\\n\\n52\\n\\nGlu Ly. Phe Ala Ala Net A p Tyz\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 53\\nLENGTH\\nTYPE\\nORGANISN homo aapzen\\n\\n107\\n\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n53\\n\\n4 p Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly\\n\\n1\\n\\n5\\n\\n10\\n\\n15\\n\\nAsp Arg Val Thr Zle Thr Cys Arg Ala Ser Gln Gly Zle Ser Ser Ala\\n\\n20\\n\\n25\\n\\n30\\n\\nLeu Ala Tzp Tyr Gln Gln Lya Pzo Gly Lys Ala Pro Ly- Leu Leu Ile\\n\\n35\\n\\n40\\n\\n45\\n\\nTyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly\\n\\n50\\n\\n55\\n\\n60\\n\\nSer Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro\\n65\\n80\\n\\n75\\n\\n70\\n\\nGlu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Ser Leu Trp Arg\\n\\n85\\n\\n90\\n\\n95\\n\\nThr Phe Gly Gln Gly Thr Lye Leu Glu Ile Ly\\n\\n100\\n\\n105\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 54\\nLENGTH\\nTYPE\\nORGANISN homo sapzen\\n\\n118\\n\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n54\\n\\nGln Val Gln Leu Val Gln ser Gly Ala Glu Val Lys Lys Pro Gly Ala\\n1\\n\\n10\\n\\n5\\n\\n15\\n\\nSer Val Ly\" Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr\\n\\n20\\n\\n25\\n\\n30\\n\\nTyr Net Hzs Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net\\n\\n35\\n\\n40\\n\\n45\\n\\nGly Glu Ile Ser Pro Phe Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe\\n\\n50\\n\\n55\\n\\n60\\n\\nLys Ser Arg Val Thr Net Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr\\n65\\n\\n75\\n\\n80\\n\\n70\\n\\nNet Glu Leu Ser Ser Leu Arg Ser Glu Psp Thr Ala Val Tyr Tyr Cys\\n\\n85\\n\\n90\\n\\n95\\n\\nAla Arg Glu Arg Pro Leu Tyr Ala Ser Asp Leu Trp Gly Gln Gly Thr\\n\\n100\\n\\n105\\n\\n110\\n\\nThr Val Thr Val Ser Ser\\n\\n115\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n9\\nPRT\\n\\nSEQ ID NO 55\\nLENGTH\\nTYPE\\nORGANIS\\'N Artzfzczal Sequence\\nFEATURE:\\nOTHER INPORNATIOE Synthetzc\\n\\n400\\n\\nSEQUENCE\\n\\n55\\n\\n\\x0c85\\n\\n86\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\nGln Gln Tyr Ser Lys Leu Pro Phe Thr\\n5\\n\\nc210\\nc211\\n212\\n213\\n220\\n223\\n\\n10\\n\\nSEQ ID NO 56\\nLENGTH\\nPRT\\nTYPE\\nORGANISE Artific\\nFEATURE\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n56\\n\\nial Sequence\\n\\nSynthetic\\n\\nGly Tyr Thr Phe Thr Asp Tyr Tyr Net F.cn\\n1\\n\\n10\\n\\n5\\n\\n10\\n\\nSEQ ID NO 57\\n\\n210\\n211s LENGTH\\n212\\n213\\n220\\n223\\n\\nPRT\\nTYPE\\nORGANISE Artific\\nFEATUPE\\nOTHER INFORNITION\\n\\n400\\n\\n6\\'EQUENCE\\n\\n57\\n\\nial Sequence\\n\\nSynthetic\\n\\nGly Tyr Thr Phe Thr Ser Tyr Trp Net Mi\\nI\\n10\\n\\n5\\n\\n210\\n211\\n212\\n213\\nc220\\n223\\n\\n10\\n\\nSEQ ID NO 58\\nLENGTH\\nPRT\\nTYPE\\nORGAEISN Artific\\nFEATURE:\\nOTHER Il\\'IFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n58\\n\\nial Sequence\\n\\nSynthetic\\n\\nGly Phe Thr Phe Ser Asp Tyr Tyr Net Ala\\nI\\n\\n10\\n\\n5\\n\\n10\\n\\nSEQ ID NO 59\\nLENGTH\\nTYPE\\n\\n210\\n211\\n212\\n213s ORGWIISN ArtifiC\\n220. FEATURE.\\n223\\n\\nOTHER INFORNATION\\n\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n59\\n\\nial Sequence\\n\\nSyntlietic\\n\\nGly Tyr Thr Phe Thr Ser Tyr Tyr Net His\\n10\\n\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 60\\nLENGTH\\n7\\nPRT\\nTYPE\\nORGANISE Artific\\nFEATURE\\nOTHER INPORKATION\\n\\n400\\n\\nSEQUENCE\\n\\n60\\n\\nial Sequence\\n\\nSynthetic\\n\\nGly Tyr Thr Phe Thr Ser Tyr\\n1\\n\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 61\\nLENGTH\\n6\\nPRT\\nTYPE\\nORGANISE Artific\\nFEATURE.\\nOTHER INFORHATION\\n\\n400\\n\\n6\\'EQUENCE\\n\\n61\\n\\nSer Pro Phe Gly Gly Arg\\n\\nial Sequence\\n\\nSynthetic\\n\\n\\x0c87\\n\\n88\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n210\\n211\\n.212\\n.213\\n220\\n223\\n\\nSEQ ID NO 62\\nLENGTH\\n0\\nPRT\\nTYPE\\nORGANIS14 Artrfrc\\nFEATURE:\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n62\\n\\nral Sequence\\n\\nSynthetrc\\n\\nGln Asp Val Ser Thr Ala Val Ala\\n5\\n\\n11\\n\\nSEQ ID NO 63\\nLENGTH\\nTYPE\\n\\n210\\n211\\n212\\n213 s ORGMIISN ArtrftC\\n220\\n223\\n\\nFEATURE\\nOTHER INPORKATION\\n\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n3\\n\\nral Sequence\\n\\nSynthetrc\\n\\nGly Gly Thr Arg Val Val Ser Thr Ala Val Ala\\n1\\n\\n5\\n\\n10\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n4\\n\\n10\\n\\nSEQ ID NO\\nLENGTH\\nPRT\\nTYPE\\nORGANISN Artrfrc\\nFEATURE\\nOTHER INPORKATION\\n\\n400\\n\\nSEQUENCE\\n\\n64\\n\\nral Sequence\\n\\nSynthetrc\\n\\nArg Gly Asp Phe Val Ser Thr Ala Val Ala\\n10\\n1\\n\\n5\\n\\n17\\n\\nSEQ ID NO 65\\nLENGTH\\nPRT\\nTYPE\\nORGANISN Artrfrc\\nFEATURE:\\n\\n210\\n211\\n212\\n213\\n220\\n223. OTHER INPOPNATION\\n\\n400\\n\\nSEQUENCE\\n\\n5\\n\\nral Sequence\\n\\nSynthetrc\\n\\n1\\n\\nSer\\n\\n1\\n\\nSer\\n\\n5\\n\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 66\\nLENGTH\\nPRT\\nTYPE\\nORGANISE Artrfrc\\nFEATURE\\nOTHER INPORKATION\\n\\n400\\n\\nSEQUENCE\\n\\n66\\n\\ntal Sequence\\n\\nSynthetrc\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n7\\n\\n17\\n\\nSEQ ID NO\\nLENGTH\\nPRT\\nTYPE\\nORGANIS\\'N Artrfrc\\nFEATURE:\\nOTHER INPORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n67\\n\\nral Sequence\\n\\nSynthetrc\\n\\nGlu Ile Asn Pro Ser Gly Gly Arq Thr Asn Tyr Asn Glu Lys Phe Lys\\n\\n10\\n\\n15\\n\\nGlu Ile Aen Pro Ser Ser Gly Arg Thr Aen Tyr Aen Glu Ly. Phe Lya\\n\\n10\\n\\n15\\n\\n\\x0c89\\n\\n90\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\nGlu Ile Asn Pro Ser Thr Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\n\\n5\\n\\n10\\n\\nGlu Ile Asn Pro Ser Ile Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGlu Ile Asn Pzo Ser Asp Ser Azg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGlu Ile Asn Pzo Ser Gly Asn Azg Thz Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGlu Ile Asn Pro Ser Ser Ser Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID I\\'10 68\\nLENGTH\\nPRT\\nTYPE\\nORGANISM Artzfzc\\nFEATURE\\nOTHER INFORMATION\\n\\n400\\n\\nSEQUENCE\\n\\n68\\n\\nzal Sequence\\n\\nSynthetzc\\n\\n17\\n\\nSEQ ID NO 69\\nLENGTH\\nTYPE\\n\\n210\\n211\\n212\\n213 ORnaNISM Aztzfrc\\n220\\n223\\n\\nFEATURE:\\nOTHER IEFORMATION\\n\\nPRT\\n\\n400\\n\\nSEQUENCE\\n\\n9\\n\\nzal Sequence\\n\\nSynthetrc\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 70\\nLENGTH\\nPRT\\nTYPE\\nORGANISN Artzftc\\nFEATURE\\nOTHER INFORMATION\\n\\n400\\n\\nSEQUENCE\\n\\n70\\n\\nzal Sequence\\n\\nSynthetzc\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nI\\n\\n17\\n\\nSEQ ID NO\\nLENGTH\\nPRT\\nTYPE\\nORGANISN Aztzfrc\\nFEATURE:\\nOTHER INFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n71\\n\\nral Sequence\\n\\nSynthetzc\\n\\nSer\\n\\nSez\\n\\nSer\\n\\nSez\\n\\nSer\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 72\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artrfrc\\nFEATURE\\nOTHER INFORMATION\\n\\n400\\n\\nSEQUENCE\\n\\n72\\n\\ntal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pzo Leu Tyr Ala Met Asp Tyz\\nI\\n5\\n\\n\\x0c91\\n\\n92\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n210\\n211\\n212\\n213\\n220\\nr223\\n\\nSEQ ID NO 73\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAEISN Artzfrc\\nFEATURE\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n73\\n\\ntal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Ala Asp Tyr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 74\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artrftc\\nPEATURE:\\nOTHER INPORI6ATION\\n\\n400\\n\\nSEQUENCE\\n\\n74\\n\\nral sequence\\n\\nsynthetrc\\n\\nGlu Arg Pro Leu Tyr Ala Ile Asp Tyr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n400\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 75\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Arttftc\\nFEATURE.\\nOTHER INFORH\\'TION\\n\\nSEQUENCE\\n\\n5\\n\\ntal Sequence\\n\\nSynthetzc\\n\\nGlu \\'rg Pro Leu Tyr Ala Azg A p Tyr\\nI\\n\\n5\\n\\n9\\nPRT\\n\\nSEQ ID NO 76\\nLENGTH\\nTYPE\\nORGANISE\\nFEATURE.\\nOTHER INFORHATION\\n\\n.Artrftc\\n\\ntal Sequence\\n\\nSynthetzc\\n\\n400\\n\\nSEQUENCE\\n\\n76\\n\\nGlu Arg Pro Leu Tyr Ala Gly Asp Tyr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n7\\n\\nSEQ ID NO\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artzfrc\\nFEATURE:\\nOTHER INFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n77\\n\\nral Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Lys Asp Tyr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 78\\nLEI\\'GTH 9\\nPRT\\nTYPE\\nORGANISE Artrftc\\nPEATURE:\\nOTHER INFORHATIOE\\n\\n400\\n\\nSEQUENCE\\n\\n78\\n\\nral sequence\\n\\nSynthetrc\\n\\nGlu Arg Pro Leu Tyr Ala Pro Asp Tyr\\nI\\n5\\n\\n210\\n211\\n\\nSEQ ID NO 79\\nLENGTH\\n\\n9\\n\\n\\x0c93\\n\\n94\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n212\\n213\\n220\\n223\\n\\nPRT\\n\\nTYPE\\nORGANISM Artificial Sequence\\nFEATURE\\nOTHER INFORHPTION Synthetic\\n\\ns400\\n\\nSEQUENCE\\n\\n79\\n\\nGlu Arg Pro Leu Tyr Ala Ser 8 p Tyr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n9\\nPRT\\n\\nSEQ ID NO 80\\nLENGTH\\nTYPE\\nORGANISN Artificial Sequence\\nFEATURE.\\nOTHER INFORMATION Synthetic\\n\\n400\\n\\nSEQUENCE\\n\\n80\\n\\nGlu Arg Pro Leu Tyr Ala Leu Asp Tyr\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n9\\nPRT\\n\\nSEQ ID NO 81\\nLENGTH\\nTYPE\\nORGPSHSN Artificial Sequence\\nFEATURE.\\nOTHER INPORHATION Synthetic\\n\\n400\\n\\nSEQUENCE\\n\\n81\\n\\nGlu Arg Pro Leu Tyr Ala Val Asp Tyr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n9\\nPRT\\n\\nSEQ ID NO 82\\nLENGTH\\nTYPE\\nORGANISN Artificial Sequence\\nFEATURE\\nOTHER INFORMATION Synthetic\\n\\n400\\n\\nSEQUENCE\\n\\n82\\n\\nGlu Arg Pro Leu Tyr Ala Trp Asp Tyr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n9\\nPRT\\n\\nSEQ ID NO 83\\nLENGTH\\nTYPE\\nORGANISM Artificial Sequence\\nFEATURE\\nOTHER INFORMATION Synthetic\\n\\n400\\n\\nSEQUENCE\\n\\n83\\n\\nGlu Arg Pro Leu Tyr Ala His Asp Tyr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n9\\nPRT\\n\\nSEQ ID NO 84\\nLENGTH\\nTYPE\\nORGANIISH Artificial Sequence\\nFEATURE.\\nOTHER INFORMATION Synthetic\\n\\n400\\n\\nSEQUENCE\\n\\n84\\n\\nGlu Arg Pro Leu Tyr Ala Phe Asp Tyr\\n5\\n\\n210\\n211\\n212\\n213\\n\\nSEQ ID NO 85\\nLENGTH\\nTYPE\\nORGANISM Artificial Sequence\\n\\n9\\nPRT\\n\\n\\x0c95\\n\\n96\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n220\\n223\\n\\nPEATURR.\\nOTHER INFORN\"ZION Synthetzc\\n\\n400\\n\\nSEQUENCE\\n\\n85\\n\\nGlu Arg Pro Leu Tyr Ala Thr .. p Tyr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 86\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artzfzc\\nFEATURE\\nOTHER INPORFLATZON\\n\\n400\\n\\nSEQUENCE\\n\\n86\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Phe Ser Thr Pro Arg Thr\\n5\\n1\\n\\n9\\nPRT\\n\\nSEQ ID NO 87\\nLENGTH\\nTYPE\\n\\n210\\n211\\n212\\n213 DRONISH Aztzfzc\\n220\\n223\\n\\nFEATURE:\\nOTHER IEFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n87\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Prg Tyr Ser Aep Trp Azg Thr\\nI\\n5\\n\\ne210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 88\\nLEZ\\'GTH\\n9\\nPRT\\nTYPE\\nORGAIIISH Artzftc\\nFEATURE.\\nOTHER INFORKATION\\n\\n400\\n\\nSEQUENCE\\n\\n88\\n\\ntal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Ser Trp Arg Thr\\n5\\n1\\n\\n210a SEQ ID NO 89\\n211\\nLENGTH\\n9\\n212\\nPRT\\nTYPE\\nORGANISN Artzftc\\n213\\n220\\nFEATURE\\nOTHER INFORH\\'TION\\n223\\n\\n400\\n\\nSEQUENCE\\n\\n89\\n\\ntal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Thr Ala Azg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 90\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artzfzc\\nFEATURE\\nOTHER INPORHATION\\n\\n400\\n\\nSEOUENCE\\n\\n90\\n\\nzal Sequence\\n\\nsynt.hetzc\\n\\nGln Gln Arg Tyr Ser Leu Tyr Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 91\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Aztzfzc\\nFEATURE.\\nOTHER INFORMATION\\n\\nzal Sequence\\n\\nSynthetzc\\n\\n\\x0c97\\n\\n98\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n400\\n\\nSEQUENCE\\n\\n91\\n\\nGln Gln Arg Tyr Ser Phe Trp Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID I\\'10 92\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Arttftc\\nFEATURE\\nOTHER INFORIAATION\\n\\n400\\n\\nSEQUENCE\\n\\n92\\n\\ntal Sequence\\n\\nSynthettc\\n\\nGln Gln Arg Tyr Ser Prc Trp Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 93\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Arttftc\\nFEATURE:\\nOTHER INPORINATION\\n\\n400\\n\\nSEQUENCE\\n\\n93\\n\\ntal Sequence\\n\\nSynthettc\\n\\nGln Gln Arg Tyr Ser Gly Trp Arg Thr\\nI\\n5\\n\\n210\\n211\\nc212\\n213\\n220\\n223\\n\\nSEQ ID NO 94\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANIISN Arttfrc\\nFEATURE:\\nOTHER INFORNATZON\\n\\n400\\n\\nSEQUENCE\\n\\n94\\n\\ntal Sequence\\n\\nSynt hat rc\\n\\nGln Gln Arg Tyr Ser Ile Trp Arg Thr\\nI\\n5\\n\\nSEQ ID NO 95\\n\\n210\\n211e LENGTH\\n212a T\\'IPE\\n213\\n220\\n223\\n\\n9\\nPRT\\nORGANISE Arttftc\\nFEATURE:\\nOTHER INFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n95\\n\\ntal sequence\\n\\nSynthettc\\n\\nGln Gln rrg Tyr Ser Ala Trp Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 96\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artrfrc\\nFEATURE\\nOTHER INFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n96\\n\\ntal Sequence\\n\\nSynthettc\\n\\nGln Gln Arg Tyr Ser Leu Phe Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 97\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANIS\\'N Artrfrc\\nFEATURE:\\nOTHER INPORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n97\\n\\ntal Sequence\\n\\nSynthettc\\n\\n\\x0c99\\n\\n100\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\nGln Gln Arg Tyr Ser Thr Arg Arg Thr\\n5\\n\\nr210\\nr211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 98\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artific\\nFEATURE\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n98\\n\\nial Sequence\\n\\nSynthetic\\n\\nGln Gln Arg Tyr Ser Thr Leu Tyr Thr\\n5\\n1\\n\\nSEQ ID NO 99\\n\\n210\\n211e LENGTH\\n212\\n213\\n220\\n223\\n\\n9\\nPRT\\nTYPE\\nORGANISE Artific\\nFEATUPE\\nOTHER INFORNITION\\n\\n400\\n\\n5\\'EQUENCE\\n\\n99\\n\\nial Sequence\\n\\nSynthetic\\n\\nGln Gln Arg Tyr Ser Thr Trp Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\nr220\\n223\\n\\nSEQ ID NO 100\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAEISN Artific\\nFEATURE:\\nOTHER Il\\'IFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n100\\n\\nial Sequence\\n\\nSynthetic\\n\\nGln Gln Arg Tyr Ser Leu Ala Arg Thr\\nI\\n5\\n\\n9\\nPRT\\n\\nSEQ ID NO 101\\nLENGTH\\nTYPE\\n\\n210\\n211\\n212\\n213a ORGWIISN ArtifiC\\n220. FEATURE.\\n223\\n\\nOTHER INFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n101\\n\\nial Sequence\\n\\nSyntlietic\\n\\nGln Gln Arg Tyr Ser Ser Glu Arg Thr\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 102\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artific\\nFEATURE\\nOTHER INPORKATION\\n\\n400\\n\\nSEQUENCE\\n\\n102\\n\\nial Sequence\\n\\nSynthetic\\n\\nGln Gln Arg Tyr Gly Thr Ala Arg Thr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 103\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artific\\nFEATURE.\\nOTHER INFORHATION\\n\\n400\\n\\n5\\'EQUENCE\\n\\n103\\n\\nial Sequence\\n\\nSynthetic\\n\\nGln Gln Arg Tyr Ser Gln !\\\\la !\\\\rg Thr\\n\\n\\x0c101\\n\\n102\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n210\\n211\\n.212\\n.213\\n220\\n223\\n\\nSEQ ID NO 104\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANIS14 Aztzfzc\\nFEATURE:\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n104\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Azg Tyr Ser Leu Hza Azg Thr\\n5\\n\\n9\\nPRT\\n\\nSEQ ID NO 105\\nLENGTH\\nTYPE\\n\\n210\\n211\\n212\\n213 a ORGM4ISN ArtzfzC\\n220\\n223\\n\\nFEATURE\\nOTHER INPORKATION\\n\\n400\\n\\nSEQUENCE\\n\\n105\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Azg Tyz Ser Gly Val Azg Thz\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 106\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAEISN Artzfzc\\nFEATURE\\nOTHER INPORKATION\\n\\n400\\n\\nSEQUENCE\\n\\n106\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Gln Ser .\\'. g Thr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 107\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAEISN Aztzfzc\\nFEATURE:\\nOTHER INPOPNATION\\n\\n400\\n\\nSEQUENCE\\n\\n107\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Prg Tyr Ser Ala Glu Arg Thr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 108\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artzfzc\\nFEATURE.\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n108\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Azg Tyr Ser Gln Phe Azg Thr\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n9\\nPRT\\n\\nSEO ID NO 109\\nLENGTH\\nTYPE\\nORGANISE\\nFEATURE\\nOTHER INPORKATION\\n\\n.Artzfzc\\n\\n400\\n\\nSEQUENCE\\n\\n109\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Azg Tyz Ser Sez Azg Azg Thz\\n5\\n1\\n\\n\\x0c103\\n\\n104\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n210\\n211\\n212\\n213\\na220\\na223\\n\\nSEQ ID NO 110\\nLElzGTH\\n9\\nPRT\\nTYPE\\nORGAMISN Artzfzc\\nFEATURE;\\nOTI\\'ER INPORIMATION\\n\\n400\\n\\nSEQUENCE\\n\\n110\\n\\nzal Sequence\\n\\nSvnthetzc\\n\\nGln Gln Arg Tyr Ser Cye Ser Arg Thr\\nI\\n5\\n\\nSEQ ID NO 111\\nLEIIGTH\\n9\\nPRT\\nTYPE\\nORGANISM Artzfzc\\nPEATURE:\\n\\n210\\n211\\n212\\n213\\n220\\n223. OTHER INFORMATION\\n\\n400\\n\\nSEQUENCE\\n\\n111\\n\\nzal sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Thr Aen Arg Arg\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID EO 112\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISFI Artzfzc\\nFEATURE\\nOTHER INFORMITION\\n\\n400\\n\\nSEQUENCE\\n\\n112\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Zzg Tyr Ser Arg Trp Azg Thz\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 113\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAMISN Artzfzc\\nFEATURE.\\nOTI\\'ER INFORFIATION\\n\\n400. SEQUENCE\\n\\n113\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Prc Tyz Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 114\\nLElzGTH\\n9\\nPRT\\nTYPE\\nORGPIIISH Artzfzc\\nFEATURE;\\nOTHER INPORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n114\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Tyr Trp Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 115\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISM Artzfzc\\nFEATURE\\nOTHER INFORMATION\\n\\n400\\n\\nSEQUENCE\\n\\n115\\n\\nzal sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Gly Phe Arg Thr\\nI\\n5\\n\\n210\\n\\nSEQ ID NO 11\\n\\n\\x0c105\\n\\n106\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n211\\n212\\n213\\n220\\n223\\n\\nLENGTH\\n9\\nPPT\\nTYPE\\nORG62IISN Artrfrc\\nFEATURE\\nOTHER INFORFZATZON\\n\\nral Sequence\\n\\nSynthetrc\\n\\nc400\\n\\nSEQUENCE\\n\\n116\\n\\nGln Gln Arg Tyr Ser Tyr Trp I\\\\rg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 117\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAEISN Artrfrc\\nFEATURE:\\nOTHER INPORHATION\\n\\n400. SEQUENCE\\n\\n117\\n\\nral Sequence\\n\\nSynthetrc\\n\\nGln Gln frg Tyr Ser Phe Lye Arg Thr\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n6\\'EQ ID NO 115\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artrfrc\\nPEATURR.\\nOTHER INFORFZATION\\n\\n400\\n\\nSEQUENCE\\n\\n119\\n\\nral Sequence\\n\\nSynthetrc\\n\\nGln Gln Arg Tyr Ser Ala Arg Arg Thr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 119\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artrfrc\\nFEATURE\\nOTHER INPORFZATZON\\n\\n400\\n\\nSEQUENCE\\n\\n119\\n\\nral Sequence\\n\\nSyntretrc\\n\\nGln Gln Arg Tyr Ser Arg Tyr Arg Thr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 120\\nLENGTH\\n9\\nPPT\\nTYPE\\nORGIUIISN Artrfrc\\nFEATURE:\\nOTHER IEFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n120\\n\\nral Sequence\\n\\nSynthetrc\\n\\nGln Gln Arg Tyr Ser Leu Gln I\\\\rg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 121\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGPIIISN Artrfrc\\nFEATURE:\\nOTHER INPORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n121\\n\\nral Sequence\\n\\nSynthetrc\\n\\nGln Gln frg Tyr Ser Thr Ser Arg Thr\\n5\\n1\\n\\n210\\n211\\n212\\n\\n6\\'EQ ID NO 122\\nLENGTH\\nTYPE\\n\\n9\\nPRT\\n\\n\\x0c107\\n\\n108\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n213\\n220\\n223\\n\\nORGANISM Arttftc\\nFEATURE\\nOTHER INFORM\\'TION\\n\\ntal Sequence\\n\\nSynthetzc\\n\\n400\\n\\nSEQUENCE\\n\\n122\\n\\nGln Gln Arg Tyr Ser Hz\\n1\\n\\n5\\n\\n6;la Arg Thr\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 123\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAEISN Artzfzc\\nFEATURE.\\nOTHER INFORMATION\\n\\n600\\n\\nSEQUENCE\\n\\n123\\n\\ntal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr ser Lye Tyr Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 124\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artzfzc\\nFEATURE:\\nOTHER IMFOPMATIOM\\n\\n400\\n\\nSEQUENCE\\n\\n124\\n\\nral Sequence\\n\\nSynthettc\\n\\nGln Gln Arg Tyr Ser Gln Ser Arg Thr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID I\\'10 125\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISM Artrftc\\nFEATURE\\nOTIIER INFORNFTIOM\\n\\n400\\n\\nSEQUENCE\\n\\n125\\n\\nral Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Thr Ala Phe Thr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 126\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artzfrc\\nFEATURE\\nOTHER INFORM\\'TION\\n\\n400\\n\\nSEQUENCE\\n\\n126\\n\\ntal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Thr Cya Cya Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 127\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAEISN Artzfzc\\nPEATURE:\\nOTHER INFORNATZON\\n\\n400\\n\\nSEQUENCE\\n\\n127\\n\\ntal Sequence\\n\\naynt hat zc\\n\\nGln Gln Arg Tyr Ser Thr !\\\\ep !\\\\rg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n\\n9\\nPRT\\n\\nSEQ ID NO 128\\nLENGTH\\nTYPE\\nORGAMISN Artzfzcral Sequence\\nFEATURE\\n\\n\\x0c109\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n223\\n\\nOTHER INPORNATION Synthetic\\n\\n400\\n\\nSEQUENCE\\n\\n128\\n\\nGln Gln Arg Tyr Ser Glu Aep Azg Thr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 129\\nLENGTH\\n8\\nPRT\\nTYPE\\nORGANISN Artific\\nFEATURE\\nOTHER INFORHPTION\\n\\n400\\n\\nSEQUENCE\\n\\n129\\n\\nial Sequence\\n\\nSynthetic\\n\\nGln Gln Arg Iiz Val Gly Arg Thr\\n5\\n\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 130\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artific\\nFEATURE:\\nOTHER INPORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n130\\n\\nial Sequence\\n\\nSynthetic\\n\\nGln Gln Arg Tyr Ser Leu Ser Arg Thr\\n5\\n\\n210\\ne211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 131\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANIISN Artific\\nFEATURE.\\nOTHER INFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n131\\n\\nial sequence\\n\\nSynthetic\\n\\nGln Gln Arg Tyr Ser Leu Gly Azg Thr\\n5\\n1\\n\\n210a SEQ ID NO 132\\n211a LENGTH\\n212\\n213\\n220\\n223\\n\\n9\\nPRT\\nTYPE\\nORGANISbl Artific\\nFEATUPE\\nOTHER INPORNTTION\\n\\n400\\n\\nSEQUENCE\\n\\n132\\n\\nial Sequence\\n\\nSynthetic\\n\\nGln Gln Arg Tyr Ser Arg Ala Arg Thr\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 133\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAEISN Artific\\nFEATURE\\nOTHER INFORNPTION\\n\\n400\\n\\nSEQUENCE\\n\\n133\\n\\nial Sequence\\n\\nSynthetic\\n\\nGln Gln Arg Tyz Ser Hi. Ala I.rg Thz\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 134\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artific\\nFEATURE:\\nOTHER INFORNATION\\n\\nial Sequence\\n\\nSynthetic\\n\\n\\x0c111\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\nGlu Ile Gln Val Ser Gly Gly Arg Thr Asn Tyr Asn Glu Lys Plae Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\n400\\n\\nSEQUENCE\\n\\n134\\n\\nGln Gln Arg Tyr Ser Thr Pro Asp Thr\\nI\\n5\\n\\ns210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 135\\nLEI\\'GTH 9\\nPRT\\nTYPE\\nORGANISE Artzfzc\\nFEATURE.\\nOTHER INFORSIATION\\n\\n400\\n\\nSEQUENCE\\n\\n135\\n\\ntal Sequence\\n\\nSynthetrc\\n\\nGln Gln Arg Tyr Gln Gln Pro Arg Thr\\nI\\n5\\n\\n17\\n\\n210s SEQ ID NO 136\\n211\\nLEHGTH\\n212\\nPRT\\nTYPE\\nORGANISN Artrfzc\\n213\\n220\\nFEATURE\\n223\\nOTHER INFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n136\\n\\nzal Sequence\\n\\nSynthetic\\n\\n17\\n\\nSEQ ID NO 137\\nLENGTH\\nPRT\\nTYPE\\nORGANIISN Artzfzc\\nFEATURE.\\nOTHER INFORHATION\\n\\nIal sequence\\n\\nSynthetrc\\n\\n400\\n\\nSEQUENCE\\n\\n137\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 138\\nLENGTH\\nPRT\\nTYPE\\nORGANISN Artrfzc\\nFEATURE\\nOTHER INFORH\\'TION\\n\\n400\\n\\nSEQUENCE\\n\\n138\\n\\nzal Sequence\\n\\nSynthetzc\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 139\\nLENGTH\\nPRT\\nTYPE\\nORGAIIISH Artzfzc\\nFEATURE:\\nOTHER INPORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n139\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nSer\\n\\n210\\ns211\\n212\\n213\\n220\\n223\\n\\nSer\\n\\nSer\\n\\nSer\\n\\n210\\n\\nSEQ ID NO 140\\n\\nGlu Ile Asn Pro Trp Gln Gly Arg Thr F.cn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGlu Ile Asn Pro Val Gln Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGlu Ile Ser Pro Tyr Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\n\\x0c113\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\nGlu Ile Gln Glu Ser Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\n17\\n\\nPPT\\n\\nLENGTH\\nTYPE\\n\\n211\\n212\\n213 DEREISM Artrfrc\\n220\\n223\\n\\nFEATURE\\nOTHER INFORFLATION\\n\\nral Sequence\\n\\nSynthetrc\\n\\ns400\\n\\nSEQUENCE\\n\\n140\\n\\n17\\n\\nSEQ ID NO 141\\nLEIIGTH\\nPRT\\nTYPE\\nORGANISM Artrfrc\\nPEATURE:\\n\\n210\\n211\\n212\\n213\\n220\\n223. OTHER INFORMATION\\n\\n400\\n\\nSEQUENCE\\n\\n141\\n\\nral sequence\\n\\nSynthetrc\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 142\\nLENGTH\\nPRT\\nTYPE\\nORGAEISN Artrfrc\\nFEATURE\\nOTHER INPORKATION\\n\\n400\\n\\nSEQUENCE\\n\\n142\\n\\nral Sequence\\n\\nSynthetrc\\n\\n210\\n211\\n212\\n213 s\\n220.\\n223\\n\\n17\\n\\nSEQ ID NO 143\\nLENGTH\\nPRT\\nTYPE\\nORGWIISM Artrfrc\\nFEATURE.\\nOTHER INFORMATION\\n\\n400\\n\\nSEQUENCE\\n\\n143\\n\\nral Sequence\\n\\nSyntlsetrc\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 144\\nLENGTH\\nPRT\\nTYPE\\nORGANISN Artrfrc\\nFEATURE\\nOTHER INFORMATION\\n\\n400\\n\\nSEQUENCE\\n\\n144\\n\\nral Sequence\\n\\nSynthetrc\\n\\nSer\\n\\nSer\\n\\nSer\\n\\nSer\\n\\nSer\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 145\\nLENGTH\\nPRT\\nTYPE\\nORGANISM Artrfrc\\nFEATURE.\\nOTHER INFORMATION\\n\\nral Sequence\\n\\nSynthetrc\\n\\nGlu Ile Ser Pro Ile Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGlu Ile Asn Pro Glu Hr Gly .\\'. g Tlr ann Tyr Asn Glu Ly\\nI\\n\\n10\\n\\n5\\n\\nPhe \\'\\n15\\n\\nGlu Ile Asn Pro Ser Glu Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\n\\n5\\n\\n10\\n\\nGlu Ile Asn Pro Trp Met Gly Arg Thr A n Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\n\\x0c115\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n400\\n\\nSEQUENCE\\n\\n145\\n\\nGlu Ile Asn Pro Gln Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGlu Ile Aan Pro Val Lys Gly Arg Thr aan Tyr Asn Glu Lys Phe Ly-\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGlu Ile Gly Pro Trp Gly Gly Arg Thr Psn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGlu Ile Asn Pro lie Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nSer\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n400\\n\\nSer\\n\\nSer\\n\\nSer\\n\\nSer\\n\\n17\\n\\nSEQ ID NO 14\\nLENGTH\\nPRT\\nTYPE\\nORGAEISN Artzfrc\\nFEATURE\\nOTHER INPORFZATION\\n\\nSEQUENCE\\n\\n146\\n\\nral Sequence\\n\\nSynthetzc\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 147\\nLENGTH\\nPRT\\nTYPE\\nORGPIIISH Artrfzc\\nFEATURE.\\nOTHER INPORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n147\\n\\nral Sequence\\n\\nSynthettc\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 148\\nLENGTH\\nPRT\\nTYPE\\nORGIZNISH .Artzftc\\nFEATURE.\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n148\\n\\ntal Sequence\\n\\nSynthetzc\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 149\\nLENGTH\\nPRT\\nTYPE\\nORG.AIISN AZtrfrC\\nPEATURR.\\nOTHER INFORSIATION\\n\\n400\\n\\nSEQUENCE\\n\\n149\\n\\nral Sequence\\n\\nSynthettc\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID I\\'10 150\\nLENGTH\\nPRT\\nTYPE\\nORGANISE Artzftc\\nFEITURE\\nOTHER INFORFIATION\\n\\n400\\n\\nSEQUENCE\\n\\n150\\n\\ntal Sequence\\n\\nSynthetzc\\n\\nGlu Ile Gln Ile Ser Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\nGlu Ile Asn Pro Gln Gly Thr Arg Thr F.cn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\n\\x0c117\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\nSer\\n\\n210\\ne211\\ne212\\n213\\n220\\n223\\n\\nSEQ ID NO 151\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANNSN Artzfzc\\nFEATURE.\\nOTHER INFORMATION\\n\\nzal Sequence\\n\\nSynthetzc\\n\\n400\\n\\nSEQUENCE\\n\\n151\\n\\nGlu Arg Pro Leu Tyr Ala Ser Asp Ser\\nI\\n5\\n\\n210\\n211\\n212e T\\'ZPE\\n213\\n220\\n223\\n\\nSEQ ID I\\'10 152\\nLENGTH\\n\\n9\\nPRT\\nORGANISE Artzfzc\\nFEZTURE\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n152\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Ser 5 p Arg\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\ne223\\n\\nSEQ ID NO 153\\nLEI\\'GTH 9\\nPRT\\nTYPE\\nORGANISN Artzfzc\\nFEATURE\\nOTHER INPORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n153\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Het Asp Arg\\nI\\n5\\n\\nSEQ ID NO 154\\n9\\nLEIZGTH\\nPRT\\nTYPE\\nORGANIS\\'N Artzfzc\\n\\n210\\n211\\n212\\n213\\n220. PEATURE.\\n223. OTHER INFORNATION\\n\\n400\\n\\nSEQURNCE\\n\\n154\\n\\nzal Sequence\\n\\nsynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Asn Asp Ala\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID EO 155\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artzfzc\\nFEATURE.\\nOTHER INPORHATI014\\n\\n400\\n\\nSEQUENCE\\n\\n155\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Asn Asp Val\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID I\\'10 156\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artzfzc\\nFEZTURE\\nOTHER INFORFIATION\\n\\n400\\n\\nSEQUENCE\\n\\n156\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyz Ala Hzs A p Val\\nI\\n5\\n\\n\\x0c119\\n\\n120\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n210\\n211\\n212\\ns213\\ns220\\n223\\n\\nSEQ ID NO 157\\nLENGTH\\n9\\nPRT\\nTYPE\\nORG.OIISN AZtzfzC\\nFEATURE:\\nOTHER 11\\'IFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n157\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Ser Asp Tyr\\nI\\n\\nSEQ ID NO 158\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGWIISN Artzfzc\\n\\n210\\n211\\n212\\n213\\n220. FEATURE.\\n223\\n\\nOTHER INFORN\\'ZION\\n\\n400\\n\\nSEQUENCE\\n\\n158\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Ser Asp Val\\nI\\n5\\n\\n9\\nPRT\\n\\nSEQ ID NO 159\\nLENGTH\\nTYPE\\n\\n210\\n211\\n212\\n213 ORnaIIISH Artzftc\\n220\\n223\\n\\nFEATURE\\nOTHER INFORteATION\\n\\ntal Sequence\\n\\nSynthetzc\\n\\ns400\\n\\nSEQUENCE\\n\\n159\\n\\nGlu Arg Pro Leu Tyr Ala Ser A p Ala\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 160\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAEISH Artzfzc\\nFEATURE.\\nOTHER INFORHATION\\n\\n400. SEQUENCE\\n\\n160\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Asn Asp Ser\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 161\\nLENGTH\\n9\\nPRT\\nTYPE\\nORG.OIISN AZtzfzC\\nPEATURR.\\nOTHER INFORtZATION\\n\\n400\\n\\nSEQUENCE\\n\\n161\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Thr Asp Leu\\nI\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 162\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Arttftc\\nFEATURE\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n162\\n\\ntal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Ser Asp Ser\\nI\\n5\\n\\n\\x0c121\\n\\n122\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n210\\n211\\n212\\n213\\n220\\na223\\n\\nSEQ ID NO 163\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAEISN Artzfzc\\nFEATURE\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n163\\n\\ntal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Asn Asp Net\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 164\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artzftc\\nPEATURE:\\nOTHER INPORI4ATION\\n\\n400\\n\\nSEQUENCE\\n\\n164\\n\\nzal sequence\\n\\nsynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Hts Asp Leu\\nI\\n\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 165\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artzfzc\\nFEATURE.\\nOTHER INFORH\\'TION\\n\\n400\\n\\nSEQUENCE\\n\\n165\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGlu \\'rg Pro Leu Tyr Ala Hzs A p Ile\\nI\\n\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n9\\nPRT\\n\\nSEQ ID NO 166\\nLENGTH\\nTYPE\\nORGANISE\\nFEATURE.\\nOTHER INFORHATION\\n\\n.Artzfzc\\n\\n400\\n\\nSEQUENCE\\n\\n166\\n\\ntal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Asn Asp Val\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO I 7\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artzfzc\\nFEATURE:\\nOTHER INFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n167\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Ser Asp Tyr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 168\\nLEI\\'GTH 9\\nPRT\\nTYPE\\nORGANISE Artzftc\\nPEATURE:\\nOTHER INFORHATIOE\\n\\n400\\n\\nSEQUENCE\\n\\n168\\n\\nzal sequence\\n\\nSynthetzc\\n\\nGlu Arg Pro Leu Tyr Ala Ser Asp Arg\\nI\\n5\\n\\n210\\n211\\n\\nSEQ ID NO 169\\nLENGTH\\n\\n9\\n\\n\\x0c123\\n\\n124\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n212\\n213\\n220\\n223\\n\\nPRT\\nTYPE\\nORGANISM Artific\\nFEATURE\\nOTHER INFORHPTION\\n\\nial Sequence\\n\\nSynthetic\\n\\ns400\\n\\nSEQUENCE\\n\\n169\\n\\nGlu Arg Pro Leu Tyr Ala Ser 5 p Val\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 170\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artific\\nFEATURE.\\nOTHER INFORffATION\\n\\n400\\n\\nSEQUENCE\\n\\n170\\n\\nial Sequence\\n\\nSynthetic\\n\\nGlu Arg Pro Leu Tyr Ala Hls Asp Val\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 171\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGPIIISH Artific\\nFEATURE.\\nOTHER INPORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n171\\n\\nial Sequence\\n\\nSynthetic\\n\\nGlu Arg Pro Leu Tyr Ala Asn Asp Net\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 172\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISN Artific\\nFEATURE\\nOTHER INFORMATION\\n\\n400\\n\\nSEQUENCE\\n\\n172\\n\\nial Sequence\\n\\nSynthetic\\n\\nGlu Arg Pro Leu Tyr Ala His Asp Leu\\n5\\n1\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 173\\nLENGTH\\nPRT\\nTYPE\\nORGANISM Artific\\nFEATURE\\nOTHER INFORMATION\\n\\n400\\n\\nSEQUENCE\\n\\n173\\n\\nial Sequence\\n\\nSynthetic\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 174\\nLEI\\'GTH 17\\nPRT\\nTYPE\\nORGANISM Artific\\nPEATURE:\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n174\\n\\nial sequence\\n\\nSynthetic\\n\\nSer\\n\\n1\\n\\nSer\\n\\nGlu Ile Asn Pro Trp Gln Gly Arg Thr Asn Tyr Asn Glu Lys Phe Ly\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGlu Ile Asn Pro Val Gln Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\n\\n5\\n\\n10\\n\\n15\\n\\n\\x0c125\\n\\n126\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\nGlu Ile Ser Pro Tyr Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nGlu Ile Gly Pro Trp Gly Gly Arg Thr Asn Tyr Asn Glu Zys Phe Ly-\\nI\\n\\n15\\n\\n10\\n\\n5\\n\\nSer\\n\\nSer\\n\\n210\\n211\\n212\\n213\\n220\\nr223\\n\\n210\\n211\\n212\\n213\\n220\\nr223\\n\\n17\\n\\nSEQ ID NO 175\\nLENGTH\\nPRT\\nTYPE\\nORGANISN Artzfzc\\nFEATURE\\nOTHER INFORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n175\\n\\ntal Sequence\\n\\nSynthetzc\\n\\n17\\n\\nSEQ ID NO 174\\nLENGTH\\nPRT\\nTYPE\\nORGWIISN Artzfzc\\n\\n210\\n211\\n212\\n213\\n220. FEATURE.\\n223\\n\\nOTHER INFORN\\'TION\\n\\n400\\n\\nSEQUENCE\\n\\n17\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nSEQ ID NO 177\\nLEI\\'GTH 9\\nPRT\\nTYPE\\nORGANISN Artzfzc\\nFEATURE\\nOTHER INPORNATION\\n\\nzal Sequence\\n\\nSynthetzc\\n\\n400\\n\\nSEQUENCE\\n\\n177\\n\\nGln Gln Arg Tyr Ser Asp Trp Arg Thr\\nI\\n5\\n\\nSEQ ID NO 178\\nLEIIGTH\\n9\\nPRT\\nTYPE\\nORGANIS\\'N Artzfzc\\n\\n210\\n211\\n212\\n213\\n220. PEATURE.\\n223. OTHER INFORNATION\\n\\n400\\n\\nSEQURNCE\\n\\n178\\n\\nzal Sequence\\n\\nsynthetzc\\n\\nGln Gln Arg Tyr Ser Ser Trp Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID EO 179\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artzfzc\\nFEATURE.\\nOTHER INPORHATION\\n\\n400\\n\\nSEQUENCE\\n\\n179\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Ala Glu Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID I\\'10 180\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artzftc\\nFEITURE\\nOTHER INFORFIATION\\n\\n400\\n\\nSEQUENCE\\n\\n180\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Leu Hzs Arg Thr\\nI\\n5\\n\\n\\x0c127\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n210\\n211\\n212\\nc213\\nc220\\n223\\n\\nSEQ ID NO 181\\nLENGTH\\n9\\nPRT\\nTYPE\\nORG.SIISN AZtzfzC\\nFEATURE:\\nOTHER 11\\'ZFORNATION\\n\\n400\\n\\nSEQUENCE\\n\\n181\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Ser Glu Arg Thr\\nI\\n\\nSEQ ID NO 182\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGWIISN Artzfzc\\n\\n210\\n211\\n212\\n213\\n220. FEATURE.\\n223\\n\\nOTHER INFORN\\'ZION\\n\\n400\\n\\nSEQUENCE\\n\\n182\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Azg Tyr Ser Leu Gln Azg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 183\\nLENGTH\\n9\\nPRT\\nTYPE\\nORG431ISH Artzfzc\\nFEATURE\\nOTHER INFORFZATION\\n\\nc400\\n\\nSEQUENCE\\n\\n183\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Thr Zlzg Arg Thr\\nI\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID NO 184\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGAEISH Artzfzc\\nFEATURE.\\nOTHER INFORHATION\\n\\n400. SEQUENCE\\n\\n184\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Azg Tyr Ser Asp Trp Zlrg Thr\\n5\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\n17\\n\\nSEQ ID NO 185\\nLENGTH\\nPRT\\nTYPE\\nORG.SIISN AZtzfzC\\nPEATURR.\\nOTHER INFORBZATION\\n\\n400\\n\\nSEQUENCE\\n\\n185\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nSer\\n\\n210\\n211\\n212\\n213\\n220\\n223\\n\\nSEQ ID I\\'10 186\\nLENGTH\\n9\\nPRT\\nTYPE\\nORGANISE Artzfzc\\nFEITURE\\nOTHER INFORFIATION\\n\\n400\\n\\nSEQUENCE\\n\\n186\\n\\nzal Sequence\\n\\nSynthetzc\\n\\nGln Gln Arg Tyr Ser Arg Ser Arg Thr\\nI\\n5\\n\\nGlu Ile Ser Prc Tyr Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\\nI\\n\\n15\\n\\n10\\n\\n\\x0c129\\n\\n130\\n\\nUS 8,080,243 B2\\n\\n-continued\\n\\n210\\n211\\n212\\na213\\na220\\n223\\n\\n7\\nPRT\\n\\nSEQ ID No 187\\nLENGTH\\nTYPE\\nORGAN11SN ArtrfrCral SequenCe\\nFEATURE:\\nOTHER INFORNATION svntuetrc\\n\\n400\\n\\nSEQUENCE\\n\\n187\\n\\nAsp Ala Ser rsn Arg Ala Tar\\n1\\n\\nIt is claimed:\\nl. An Lso lated antibody which specifically binds to PCSK9\\nand comprises a heavy clmtn venable regton (VII) comple-\\nmentary determining region one (CORI) lmving the amino\\namd sequence shnw n in SI\\'Q ID NO g. 59. or 60, 0 Vl I CDR2\\nhaving the tuntno actd sequence sho~n in SFQ ID NO;9 or\\n61, 0 VH (\\'DR3 havins the anlino acid sequence shown in\\nSl\\'.Q ID NO 10. a light chain varinble region (VL) (\\'DR I\\nhaving the amino acid sequence shown in SL\\'Q ID NO:11, 0\\nVl, (\\'DR2 having tlm amino acid scqtmncc shown in SFQ ID\\nNO 12. Snd a VI, CDR3 havulg the untno acid sequence\\nshown in SFQ 117 NO:13.\\n\\n2. An Isolated antibody comprising a heavy clmin variable\\nregion (VI I) mid a light chain variable region (Vl h tvberein\\nthe VI I region comprises the unulo actd sequence of SLQ ID\\nNO: 54 and the VL region comprises the amino acid sequence\\n\\n„„of SFQ ID NO 53.\\n\\n3. A humalured anttbody compnstn a hatt chatn havtn\\nthc amino acid sequence of SFQ ID NO 14 and a hcaty clmin\\nhavtng the amino acid sequence of SI\\',Q ID NO:15. wtth or\\nwithout the (utenninal lysine of the amino acid sequence of\\nSFQ ID NO 15\\n\\n\\x0c'\n"
     ]
    }
   ],
   "source": [
    "print(repr(text))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "distinguished-salmon",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII\n",
      "US008080243B2\n",
      "\n",
      "(») United States Patent\n",
      "\n",
      "Liang et al.\n",
      "\n",
      "(io) Patent No.:\n",
      "(4s) Date of Patent:\n",
      "\n",
      "US 8,080,243 $2\n",
      "Dec. 20, 2011\n",
      "\n",
      "(54)\n",
      "\n",
      "(73)\n",
      "\n",
      "ISOLATI(D ANTIBODY WHIC'H\n",
      "SPEC'ii'ICALLY BINDS TO PCSK9\n",
      "\n",
      "Iuva&iorsz Hung I.iang, Snu Francisco. C'A (IJS).\n",
      "Yasmina Noubia Abdiche, Mountain\n",
      "Y&ew, CA (US); Javier Fernando\n",
      "Chaparro Riggers. Sau Mateo, CA\n",
      "(IJS): Bruce C'buries Onmes,\n",
      "Ashburuimm. iVLA (LIS): Juiie Jia Li\n",
      "Hawhins. Old Lyme, Ci'(US): Jaume\n",
      "Pons, Sau Bruno, CA (IJS), Yuii Wang,\n",
      "San 1)iego, ('A (US)\n",
      "\n",
      "(73) Assignees. Riuut Neuruscience Corp.. Swah Sau\n",
      "Francisco, CA (US). Pfizer Inc« New\n",
      "York, NY (US)\n",
      "\n",
      "(\n",
      "\n",
      ") Notice\n",
      "\n",
      "Subject to any d&sclsuuer. the teuu oi'this\n",
      "patent is exmuded or adjusted under 35\n",
      "U.S.(2 154(b) by 0 days.\n",
      "\n",
      "(21) Appl. No. 12/558,312\n",
      "\n",
      "(22)\n",
      "\n",
      "Filed:\n",
      "\n",
      "Sep. II& 2009\n",
      "\n",
      "Prior Publication Data\n",
      "\n",
      "IJS 2010/0068199 A I\n",
      "\n",
      "Mar. 18. 2010\n",
      "\n",
      "Related U.S. Appiicstiou Data\n",
      "\n",
      "(65)\n",
      "\n",
      "(60)\n",
      "\n",
      "Prov&s&ouai apphcauou No. 61(235.643, filed on Aug.\n",
      "20, 2009, provisional application No. 61/232,161,\n",
      "Iiied on Aug. 7. 200'I, provisional application No.\n",
      "61/096.716, iiled on Sep 12, 2008.\n",
      "\n",
      "(5 1\n",
      "\n",
      ")\n",
      "\n",
      "Int. CI.\n",
      "d 6IIC 392395\n",
      "\n",
      "(2006.01)\n",
      "\n",
      "(52) U.S. C:I..................... 424/130.1; 424/133.1\n",
      "(58) Field of Classification Search............ None\n",
      "Sec application file Ii&r complete search history\n",
      "\n",
      "(56)\n",
      "\n",
      "Referenws Cited\n",
      "\n",
      "I J S PATleNT DOC'UMFNTS\n",
      "\n",
      "7,261,893 02 &\n",
      "7,456,264 B2'12008 Kclcretel\n",
      "\n",
      "8 2007 Veldman et al\n",
      "\n",
      "2009 014»352 A I\n",
      "\n",
      "C&'2009\n",
      "\n",
      "Jackson et al\n",
      "\n",
      "424 145 I\n",
      "530 3884\n",
      "\n",
      "WO\n",
      "WO\n",
      "WO\n",
      "WO\n",
      "WO\n",
      "IVO\n",
      "\n",
      "WOOI&57081 A2\n",
      "\n",
      "IVO 2008 0(7457\n",
      "WO 2008&057458 A2\n",
      "IVO 2008 057459 A2\n",
      "W(J 2008&lÃ647 A2\n",
      "WO 2009 0557&B A2\n",
      "\n",
      "8(2001\n",
      "I'&008\n",
      "5 2008\n",
      "5 2008\n",
      "11'2008\n",
      "4 2009\n",
      "\n",
      "OTHF.R PUBLICATIONS\n",
      "\n",
      "Albornet el., C1&n Chem 53. 1814-1819,2007P\n",
      "C\"ham&«and Ashkana(i, T&bterh 14 52-60, 1979(i\n",
      "\n",
      "\"'ud&koffet sl., Proc. Natl, Aced Sc& 79 1979-1983, 1982.»\n",
      "\n",
      "d&ct&on, pp 492-495. 1994 \"\n",
      "Bottomlcy. M . et al . \"Stnictuiel and B&ochanical C'hmactcnzat&on\n",
      "of ihe Vyild Iype PC.'SK&J-L('1(AB) Complex and Natural I mrulial\n",
      "\n",
      "Wells, 1990. B&ochanistiy 29 8509-8517'goet al . The Protein Folding Problem and Tenisry Stn&cture Pi e-\n",
      "\n",
      "Ilypercholesterolemia Mutantsy ihe Journo/ of Bioiog&r&d C'(ie«u»-\n",
      "(ri; 2009, 1311-1321, vol 284, Vo 2\n",
      "C'han. J, et al, \"A Propiotein Convcrtase Subtilisin Kes&n Type 9\n",
      "i&eat&ah(&n AntibodykeducesSerum(holesteiolinM&cean&IVon-\n",
      "human P«matesy Prmeedi&i os of(he ¹uonai I cudemi of Sa nrei\n",
      "of iiie Lyin &ed S(o(e» ofrtiseiiru, 2009, &(8209825, sot 106, No 24\n",
      "C:unninghanx D „et al. \"Structural and Biophysical Studies of\n",
      "PCSK9 and &ts Mu&ants L&nked to I mrul&al Hypercholeste&olem&sy\n",
      "Vonire,S&rurrvrni a .Volecsisr Bio iogi\n",
      ". 2007, 413-419, vol 14. Vo\n",
      "\\\n",
      "Grefhorst 5, e& al. \"Plasma PCSK9 P&eferent&ally Reduces I ner\n",
      "LDL Recepiois m M&cey dos«in/ &i/'Lipid krieoi&/i, 2008, 1303-\n",
      "1311, vol 49\n",
      "Kwon. H, ct al, \"Molecular Basis ioi I.DI. Racptoi Rsvognit&on by\n",
      "PCSK'JP I'rocee&iisg& of (h» Nvuonsi.&cad& mi oi'Science» of B&r\n",
      "L'm(ed S(oies ofdsiemra, 2008. 1820-I 825, vol. 10(. No. 6\n",
      "Pandit. S., et al, \"I unctional Analysis of Sites wuhin P('SK9\n",
      "Rmponuble fo& Hypacholesterolemisy,hi«rani o//»pid Reseoirh,\n",
      "2008, 17&1-1343 &ol 49\n",
      "Peter~on, A ei al, \"P('SK9 I unction and Physiologyy Journo/ of\n",
      "Lipid /(eseorcii, 2008. 1595-1599, vol 49\n",
      "'*St«&ct&ual Rcqu&remen&a t'or PCSK9-Mcd&ated\n",
      "Lhang, D, ct al .\n",
      "Degradat&on of the I ow-Density I ipop&otein Receptor,*'mreed\n",
      "\n",
      "&sgi of (/ie.V&(iona/.(eadem& o/'Sae&ice» of (he (I«ied S(ore&o/'Imemco.2008, 13045-13050, vol 105, No 35\n",
      "\n",
      "'*Iherapeut&c RVA& target&ng P('SK9\n",
      "lrank-Kmnenetsky, et al..\n",
      "acutely lowers plasma choleste&ol &n rodents and I.DL choleste&ol &n\n",
      "nonhuman pmnatesy Pioceed&ngs of the Nat&onal Aciulemy of Sc&-\n",
      "ences of the L'mted States, Aug 2008. Pp 119i 5-11920, vol 105,\n",
      "No 13\n",
      "Grab&un, \"Anusense mh&b&&&on of prop«&te&n convertase subt&l&s&n\n",
      "kex&n type 9 reduces semm LDL in hyperl&pidem&c nu cep Joamia i of\n",
      "Lipid Research, Apr 2007. pp 763-767, vol 48, No 4\n",
      "Horton et al, \"Molcculm biolo yof PCSK9 its role in I DI mctabo-\n",
      "l&smy Trend» iii Bia hem&(oi Srien(er, 2007, pp 71-77, sot 32\n",
      "Inrcrnational P&el&mmmy Fxaminat&on Repo&t issued Jun 30, 2010,\n",
      "for Inte&national Patent Apphcat&on No PC:7'IB2009 053990\n",
      "Inta national Prclnn&na&y Fxam&nation Rcpoit &ssucd Dcc 15, 2010,\n",
      "for Inte&na&ional Patent Apphcat&on No PC'T 102009'053990\n",
      "International Search Report mailed Jun I, 2010, for International\n",
      "Patent Spphcat ion No PC.'7'102009 051990\n",
      "I opcz. D, lnlub&t&on of PC'SK9 as a novel stiatcgy foi thc ticatmcnt\n",
      "ofhipar/m/e&(em/esne, Dm Vev s g Perspectives, 2008, pp 321-\n",
      "330, vol. 21\n",
      "\n",
      "(('outinued)\n",
      "\n",
      "Prim«O Emminer\n",
      "(74) .Ikorue&, »Igeu(, or F/rm Pfizer iuc.\n",
      "\n",
      "Ciyau Chm&drn\n",
      "\n",
      "The prmseut &us& i&i&ut& pu&sides autugo&uiing m&t&bod&es. m&ti-\n",
      "gen-binding portions thereof. und aptumem that bind tu pro-\n",
      "pmiein convertmsc subtilisiu kcxin type 'I (PC'.SK9). Also\n",
      "provided ure ant&bodies d&rected to peptides, in v;hich the\n",
      "antibodies bind tu P(JSK9. Tim invention further provides a\n",
      "method of obtain&ug such m&t&bodies aud aut&body-encod&u\n",
      "nucleic acid. The invention f&irther relates to therapeutic\n",
      "nwthods for use of thesv. antibodies und antigen-binding por-\n",
      "uous thereof to reduce LDL-chuiesteml levels aud/or for the\n",
      "treatment mtd/or prevention of cardiovascular diseuse,\n",
      "u&cludmg treatment of hypercholesterolemia\n",
      "\n",
      "3 Claims, 30 i)rawing Sheets\n",
      "\n",
      "FORFIGN PATI'.NT DO( UMI:,NTS\n",
      "\n",
      "(57)\n",
      "\n",
      "&&BSTR,ACT\n",
      "\n",
      "\f",
      "US 8,080,243 $2\n",
      "Page 2\n",
      "\n",
      "OTHER PUB LIOATI 01&IS\n",
      "I open, D, \"pCSK9'n enig&natic piotcimscy Siorhemirc oil&i\n",
      "Bivphy&iin.tcm. 200S, pp 194-191, vol. 170 I\n",
      "McKutt M C, ct al., '*Antagonism of sccicted PCSK9 increases lorn\n",
      "density lipoprotein rcccptor exp& cssion in HcpO2 cellsigiouruai of\n",
      "II&olog&col i'ii&morrlv 2009,pp. 10561-10570, vol 2S4\n",
      "\n",
      "Otfic&al Conunun&cat&on issued h ov. I(, 2010, m connection volh\n",
      "Internalmnal Pateni Application Vo Pi \"I 'IB 2009,'053990\n",
      "(('«nen Opinion of thc ISA issued Slay 2 (, 2010. for Intenmtional\n",
      "Patent Application go, PC'I IB2009&tl(3990,\n",
      "'ited bv cxanllllcr\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec.20,2011\n",
      "\n",
      "Sheet I of30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "A mPCSK9\n",
      "(100nM)\n",
      "\n",
      "mAb(nM)\n",
      "\n",
      "800 40Q200100 50 25\n",
      "\n",
      "0\n",
      "\n",
      "0\n",
      "\n",
      "6F6.G10.3 Q W rt@.-::,:.,'.=:::-:.;.::,,::::;:;:: ~4\n",
      "»44 WM4~+~4\n",
      "\n",
      "8\n",
      "\n",
      "hPCSK9\n",
      "(100nM)\n",
      "mAb(nM)\n",
      "\n",
      "6F6.G10.3\n",
      "\n",
      "800 4002001QQ 50 25\n",
      "\n",
      "0\n",
      "\n",
      "0\n",
      "\n",
      "4A5G3 M@NeWuN\n",
      "\n",
      "4A5.G3\n",
      "\n",
      "5A10 88\n",
      "\n",
      "Figure 1\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 2 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "Human PGSK9{0.4nM}- human LDLR Binding\n",
      "pH7.5\n",
      "\n",
      "o I\n",
      "\n",
      "0\n",
      "O 0.5\n",
      "\n",
      "0\n",
      "\n",
      "o\n",
      "\n",
      "0\n",
      "\n",
      "2.5\n",
      "\n",
      "2\n",
      "\n",
      "1.5\n",
      "\n",
      "0.5\n",
      "\n",
      "0\n",
      "\n",
      "1.0E-03\n",
      "\n",
      "1.0E-02 1.0E-01\n",
      "\n",
      "1.0E+00 1.0E+01 1.0Et02 1.0Ee03\n",
      "\n",
      "mAb Concentration (nM)\n",
      "\n",
      "Mouse PGSK9 {0.8nM)- human LDLR Binding\n",
      "pH7.5\n",
      "\n",
      "1.0E 03\n",
      "\n",
      "1.0E 02\n",
      "\n",
      "1.0E 01\n",
      "\n",
      "1.0E+00\n",
      "\n",
      "1.0E+01\n",
      "\n",
      "1.0E+02\n",
      "\n",
      "1.0E+03\n",
      "\n",
      "mAb Concentration {nM)\n",
      "\n",
      "Figure 2\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 3 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "40\n",
      "\n",
      "30\n",
      "\n",
      "20\n",
      "\n",
      "10\n",
      "\n",
      "CI\n",
      "\n",
      "0\n",
      "\n",
      "0.1\n",
      "\n",
      "+ 4,i',\n",
      "\n",
      "IC50='?.I nM\n",
      "\n",
      "1\n",
      "\n",
      "10\n",
      "rnAb concentration (nM)\n",
      "\n",
      "100\n",
      "\n",
      "1000\n",
      "\n",
      "Figure 3\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 4 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "A\n",
      "\n",
      "B Normahxed binding by premixed 29.70M hPCSK9 and rgG\n",
      "\n",
      "U~ Fcx-6F6 G10 3\n",
      "\n",
      "9 l c 3= 641 0 36\n",
      "Bl c2=4A6643\n",
      "\n",
      "NPCGIIO\n",
      "\n",
      "8 F6 010 3\n",
      "\n",
      "704 4\n",
      "\n",
      "5410 08\n",
      "\n",
      "4AF C3\n",
      "\n",
      "GEI C4\n",
      "\n",
      "'IF\" FG\n",
      "\n",
      "c6 HI 0\n",
      "\n",
      "Gl 5 HI I\n",
      "\n",
      "41.1 0 I\n",
      "\n",
      "56 610\n",
      "\n",
      "%5 C4 41\n",
      "\n",
      "40121 8\n",
      "\n",
      "4E4 010\n",
      "\n",
      "Figure 4\n",
      "\n",
      "0\n",
      "\n",
      "20\n",
      "\n",
      "40\n",
      "\n",
      "0\n",
      "\n",
      "PO\n",
      "\n",
      "103\n",
      "\n",
      "120\n",
      "\n",
      "Ncr mzlizcd hlnding\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 5 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "4A5 5A10 6F6\n",
      "\n",
      "6G7 7D4 42H7\n",
      "\n",
      "~ PCSK9\n",
      "\n",
      "PCS K9\n",
      "\n",
      "PCSK9\n",
      "\n",
      "Human\n",
      "\n",
      "Cyno Monkey\n",
      "\n",
      "Mouse\n",
      "\n",
      "Rat\n",
      "\n",
      "Figure 5\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 6 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "ESI Control mAb {30rng/kg/day)\n",
      "\n",
      "g/kg/day)\n",
      "\n",
      "150\n",
      "\n",
      "0 &oo\n",
      "O\n",
      "ttt\n",
      "O\n",
      "0\n",
      "o 5o\n",
      "\n",
      "pre total post total pre HDL post HDL\n",
      "\n",
      "Figure 6\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 7 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "PCSK9 {6ug/ml)\n",
      "CRN6 pAb (100ug/ml)\n",
      "\n",
      "—\n",
      "\n",
      "—\n",
      "\n",
      "Hu Hu\n",
      "\n",
      "— Mu Mu\n",
      "\n",
      "—\n",
      "\n",
      "+\n",
      "\n",
      "—\n",
      "\n",
      "—\n",
      "\n",
      "+\n",
      "\n",
      "B B\n",
      "\n",
      "I Control mAb (30mg/kg/day)\n",
      "\n",
      "/kg/day\n",
      "\n",
      "150\n",
      "\n",
      "o 100\n",
      "\n",
      "sr\n",
      "o\n",
      "V 50\n",
      "\n",
      "0\n",
      "\n",
      "pratotal post total pre HDL postHDL\n",
      "\n",
      "Figure 7\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 8 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "C3 7D4 (10mg/kg i v)\n",
      "R Saline\n",
      "\n",
      "A='a\n",
      "\n",
      "100\n",
      "\n",
      "Vl\n",
      "E\n",
      "\n",
      "0\n",
      "Cl\n",
      "\n",
      "Vle\n",
      "0\n",
      "U\n",
      "C\n",
      "0I-\n",
      "\n",
      "B\n",
      "\n",
      "0\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "80\n",
      "\n",
      "60\n",
      "\n",
      "40\n",
      "\n",
      "20\n",
      "\n",
      "1day 2 day 4day 7 day 14day21day\n",
      "\n",
      "1 day 2 day 4 day 7 day 14 day 21 day\n",
      "\n",
      "Figure 8\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 9 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "ta\n",
      "\n",
      "0\n",
      "et\n",
      "Iee 'U\n",
      "sots 5\n",
      "o E\n",
      "o\n",
      "\n",
      "2\n",
      "\n",
      "60\n",
      "\n",
      "st Sa\n",
      "\n",
      "E aa\n",
      "\n",
      "cr 20X\n",
      "\n",
      "\"la\n",
      "\n",
      "I 0 1mg/kg/day (n=at\n",
      "\n",
      "t((()t)t 0 3mg/kglday (n =8)\n",
      "%31mg/kg/day (n=8)\n",
      "EZI 3mg/kgfday (ne8)\n",
      "E310mg/kg/day (ne8)\n",
      "IZB 30ntgfkgfday (n=8)\n",
      "\n",
      "pre dosing\n",
      "\n",
      "post dosing\n",
      "\n",
      "10.0\n",
      "\n",
      "7.5\n",
      "\n",
      "ot\n",
      "E 5.0\n",
      "cr\n",
      "\n",
      "2.5\n",
      "\n",
      "0,0\n",
      "\n",
      "Figure g\n",
      "\n",
      "pre dostng\n",
      "\n",
      "post dosing\n",
      "\n",
      "pre dosing\n",
      "\n",
      "post dosing\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 10 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "\"liijiii} 0.1\n",
      "%30.3\n",
      "E31\n",
      "[ZD3\n",
      "IZ310\n",
      "EZI saline\n",
      "\n",
      "EE90.3\n",
      "EKI1\n",
      "E33\n",
      "IZZI10\n",
      "KZZI Sahne\n",
      "\n",
      "I-I\n",
      "\n",
      "A\n",
      "\n",
      "80\n",
      "\n",
      "70\n",
      "\n",
      "60\n",
      "\n",
      "o\n",
      "L~~50\n",
      "N ot\n",
      "r\n",
      "0\n",
      "\n",
      "30\n",
      "\n",
      "20\n",
      "\n",
      "10\n",
      "\n",
      "0\n",
      "\n",
      "I\n",
      "\n",
      "t=\n",
      "\n",
      "0\n",
      "Cl\n",
      "\n",
      "— E\n",
      "\n",
      "D\n",
      "\n",
      "110\n",
      "100\n",
      "90\n",
      "80\n",
      "70\n",
      "60\n",
      "50\n",
      "\n",
      "30\n",
      "20\n",
      "10\n",
      "0\n",
      "\n",
      "~o\n",
      "\n",
      "oe\n",
      "\n",
      "Dose (mg/kg/day, 4x)\n",
      "\n",
      "0.3\n",
      "\n",
      "1\n",
      "\n",
      "3\n",
      "10\n",
      "Dose (mg/kg, 1x)\n",
      "\n",
      "Saline\n",
      "\n",
      "Figure 10\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 11 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "4A5\n",
      "\n",
      "ml0.3\n",
      "ER91\n",
      "E33\n",
      "CZ310\n",
      "EZ3 Saline\n",
      "\n",
      "II0.3\n",
      "%31\n",
      "E33\n",
      "62310\n",
      "EZ3Saline\n",
      "\n",
      "100\n",
      "\n",
      "75\n",
      "\n",
      "50\n",
      "\n",
      "'g\n",
      "Vl\n",
      "E\n",
      "\n",
      "C\n",
      "Q\n",
      "C\n",
      "0\n",
      "4\n",
      "i\n",
      "ttj\n",
      "\n",
      "ttt\n",
      "\n",
      "0\n",
      "V\n",
      "t5\n",
      "\n",
      "0I-\n",
      "\n",
      "90\n",
      "\n",
      "80\n",
      "\n",
      "70\n",
      "\n",
      "30\n",
      "\n",
      "20\n",
      "\n",
      "10\n",
      "\n",
      "0\n",
      "\n",
      "60\n",
      "OU50\n",
      "\n",
      "o\n",
      "V\n",
      "\n",
      "0I-\n",
      "\n",
      "0.3\n",
      "\n",
      "1\n",
      "\n",
      "10\n",
      "\n",
      "3\n",
      "Dose (mglkg, i.v. on Day 0)\n",
      "6F6\n",
      "\n",
      "Saline\n",
      "\n",
      "0.3\n",
      "\n",
      "3\n",
      "Dose (mg/kg, i.v. on Day 0)\n",
      "\n",
      "10\n",
      "\n",
      "Saline\n",
      "\n",
      "Figure 11\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 12 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "4A5\n",
      "\n",
      "5A10\n",
      "\n",
      "GF6\n",
      "\n",
      "7D4\n",
      "\n",
      "PBS\n",
      "\n",
      "LDLR ~ ~~~~yeae rtrrrrtrewee~~ ews~ eww \"\"»\n",
      "GAPDH ~\n",
      "\n",
      "Figure 12\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 13 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "300\n",
      "\n",
      "200\n",
      "\n",
      "100\n",
      "\n",
      "Total\n",
      "\n",
      "HDL\n",
      "\n",
      "LDL\n",
      "\n",
      "Figure 13\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 14 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "C3 PBs\n",
      "53 4A5\n",
      "E3 5A10\n",
      "[PD 6F6\n",
      "IZ3 7I34\n",
      "\n",
      "100\n",
      "\n",
      "80\n",
      "\n",
      "'V\n",
      "\n",
      "E\n",
      "\n",
      "60\n",
      "\n",
      "I\n",
      "-'00\n",
      "\n",
      "0\n",
      "\n",
      "20\n",
      "\n",
      "0\n",
      "\n",
      "1mg/kg\n",
      "\n",
      "10mg/kg\n",
      "\n",
      "Figure 14\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 15 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "A\n",
      "\n",
      "$ 4\n",
      "0J 2\n",
      "\n",
      "1\n",
      "\n",
      "9 1\n",
      "I 1\n",
      "0\n",
      "8\n",
      "N\n",
      "\n",
      "8\n",
      "0\n",
      "\n",
      "E\n",
      "\n",
      "thb\n",
      "tJ\n",
      "\n",
      "c\n",
      "O.\n",
      "\n",
      "cI\n",
      "Z\n",
      "\n",
      "30\n",
      "\n",
      "28\n",
      "\n",
      "10\n",
      "\n",
      "0\n",
      "\n",
      "G\n",
      "\n",
      "E\n",
      "Ol\n",
      "\n",
      "a\n",
      "cC\n",
      "E\n",
      "\n",
      "m'3\n",
      "\n",
      "Z\n",
      "\n",
      "D\n",
      "\n",
      "IIIera\n",
      "\n",
      "III\n",
      "O.\n",
      "\n",
      "rc\n",
      "\n",
      "Tll\n",
      "0\n",
      "\n",
      "88\n",
      "\n",
      "7\n",
      "\n",
      "2\n",
      "\n",
      "F\n",
      "\n",
      "4\n",
      "\n",
      "Ul 3\n",
      "E\n",
      "e\n",
      ";2\n",
      "\n",
      "01\n",
      "\n",
      "3800\n",
      "\n",
      "2000\n",
      "\n",
      "Olc\n",
      "\n",
      "Y\n",
      "or 1800\n",
      "47\n",
      "c.\n",
      "\n",
      "DO D2 D7 D9 D11 D14 D21 D28\n",
      "\n",
      "DO D2 Dr D9 D11 D14 D21 D28\n",
      "\n",
      "DO D2 D7 D9 D11 914 D21 D28\n",
      "\n",
      "0% 0S 08\n",
      "\n",
      "0%\n",
      "\n",
      "bb\n",
      "b+\n",
      "0 0 0\n",
      "\n",
      "0\n",
      "\n",
      "00\n",
      "\n",
      "0%\n",
      "\n",
      "0& 04\n",
      "\n",
      "wb\n",
      "0\n",
      "mhb Concentrations in Plasma\n",
      "\n",
      "bb\n",
      "0\n",
      "\n",
      "0\n",
      "\n",
      "0\n",
      "\n",
      "DO D2 D7 D9 D11 D14 D21 D28\n",
      "\n",
      "H\n",
      "\n",
      "PCSK9 Concentrations in Plasma\n",
      "\n",
      "DO D2 Dr D9 D11 D14 D21 D28\n",
      "\n",
      "DO D2 D7 D9 D11 D14 D21 D28\n",
      "\n",
      "Figure 15\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 16 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "20 mg/kg TD4\n",
      "\n",
      "3 mg/kg 7D4\n",
      "\n",
      "'0\n",
      "\n",
      "E\n",
      "\n",
      "d\n",
      "\n",
      "Ul\n",
      "E\n",
      "\n",
      "d\n",
      "\n",
      "Vl\n",
      "E\n",
      "d\n",
      "\n",
      "Ot\n",
      "E\n",
      "\n",
      "d\n",
      "\n",
      "00\n",
      "\n",
      "02 D7 DS\n",
      "\n",
      "011 D14 D21 D28\n",
      "\n",
      "00 D2 D7\n",
      "\n",
      "09 D11 D14 D21 028\n",
      "\n",
      "1 mg/kg 7D4\n",
      "\n",
      "0.3 mg/kg 7D4\n",
      "\n",
      "DO D2 D7 DS D11 D14 D21 D28\n",
      "\n",
      "DO D2 D7\n",
      "\n",
      "DS D11 D14 D21 D28\n",
      "\n",
      "Figure 16\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 17 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "100\n",
      "\n",
      "62~ 60\n",
      "\n",
      "1\n",
      "\n",
      "CI\n",
      "\n",
      "100\n",
      "\n",
      "cr~ 60\n",
      "\n",
      "1\n",
      "\n",
      "g\n",
      "\n",
      "CI\n",
      "\n",
      "o''e O'~ O'e Oe o\n",
      "\n",
      "6F6\n",
      "\n",
      "D-2 Do D1\n",
      "\n",
      "D2 D4 D6 D9 D1 4\n",
      "\n",
      "7D4\n",
      "\n",
      "D-2 Do\n",
      "\n",
      "D1\n",
      "\n",
      "D2 D4 D6 D9 D14\n",
      "\n",
      "D-2 D0\n",
      "\n",
      "D1\n",
      "\n",
      "D2 D4 D6 D9 D1 4\n",
      "\n",
      "Figure 17\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet IS of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "33.4% Keel fat, 0.1% cholesterol diet\n",
      "\n",
      "~ saline\n",
      "~ 7D4\n",
      "\n",
      "N=3\n",
      "\n",
      "225\n",
      "\n",
      "200\n",
      "o 175\n",
      "I= 150\n",
      "s 125\n",
      "g 100\n",
      "75\n",
      "\n",
      "50\n",
      "\n",
      "25\n",
      "\n",
      "0\n",
      "\n",
      "o~ o~ c~ oooo oooo oooooooo oooooooooooo oooo\n",
      "o o o o o o o o o 'o o o o o o o o o\n",
      "\n",
      "s nx nx+nx+n)+nx+nxo\n",
      "\n",
      "Date\n",
      "\n",
      "Figure 18\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 19 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "+ + + +\n",
      "\n",
      "+\n",
      "\n",
      "+ +\n",
      "\n",
      "400 200100 50 25 12.5\n",
      "\n",
      "0\n",
      "\n",
      "0\n",
      "\n",
      "(100nM)\n",
      "mAb (nM)\n",
      "\n",
      "Human PCSK9\n",
      "\n",
      "Mouse PCSK9\n",
      "\n",
      "Figure 19\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 20 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "0,36nM Human PGSK9 pH7,5\n",
      "\n",
      "OL1L3~ 5A10\n",
      "\n",
      "* 42H7\n",
      "\n",
      "oo. I„s'% so\n",
      "\n",
      "0.35nM Human PCSK9 pH 5.3\n",
      "\n",
      "B\n",
      "\n",
      "1.5\n",
      "\n",
      "0Is'b !b\n",
      "\n",
      "o\n",
      "\n",
      "e 4''\n",
      "\n",
      "b\n",
      "\n",
      "b'\n",
      "\n",
      "0.31nM Mouse PGSK9 pH 7.5\n",
      "\n",
      "C\n",
      "\n",
      "1.5\n",
      "\n",
      "0.5\n",
      "\n",
      "1.5\n",
      "\n",
      "0.5\n",
      "\n",
      "0.31 nM Mouse PGSK9 pH 5.3\n",
      "\n",
      "so'p'o o''''''\n",
      "\n",
      "o~ y oA\n",
      "\n",
      "oo\n",
      "\n",
      "s~\n",
      "\n",
      "Po\n",
      "\n",
      "po\n",
      "\n",
      "oA\n",
      "\n",
      "o&\n",
      "\n",
      "oo\n",
      "\n",
      "oo\n",
      "\n",
      "Figure 20\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 21 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "0\n",
      "01 26 'Z$\n",
      "o\n",
      "oE\n",
      "\n",
      "CS\n",
      "\n",
      "90\n",
      "\n",
      "60\n",
      "\n",
      "45\n",
      "\n",
      "30\n",
      "\n",
      "15\n",
      "\n",
      "2-dBys\n",
      "\n",
      "4-days\n",
      "\n",
      "7-days\n",
      "\n",
      "Figure 21\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 22 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "HDL\n",
      "\n",
      "LDL\n",
      "\n",
      "~ 5A10\n",
      "\n",
      "LIL3\n",
      "\n",
      "II\n",
      "cs\n",
      "8 100\n",
      "\n",
      "II\n",
      "\n",
      "CI\n",
      "Z\n",
      "\n",
      "50\n",
      "\n",
      "0\n",
      "\n",
      "10\n",
      "\n",
      "20\n",
      "\n",
      "30\n",
      "\n",
      "Days\n",
      "\n",
      "8\n",
      "\n",
      "18\n",
      "\n",
      "28\n",
      "\n",
      "Days\n",
      "\n",
      "150\n",
      "\n",
      "Cl\n",
      "\n",
      "ISs 100\n",
      "8\n",
      "V\n",
      "\n",
      "g\n",
      "\n",
      "CI\n",
      "\n",
      "50\n",
      "\n",
      "0\n",
      "\n",
      "-2\n",
      "\n",
      "Figure 22\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 23 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "L1L3 F\n",
      "\n",
      "LOLR-EGF\n",
      "\n",
      "PCSK9\n",
      "\n",
      "PCSK9\n",
      "\n",
      "PCSK9\n",
      "\n",
      "PCSK9\n",
      "\n",
      "p\n",
      "\n",
      "L1L3 Epitoper\n",
      "\n",
      "LDLR EGF Epitopo\n",
      "\n",
      "Figure 23\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20, 2011\n",
      "\n",
      "Sheet 24 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "o\n",
      "X\n",
      "\n",
      "O\n",
      "\n",
      "O\n",
      "\n",
      "O o o O\n",
      "Y\n",
      "(0\n",
      "\n",
      "m\n",
      "\n",
      "CQ\n",
      "\n",
      "(C\n",
      "\n",
      "0.\n",
      "\n",
      "UJ\n",
      "\n",
      "(A\n",
      "\n",
      "Cj6\n",
      "\n",
      "IZ\n",
      "UJ\n",
      "\n",
      "Cj\n",
      "\n",
      "0\n",
      "CC\n",
      "IJJ\n",
      "\n",
      "cj\n",
      "IK\n",
      "\n",
      "CL\n",
      "\n",
      "UJ\n",
      "\n",
      "cj\n",
      "Y\n",
      "(C\n",
      "\n",
      "0.\n",
      "(0\n",
      "~J\n",
      "\n",
      "cj\n",
      "0.\n",
      "\n",
      "0.\n",
      "\n",
      "UJ\n",
      "\n",
      "cj\n",
      "tll\n",
      "\n",
      "IL\n",
      "IZ\n",
      "QI\n",
      "\n",
      "Cj\n",
      "\n",
      "Cl\n",
      "\n",
      "Cj\n",
      "\n",
      "IL\n",
      "CC\n",
      "IU\n",
      "\n",
      "0\n",
      "\n",
      "O\n",
      "\n",
      "Q.\n",
      "\n",
      "LL\n",
      "\n",
      "m\n",
      "\n",
      "CJx\n",
      "\n",
      "Q.\n",
      "Z\n",
      "IJJ\n",
      "\n",
      "'0\n",
      "\n",
      "N\n",
      "\n",
      "LU\n",
      "\n",
      "Z\n",
      "Z\n",
      "\n",
      "CQ\n",
      "UI\n",
      "N\n",
      "(L\n",
      "Z\n",
      "UJ\n",
      "\n",
      "N\n",
      "\n",
      "UJZ\n",
      "Z\n",
      "(0\n",
      "(7\n",
      "(0\n",
      "(0\n",
      "Q.\n",
      "Z\n",
      "IU\n",
      "\n",
      "CQ\n",
      "Y\n",
      "Y\n",
      "\n",
      "UJZ)ZI-\n",
      "\n",
      "CC\n",
      "(7\n",
      "Vj\n",
      "0\n",
      "Z\n",
      "UJ\n",
      "\n",
      "(0\n",
      "\n",
      "UJ\n",
      "Z\n",
      "Z\n",
      "\n",
      "Vlo\n",
      "N\n",
      "0.\n",
      "Z\n",
      "UJ\n",
      "\n",
      "IL\n",
      "Z\n",
      "Z\n",
      "\n",
      "C\"\n",
      "\n",
      "0\",\n",
      "Q.\n",
      "Z\n",
      "IL\n",
      "\n",
      "IQ\n",
      "\n",
      "N\n",
      "\n",
      "U.\n",
      "\n",
      "IU\n",
      "Z\n",
      "Z\n",
      "\n",
      "CC\n",
      "\n",
      "Z\n",
      "CQ\n",
      "N\n",
      "0.\n",
      "Z\n",
      "IU\n",
      "\n",
      "CQ\n",
      "\n",
      "IL\n",
      "\n",
      "IU\n",
      "Z\n",
      "Z\n",
      "\n",
      "N\n",
      "Vt\n",
      "N\n",
      "Q.\n",
      "Z\n",
      "UJ\n",
      "\n",
      "CU\n",
      "\n",
      "UJ\n",
      "IL'\n",
      "\n",
      "0\n",
      "\n",
      "CJ\n",
      "Cl\n",
      "\n",
      "O\n",
      "(7o\n",
      "(0\n",
      "\n",
      "VI\n",
      "\n",
      "I(\n",
      "\n",
      "m\n",
      "Z\n",
      "\n",
      "Cj\n",
      "\n",
      "CL\n",
      "\n",
      "UJ\n",
      "\n",
      "Vjv\n",
      "\n",
      "UJ\n",
      "Z\n",
      "Z\n",
      "\n",
      "CC\n",
      "\n",
      "Y\n",
      "N\n",
      "CL\n",
      "Z\n",
      "UJ\n",
      "\n",
      "VJ\n",
      "\n",
      "IL\n",
      "\n",
      "CL\n",
      "\n",
      "Vj\n",
      "\n",
      "Cj\n",
      "cj\n",
      "\n",
      "CC\n",
      "\n",
      "N\n",
      "N\n",
      "\n",
      "O\n",
      "\n",
      "N\n",
      "\n",
      "Cj\n",
      "c(\n",
      "Vj\n",
      "\n",
      ")\n",
      "\n",
      "N\n",
      "\n",
      "CQ\n",
      "CV\n",
      "\n",
      "N)\n",
      "\n",
      "C!\n",
      "c(\n",
      "\n",
      "CJ\n",
      "\n",
      "IL\n",
      "\n",
      "LJ\n",
      "\n",
      "N\n",
      "O\n",
      "\n",
      "Z\n",
      "Z\n",
      "\n",
      "C7\n",
      "\n",
      "0'I\n",
      "0.\n",
      "Z\n",
      "LJ\n",
      "\n",
      "N\n",
      "\n",
      "Q.\n",
      "\n",
      "Vj\n",
      "\n",
      "CI\n",
      "Cj\n",
      "\n",
      "0(\n",
      "\n",
      "Z\n",
      "\n",
      "Vj\n",
      "\n",
      "Vj\n",
      "\n",
      "o\n",
      "m\n",
      "\n",
      "N\n",
      "\n",
      "Cj\n",
      "ci\n",
      "\n",
      "Vf\n",
      "\n",
      "Cj\n",
      "\n",
      "CL\n",
      "CC\n",
      "IU\n",
      "\n",
      "N\n",
      "Y\n",
      "IL\n",
      "\n",
      "UJ\n",
      "Z\n",
      "Z\n",
      "(0\n",
      "U\n",
      "N\n",
      "ILZ\n",
      "\n",
      "UJ\n",
      "\n",
      "Z\n",
      "\n",
      "N\n",
      "\n",
      "(7\n",
      "\n",
      "(0\n",
      "N\n",
      "N\n",
      "\n",
      "(7\n",
      "\n",
      "N\n",
      "\n",
      "Cj\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20, 2011\n",
      "\n",
      "Sheet 25 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "O\n",
      "I!\n",
      "N\n",
      "\n",
      "C\n",
      "X\n",
      "Ll\n",
      "\n",
      "'Io\n",
      "\n",
      "if\n",
      "\n",
      "7\n",
      "O o\n",
      "I!\n",
      "\n",
      "'!o\n",
      "\n",
      "I!\n",
      "\n",
      "C\n",
      "X\n",
      "\n",
      "O\n",
      "Ifo\n",
      "\n",
      "o\n",
      "if\n",
      "IA\n",
      "\n",
      "K\n",
      "\n",
      "CIJ\n",
      "\n",
      "K0'\n",
      "\n",
      "C\n",
      "\n",
      "IIJ\n",
      "IL\n",
      "\n",
      "C.0\n",
      "\n",
      "Cf\n",
      "\n",
      "Di\n",
      "\n",
      "K\n",
      "0\n",
      "\n",
      "N\n",
      "\n",
      "CC\n",
      "\n",
      "f/i\n",
      "\n",
      "CC0\n",
      "I3\n",
      "\n",
      "K\n",
      "\n",
      "K\n",
      "0\n",
      "0\n",
      "\n",
      "'JJ\n",
      "\n",
      "T\n",
      "3\n",
      "'3 00\n",
      "\n",
      "K'\n",
      "\n",
      "IJJ\n",
      "\n",
      "K0\n",
      "0\n",
      "\n",
      "0\n",
      "\n",
      "K0\n",
      "0\n",
      "\n",
      "K\n",
      "\n",
      "fo\n",
      "\n",
      "CL'\n",
      "\n",
      "K\n",
      "\n",
      "IJJ\n",
      "\n",
      "K0\n",
      "\n",
      "CI\n",
      "\n",
      "K\n",
      "\n",
      "IL'IJ\n",
      "\n",
      "K\n",
      "0\n",
      "0\n",
      "\n",
      "ffi\n",
      "\n",
      "K0\n",
      "\n",
      "f3\n",
      "\n",
      "K\n",
      "\n",
      "K00\n",
      "\n",
      "C!f!\n",
      "\n",
      "fL\n",
      "Cf\n",
      "\n",
      "III\n",
      "\n",
      "K\n",
      "CI\n",
      "CI\n",
      "\n",
      "K\n",
      "ill\n",
      "IJJ\n",
      "IIJ\n",
      "\n",
      "0'\n",
      "\n",
      "o\n",
      "\n",
      "K\n",
      "\n",
      "0\n",
      "\n",
      "CE\n",
      "CJ\n",
      "\n",
      "O\n",
      "\n",
      "K\n",
      "c(0\n",
      "\n",
      "ffi\n",
      "\n",
      "CC0\n",
      "f3\n",
      "\n",
      "CIJ\n",
      "\n",
      "I3\n",
      "\n",
      "O3\n",
      "\n",
      "Cff\n",
      "\n",
      "CU\n",
      "\n",
      "0\n",
      "\n",
      "Y'K\n",
      "\n",
      "O\n",
      "I!\n",
      "N\n",
      "\n",
      "n\n",
      "\n",
      "CL\n",
      "K\n",
      "lij\n",
      "\n",
      "o\n",
      "\n",
      "nI-\n",
      "\n",
      "CL\n",
      "\n",
      "lli\n",
      "\n",
      "N\n",
      "X\n",
      "\n",
      "N\n",
      "\n",
      "Q\n",
      "\n",
      "K\n",
      "IIJ\n",
      "\n",
      "IG\n",
      "Y\n",
      "I!\n",
      "Y\n",
      "llJZ\n",
      "Z\n",
      "\n",
      "ffi\n",
      "Z\n",
      "tli\n",
      "\n",
      "IL\n",
      "\n",
      "fCJ\n",
      "\n",
      "CC\n",
      "\n",
      "N\n",
      "\n",
      "K\n",
      "\n",
      "flJ\n",
      "Ã\n",
      "\n",
      ")0\n",
      "\n",
      "Ã\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 26 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 27 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "O\n",
      "X\n",
      "\n",
      "I\n",
      "\n",
      "IC\n",
      "\n",
      "O\n",
      "X\n",
      "\n",
      "O\n",
      "X\n",
      "\n",
      "7\n",
      "O\n",
      "X\n",
      "O\n",
      "\n",
      "O\n",
      "\n",
      "CC\n",
      "\n",
      "I\n",
      "\n",
      "O\n",
      "\n",
      "X\n",
      "\n",
      "X\n",
      "\n",
      "O\n",
      "\n",
      "CQ\n",
      "\n",
      "CQ\n",
      "\n",
      "N\n",
      "\n",
      "LUZ\n",
      "Z\n",
      "\n",
      "CC\n",
      "N\n",
      "\n",
      "rO\n",
      "\n",
      "ei\n",
      "LU\n",
      "\n",
      "VJ\n",
      "\n",
      "IL\n",
      "\n",
      "IU\n",
      "Z\n",
      "Z\n",
      "\n",
      "CQ\n",
      "\n",
      "Q.2\n",
      "\n",
      "UJ\n",
      "\n",
      "U\n",
      "\n",
      "UJ\n",
      "Z\n",
      "Z\n",
      "\n",
      "IC\n",
      "\n",
      "CO\n",
      "Y\n",
      "IL\n",
      "\n",
      "LUZ\n",
      "Z\n",
      "\n",
      "CC\n",
      "CI\n",
      "CO\n",
      "IL\n",
      "CL\n",
      "CO\n",
      "\n",
      "UJ\n",
      "\n",
      "Vf\n",
      "CO\n",
      "\n",
      "Vl\n",
      "Y\n",
      "IL\n",
      "\n",
      "IU\n",
      "Z\n",
      "Z\n",
      "Z\n",
      "\n",
      "CQ\n",
      "\n",
      "Q\n",
      "IO\n",
      "\n",
      "LU\n",
      "\n",
      "O\n",
      "\n",
      "N\n",
      "Y\n",
      "\n",
      "UJ\n",
      "Z\n",
      "Y\n",
      "Z\n",
      "\n",
      "CC\n",
      "fQ\n",
      "\n",
      "CQ\n",
      "ICJ\n",
      "UI\n",
      "CI\n",
      "\n",
      "LU\n",
      "\n",
      "LL\n",
      "\n",
      "UJZ\n",
      "Z\n",
      "\n",
      "CL'Q\n",
      "\n",
      "CQ\n",
      "\n",
      "CL\n",
      "VI\n",
      "IU\n",
      "\n",
      "CC\n",
      "\n",
      "N\n",
      "\n",
      "IL\n",
      "\n",
      "LU\n",
      "\n",
      "Z\n",
      "Z\n",
      "\n",
      "fQ\n",
      "Z\n",
      "IU\n",
      "Q.\n",
      "Z\n",
      "Uj\n",
      "\n",
      "CO\n",
      "Y\n",
      "IL\n",
      "\n",
      "IU\n",
      "Z\n",
      "Z\n",
      "Z\n",
      "N\n",
      "UI\n",
      "IO\n",
      "Q.\n",
      "Z\n",
      "\n",
      "LU\n",
      "\n",
      "N\n",
      "\n",
      "UJZ\n",
      "Z\n",
      "IC\n",
      "CQ\n",
      "Z\n",
      "\n",
      "Z\n",
      "UJ\n",
      "\n",
      "N\n",
      "Y\n",
      "Y\n",
      "IJJ\n",
      "Z\n",
      "Z\n",
      "\n",
      "IC\n",
      "CQ\n",
      "\n",
      "CO\n",
      "\n",
      "cf\n",
      "fL\n",
      "Y\n",
      "Ul\n",
      "\n",
      "UJ\n",
      "Z\n",
      "Z\n",
      "\n",
      "CC\n",
      "\n",
      "CQ\n",
      "Y\n",
      "\n",
      "Q.\n",
      "Z\n",
      "IU\n",
      "\n",
      "N\n",
      "\n",
      "UJZ\n",
      "Z\n",
      "\n",
      "CC\n",
      "\n",
      "CQ\n",
      "IQ\n",
      "\n",
      "fO\n",
      "UJ\n",
      "\n",
      "K\n",
      "\n",
      "IL\n",
      "Z\n",
      "Z\n",
      "\n",
      "U.\n",
      "\n",
      "OC\n",
      "I\n",
      "\n",
      "Vi\n",
      "\n",
      "IL\n",
      "\n",
      "Ul\n",
      "Z\n",
      "Z\n",
      "\n",
      "CQ\n",
      "CJ\n",
      "rO\n",
      "\n",
      "Cf\n",
      "IU\n",
      "\n",
      "Q\n",
      "\n",
      "CIJ\n",
      "\n",
      "JJJ\n",
      "\n",
      "0\n",
      "\n",
      "CCZ\n",
      "\n",
      "CC\n",
      "\n",
      "Z\n",
      "\n",
      "CQ\n",
      "\n",
      "O\n",
      "\n",
      "CL'/J\n",
      "\n",
      "N\n",
      "\n",
      "Cf\n",
      "Cf\n",
      "\n",
      "CC\n",
      "\n",
      "CO\n",
      "N\n",
      "\n",
      "CC\n",
      "C1\n",
      "CJ\n",
      "\n",
      "V&\n",
      "\n",
      "CC\n",
      "CJ\n",
      "\n",
      "CC\n",
      "\n",
      "CCZ\n",
      "\n",
      "U0\n",
      "\n",
      "CQ\n",
      "IL\n",
      "N\n",
      "\n",
      "CC\n",
      "Cf\n",
      "l3\n",
      "\n",
      "I-\n",
      "IC\n",
      "Q\n",
      "\n",
      "cf0\n",
      "\n",
      "CC\n",
      "CJ\n",
      "CJ\n",
      "\n",
      "CJ\n",
      "\n",
      "Q.\n",
      "IU\n",
      "UJ\n",
      "\n",
      "CO\n",
      "N\n",
      "Y\n",
      "LL\n",
      "\n",
      "UJ\n",
      "Z\n",
      "Z\n",
      "\n",
      "CQ\n",
      "\n",
      "N\n",
      "Q.\n",
      "\n",
      "LU\n",
      "\n",
      "Z\n",
      "\n",
      "VJ\n",
      "\n",
      "CO\n",
      "\n",
      "IC\n",
      "Q.\n",
      "\n",
      "CO\n",
      "\n",
      "IU0\n",
      "\n",
      "CJ\n",
      "\n",
      "N\n",
      "\n",
      "O\n",
      "\n",
      "CO\n",
      "\n",
      "CJ\n",
      "CJ\n",
      "VJ\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20, 2011\n",
      "\n",
      "Sheet 2S of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "O\n",
      "\n",
      "0\n",
      "Z\n",
      "\n",
      "Q.\n",
      "E\n",
      "UJ\n",
      "\n",
      "O\n",
      "\n",
      "IO\n",
      "\n",
      "0\n",
      "Z\n",
      "\n",
      "CL\n",
      "IC\n",
      "UJ\n",
      "\n",
      "O\n",
      "\n",
      "IC\n",
      "t\n",
      "\n",
      "0\n",
      "N\n",
      "\n",
      "Q.\n",
      "IC\n",
      "IU\n",
      "\n",
      "IC\n",
      "Ct\n",
      "\n",
      "IQ\n",
      "\n",
      "IL'\n",
      "\n",
      "IL\n",
      "\n",
      "tri\n",
      "\n",
      "0\n",
      "2\n",
      "\n",
      "IL\n",
      "fL\n",
      "LU\n",
      "\n",
      "Jj\n",
      "\n",
      "IQ\n",
      "\n",
      "M\n",
      "\n",
      "X\n",
      "JJ\n",
      "\n",
      "0\n",
      "M\n",
      "\n",
      "Q\n",
      "CC\n",
      "UJ\n",
      "\n",
      "O O\n",
      "\n",
      "CC\n",
      "\n",
      "CC\n",
      "CO\n",
      "\n",
      "O\n",
      "X\n",
      "CO\n",
      "\n",
      "CO\n",
      "CO\n",
      "\n",
      "0\n",
      "Z\n",
      "\n",
      "Q\n",
      "CC\n",
      "Ul\n",
      "\n",
      "0\n",
      "M\n",
      "\n",
      "I\n",
      "Q.\n",
      "CC\n",
      "IU\n",
      "\n",
      "0\n",
      "\n",
      "Q.\n",
      "\n",
      "Ul\n",
      "\n",
      "cf0\n",
      "N\n",
      "*C\n",
      "\n",
      "Q\n",
      "IZ\n",
      "LU\n",
      "\n",
      "N0\n",
      "Z\n",
      "\n",
      "Q.\n",
      "IC\n",
      "LU\n",
      "\n",
      "N0 0I- M\n",
      "\n",
      "Q.\n",
      "\n",
      "IU\n",
      "\n",
      "CL\n",
      "\n",
      "IU\n",
      "\n",
      "IA\n",
      "CO\n",
      "\n",
      "0\n",
      "Z\n",
      "\n",
      "C\n",
      "\n",
      "UJ\n",
      "\n",
      "IVI\n",
      "\n",
      "0\n",
      "x\n",
      "\n",
      "cC\n",
      "\n",
      "Q.\n",
      "fL\n",
      "UJ\n",
      "\n",
      "CO\n",
      "\n",
      "0\n",
      "N\n",
      "\n",
      "Q.\n",
      "IC\n",
      "IU\n",
      "\n",
      "0\n",
      "Z\n",
      "\n",
      "CL\n",
      "\n",
      "E\n",
      "Ul\n",
      "\n",
      "0\n",
      "M\n",
      "\n",
      "L0\n",
      "\n",
      "N\n",
      "\n",
      "Q\n",
      "IC\n",
      "IJJ\n",
      "\n",
      "UJ\n",
      "\n",
      "tJJ\n",
      "\n",
      "6\n",
      "\n",
      "LL\n",
      "\n",
      "O\n",
      "X\n",
      "CO\n",
      "\n",
      "CJ\n",
      "\n",
      "M\n",
      "\n",
      "LLZ\n",
      "Lll\n",
      "Z\n",
      "Z\n",
      "\n",
      "ICI-\n",
      "00\n",
      "\n",
      "Q.\n",
      "Z\n",
      "ITI\n",
      "\n",
      "Z\n",
      "\n",
      "Ot\n",
      "Z\n",
      "\n",
      "Z\n",
      "\n",
      "Ct\n",
      "\n",
      "0\n",
      "\n",
      "CL\n",
      "IC\n",
      "Ul\n",
      "\n",
      "ICI\n",
      "\n",
      "N\n",
      "\n",
      "IL\n",
      "\n",
      "IU\n",
      "Z\n",
      "Z\n",
      "\n",
      "CC0\n",
      "\n",
      "LO\n",
      "M\n",
      "Q.\n",
      "Z\n",
      "UJ\n",
      "\n",
      "N\n",
      "\n",
      "LO\n",
      "\n",
      "CC\n",
      "CL\n",
      "\n",
      "N\n",
      "\n",
      "Cf\n",
      "\n",
      "0\n",
      "\n",
      "Ot\n",
      "\n",
      "N\n",
      "Cl\n",
      "N\n",
      "\n",
      "O\n",
      "\n",
      "N)0\n",
      "0\n",
      "N\n",
      "\n",
      "O\n",
      "\n",
      "LU\n",
      "\n",
      "N\n",
      "V\n",
      "LL\n",
      "\n",
      "UJZ\n",
      "Z\n",
      "\n",
      "CC\n",
      "\n",
      "Cjt\n",
      "Q.\n",
      "Z\n",
      "IJJ\n",
      "\n",
      "Z\n",
      "\n",
      "I 'I\n",
      "\n",
      "CC\n",
      "Q\n",
      "\n",
      "'Jl\n",
      "\n",
      "0\n",
      "\n",
      "CC\n",
      "\n",
      "M\n",
      "\n",
      "Cri\n",
      "\n",
      "O\n",
      "\n",
      "Cri\n",
      "\n",
      "Lj\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 29 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "Ch\n",
      "N\n",
      "N\n",
      "\n",
      "ff Li\n",
      "P I\n",
      "\n",
      "Ih\n",
      "I\n",
      "\n",
      "p\n",
      "Ih\n",
      "\n",
      "Q.\n",
      "E\n",
      "IU\n",
      "\n",
      "p\n",
      "th\n",
      "\n",
      "Q.\n",
      "IU\n",
      "LU\n",
      "\n",
      "p\n",
      "ih\n",
      "\n",
      "Q.\n",
      "\n",
      "UJ\n",
      "\n",
      "ih\n",
      "\n",
      "IL\n",
      "\n",
      "UJ\n",
      "\n",
      "Z\n",
      "IL\n",
      "IQ\n",
      "Ig\n",
      "IL\n",
      "Q\n",
      "Ih\n",
      "UJ\n",
      "\n",
      "p\n",
      "Ih\n",
      "\n",
      "Q.\n",
      "IU\n",
      "UJ\n",
      "\n",
      "Ih\n",
      "\n",
      "IL\n",
      "\n",
      "Ul\n",
      "Z\n",
      "Z\n",
      "\n",
      "LL\n",
      "\n",
      "p\n",
      "Q.\n",
      "Ih\n",
      "Ul\n",
      "\n",
      "LL\n",
      "\n",
      "Ul\n",
      "Z\n",
      "Z\n",
      "\n",
      "LL\n",
      "\n",
      "LQ\n",
      "\n",
      "Q.\n",
      "ih\n",
      "Ul\n",
      "\n",
      "C\\\n",
      "\n",
      "I-\n",
      "x\n",
      "\n",
      "V,\n",
      "7.\n",
      "IU\n",
      "\n",
      "IU\n",
      "\n",
      "0'\n",
      "\n",
      "K\n",
      "\n",
      "IU\n",
      "\n",
      "p\n",
      "\n",
      "N\n",
      "\n",
      "6\n",
      "Ih\n",
      "E\n",
      "\n",
      "III\n",
      "ih\n",
      "Ih\n",
      "\n",
      "8\n",
      "\n",
      "o\n",
      "\n",
      "p\n",
      "x\n",
      "\n",
      "Q\n",
      "LL\n",
      "UJ\n",
      "\n",
      "N\n",
      "\n",
      "p\n",
      "X\n",
      "\n",
      "Q.\n",
      "IU\n",
      "UJ\n",
      "\n",
      "Zh'\n",
      "\n",
      "JJ\n",
      "\n",
      "I\n",
      "Ih\n",
      "\n",
      "JJ\n",
      "\n",
      "Ih\n",
      "Y\n",
      "U.\n",
      "Y\n",
      "LUZ\n",
      "\n",
      "IL0\n",
      "\n",
      "Cf\n",
      "\n",
      "Z\n",
      "\n",
      "LLI\n",
      "\n",
      "Ih\n",
      "Y\n",
      "\n",
      "~J\n",
      "Z\n",
      "Z\n",
      "00\n",
      "Z\n",
      "~J\n",
      "\n",
      "fh\n",
      "Y\n",
      "IL\n",
      "\n",
      "UJ\n",
      "Z\n",
      "Z\n",
      "\n",
      "p\n",
      "0\n",
      "Q.\n",
      "lh\n",
      "UJ\n",
      "\n",
      "Ih\n",
      "\n",
      "Z\n",
      "Z\n",
      "\n",
      "IL\n",
      "\n",
      "Q.\n",
      "fh\n",
      "\n",
      "(C\n",
      "\n",
      "LL\n",
      "\n",
      "Z\n",
      "Z\n",
      "\n",
      "IZ\n",
      "\n",
      "fQ\n",
      "\n",
      "LL\n",
      "\n",
      "Z\n",
      "\n",
      "N\n",
      "\n",
      "\f",
      "U.S. Patent\n",
      "\n",
      "Dec. 20,2011\n",
      "\n",
      "Sheet 30 of 30\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "0\n",
      "\n",
      "Ill\n",
      "\n",
      "D\n",
      "0\n",
      "\n",
      "CD\n",
      "\n",
      "CDo\n",
      "\n",
      "CCD\n",
      "CD\n",
      "\n",
      "N\n",
      "Z\n",
      "\n",
      "N\n",
      "0\n",
      "\n",
      "Z\n",
      "N\n",
      "\n",
      "Cj\n",
      "\n",
      "o\n",
      "\n",
      "0\n",
      "\n",
      "E\n",
      "UJ\n",
      "\n",
      "LL\n",
      "\n",
      "UJ\n",
      "Z\n",
      "Z\n",
      "t-\n",
      "E\n",
      "0\n",
      "0\n",
      "\n",
      "LL\n",
      "\n",
      "UJ\n",
      "\n",
      "N\n",
      "\n",
      "0\n",
      "\n",
      "E\n",
      "\n",
      "Uj\n",
      "\n",
      "Uj\n",
      "\n",
      "0 o o\n",
      "\n",
      "C5\n",
      "Ut\n",
      "\n",
      "t1\n",
      "E\n",
      "IU\n",
      "\n",
      "CI\n",
      "N\n",
      "\n",
      "LL\n",
      "IU\n",
      "LU\n",
      "\n",
      "IA\n",
      "\n",
      "CCI\n",
      "\n",
      "0\n",
      "Uj\n",
      "\n",
      "E\n",
      "Ul\n",
      "\n",
      "Uj\n",
      "\n",
      "LL\n",
      "\n",
      "UJ\n",
      "Z\n",
      "Z\n",
      "E\n",
      "0\n",
      "0\n",
      "\n",
      "Q\n",
      "tlj\n",
      "UJ\n",
      "\n",
      "E\n",
      "Uj\n",
      "IL'\n",
      "\n",
      "Ct0\n",
      "\n",
      "0\n",
      "N\n",
      "\n",
      "Q\n",
      "\n",
      "E\n",
      "IU\n",
      "\n",
      "N\n",
      "\n",
      "IL\n",
      "\n",
      "LUZ\n",
      "Z\n",
      "IU0\n",
      "0\n",
      "IL\n",
      "Q.\n",
      "N\n",
      "UJ\n",
      "\n",
      "0\n",
      "Uj\n",
      "\n",
      "Q\n",
      "E\n",
      "Ul\n",
      "\n",
      "Uj\n",
      "\n",
      "jL'L'J\n",
      "\n",
      "Z\n",
      "Z\n",
      "E\n",
      "0\n",
      "0\n",
      "IL\n",
      "Q.\n",
      "\n",
      "LLI\n",
      "\n",
      "Ct0\n",
      "\n",
      "F\n",
      "Qt o\n",
      "\n",
      "I\n",
      "\n",
      "Ct\n",
      "\n",
      "D\n",
      "\n",
      "Cj\n",
      "\n",
      "o\n",
      "\n",
      "CI\n",
      "\n",
      "t1\n",
      "\n",
      "UJ\n",
      "\n",
      "ICI\n",
      "\n",
      "Z\n",
      "\n",
      "Z\n",
      "\n",
      "CCC\n",
      "\n",
      "Cj\n",
      "\n",
      "Q.\n",
      "E\n",
      "UJ\n",
      "\n",
      "N\n",
      "\n",
      "LL\n",
      "\n",
      "UJ\n",
      "Z\n",
      "Z\n",
      "I-\n",
      "E\n",
      "0\n",
      "0\n",
      "\n",
      "LL\n",
      "\n",
      "Z\n",
      "IU\n",
      "\n",
      "0\n",
      "\n",
      "tZ\n",
      "Q\n",
      "N\n",
      "Z\n",
      "Ct0\n",
      "\n",
      "N\n",
      "Cj0\n",
      "N\n",
      "\n",
      "\f",
      "tjs 8,080,243 B2\n",
      "\n",
      "1\n",
      "ISOI.ATKH ANTIBODY YVHIC.'H\n",
      "SPEC'IFICALLY Rl ~ HS TO PCSK9\n",
      "\n",
      "in individuals with mitosomal dominmu hypercholcster-\n",
      "olemia, v,bile other \"loss-of-function\" (LOF) nmtations are\n",
      "linked with reduced plasma cholesterol. Morbidity and mor-\n",
      "ialiiy studio~ in Ibis group clearly dcmnnstratext thai riducing\n",
      "PCSK9 I'unction significmltly diminished thc risk of cardio-\n",
      "vascular disease.\n",
      "\n",
      "filed\n",
      "\n",
      "This applicatmn claims priority, ulxler 35 IJSC'5119fc), to\n",
      "ilm liillou ing US provisional applications, IJ.S Appl No\n",
      "61/096,716, filed Sep. 12, 200K U.S. Appl. No. 61/232.161,\n",
      "Au. 7. 2009, and U S. Appl. No. 61/235 643, filed Aug.\n",
      "\n",
      "20. 2009.\n",
      "\n",
      "Of sigiuficant importance to the treatment of CVD. a LOF\n",
      "mutation may sensitize humans to statins, allouing for efii-\n",
      "cacy nt a lower dose fhcncc, improving risks associatixI with\n",
      "safety and tolerance) and potentially achieving lower plasma\n",
      "cholesterol levels than with current therapies.\n",
      "\n",
      "RFFFRI',NC'I'. TO SFQIJFN('I'. I,ISTIN(i\n",
      "\n",
      "tocytes. Cienetic modulation of PCSK9 in miceconfimled\n",
      "\n",
      "'Elis application is being filed electronically via EFSHVeb\n",
      "and includes nn elcctrmiically submitted scqucncc listing\n",
      "in ixi fomiat Thc.ixt lile contains a sequence listing entitled\n",
      "\"PC33713 A SequenceListing.txt\" created on Sep 10, 2009\n",
      "and having a size of 51 KB The scqucncc listing mmtaiimd in\n",
      "this .txt file Is part of the spe ulication and is herein incorpo-\n",
      "rated by reference in its entirety.\n",
      "\n",
      "PC'SK 9 Is secreted into ilm plasma predomuinnilv by hei(a-\n",
      "th\n",
      "ability of PCSK9 to regulate blood lipids, and suoogested tint\n",
      "lishedd.\n",
      "it acts to dou.n-regulate hepatic LDLR protein levels.\n",
      "\n",
      "ln\n",
      "\n",
      "Ffiil D OF THI', INVEN1 ION\n",
      "\n",
      "\"o\n",
      "\n",
      "The present invention relates to antibodies. e.g.. full lenbuh\n",
      "antibodies or antioen-binding portions thereof, pcptides, and\n",
      "aptamers that anta onize the activity of extracellular propro-\n",
      "teln convertase subtilisin kexin type 9 ft'CSK9), including its\n",
      "\n",
      "\"-'nieractionwith die lou density lipoprotein (I,DI.) receptor\n",
      "\n",
      "(LDLR). More specifically. the invention relates to compos&-\n",
      "tions comprising antagonist PC'SK9 antibodie~, peptides,\n",
      "and/or aptamers uid methods of using these uitibodies and/or\n",
      "peptldes and/or aptamers as n medicament. 1he antagonist \"\"\n",
      "PC'SK9 mitibodicx peptides, aml aptamers can bc used thera-\n",
      "peutlmilly to lover I Dlocholesterol levels in blood, and can\n",
      "bc used in tfm prevention and/or treatment of cholesterol and\n",
      "lipoprotmn metabolism disorders, including fninilial hyperc-\n",
      "holesterolemim athemgenlc dyslipidenum atherosclerosis,\n",
      "mid. more generally, cardiovascular disease (C'VD).\n",
      "\n",
      "\"\"\n",
      "\n",
      "BA('K(iROI JND OF THF, INVFNTION\n",
      "\n",
      "Millions of people in tile U.S. are at risk for heart disease so\n",
      "\n",
      "tmd resulting cardiac events (JV D and underlying atheroscle-\n",
      "rosis Is the leading cause of death among all demograpluc\n",
      "groups, despite the availability of themspies directed at its\n",
      "multiple risk lactors Atherosclerosis is a disease of the niter-\n",
      "Ies and Is responsible for coronary heart disease associated 4.\n",
      "with many deaths in industrialized countries. Several risk\n",
      "factors for comnary heari disease have nov, been identified:\n",
      "dysllpldemias. h)pertension, diabete~. snxiking, poor diet.\n",
      "uiaciivity and straws. The most clinically relevmit and com-\n",
      "mon dyslipldenuas are clmractenzed by an increase in beta-\n",
      "lipopmtmns (very low density lipoprotein (VLDL) and LDL)\n",
      "unh hypercholcsterolemia in theabsence or preselxe\n",
      "\n",
      "o\n",
      "\n",
      "ol'ypeitnglyceridemta(Frednckson et al.. 1967, N L'ngl 1 Med.\n",
      "276 34-42. 94-10'3, 143-1 56, 215-225. and 273-2g I ). I'here is\n",
      "a long-I'elt sigmficmu unmet oined with respect to CVD with\n",
      "60-70Ao of cardiovascular events. heart attacks and strokes\n",
      "occimillg despite illc ircaiirlcllt u itll staiiils (tlm cllrrcrli si ul-\n",
      "dard of care in atherosclerosis). Moreover, neiv guidelines\n",
      "suggest that even loiver LDI, levels should be achieved in\n",
      "order to pmtect hi h risk patients from prmnature C.'VD [Na- mi\n",
      "tional ('holesterol 1.'ducation I'rogram fNCEP). 2004].\n",
      "\n",
      "1\n",
      "\n",
      "PCS K9, also known ns NAR(u I, was idenrified as a pmtcin\n",
      "wltll a gcilcilc illa t'Itloll 111 soillc forllls of filluillal hl'pci'cho-\n",
      "lestemlemia. I'('SK9 Is synthesized as a zymogen that under-\n",
      "goes mitocatalytic processing at tlm niotif LVFAQ in the (\n",
      "endoplasnuc reticulum. Population studies have shown tlmt\n",
      "some PCSK9 mutations are \"gain-of-function'* and are found\n",
      "\n",
      "Thc mechanism by which. and the site ai which, P( SK9\n",
      "down-regulates I DI,R protein has not been clmlrly estab-\n",
      "(Vien over expressed. PCSK9 may act both witlun the\n",
      "hapatecyse and as a secreted ligaud for I,DI.R. There is strong\n",
      "evidence that extracellular PC:SK9 binds io cell surface\n",
      "I,DLR and promotes LDLR degmdation at an intmcellular\n",
      "site. I lou ever, It Is also possible that PCSK9 could uiteract\n",
      "with the LDLR when the two proteins are translated witlun\n",
      "the endoplasmic reticulum fER) and traffic tlu'ough endoso-\n",
      "mal compartnienms iimnrds the cell membrane Maxwell et\n",
      "ul., 2005. Ciur. Opin. Lipidol. 16;167-172. showed that\n",
      "P( SKI)-midiaticd I DI,R cndocytosis tmd degradation v;as\n",
      "not altered by proteosome inhibitors nor was it modulatesf by\n",
      "different classes of lysosomal and nonlysosomal proteases.\n",
      "Two naturally occurring familial hypcrcholesterolmnia nuita-\n",
      "tions, S127R mid D I 29CJ, have beeo reported to be defective\n",
      "in mitoprocessing and secretion as levels of tlmse nmtant\n",
      "pmteins u erc greatly reduccxt or undetectable in lhe media of\n",
      "trutsfectwf cells. Yet\n",
      "these mutants demonstrated an\n",
      "enhanced ability to doiin-regulate I.DI,R, consistent widi\n",
      "their identilicaiion ui\n",
      "individuals with high pissant I.DI.\n",
      "fHomer et al., 200g, Athemsclerosis 196:659-(166: Cameron\n",
      "ct al, 2006 Hummi Molecular Cienctics 15 1551-155g, I.am-\n",
      "bert et al., 200 Cx TRENDS in Lndocnno logy and Metabolism\n",
      "17 79-31. Since these mutants apparently do not get secreted\n",
      "extracdlularly, and ivt do downregulate I DI R, this strongly\n",
      "suggests that an intracellufar site of action Is physiologically\n",
      "imponant.\n",
      "\n",
      "From the inliirmauon available in the ari, and prior to the\n",
      "present Imention, it renmined unclear whether the Introduc-\n",
      "tion of'i antibody-, peptide-, or apiamcr-based PC'SK9\n",
      "antagoiust into the blood circulation to selectively antagonize\n",
      "extracellular PCSK9 would be effective to reduce hypercho-\n",
      "lesierolenun and the associnicd incidence of C'VD and. if so,\n",
      "uhat properties of a PCSK9 mit Igonist are needed for such In\n",
      "vive cffcctlvcniss\n",
      "\n",
      "SUMIVIARY OF THI, INVFNTION\n",
      "\n",
      "This invention relates to antagonist antibodies. peptides,\n",
      "and apiamers thm solcctivcly intcmcl with and inhibit P( SK9\n",
      "funcuon. It is demonstrated for the first time that certaui\n",
      "P(:SK9 antagonists are effective in vivo to loumr blood cho-\n",
      "lesterol\n",
      "\n",
      "In one embodiment.\n",
      "\n",
      "the invention provides an isolated\n",
      "antagonist of P( SK9 which comprises nn antibody. a peptide,\n",
      "or an aptamer, which interacts v, ith PCSK9 and when achnin-\n",
      "istered to a subject lowers the LDL-cholesterol level in blood\n",
      "of said subject. Tlm antagonist can be an antibody, for\n",
      "example, a monoclonal antibody or human. Iuunaiuzed, or\n",
      "chimeric antibody.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "In another mrbodinwnt, the invm&tion provides an isolated\n",
      "ant&-PCS K9 antibody tvluch specifically binds to PCS K 9 and\n",
      "wluch is a full antagonist of the PCSK9-mediated etTect on\n",
      "I BI,R le&mls when nwasurcd in vitro using the 13)I,R down\n",
      "regulat&on assay &n lluh7 cells d&sclosed here&n.\n",
      "\n",
      "In yet another embodiment, the invention prov ides an iso-\n",
      "lated an rhody &v hich antagonizes the extracellular interact &on\n",
      "of PCS K9 with the LDLR. as measured by PCS K9 bu&du&g to\n",
      "the I BI.R in vitro. mxi. &vien administcrcdl to a subject,\n",
      "louers the LDL-cholesterol level &n blood of sa&d subiect.\n",
      "Preferably. the antibody recoyuzes an epitope on luunan\n",
      "PC'SK9 that overlaps &vith tuore &ban about 75\",z& of the surface\n",
      "on PCSK9 that u&temcts with the EGF'-hke dommn of the\n",
      "I,BI.R as described in Kwon et nl., 2008, PNAS, 105. 1820-\n",
      "1825\n",
      "\n",
      "In yet another embodiment. the invent&on provides an anti-\n",
      "body that recognizes a tirst epitopo of PC'SK9 that overlaps\n",
      "w&th a second epitope that is recoguzed by a monoclonal\n",
      "m&tibody selected from the group consisting of 5A10, which\n",
      "line dcpositcdi with thc\n",
      "is producod by a hybridoma cell\n",
      "American Type Culn&re Collection and assigned accession\n",
      "number IzIA-8986; 4A5. which is produced by u hybridoma\n",
      "cell l&ne deposited u ith the Amertc ul Type Culture Collect&on\n",
      "and assim&ed accession number I'TA-8985; C&F6, which is\n",
      "produced by a hybridoma cell linc dcpositcd u ith tl&o Ameri-\n",
      "can Type Culture Collect&on and assigned access&on number\n",
      "PTA-8984, and 7D4. wlfich is produced by a hybridoma cell\n",
      "linedcpositedwiththeAmericm& TypeCultureCofiect&onand\n",
      "ass&y&ed accession number PIA-8983.\n",
      "\n",
      "hl anothcr clnbodiment, thc invention pmvidcs nn antibody\n",
      "to humm& PCSK9, ~herein the antibody recognwes an\n",
      "epitope on luunan PCSK9 comprising anuno acid residues\n",
      "153-1 &5, 194, 195, 197, 237-239, 367, 369, 374-379 nnd 381\n",
      "of the PCSK9 amu&o ac&d sequence ol'EQ ID NO: 53.\n",
      "Preferably. the m&tibodv cpitopc on human PCSK9 does not\n",
      "comprise one or morc oi'amino acid rcsiducs 71. 72, 150-152.\n",
      "187-192, 198-202. 212, 214-217, 220-226, 243. 255-258,\n",
      "317, 318, 347-351, 372, 373, 380, 382, and 383.\n",
      "\n",
      "In still unotber embodu&mnt, dw.\n",
      "\n",
      "invent&on prov&des un\n",
      "ant&body which specifically binds PCSK9 comprising a VH\n",
      "con&pten&cntary detem&ining region one (( BR I) having thc\n",
      "anuno acid sequence shown in SL&Q ID NO:8 (SYYNIII). a\n",
      "VH C'DRZ having the amino acid sequence shou n in SLQ ID\n",
      "NO 9 (IIISPF(i(iRTNYNFKFKS), and/or VH CBR3 having\n",
      "the anuno acid sequence shown u& SL'Q ID NO:10 (ERI'L-\n",
      "YASi)1 ), or a variant therm&f having one or more conserva-\n",
      "trte mn&no acid substitutions in said sequences of CDRI,\n",
      "CDR2, and/or CDR3, wherein the variant retains essentially\n",
      "thc same binding specitimty as the CBR defined by said\n",
      "sequences. Preferably. the vanant comprtses up to about ten\n",
      "anuno acid substitut&ons and, more preferably, up to about\n",
      "I'our mnino ac&d substituuons.\n",
      "\n",
      "ant &body\n",
      "\n",
      "The invention &s further d&rected to an\n",
      "\n",
      "comprt s&ng\n",
      "a VI, C'BR I having the an&inn acid svqucncc six&w n in S I',Q IB\n",
      "NO 11 (RASQCiISSAI,A). a C'DR2 hav&ng the am&no amd\n",
      "sequence shown in SFQ ID NO:12 (SASYRYTk and&or\n",
      "CBR3 having thc mnino acid sequence shown in SFQ IB\n",
      "NO.13 (QQRYSI.WRT). or a vartant thereof lmvmg m&e or\n",
      "more conservative muino acid substitutions in said sequences\n",
      "oi'(. DRI. C'.DR2. and.'or CBRS, uhclehl thc varimlt retains\n",
      "essent&ally the same binding specitic&ty as the CDRI defined\n",
      "by said sequences. Prefembly, the variant comprises up to\n",
      "about ten mnino ac&d subst&tut&ons and, more preferably. up to\n",
      "about four amino ac&d subst&tutions.\n",
      "\n",
      "In another embodiment, the invention pmvides an m&tibody\n",
      "comprisu&g specific VL CDRI. CDR2. and/or CDIL)\n",
      "sequences, or a variant thereof lmving one or more conserva-\n",
      "\n",
      "s\n",
      "\n",
      "tive amino acid substitutions in ( DR I, ( BR2, and/or C'BR3\n",
      "und further compris&ng a VH complementary detenmiun\n",
      "region CDRI having the amino acid sequence shown in Sk.Q\n",
      "ID NO:59, 60, or 8, a VH C:DR2 having the an&ino acid\n",
      "sequence shown in SEQ ID NO:61 or 9. and/or VH CDR3\n",
      "having the amino acid sequence shown in SFQ ID NO:10, or\n",
      "a variant thereof lmv it&8 one or nulre conserve t&ve amino ac&d\n",
      "subst&tutions in said sequences of CDRI, CDR2. und/or\n",
      "C'DR'3. u herein thc variant retains essentially the sanlc bind-\n",
      "nl u&g specitic&ty as the CDRI. CDR2. u&d/or CDR3 defined by\n",
      "said sequences. Preferably. the variant comprises up to about\n",
      "twenty mnino acid substitutions and, morc prclbrably. up to\n",
      "about e&J&t amu&o acid subst&tutions. In another preferred\n",
      "embodinwnt, the antibody of the invention h&ms n variable\n",
      "heavy clmu& sequence con&prts&ng or consistu&g of SI.Q ID\n",
      "NO: 54 and u variable fi&J&t chain sequence comprising or\n",
      "ciulsisting of SEIQ IB NO: 53\n",
      "\n",
      "The invention also pmvides a humanized m&tibody mnu-\n",
      "prising polypeptides selected from the groups consisting of\n",
      "o SFQ ID NO 14. SFQ IB NO.15, or both SFQ ID NO 14 nnd\n",
      "SFQ ID NO:IS, or a vanant thereof having one or more\n",
      "conservative amino acid substitutions in said sequences,\n",
      "where&nthevanantreta&nsessenuallythesamebind&n spec&-\n",
      "tic&ty as the ant&body defined by said sequence(s). It also\n",
      "includes an antibody lacking a terminal lysinc on the heavy\n",
      "chain, as tlus &s normally lost in a proportion of ant&bodies\n",
      "during manufacture.\n",
      "\n",
      "lo amino acid substitution~. Prefi.rably,\n",
      "\n",
      "Preferably. the variant compnses up to about turn&ty amu&o\n",
      "acid subst&tut&ons and more preferably. up to about eight\n",
      "thc antibody furtlwr\n",
      "comprtses an unmunolog&cally u&ert constant re ion, and/or\n",
      "the antibody has an &sotype that &s selected fmm the youp\n",
      "consisting of'gC»,,\n",
      "lgCis. 18CI&aw 18CI«s, Ig(iszc IgCis\n",
      "S228 P. IgG«s S228P and IRCis „S22 8P. In another preferred\n",
      "\n",
      "\"» embodiment, the constant region is aglycosylatcd Fc.\n",
      "\n",
      "In onc mnboduncnk the invention provides a n&cthod for\n",
      "reducu&g a level ol LDL. LDL-cholesterol, or total cholesterol\n",
      "in blood, serum, or plasmn of a subject\n",
      "in need thereof,\n",
      "comprisuig adininistcring to the subjcmt a therapeutically\n",
      "\n",
      "so efibctive amount of an antagonist of the invention.\n",
      "\n",
      "In ime embodinwnt, the invention provides a therapeuti-\n",
      "cally effect&ve amount of an antagonist of the invention for\n",
      "use in reducing a level of I.DL, LDI.-cholesterol, or total\n",
      "cholostcrol in blood, serum, or plasma of a subjoct in need\n",
      "thereof. The u&venuon further provides the use of a therapeu-\n",
      "tically etTective amount of an antagonist of the invention in\n",
      "the manufacture ofa medicament for reduc&ng a level ofLDI.,\n",
      "LDL-cholesterol, or total cholesterol\n",
      "in blood, sertuu, or\n",
      "plasma of a sub)cct in need thereof.\n",
      "In yet another embod&ment,\n",
      "\n",
      "the invent&on provides a\n",
      "metlald of preparing an ant&body wluch specifically binds\n",
      "PCSK9. which comprises: a) prtlviding a PCSK9-negative\n",
      "host aiumal: b) imnuuuzu&g sa&d P( SK9-ne at&ve host a&u-\n",
      "n&al with P('SK9; and c) obtaining an tmtibody An m&tibody-\n",
      "s pmducmg cell, or an anubody-encodu&g nucleic amd from\n",
      "amid p( SK9 negative host animal. and preparing an antibody\n",
      "from said antibody-producing cell or said antibody-cnm&ding\n",
      "nucleic ac&d.\n",
      "\n",
      "u\n",
      "\n",
      "The invention also comprises a method t'or reducing the\n",
      "m& level of I.BI, in bk&od ofa subject in nccd thcreol'. comprismg\n",
      "adnunistering to the subject a therapeutically effective\n",
      "amount of the m&tibody prepnrcd according to tl&o invention.\n",
      "The sub&act can be further treated by arhuimsteru& a stern. In\n",
      "a preferred embodiment, the subject is a lorn&an subject.\n",
      "\n",
      "In onc cmbodimem. thc antibody is adn&inistcred in u for-\n",
      "mulation as a sterile aqueous solution lmving a pit that ranges\n",
      "from about S.O to about 6.5 m&d compris&ng from about I\n",
      "\n",
      "\f",
      "DRI \n",
      "\n",
      "In uiother embodunent, the invention pmvides a thempeu-\n",
      "tically elTective unount ol'the antibody prepared accorduig to\n",
      "the invention for use in reducing thc leiml of I DI in blood of\n",
      "a subfect in need thereof. The invention further provides the\n",
      "use of a thempeutically effective amount of the antibody\n",
      "prepared uccording to the invention in the mmiuiacture ol'a\n",
      "in blood of a\n",
      "medicament for rixfucing the level of LDI\n",
      "subject in need thereof. 'fhe thempeutically effective amount\n",
      "can optionally be combuied ivith a thempeuncally effective\n",
      "aniount of a suitin.\n",
      "\n",
      "5\n",
      "mg/nil to nbout 200 nig/ml of antibody. front about I milli-\n",
      "molar to about 100 mill imo far of histidine buffer, from nbout\n",
      "0.01 mg/ml to about 10 mg/ml of polysorbate 80, from about\n",
      "100 nli I limo far ur aboui 400 m ill i molar of treha lose. and I'rom\n",
      "about 0.01 millumilar to about I 0 millimolm ol'disodmm\n",
      "EDIA dihydrate.\n",
      "\n",
      "111 aliothcr clnbilifilnclit, tlm inventioll provides a hybri-\n",
      "doma cell line that produces a I'CSK9-specific antibody or an\n",
      "anti en-bmding portion theresrf. wherem the hybridomn cell\n",
      "\n",
      "1 (1\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "line is selected from the group consistingol'AShaving an AT('(: Accession No. of PTA-8985:\n",
      "\n",
      "5A10 lmving an ATCC Accession No. of PTA-8986:\n",
      "61'6 having ml ATCC Accession No of PTA-8984; and\n",
      "7D4 havuig an ATCC Accession No. of PTA-8983.\n",
      "In miother emboduuent, the invenuon promdes cell luis\n",
      "tluit recombulantly pmduces an mitibody wluch specifically\n",
      "binds to P('SK9 mid comprises a heavy chain variable region\n",
      "(VI I) complementary d el ann i lung region one (C\n",
      ") havulg\n",
      "the amino acid sequence shown ui SFQ ID NO;8. 5'&, or 60, a \"\"\n",
      "VH CDR2 having the mnino ncid sequence shown in SFQ ID\n",
      "NO 9 or 61. and/or VH CDR3 having the amino amd\n",
      "sequence shown in Sk Q ID NO.10. or a variant therixif hav-\n",
      "iilg. Cnc or iliore cotlsurvativc amiil&1 acid substitutions iil\n",
      "CDRI, CDR2. mid/or CDR3, ulrpor compnses a light chain \"\"\n",
      "variable region (Vf,) ('DR I Imving the amino acid scxfuence\n",
      "shown in SFQ ID NO I l. a VI CDR2 having the mnino acid\n",
      "sequence shown in SEQ ID NO:12. and/or VL (.'DR3 having\n",
      "the mnino acid sequence shown in SFQ ID NO:13, or a\n",
      "vanant thereof havulg one or more conservative amino acid sn\n",
      "substitutions in Cf&RI, ('DR2, anipor CDR3. Preferably, the\n",
      "line riecimibinmitly produces an antibody comprising\n",
      "cell\n",
      "SF Q ID NO: 53 anChor 54, and, more preferably, SF Q ID NO;\n",
      "14 and/or 15\n",
      "\n",
      "BRIkl'l'.S(.'RIPTION OF 1HE\n",
      "FIGLIRES!DRsrWINGS\n",
      "\n",
      "FKr'\n",
      "\n",
      "illustratms the efTect ol'nti-PC'SK9 antagonistic\n",
      "monoclonal antibodies 7D4.4. 4AS.C13. 61'6.G103 and\n",
      "SAIO.BS on the ability of mouse PCSK9 (A) and lnunan\n",
      "PCSK9 (B) to down regulate I,DI R ui cultured 1luh7 cells\n",
      "61'CxG10,3 is a subclone of 6F6, 7D4.4 is a subclone of 7D4.\n",
      "4AS (13 is a subclone of 4AS, and SA10 BS is n subclone of\n",
      "5A10.\n",
      "\n",
      "u\n",
      "\n",
      ":r\n",
      "\n",
      "FKi. 2 if lastmtes the dose-response of anti-P( SK9 antago-\n",
      "nist mmioclonal antibodies 6F6(il03. 7D44. 4AS C13.\n",
      "SA I 0.BS, negative control antibody 421 17. and PBS to block\n",
      "the binding of recombinant biotinylated Inunan P('SK9 (A)\n",
      "and nxrusm PC:SK9 (B) to immobilixml ricombinmit I,DI.R ai\n",
      "extracellular domain in vitro.\n",
      "\n",
      "FKi. 3 illustrates the dose-response of anti-P('SK9 mono-\n",
      "clonal antagonist antibodies 61'6.G10.3. 7D4.4. 4AS.G3 and\n",
      "SAIO.BS to block binding of recombinant biotinyfated\n",
      "humnn PC'SK9 (30 nM) to Furopium labeled rccombinmit\n",
      "LDLR extmcellular domain (10 CM) ui solution at neutral pH\n",
      "in vitro.\n",
      "\n",
      "(\n",
      "\n",
      "FKi. 4 illustrates comparative cpitope binding of anti-\n",
      "\n",
      "PCSK9 antibodies.\n",
      "\n",
      "FICi. 5 illustrates Western blots of binding of anti-I'('SK9\n",
      "\n",
      "antibodies to scnim P('SK9 front diffi:rent species\n",
      "\n",
      "11Cr. 6 illustrates the effect of anti-PCSK9 monoclonal\n",
      "\n",
      "antibody 7D4 on blood clxilesterol levels in mice.\n",
      "\n",
      "FICi. 7 illustrates (A) the effect of a pariuil anuigonist\n",
      "polyclonal anti-PCSK9 mAb CRN6 on LDLR doivn regula-\n",
      "uon mid (B) the lack of'clif:ct mi cholestcnil levels in micm\n",
      "FICi. 8 illustrates the time course of the cholesterol lower-\n",
      "ing effect obtained using anti-PCSK9 antagonist antibody\n",
      "7D4 ill nliCe\n",
      "\n",
      "FIG. 9 illustrates the dose dependence of the anti-PCSK9\n",
      "antagonist mAb 7D4 on the reduction of serum total choles-\n",
      "teml. IIDI, and LDI, in mice.\n",
      "\n",
      "FKi. 10 illustrates the dose dependence of the cftofesterof\n",
      "lowering etTi.ct of anti-PC'SK9 antagonist mitibody 5A10 in\n",
      "tutee.\n",
      "\n",
      "FICi. 11 illustrates the dose dependence of the cholesterol\n",
      "loss cring cfli:ct of'anti-PCSK9 nntagmiist mltibixlies (A) 4AS\n",
      "and (B) 6F6 in nuce.\n",
      "\n",
      "FICi. 12 depicts Western blots of anti-P('SK9 antagonist\n",
      "\n",
      "atuibodies etl'ect on liver LDLR levels.\n",
      "\n",
      "FBI. 13 illustrates the lack ofeffect of anti-I'C SK9 antago-\n",
      "\n",
      "nist antibody 4A5 in an I.DI,R-/- mouse model\n",
      "\n",
      "FIG. 14 illustrates the effect on total serum cholesteml of\n",
      "nuiltiple administrations of anti-PCSK9& antagonist mitibod-\n",
      "ies ul nues over a longer tune course tlmu seen is ah a single\n",
      "dose.\n",
      "\n",
      "FKi. 15 illustrate the tinw. course. of the elTimts of mlti-\n",
      "PCSK9 autagomstic mubodv 7D4 on lipid parameters in a\n",
      "cynomolgus monkey model.\n",
      "\n",
      "FICi. 16 illustrates lhe dose- and time-response of anti-\n",
      "PCSK9 mltagonistic auubody 7D4 on serum cholestenil lev-\n",
      "els in thc cynomolgus monkey\n",
      "\n",
      "FICi. 17 illustrates a compmison of anti-PC SK9 antagonis-\n",
      "uc antibodies 4AS, SA10. 6F6 and 7D4 on serum cholesterol\n",
      "lcimks in the cynomolgus monkey.\n",
      "\n",
      "FICi. 18 illustrates thc time course oi'he sfl'ecl of'ui-\n",
      "I'('SK9 mitagonist antibody 7D4 on plasma cholesterol liw els\n",
      "of cynomolgus monkeys fed a 33A% kcal fat diet suppli-\n",
      "mented with 0.1% cholesterol.\n",
      "\n",
      "FICi. 19 illustmtes the effect of LIL3 (lnunanized anti-\n",
      "P('SK9 monoclonal antibody) on down regulation of IJ&I,R\n",
      "in Huh7 cells.\n",
      "\n",
      "FICf. 20 illustrates the dose-response of LIL3 fnimanived\n",
      "antibody. the mouse precursor SA10, and negative control\n",
      "antibody 42H7 on b le ckuig the binding of recombinant bioti-\n",
      "nylated human PCSK9 (A and B) and mouse PCSK9 (C'nd\n",
      "D) to immobilized recombinmit LDLR extnscellulur domain\n",
      "in vitro at pll 7.5 (A and C) and pH 5.3 (B and D).\n",
      "\n",
      "FICr. 21 illustrates the elTiect on serum cholesterol of trmit-\n",
      "\n",
      "ment ofmicewith 10mg/k LIL3.\n",
      "\n",
      "FKi. 22 illustrates the elTimt ol'dministration of 5A10\n",
      "antibody or L11,3 to cynomolgus monkeys and measurement\n",
      "of changes in serum HDL (A) and serum L1&1. (B) as a\n",
      "function of liam.\n",
      "\n",
      "I'ICI. 23A depic(s the crystal structure of the PC'SK9 (hght\n",
      "gmy surface representation) bound to the LH 3 antibody\n",
      "(black caruion rcqrrcscntatton) FKi 23B depicts ihc crystnl\n",
      "stnicnire of the I'CSK9 (light pay surface representation)\n",
      "bound to the fkil'-like domnin ol'lm I.DI,R (black cartoon\n",
      "representation) (Kwon et al., PNAS, 105, 1820-1S25, 2008).\n",
      "FICi. 23('hoivs tile surface area representation of PCSK9\n",
      "with the f,l I 3 cpitopc shown in dark gray. FKi 23D shows\n",
      "the surface area representation of PCSK9 with the LDLR\n",
      "ECrp-like domain epitope sluiwn in dark gvray.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "I'1(IS 24 A-(i dh7ict the substitutiims made in the ( DRs of\n",
      "antibody 5A10 in thc course of affinity maturation and opti-\n",
      "mization and to aclu eve particular properties. PCS K9 bu&du&\n",
      "assocmted w&th antibi&dies having these C'DR substitutions is\n",
      "also reprcsvnted The number following each svqucnce is thc\n",
      "SL'Q ID NO desi~a&ed for each sequence.\n",
      "\n",
      "DETAILED DESCRIPTION OF TIIE INVL'NTION\n",
      "\n",
      "ia\n",
      "\n",
      "The present invention relates to antibodies, pep&ides, anil\n",
      "aptamers that antagonize the iiu&ct&on of extracellulm PCS K9\n",
      "including its interaction with tlm IJ&I,R. More specifically.\n",
      "the invi:ntion relates to methixis oi nmking nnta onist PC'SK9\n",
      "ant&bodies, peptides, and aptamers, compositions comprising\n",
      "tlmsc m&tibodies, peptidcs, and/or aptamers. and nwthods of la\n",
      "us&ng these antibodies, peptides. and/or nplamers as a med&-\n",
      "11&e antagonist VCSK9 antibodies and peptides can\n",
      "cament\n",
      "bc usod to lower blood I DI -clx&lcstcrol levels, and cm& bc\n",
      "used in the prevent&on and/or treatment of cholesteml and\n",
      "lipopmtein metabolism disordem, including familial hyperc- zc\n",
      "holesterolemi\n",
      "and. more generally, ('VD.\n",
      "Cienc& sl Teclmiquas\n",
      "\n",
      "&, athemgen&c dyshpidem&a. atheroscleros&s.\n",
      "\n",
      "The pract&ce of the present invent&on w&11 employ, unless\n",
      "\n",
      "\"\"\n",
      "\n",
      "othenvise ind&cated, conventional techniques of molecular\"-'iology(including recombinant techniques). m&crobiology,\n",
      "\n",
      "cel I biology, biochenu stry and inuuuno logy, winch are witlun\n",
      "tlm ~kill of the art Such tcchniqucs nre explained fully in thc\n",
      "literature. such as, Molecular C'loning A I.abomtory Manual.\n",
      "second ediuon (Sambrook et al., 1989) Cold Spnn llarbor \"\"\n",
      "Press, Oligom&cleotide Syntlmsis (M. J. Ciait, ed, 1984),\n",
      "Methods &n Molecular B&ology, I lumana Press, C'ell B&ology:\n",
      "A I aboratory Notebook (J. I'I Ccllis, ed., 1998) Academic\n",
      "Press, Animal Cell C'ulture (R I Frcshncy, ed . 1987), Intro-\n",
      "ducuon to Cell and Tissue Culture (J. P. Mather m&d P. Ls\n",
      "Robert~. 1998) Vien&un Press: (.'ill and Tissue ('ulture I.abo-\n",
      "I dtory Procedures (A. Doyle .I B. C&'rifiiths. and D. C& New&all.\n",
      "eds.. 1993-1998) J. Wilev and Sons; Methods in Enzvmology\n",
      "(Acadmnic Press. Inc ): Handbook of Fxperimcntal Immu-\n",
      "nology (D. M. We&r and C. C. Bluckv ell, eds.); C&ene Transfer sc\n",
      "Vectors for Mammalian (.'ella (J. M. Miller and M. P. ('alos.\n",
      "cds.. 1987), ( urrent Protocols in Molecular Biology (F M\n",
      "Ausubel et al., eds., I')87); PCR: The Polymerase Chain\n",
      "Reaction, (Mullis et al.. eds., 1994); ('urrent Protocols in\n",
      "Immunolo y(J E Col&gauetel.. eds..1991): ShortProtocols ss\n",
      "&n Molecular Biology (Wiley and Sons, 1999): Inumu&obiol-\n",
      "ogy (C'. A. Jancway and P. Travers, 1997), .Antiboilics (P\n",
      "Fu&ch, 1997): Annbodies; a pnsctical approach (D. Catty.. ed.,\n",
      "IRL Vress. 1988-1989); Monoclonal antibodies: a practical\n",
      "apprmich (P. Shepherd and C De m, eds, Oxli&rd IJni&vrs&ty su\n",
      "Press, 2000); Using antibodies. a laboratory manual (E. Ihu-\n",
      "low and D. Lm&c (('old Spring Harbor Laboratory Press,\n",
      "1999), The Anubodics (M. Panetu and J. D Capra. cxls.\n",
      "Ha&wood Academic Vublishers, 1995).\n",
      "\n",
      "l&EVINI1IONS\n",
      "\n",
      "An '*ant&body\" is an inm&umiglobulu& inolecule capable of\n",
      "specific binding to a target, such as a carbohydrate. poly-\n",
      "nucisx&tide. lipid. polypcptickx ctc, thmugh at least onc ant&- m&\n",
      "gen recognit&on site, located in the vanable region of the\n",
      "immunoglobulin molecule As used herein. the tenn encim&-\n",
      "passes not only u&tact polyclonal or monoclonal ant&bodies,\n",
      "but also fragments thereof (such as Fab, Fabk F(ab')s. Fv),\n",
      "single chain (ScFv) m&d domain antibodies), and fusion pro-\n",
      "te&ns comprising an antibody portion, and any other mod&fied\n",
      "configuration of the inununooJobufin molecule that com-\n",
      "\n",
      "(\n",
      "\n",
      "prises an nnrigen recognition site. An antibody includes m&\n",
      "annbody of any class, such as IgO. IgA. or IgM (or sub-class\n",
      "thereof) and the antibody need not be of any part&cular class.\n",
      "Depending on the antibody amino acid sequm&ce of the con-\n",
      "stant doma&n of &ts heavy cha&ns. immunoglobulins can be\n",
      "assigned to difTerent classes. There are five major classes of\n",
      "u&ununoglobuln&s: IgA, IgD. IgE. IgCI. m&d lgM. u&d several\n",
      "of these may be further div&ded into subclasses (iso&&T&es),\n",
      "c.g, IgCil. IgC12, Ig()3, Ig(14. IgAI and ISA2 Thc lmavy-\n",
      "chain constant domau&s that correspond to the difierent\n",
      "classes of &nununoglobulins are called alplm, delta, eps&ion,\n",
      "gamma and im&, respcctivcly. The auburn& structures a&xl\n",
      "tluee-dimensional conti urat&ons of diferent classes of\n",
      "&&ainu&&ogl(lbu1ins are well known\n",
      "\n",
      "As usvd hereu&. '*monoclonal anl&body*'eli:rs to an mui-\n",
      "body obtained from a population of substantially homoge-\n",
      "ncoms antibodiew i c., tlm individual antibodies comprising\n",
      "the population are identimd except lor possible naturally-\n",
      "occurring mutations that may be present in minor amounts.\n",
      "Monockmal antibodies nre highly spccilic., being directed\n",
      "against a single m&tigenic site. Furthermore. &n contrast to\n",
      "polyclonal antibody prepamtions, which typically include\n",
      "d&fferent antibod&es directed s ainst d&fferent detenn&nants\n",
      "(ep&topes). each monoclonal antibody is d&rected against a\n",
      "'11&e modifier \"mono-\n",
      "single determinant on the nntigcn.\n",
      "clonal\" u&d&cates\n",
      "the character of the anubody as be&n\n",
      "obtmned from a substantially homogeneous populat&on of\n",
      "a&uibodics, m&d &s nol to be coustrucxI as requ&ring producuon\n",
      "of the ant&bodv by any particular method. 1&or example, the\n",
      "monoclonal antibodies to be uscxI in accordmlcc with thc\n",
      "present invention nuiy be made by the hybridoma method lira&\n",
      "described by Kohier and Milste&n, 1975, Nature 25Cx495, or\n",
      "may bc m&xle by r&vombinant DNA methods such as\n",
      "described u& U S. Pat No. 4.816.567. The monoclonal anti-\n",
      "bodies may also be isolatscd from phage libraries genernted\n",
      "using thc techniquca dcscribcd in McCaiTerly cl al, 1990.\n",
      "Nature 348. 552-554. for example.\n",
      "\n",
      "As used herein, \"lnunanized'ntibody refers to filnns of\n",
      "non-lummn (e g, im&rine) mitibodies ihal are chuu eric immu-\n",
      "noglobulins, inununoglobulin clm&ns, or fraynents thereof\n",
      "(such as Fv. Fab. Fab'. F(ab')s or other antigen-binding sub-\n",
      "sequences of ant&bod&es)\n",
      "that contain m»umnl sequence\n",
      "derived from non-human inununoglobulin. Preferably,\n",
      "humnnizcd antibodies me humnn immunoglobulins (recipi-\n",
      "ent ant&body) in wluch res&dues from a complementary deter-\n",
      "mining region (CI&R) ofthe recipim&t are replacsxl by residues\n",
      "from a CDR ofa non-human spec&es (donor ant&body) such as\n",
      "mouse, mt. or rabbit hav&ng the des&red specific&ty, affinity,\n",
      "and capacity. In some instiu&ces, F& I'ramev'ork reg&mt (FR)\n",
      "residues of the hmnan inununoglobulu& are replaced by cor-\n",
      "respond&ng non-human res&dues. Furthermore, the human-\n",
      "ized m&t&body may comprise residues thai are found neither u&\n",
      "the recipient antibody nor in the imported C DR or framework\n",
      "sequcnccs, but arc included to furtlmr refine and optimize\n",
      "antibody perfonnance. In general. the humanized antibody\n",
      "will comprise substantially all of at least one, and typically\n",
      "two. variable dmnains. in && hich all or substantially all oi'he\n",
      "CDR reg&ons correspi&nd lo those o I'a non-human unnn&no-\n",
      "globulin and all or substantially all ofthe FR regions are those\n",
      "of a human immunoglobulin consensus sequence The\n",
      "human&zed antibody optimally also w&11 comprise at least a\n",
      "portion of an imnnu&oglobulin consmnt region or domain\n",
      "(Fc), typically that ofa luunan immunoglobulin. Preferred are\n",
      "antibodies having Vc regions mod&fied as described u& WO\n",
      "99/58572. Othm fonna of hmnanizixI nntibodics have one or\n",
      "more CDRs (CDR L i. CDR L2, CDR L3. CDR I I I. CDR 1 12.\n",
      "and/or CDR H3) which are altersxI w ith respect to the original\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "mitibody. which are also termed one or morc Cl&Rs \"derived\n",
      "from\" one or more CDRs from the oriynal antibody.\n",
      "\n",
      "As used herein, \"human antibody\" means an antibody hav-\n",
      "ing an mnino acid scqucncc corresponding to tlu&t of an anti-\n",
      "body that can be produced by a human and/or which has been s\n",
      "made using any ofthe teclmiques for making Inunan antibod-\n",
      "ies known to those sloiled in the an or disclosed herein. This\n",
      "definition of a lnunan antibody includes antibodies compos-\n",
      "ing at least one human hcavy chain polypeptide or at least onc\n",
      "hunt ut light chain polypepude. One such example is an anti- ui\n",
      "body comprismg nninne light chain and human heavv clmin\n",
      "polypcptidcs I lumen mitibodies can bc pmduccd using ven-\n",
      "ous teciuuques intown in the art. In one embodiment, the\n",
      "lnunmi antibody is scicctcd from a phage library, where tlmt\n",
      "phage library expresses human mitibodies (Mmighan et nl .\n",
      "1996. Nature B iotechnoloay. 14: 309-314; Sheets et al., 19(J8,\n",
      "(IJSA) 95:6157-6162: Hoogcnboom\n",
      "Proc. Natl Acad. Sci\n",
      "and Winter, 1991, .1. Mol. Bml,, 227:381: Mnrks et al.. 1991.\n",
      "J. Mol. Biol., 222 581). Human antibodies cmi also be made\n",
      "by immunira1ion of aninials into which bun(an immunoglo-\n",
      "bulin loci have been trmisgenically introduced in place of the\n",
      "endogmiom loci, e.g., mice in which the endogenous inumi-\n",
      "noglobulin enes have been partially or completely uiacti-\n",
      "vated. This approach is des cubed in U.S. Pat. N os. 5,545,807;\n",
      "5,545,80(i: 5,569,825, 5,(i25,126; 5,633.425; and 5,661,016&\n",
      "the lnunan antibody &nay be prepared by\n",
      "Alternatively,\n",
      "immortalizing lmnmn B lymphocytes that produce an anti-\n",
      "body (irected against a tar et antigen (such B lymphocytes\n",
      "may be recovered from an individual or may have been immu-\n",
      "niz(d in vitro) Scc, e g, Cole et al Monoclonal Antibodies io\n",
      "and Cancer Therapy Alan R. I isa, p. 77, 1985. Boerner et al,\n",
      "1991. J. Inuuunol., 147 (I):86-95: and U.S. Pat. No. 5,750,\n",
      "373\n",
      "\n",
      "io\n",
      "\n",
      "A '*vanable region\" of an antibody refers to the vera&hie\n",
      "region ofthe antibody light chain or the variable region ofthe \"»\n",
      "antlb(xlv heavv'fraul, el&be( alone or u1 co&nbinatlon As\n",
      "known ut the a&t. the venable regions of the heavy and light\n",
      "chain each consist of f(iur fmmework regions (FR) connected\n",
      "by three complementarity determining regions (C'DRs) tlmt\n",
      "contain hypervariable regions. The ( DRs in each chain are so\n",
      "lmld togetlmr in close proximity by tlm FRs and, with thc\n",
      "CDRs from the other chain, contribute to the fomiation ofthe\n",
      "antigen-binding site of antibodies. There are at least two\n",
      "techniques for determining CDRs: (I) an approach based on\n",
      "cross-species\n",
      "Sequences of Vroteins of Immunological Interest, (5th ed.,\n",
      "1991. National Institutes of I iealth. Bethesda Md.)k and (2)\n",
      "an approach based on c&ystalloyaphic studies of antigen-\n",
      "antibody complexes (Al-lazikani ei al, 1997, I Molec Biol\n",
      "273:927-948). As used herein. a CDR may refer to CDRs\n",
      "defined by either approach or by a combination of both\n",
      "approaches\n",
      "\n",
      "sequence vanability (i.e., Kabat\n",
      "\n",
      "al. 4.\n",
      "\n",
      "et\n",
      "\n",
      "o\n",
      "\n",
      "As known in the art u \"constmit re@on\" of an antibody\n",
      "refers to dw. constant region of the antibody light chain or tlm\n",
      "constant region ol'the mtibody heavy cluiin, either alone or in\n",
      "colllbination.\n",
      "\n",
      "1\n",
      "\n",
      "As used herein. thc tcmi \"PCSK9\" refers to any formoi'CSK9and vanants thereol'hat retaui ai least part of the\n",
      "\n",
      "activity of PCSK9 Unless indicated differently, such as by\n",
      "spccilic refcrmicc to human PCSK9. P('SK9 includes all ni\n",
      "manunaiian species of native sequence PCSK9, e.g., human.\n",
      "canine, feline, equiim, mid bovine. Onc exemplary human\n",
      "PCSK9 is found as Un&prot Accession Number QSNBP7\n",
      "(SLQ ID NO:16().\n",
      "\n",
      "As used lmrein, a \"PCSK9 mitagonist\" refers to an anti-\n",
      "body. pepude. or aptamer that is able to inlubit PCSK9 bio-\n",
      "logical activity and(or downstremn patlnvay(sj mediated by\n",
      "\n",
      "&\n",
      "\n",
      "10\n",
      "V( SK9 signaling, including PCSK9-mediated down-regula-\n",
      "tion of the LDLI&, and PCSK9-mediated decrease ui LDL\n",
      "blood clearance. A VCSK9 antagonist antibody encompasses\n",
      "antibodies that block, antagonize, suppress or reduce (to any\n",
      "dree including significantly) PCSK9 biological activity,\n",
      "including downstream pathways mediated by PCSK9 signal-\n",
      "uig. such as I,DI R uiteraction andior elicitation of a cellular\n",
      "response to PCSK9. For purpose of the present uivention. &t\n",
      "will be explicitly understood that the tern& \"PCSK9 antago-\n",
      "mst antibody\" encompasses all\n",
      "the previously identified\n",
      "states and clmracteristics\n",
      "terms.\n",
      "v, hereby the PCSK9 imvli. a PCSK9 biological act&Cloy (in-\n",
      "cluding but not hmited to its ability to mediate any aspect of\n",
      "interaction with the I JJI.R, down regulation of I DI.R, and\n",
      "dcmrexsed blood LDI. clearance). or the conscxluences ol'he\n",
      "biological activity, are substantially nullified, decreased, or\n",
      "neutralized in any nieaningful degree In some embodiments,\n",
      "a PCSK9 uttag(mist mitibody buids PCSK9 and preven1s\n",
      "interaction with the LDLR. 1)xampfes of VCSK9 antagonist\n",
      "alulbodlLs are provided bc&el&1\n",
      "\n",
      "titles, and functional\n",
      "\n",
      "Asusedhereina\n",
      "\n",
      "\"fullanta onist\"isanantagonistwhich,at\n",
      "an eifective concentmtion, essentially completely blocks a\n",
      "measurable effect of PCSK9. By a partial mits omst is meant\n",
      "an antagonist tltat is capable of partmlly blocking a measur-\n",
      "able eifect, but that, even at a hivhest concentration is not a\n",
      "ii&11 antagomst. By essentially completely is meant at least\n",
      "about 80%. preferably, at least about ()0(%(s more preferably, at\n",
      "least about 95%, and most preferablv, at least about 98% or\n",
      "99% of the measurable effect is blocked. The relevant \"mea-\n",
      "surable cfii:cts\" arc dcsscribmi hcrcin mid include down regu-\n",
      "lation of I.DI.R by a PCSK9 antagomst as assayed in Huh7\n",
      "cells in vitro, in vivo decrease in blood (or plasma) levels of\n",
      "total cholcsn.'rol and ill vlvo dcclcasc ln I.DI, ICYLL( ill blood\n",
      "(or plasma).\n",
      "\n",
      "As usLVI herein. tlm term \"clinically meaningful'* means at\n",
      "least a 15% rcdiuction in bio&xi I,DI,-cholesterol levels in\n",
      "h&unans or at least a 15% reduction ui total blood cholesterol\n",
      "in mice It is clear that mcasurcmcnts in plasina or senim can\n",
      "serve m surrogates I'or nicasuremmit of levels in blood\n",
      "\n",
      "As usLVI herein, the term \"PCSK9 antagonist peptide\" or\n",
      "'PCSK9 antagonist aptamer\" includes any conventional pep-\n",
      "nde or polypeptide or aptamer that blocks, antagonizes, sup-\n",
      "presses or reduces (to any degree including sigotificantly)\n",
      "PCSK9 biological activity, including downstrcnm pathways\n",
      "mediated by VCSK9 sig(&Cling, such as LDLR interaction\n",
      "and(or elicitation of a cellular response to i(CSKO. IK'SK9\n",
      "antagoiust peptides or polypeptides include I c fusions com-\n",
      "prising the LDLR and soluble portions of the LDLR, or\n",
      "mutants thereol'with higher ailimty to P( SK9\n",
      "\n",
      "The terms \"polypeptide\". \"ohgopeptide\", \"peptide\" and\n",
      "\"protein\" are used intercliangeabiy herein to refer to elmins of\n",
      "amino acids of any length. preferably, relatively short (e.g,\n",
      "10-100 iuruno acids). 11&e clmin may be linear or branched. &t\n",
      "niay comprise modified aniino acids, and/or may bc inter-\n",
      "rupted by non-amino acids The terms also encompass an\n",
      "amino acid chain that has been modified naturally or by\n",
      "intcrvmition, for example, disuliide bond liinnation, glyco-\n",
      "lip&dation. acetylatmn. phosphorylation. or uiy\n",
      "sylation.\n",
      "other manipulation or modification, such as conjugation with\n",
      "a labeling component Also inc iud(d withui thc dclinition arc,\n",
      "for example, pc l)3(Opt&des containing one or more ana logs of\n",
      "an amino acid (including, for exnmple, unnatural amino\n",
      "acids. etc ), as well as other modiiications known in the an. It\n",
      "is understood tlmt the polypeptides can occur as single chains\n",
      "or associated chains\n",
      "\n",
      "As loiov;n in the art, \"polynucleotide,\" or \"nucleic acid,\" as\n",
      "used interchangeably herein, refer to chains of nucleotides of\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "I\n",
      "\n",
      "wly length. and include DNA and RNA The nucleotides can\n",
      "be deoxyribohhuclcothdes, ribonucleotldes, modified nucle-\n",
      "otides or bases. and/or their ana logs. or any substrate that can\n",
      "bc incorporatcxl into a chain by DNA or RNA polymcrase. A\n",
      "polynucleotide may compnse modified nucleotldes, such as\n",
      "methylated nucleotides and their analogs. If present. modifi-\n",
      "cation to the nucleotide structure may be imparted before or\n",
      "after assembly of the chain. The sequence ofnucleotldes may\n",
      "be uucmipted by non-nucleotide components A polynucle-\n",
      "otlde may be further modified after polymerization, such as ni\n",
      "by conjugation with a labeling component. Other types of\n",
      "nllxiificmiOns inClude. for example. *'caps'*. substiuition ol\n",
      "one or more of the naturally occurnng mlcleotides uith an\n",
      "wlalog, intcrnuclcotide modificarions such as. I'or example,\n",
      "those 111th uncharged hnkages (e g.. methyl plmsphonates.\n",
      "plmsphotriesters, phosphoamidates. carbamates, etc.) and\n",
      "with charged linkages (e g., phosphorothioates, phospho-\n",
      "roditlnoates, etc ). those contauung peudmit moieties, such\n",
      "as, for example, proteins (e.g., nucleases, toxins, antibodies.\n",
      "s~gnal PePtidcs. Polv-l.-lyslnL. i'Ic ), Ihosi: with lillLlcilliltol's so\n",
      "those containing chelators\n",
      "(e.g., acridine, psoralen, etc.).\n",
      "(c.g.. metals, mdioactive metals, boron. Oxidative metal~,\n",
      "etc.), those contaimn alkylators. those with modified luik-\n",
      "ages (e.g.. alpha anomeric nucleic acids, etc.). as well as\n",
      "umnodified fonna of tlm polynucleotide(s). Further, any of \"\n",
      "the hydmxyl youps ordlnartly present in the sugars may be\n",
      "replaced. for exmnple, by phosphonate woups, phosptmte\n",
      "grolips, prohccIPLI by sIBlxlald prtllcctnlg gl'oops, oh'lctlvaIPd\n",
      "to prepare additional hnkages to additional nucleotides. or\n",
      "may bc conjugated to solid supports. Thc 5'nd 3'erminal\n",
      "OII can be phosphorylated or substitutsxl 111th amiues or\n",
      "orgaruc capping group moieties offrom I to 20 carbon atoms.\n",
      "Other hydroxyls may also bc derivatil,cd to standard protect-\n",
      "uig groups. Polynucleotides can also contain analogous\n",
      "fortns of ribose or deoxyribose sugars that nre gmlemliy \"»\n",
      "knou n in Ihc arL including„ for example, 2n0-methyl-. 2u0-\n",
      "allyl. 2uthioro- or 2uazido-ribose. carbocychc sugar uialogs,\n",
      "alpha- or beta-anonmric sugars, epinwric sugars such as am-\n",
      "buiosc, xyloscs or lyxoscs. pyr Bio st.'ugal s. fwalulsc sugals,\n",
      "sedoheptuloses, acyclic analogs and abasic nuclsmiside ana- sc\n",
      "logs such as methyl riboside. One or morc phosphodiester\n",
      "linkages may be replaced by alternative linking aroups. These\n",
      "alternative linking groups include, but are not limited to,\n",
      "embodiments lvhcrein phosphate is replaced by P(0)S(\"tbio-\n",
      "ate\"). I'(S)S (\"dkthioate\"), (0)NRi (\"anudate\"). V(0)R, P(0) 4.\n",
      "OR'. (.'0 or CHC (\"fonnacetal'). in which each R or R's\n",
      "uidependently I I or substituted or luisubstltuted alkvl (1-20\n",
      "(:) optionally containin an ether ( 0 ) hnkage, aryl, alk-\n",
      "enyl. cycloalkyl. cycloalkenyl or araldyl. Not all hnkages in a\n",
      "polynucleotide need be identical. The preceding descnptlon c\n",
      "applies to all polynucleotides referred to herein. including\n",
      "RNA and DNA\n",
      "\n",
      "so\n",
      "\n",
      "A \"PCSK9ants onlstaptamer,\"wluchcomprisesamicleic\n",
      "acid or pmtein sequence. is, for example, selected from a\n",
      "large pool of rwidom sequences and specifically binds\n",
      "Vt SK9. I'he nucleic acid of the aptamer is double-stranded\n",
      "DNA or single-strmid RNA Nucleic acid aptwncrs can\n",
      "uiclude moditied bases or functional groups, uicluding but\n",
      "not limited to 2ufluorine nucleotides and 2LO-methyl nucle-\n",
      "otidcs Aptamcrs can include hydrophilic polymers.\n",
      "example, polyethylene glycol. Aptamers may be made by\n",
      "methods known in the art and selected for Vt SK9 antagonist\n",
      "acuvity by routine modification of the methods ihsclosed in\n",
      "the Examples.\n",
      "\n",
      "I\n",
      "\n",
      "for ai\n",
      "\n",
      "As hhssxf herein, an mltibody, peptide, or aptahucr \"interacts\n",
      "with\" PCSK9 when the equilibrium dissociation constant ls\n",
      "equal to or less titan 20 BM, preferably less than about 6 BM,\n",
      "\n",
      "r\n",
      "\n",
      "12\n",
      "morc prefcmbly less than about 1 nM, most prcti.rably less\n",
      "than about 0.2 nM, as measured by the methods disclosed\n",
      "herein in Example 2.\n",
      "\n",
      "An epitope that \"prefcrcntially binds\" or \"specifically\n",
      "buids\" (used ulterchangeably herein) to an antibody or a\n",
      "polypeptide is a tenn ii el 1 understood in the art. and methods\n",
      "to deiernune such specdic or preterentud binding are also\n",
      "well known ln the art. A molecule is said to exlublt \"speci bc\n",
      "binding.'r *'pret'Lrential binding*'t't reacts or associates\n",
      "more frequently. more rapidly, uith greater duration and/or\n",
      "with yester affiiuty with a particular cell or substance than it\n",
      "does with altcrnatilw cells or substances An antibody \"spe-\n",
      "cifically bulds\" or \"preferential ly binds\" to a target lf it buids\n",
      "with greater atfinity, avidity, more readily, mid/or with greater\n",
      "duration Ihnn il binds to other substnnces. For ex uuple. Wi\n",
      "antibody that specificallv or preferential ly binds to a I'(.'SK9\n",
      "epitopc is an antibody that binds this epitope with greater\n",
      "afiimty, avidity. more readily, and/or lvith grwiter duration\n",
      "than it binds to other V( SK9 epitopes or non-p(.'SK9\n",
      "epitopcs. It is also understood by reading this definitiml that,\n",
      "for example, an antibody (or moiety or epltope) that specif-\n",
      "icall or preferentially binlLS to a first target may or may not\n",
      "specifically or preferentially bind to a second target. As such,\n",
      "\"specific binding\" or \"preferential binding\" does not neces-\n",
      "sarily require (although it can include) exclusive binding.\n",
      "Generally. but not necessartly. reference to binding means\n",
      "preferential binding.\n",
      "As usexf lmrein,\n",
      "\n",
      "'*substantially pure*'efi:rs to matertnl\n",
      "uhich is at least 50% pure (i.e.. free from contaminants),\n",
      "morc preferably, at least 90% pure„morc prefi:rably. at least\n",
      "95% pure. yet more preferably, at least 98% pure. and most\n",
      "preferably, at least 99% pure.\n",
      "\n",
      "A \"host cell\" includes an individiwl cell or cell culture Ihat\n",
      "c m be or has been a recipient for vector(s) for incorporation\n",
      "of polynucleotide inserts. Host cells include progeny of a\n",
      "single host cell mid the progeny may not necessartly be\n",
      "completely identical (in morpholog) or ui genonuc DNA\n",
      "complement) to thc original parent cell due to natural. acci-\n",
      "dental. or deliberate mutation A host cell mcludes celL~ trwis-\n",
      "fected in vivo with a polynucleotide(s) of tllis invention.\n",
      "\n",
      "lnstlmtes of\n",
      "\n",
      "As know n in the art. rim term \"Fc region\" is used to dctinc\n",
      "a C-ternunal region of an utuuunoglobulin heavy clmsln. The\n",
      "'Fc region\" may bee native scsquence Fc region ore variant Fc\n",
      "fcgl 011. Although hie boundaries ofthe Fc region ofan imnni-\n",
      "noglobulul heavy chain might vary, the human IgCh heaiq\n",
      "chain Fc region is usually defined to snatch from ml amino\n",
      "acid residue at position Cys226, or from Pro230. io the car-\n",
      "boxyl-terminus thereof. The numbering of the residues in the\n",
      "Fc region is that of Ihc FIJ index as in Kabat Kabai et al,\n",
      "Sequences of Proteuis of Immunological Interest, 5th Ed.\n",
      "I'ublic Ifealth Service. National\n",
      "lfealth,\n",
      "Bethesda Md, 1991 The Fc region of an immunoglobului\n",
      "enemslly comprises two constant domains. CI12 and CII3.\n",
      "As used in tlw art, 'Fc receptor\" and \"FcR'* describe a\n",
      "receptor that binds to the Fc re ion ol an uitibody. The pre-\n",
      "ferred FcR is a native sequence lnuuml FcR Moreover, a\n",
      "prcfcrrel FcR is onc which hinds an I (i antibody (a gmnma\n",
      "receptor) and includes receptors of the Fcyki, FcyRII. aod\n",
      "Fc/RIII subclasses. including allelic variants and altcma-\n",
      "tivcly spfhCLXI Iorms of thisC reCeptnr. FcyRH recLPIors\n",
      "include FcykllA (an \"activating receptor\") and FcykllB (an\n",
      "'itdfibiting receptor*'). which have similar amino acid\n",
      "sequences that hhtfer prunarily in the cysoplashuic domains\n",
      "thereof. Fcks are reviewed in Ravetch and Kinet. 1991, Ami.\n",
      "Rcv. hnnuinol.. 9457-92,\n",
      "Imnni-\n",
      "nomethods. 4:25-34: and de 1 lass et ul.. 1995. J. Lab. Clin.\n",
      "Med.. 126:330-41. \"Fck*'lso includes the neonatal receptor,\n",
      "\n",
      "I apcl et al..\n",
      "\n",
      "1994.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "13\n",
      "FcRn, which is responsible for the transfer of mnternal IgCis\n",
      "to the fetus (Ciuyer et al.. 1976 I. Inuminol., 117: SS7; and K&m\n",
      "et al.. 1994, .l. Inununol.. 24:249).\n",
      "\n",
      "n&\n",
      "\n",
      "The term *'compete*h as used hcrcin with regard to an\n",
      "ant&body. means that a first antibody. or an antigen-buid&ng s\n",
      "ponion thereof, binds to an epitope in a manner sufficiently\n",
      "sinular to the b&nd&ng of a second antibody. or a» u&ugen-\n",
      "b&ndm portion thereof. such tlmt the result of binduig of the\n",
      "firsl m&nbody u ilh ics cognate epitopc is dclcclnbly do:re&i&md\n",
      "&a the presence of the second ant&body compared to the buid-\n",
      "&ng ofthe first antibody in the absence ofthe second antibody.\n",
      "The altcmative. where thc binding ol the second anlibixly n&\n",
      "&ts epitope &s also detectably decreased in the presence of the\n",
      "tirst antibody, cnn, but need not be the case Thnr is, a tirst\n",
      "anl&body can udiibil lhe binding of a svcond antibody lo ils\n",
      "epitope u:ithout that second antibody inhibiting the binding of\n",
      "the first antibody to its respective cpitopc. However, where\n",
      "each antibody detectably inlnb&ts the binding of the other\n",
      "m&tibody with its cognate epitope or ligand, whether to the\n",
      "same, grcalcr. or lesser oxtcnh tlm antibodies are snid to sc\n",
      "\"cross-compete\" v;ith each other for bind&ng of their respec-\n",
      "tive epitope(s). Both competing and cross-competing anti-\n",
      "bodies are encompassed by the present invent&on. Regardless\n",
      "of the meclianism by &vhich such competition or cross-com-\n",
      "steric hindrance, confonnational\n",
      "petition occurs\n",
      "change, or bind&n to a conunon ep&tope. or port&on thermA,\n",
      "the skilled art& san would appreciate, based upon the teachings\n",
      "provided here&n. that such compeung and/or cmss-competing\n",
      "ant&bodies are encompassed and can be useful for the meth-\n",
      "ods disclosed hcrcin.\n",
      "\n",
      "(e.g,\n",
      "\n",
      "\"(1\n",
      "\n",
      "\"\n",
      "\n",
      "By an mu&body with an c7&tope that *'overlaps*'v&th\n",
      "another (second) ep&tope or iv&th a surface on PCSK9 tlmt\n",
      "interacts with the FCiF-bkc donuiin of the I.DI,R is meant lhc\n",
      "shanng of space in tern&a of the PCSK9 residues that are\n",
      "interactcd with. To calculate the percm&t of overlap. for \"»\n",
      "tlm percvnt overlap of ibe claimed m&t&body*a\n",
      "example,\n",
      "PCSK9 ep&tope w&th the surface of PCSK9 uhich interacts\n",
      "with thc HiF-like domain of tfm I,DI R, thc surface area of\n",
      "PC'SK9 buried when in complex u ith the I DI R is calculated\n",
      "on a per-residue basis. 'Bie buried area is also calculated for sc\n",
      "these residues in the PCSK9 nntibody complex To prevent\n",
      "more than 100% poss&ble overlap. surface area for residues\n",
      "that i&ave hind&er buried surface area in the FCSK9:antibody\n",
      "complex thm& in I,DLR PC'SK9 con&plex is sel to values from\n",
      "the LDLR:PCSK9 complex (100%). Percent surface overlap 4.\n",
      "is calcu latcxl by sununing over aff of thc LDI,R:PC'SK9 inter-\n",
      "act&ng residues u&d is v, eig&ed by the uiteraction ares.\n",
      "\n",
      "A \"functional Iic region\" possesses at least one effector\n",
      "I'unction ol'a native sequence Fc region Fxen&phuy \"elT&wtor\n",
      "fiu&ctions*'include Clq hindu&g,complement dependent cyto-\n",
      "toxicity; Fc receptor binding; ant&body-dependent cell-medi-\n",
      "ated cytoloxicity: pluigocytosis, down-regulation of cell sur-\n",
      "face receptors (e.g., B cell receptor), etc. Such effector\n",
      "functions genernl ly rcquirc thc Fc region to bc combined with\n",
      "a bindn&g domai»(e.g, ananubody vnriabledomau&) andean\n",
      "be assessed using vnrious assays kno&vn in the art for evalu-\n",
      "ating such antibody effi.ctor functions\n",
      "\n",
      "u\n",
      "\n",
      "s\n",
      "\n",
      "A 'native sequence Tc region*'ompnses mi amu&o amd\n",
      "sequence idm&tical to tlm amino acid scequm&cc ofan Fc region\n",
      "1'om&d in imturc A \"vanmu Fc region\" comprises ail a&stille s&1\n",
      "acid sequence wh&ch differs from that of a native sequence Fc\n",
      "region by virtue of at least one nmino acid moditication, yet\n",
      "retains at least one effector h&ncnon ofthe native sequence Fc\n",
      "rey'on. I'referably. the variant Fc region has at least one amino\n",
      "acid substitution con&pared to a native sequence Fc region or r\n",
      "to the I'c reg&on of a parent polypeptide. e.g.. from about one\n",
      "to about ten amino acid substin&tions, m&d preferably, from\n",
      "\n",
      "14\n",
      "about one to about five mnino acid substitutions in a native\n",
      "sequence Fc region or in the Fc region of the parent polypep-\n",
      "t&de. The vanant I'c reg&on herein w&ll prefemsbly possess at\n",
      "lmcst abiiul g0'is sequence identity u ilk a native svquence Fc\n",
      "region mid/or with mi Fc region ol'a parent polypepiidc, and\n",
      "most preferablv. at least about 90% sequence identity there-\n",
      "u&tin more prefemsbly. at least about &95%. at least about 96%,\n",
      "at least about 97\"!u at lemst about 9g%. at least about 99bv\n",
      "sequence identity therewith.\n",
      "\n",
      "As used herein. \"treatment\" is an approach for obtai&ung\n",
      "I&or purposes of this\n",
      "benefic&al or desired ch&ucal results.\n",
      "invent&on. bencticial or desired clu&ical resulcs include, but\n",
      "are not limited to, one or more ofthe folio&& ing: enhancement\n",
      "of LDL clearance and reducing incidence or mnelioration of\n",
      "aberr uit cholesterol and/or lipoprotein levels resultu&g from\n",
      "metabolic m&d/or cating disorders. or including I'amilial\n",
      "hypcrcholesterolemia, athcrogenic dyslipidemia, atlmrosclc-\n",
      "rosis, and, naire generally. cardiovascular disease (CMD).\n",
      "\n",
      "**Reducu&g mmdence\" means any of reducuig severity\n",
      "(which can utclude reducing iuwd for and/or ammmt of (e g.,\n",
      "exposure to) other drugs and/or therapies generally used tiir\n",
      "tlus condition. As &s understood by those skilled u& the art,\n",
      "ind&viduals may vary in terms of their response to treatment,\n",
      "and, as such, for example. a \"nmthod of reducing\n",
      "\n",
      "incidence*'etlectsadmuustenng the PCSK9 ants onist annbody, pep-\n",
      "\n",
      "t&de. or aptamer based on a reasonable expectat&on that such\n",
      "aihmni ~ t ration may l&kely unuse such a reduction in me&dence\n",
      "ui that part&cular ind&vidual.\n",
      "\n",
      "lo ilol\n",
      "\n",
      "*'Ameliorating*'eans a lcsscning or improvement of onc\n",
      "iir nlore sv'&lip&ellis as co&i&pareil\n",
      "a\n",
      "PCS K9 antagon&st antibody. peptide. or ap tamer. \"Amel&orat-\n",
      "ing'* also includes shortening, or rnluction in duration of a\n",
      "symptom.\n",
      "\n",
      "ail&i&i&i&slat&i&\n",
      "\n",
      "As used herein, an \"effi:ctive dosage*'r \"cffi:ctive\n",
      "amoum\" ol'drug. compound, or pharmaceutical compositmn\n",
      "&s an amount sutlic&ent to effect uiy one or more beneficial or\n",
      "dcsircxf results. For prophylactic use, bencticial or desired\n",
      "results u&elude eliminating or reducing tbc nsh, lessening thc\n",
      "severity, or delaying the outset of tl&e disease. including bio-\n",
      "clmmical, histological ancUor behavioral symptoms ul'lm\n",
      "d&sense, its compl&cat&ons and &ntermedmte pathological phe-\n",
      "notypes presenting during development of the disease. For\n",
      "therapeutic use, beneficial or dcaimd results include clinical\n",
      "results such as reducing hypercholesterolemia or one or more\n",
      "symptoms of dyslipidemia, atherosclerosis. I'irlk or coro-\n",
      "nary heart disease, decrees&ng the dose of other med&cations\n",
      "required to treat the disease, enhancing the efTect of another\n",
      "med&cat&on, and/or delaying lhe progression of&he disease\n",
      "\n",
      "ol'atients.An effective dosage cmi be ad&u&mater&xf &n one or\n",
      "\n",
      "more administmtions. For purposes of this invention, an\n",
      "effeclive dosage of dn&g. compound, or pharmaceutical com-\n",
      "posiuon is iu& amount sufficient to accomplish prophylact&c or\n",
      "thempeutic treatment either directly or indirectly As isundcr-\n",
      "effect &ve\n",
      "u& eti'ective dosage of a drug,\n",
      "stood in the clinical context.\n",
      "compound. or pharmaceutical composition may or may not\n",
      "be achieved in cmfilunction u i&h m&other drug, compomid. or\n",
      "phannaceutimd composition. Thun ui \"ell'ecuve dosage\"\n",
      "may be considered in the context of administering one or\n",
      "morc therapeutic agents. and a smgle agent may be consid-\n",
      "ered to be g&ven in an\n",
      "amoiuit & f, in conjunct&on with\n",
      "onc or more other ngents. a desirable result may be or is\n",
      "achieved.\n",
      "\n",
      "An \"individual\" or a \"subject\" is a manunal, more prefer-\n",
      "ably. a luunan Mnnm&als also include, but are not limited to,\n",
      "farm an&mals. sport anunals. pets, pnmates, horses, dogs.\n",
      "cats. mice and rats.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "15\n",
      "\n",
      "16\n",
      "\n",
      "As uscxI\n",
      "\n",
      "lmrcin, \"&veto&\" nwans n construct, which is\n",
      "capuble of del&venng. and. preferably. expressing, one or\n",
      "more gene(s) or sequence(s) of interest\n",
      "in a la&st cell.\n",
      "Fxan&ples of vsictors include, but arc not limited to, viral\n",
      "vectors. ooked DNA or RNA expression vectors. plasmid,\n",
      "cosmid or phage vectors. DNA or RNA expression vectors\n",
      "assocuued with cationic condensing a ants. DNA or RNA\n",
      "expression ~actors encapsulated in liposomes. and certain\n",
      "eukaryotic cells, such as producer cells\n",
      "\n",
      "As used herein. \"expression control sequence\" means a\n",
      "nucleic acid sequence that directs transcnption of a m&cleic\n",
      "acid An expression control svqumiee can bc a promoter. such\n",
      "as a constitutive orat& inducible pmmoter. or an enhancer. The\n",
      "expression control sequence is opembly linked to the nucleic\n",
      "acid svquence to be transcribed\n",
      "\n",
      "subject 's\n",
      "\n",
      "As used herein. \"plmrmaceutically occeptable carrier\" or\n",
      "*'phanuaccutical acceptable excipient'* includes any n&aterial\n",
      "winch. &shen comb used with mi active &ngredi ant, allows the\n",
      "ingredient to retain biological activity and is non-reactive\n",
      "with the\n",
      "in&mune systmn. Fxamp les include, but orc\n",
      "not limited to, any of the standard pharmaceutical carriers\n",
      "such as a phosphate bufferixI saline solution. water. emulsions\n",
      "such as o&l/water emulsion, and various types of &vettut\n",
      "agents. Preferred d&luents for aemsol or parenteral adnunis-\n",
      "tration ore phosphate buffered saltlm (PI)S) or normal (0 9%n)\n",
      "saline. Compositions comprising such carriers are fornn&lated\n",
      "by well known conventional methods (see. for example. Rem-\n",
      "uigto&i's Pharmaceutimd Sciences. 18th edition. A Gem&aro.\n",
      "ed., Mack Pubhslung Co.. L'aston. Pa.. 1990: and Remington,\n",
      "The Science m&d Pmctice of Plmrmacy, 20th Fd „Mack Pub-\n",
      "lisluog. 2000)\n",
      "\n",
      "Tl&e tenn \"K„„\". as used herein, refers to the rate constant\n",
      "I'or association of an muibndy to on 'mtigen Specilicnlly, thc\n",
      "rate constants (k„, and k.y) md eq&ulibuum dissociation con-\n",
      "stants are measured using~ Fab antibody fmgmmits (i.e, uni-\n",
      "voiel&t) aud P( SK9.\n",
      "\n",
      "The term \"k,f'2 as used herein. refers to the rate constmtt\n",
      "for dissociation of an m&tibody fron& the antibody/antigen\n",
      "col&&plex\n",
      "\n",
      "'lite tern& \"Kr\", as used herein. refers to the eqmlibrnuu\n",
      "\n",
      "dissociation constant of m& antibody-antigen interaction\n",
      ",A. Methods for Preventing or Treating Disorders Associated\n",
      "with Hypercholesterolemia\n",
      "\n",
      "In one aspect. the invention provides a nmthod for treating\n",
      "or preventing hypercholesterolenna. and/or at\n",
      "least one\n",
      "symptom of dyslipidemio. atherosclerosis. ('VD or coronary\n",
      "heart disease. u& an u&dividual comprising adnunistering to\n",
      "the individual an effective amount of a PCSK9 antagonist\n",
      "antibody nr peptide or aptmucr tlvu antagonizes circuloiing\n",
      "PCSK9.\n",
      "\n",
      "In a t'urther aspect, the imention provides an effective\n",
      "amnunt of a PCSK9 antagonist antibody. peptide. or apiamer\n",
      "that ants oiuzes c&rculat&n PCSK9 for use in treatin or\n",
      "preventing hypercholestcrolemia, and/or at least one symp-\n",
      "tom of dysl&p&demia, athemsclerosis, CVD or coronary heart\n",
      "disease. in an individual. The invention further provides the\n",
      "osv. ol'an e(Tcetive muoont of a P(.SK9 antagonist antibody.\n",
      "pepude. or ap tamer that antagomzes extracellular or circulat-\n",
      "ing PCS K 9 in the manufacture ofa medicament fnr treating or\n",
      "prevm&ting hyperchnlcsterolemi i, and/nr at lmist nnc symp-\n",
      "tom of dyslipidemia, atherosclerosis, CVD or coronary heart\n",
      "disease. in an individual.\n",
      "\n",
      "Advantageously, therapeuuc odmuustration of the ann-\n",
      "body. peptide. or optamer results in lower blood cholesterol\n",
      "m&d/or lower blond I,DI Preferably, blrxid cholesterol mid&or\n",
      "blood LDL &s ot least about 10% or 16%a lower than befnre\n",
      "administration. More preferably, blood cholesterol andcir\n",
      "\n",
      "is at least about 20% lower than bcf&ire adminis-\n",
      "blood I,I/I\n",
      "tration ofthe antibody Yct more preferably, blood cholesterol\n",
      "and/or blood LDL is at least 30% lower than befnre a&hnin-\n",
      "istration of ibe &u&tibndy. Advantageously. blood cholesterol\n",
      "and/or blood I,DI is a& lmist 80% lower than be(i&re o&huin-\n",
      "istration of tine antibody. More advantageously, blood cho1es-\n",
      "teml and/or blood LDL is at least 60% lower than before\n",
      "adm&mstration of the antibody. Very preferably, blood cho-\n",
      "lesterol ond/or blood LDL is ot least 60% le&vcr tlmn betiirc\n",
      "adm&nistmntion of the antibody. Most preferably. blood cho-\n",
      "lesterol ond/or blood LDL &s at least 70&/8 lower than before\n",
      "ad&a&ala&ration of the mtibody\n",
      "\n",
      "&&1\n",
      "\n",
      "With respect to all methods described herein, reference to\n",
      ", PCSK9 antagonist antibodies, peptides, and aptamers also\n",
      "uiclude compositions compris&n one or more additional\n",
      "agents Tlmsc compositim&s moy fintlmr comprise suitable\n",
      "excipients, such os plmrmaceutically acceptable excipients\n",
      "including buffers, wluch are well knov;n ui the ait. The\n",
      "n present invention ran be used alone or &n combi&rntion with\n",
      "\n",
      "other conventional methods of treatment\n",
      "\n",
      "The P(JSK9 antagonist antibody. peptide, or aptamcr can\n",
      "be a&bnimstered to an u&C&vidual via any suitable route. It\n",
      "should be apparent to a person skilled in the on tint the\n",
      "examples Ccscribcd herein are not intended to be limiting but\n",
      "to be illustrative of the tecluuques ac ulable. Accordingly. ui\n",
      "some embodiments, the I'('SK9 antagonist antibody, peptide,\n",
      "or optamer &s adm&ni ~tered to an individual ui accord &&ith\n",
      "known methods. such as &ntmvenous a&hn&n&stration. e... as a\n",
      "sn holus or by mmtinunus inl'usion over a period of tinm, by\n",
      "&nuamuscular. mtraperitoneal, &ntracerobrospu&al. uansder-\n",
      "intrasyn-\n",
      "mal, subcutaneous. &ntmn-articular, subhnguolly,\n",
      "ovial. via insufflation, intmthccal, &mil, inhalatim& or &opicol\n",
      "mutes. Ad&ouzo&rat&on can be systemic, e.g., us&ravenous\n",
      "\"» administration, or localized. Conuneiciolly available nebu-\n",
      "hzee'or bquid fom&ulations, including jct ncbuli!ers and\n",
      "ultrasonic nebul&zers are usefi&1 for admimstmnt&on. Liquid\n",
      "f&irmulations can be directly nebulized and lynphilizcd pow-\n",
      "der cun bc nebuli!ed alter reconstitutim& Alternatively,\n",
      "sn I'('SK9 antagonist antibody. peptide. oraptamer con be aero-\n",
      "snli!ed using a fluorocarbon fnnnulation and a metered dose\n",
      "uihaler. or uilialed as a lyophilized and nulled powder.\n",
      "\n",
      "In one embodiment, o P('SK9 antagonist antibody, pep-\n",
      "tiCe. or aptan&ur is administered via site-spccilic or targeted\n",
      "local delivery techniques. Examples of site-specific or tor-\n",
      "getixI local delivery techniques include varinus implontable\n",
      "depot sources of the PCSK9 antago&ust antibody. peptide. or\n",
      "aptamer or local delivery catheter~. such as mfu sion catheters,\n",
      "indwelling catheters. or ncvdle catheters. syntheuc grafts„\n",
      "n advennt&al wraps. shunts and stents or other &mplontable\n",
      "devices, site specific carriem, direct in)ection, or direct appli-\n",
      "cation See c g., PCT Publ No. W000/63211 andi).S Pot.\n",
      "No. 5.981,668.\n",
      "\n",
      "Various liinnulotions nf a PCSK9 antagonist antibody,\n",
      "s peptide. or optamer may be used for administration In some\n",
      "embodiments, the P('SK9 antagonist antibody. peptide, or\n",
      "In sonw. embodiments,\n",
      "aptamcr nt 9 bc administered neat\n",
      "PCSK9 antagonist u&tilxidy, peptide. or apt uner mtd a phar-\n",
      "maceutically acceptable cxcipient may be in various formu-\n",
      "ro latmns Pharnraceutically acceptable cxcipients are known m\n",
      "the a&t. and are relatively inert substances tint facihtate\n",
      "administration of a pharmacologically effective substance.\n",
      "I'or exmnple, an exc&pient can give fomi or consi stency. or act\n",
      "as o diluent. Suitable excipients include but are not hmited to\n",
      "stabilizing agents, wcuing and emulsifying agm&ts, salts f&ir\n",
      "varying os&nolo&sty, encapsulating agents. butTers. and skin\n",
      "penetmtion enhancers. Fxcipients as well as formulations for\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "17\n",
      "parenteral and nm&parcnteral dnig delivery are set le&th in\n",
      "Rmuington, The Science and Vmctice of Phamiacy, 20th L'd.,\n",
      "Mack Pubhshing (2000).\n",
      "\n",
      "These agents can be cou&bh&e»I\n",
      "\n",
      "ivith phannaccuiically\n",
      "acceptable vi:hiclcs such as saline, Ringer's solution, dex-\n",
      "trose solution. and the like. I'he particular dosage regimen,\n",
      "&.e.. dose„ t&m&ng and repetit&on, w&ll depend on the part&euler\n",
      "nuliv&dual and thnt u&div&dual's med&cal lustory.\n",
      "\n",
      "PCSK9 antibodies can also bc adn&inistered via inhalation,\n",
      "as descnbed hereu&. Generally, for administration of PCSK9\n",
      "ant&bodies. an iiutial candidate dosage can be about 2 mg/kg.\n",
      "For the purpose ol'the present invention, a typical daily dos-\n",
      "age mice range from about any of about 3 gg/kg to 30 gg/kg\n",
      "to 300 Pg/kg to 3 mg/kg. to 30 u&gvkg, to 100 mg/kg or nlole\n",
      "depend&ng on the factors ment&oned above. For example.\n",
      "dosave of about I mg/kg. about 2 5 mg/kg, about 5 mg/kg,\n",
      "about 10 mg/kg, and about 25 mg/kg may bc used. For\n",
      "repeated admin&strations over several days or longer. depend-\n",
      "ing on &he condition. the treatment is sustnu&ed unt&l a desirtnl\n",
      "suppression of symptoms occurs or until suifiment thernpeu-\n",
      "tic levels are achieved, for example. to reduce blood LDI.\n",
      "levels. An exemplary dosing regimen comprises adnunister-\n",
      "&ng an iiutial dose of about 2 mgkg, folloiied by a v,eekly\n",
      "maintenance dose of about I ing!kg of thc PCSK9) antibody,\n",
      "or folio&red by a ma&ntenance dose of about I &ugkg every\n",
      "other week. However, other dosage reg&mens may be useful.\n",
      "dependu&g on the pauern of phanuacok&netic decay &hnt the\n",
      "pmctitioner wishes to ac lu eve. I'or example, in some embod&-\n",
      "mcntx dosing fmm oim to liiur times a week is conte&»plate»I\n",
      "In other emboduuents dosu&g once a month or ooce every\n",
      "other month or every three months is contemplated. The\n",
      "progress of this tlmrapy is easily monitored by conventional\n",
      "teclm&ques and essays The dosu&g rein&en (including the\n",
      "P( SK9 antagonist(s) used) can vary over tinm.\n",
      "\n",
      "&(1\n",
      "\n",
      "o\n",
      "\n",
      "\"\n",
      "\n",
      "\"o\n",
      "\n",
      "For the purpose ol'hc pit.'Ni:l&t &I&vcl&&101&, tlm appfoplla&c\n",
      "dosage of a PCSK9 antago&ust ant&body. peptide, or aptamer\n",
      "will depend on tlm PF'SK9 m&tagonist m&tibody, peptide, or\n",
      "aptamer (or compos&tin&&s the&L00 en&ployexI, &bc type and\n",
      "severity of symptoms to be treated, ivhether the agent is 4o\n",
      "administered fitr preventive or themapeuti c purposes, pres ious\n",
      "therapy. the patient's eh»ical history and response to the\n",
      "agent, the patient's blood V('SK9 levels. the patient's synthe-\n",
      "sis and clearance rate fiir Pf'SKR the patient's clem ance rate\n",
      "for the admin&stered agent, and the discretion ofthe attending 4.\n",
      "physician I'ypically the clinician will administer a V( SK9\n",
      "an&agon&st antibody, pep&&de. or aptamer unt&l a dosage is\n",
      "reached tlmt achieves the desired result. Dose and/or fre-\n",
      "quency ciui vary oivr course ol'treauuent I.mpirical consid-\n",
      "emtions. such as the half-l&fe. genemlly v;ill contribute to tire\n",
      "determination of the dosage. For example, antibodies that are\n",
      "compatible with thc human inununc system, such as human-\n",
      "ized m&t&bodies or fiilly luunan antibodies, iuay be used to\n",
      "prolong half-life of thc antibody m&d to prevent the antibody\n",
      "beutg attncked by the host's imnuu&e system. Frequency ol'\n",
      "administration may be determined and adjusted over the\n",
      "course el'herapy. m&d is generally, but not accessarily, based\n",
      "on treatment and/or suppress&on and/or amehoration aud/or\n",
      "delay of symptoms, e.g., hypcrcholesterolemia. Alterna-\n",
      "lively. sustained contmuous relcasi: fiinuulations of PCSK9 ui\n",
      "antagon&st ant&bodies may be appropriate. 3/ai&ous formula-\n",
      "tions and devices fiir achieving suits inc»I release are known in\n",
      "the art.\n",
      "\n",
      "o\n",
      "\n",
      "In one embodiment. dosages for an antagonist antibody,\n",
      "peptide, or aptamer may be detcm&ined empirically in indi-\n",
      "v&duels who have been g&ven one or more adnun&stmt ion(s ) of\n",
      "an antagonist antibody, peptide, or aptamer. Individuals are\n",
      "\n",
      "4\n",
      "\n",
      "given incremm&tal dosages of a PCSK9 antagonist antibody,\n",
      "pepnde. or aptamer. To assess eiiicacy. an &nd&cator of the\n",
      "disease can be follow ed.\n",
      "\n",
      "Administration of a P(.'SK9 antagomst antibody, peptide,\n",
      "or aptmuer &n accordance w&th the method in the present\n",
      "invention can be continuous or intermittent, depending, for\n",
      "example. upon the recip&ent's phys&clog&cal cond&tion,\n",
      "whether the purpose of the administrat&on is therapeut&c or\n",
      "pmphy lactic, and otlier fee airs known to ski l lcd prueutioncrs.\n",
      "The xhnin&strat&on of a PCSK9 antagoiust anubody„peptide„\n",
      "or aptamer may be essent&ally cont&nuous over a presefected\n",
      "per»id of tmw. or may be in a si:ries ol'paced dose~\n",
      "\n",
      "In some embod&ments. more than one antagoiust antibody,\n",
      "pcq&tide, or aptamcr may bc present. At lcasr onc. at least two,\n",
      "at less& three. at least four. at least live dilferenk or more\n",
      "antagonist antibodies nnd/or peptides can be present. (Iener-\n",
      "ally, those PC'SK9 antagonist nntibodies orpcptidcs n&ay have\n",
      "complementary activities that do not adversely alfcct each\n",
      "otlmr A VCSK9 m&tagonist antibody, peptide, or aptamer can\n",
      "also bc used in conjunction with otlmr PCSK9 anuigonisis or\n",
      "VCSK9receptoranta on&sts.forexample.oneormoreofthe\n",
      "following P(JSK9 antagonists may be used: mi ant i sense mol-\n",
      "ecule directed to a PCSK9 (&nclud&ng mi anti-sense molecule\n",
      "directed to a nucleic acid encoding P('SK9), a PCSK9 inhibi-\n",
      "tory compound. and a PCSK&J stnicmral analog A P('SK9\n",
      "antagoiust antibody, peptide, or aptamer can also be used &n\n",
      "conjunct&on with other agents that serve to enl&ance and/or\n",
      "complement the elfect&veness of the ngents.\n",
      "\n",
      "Acceptable camera. exc&picots, or smb&1&zers are nontox&c\n",
      "to rivipiems a»hc dos~gas and concentrations mnploycd, ilflil\n",
      "mav a»npnse bulIers such as plmsphate, citrate. and other\n",
      "organic acids; salts such as sod&um chloride: ant&oxidants\n",
      "including ascorbic acid and methim&inc, prese&vatives (such\n",
      "as octadecyldnnethylbenzyl mnmonium chloride: hexam-\n",
      "ethonium chloride: benzalkonium chloride, benzethonium\n",
      "chloride, plmnol. butyl or bcnzyl alwihol, alkyl parabcns.\n",
      "such as methyl or propyl paraben: ca tee hob resorcinol: cyclo-\n",
      "hcxanol, 3-pentanol, and m-cresol), low molecular weight\n",
      "(less than about 10 residues) polypeptides, pro&el&&s. si&ch tls\n",
      "senun albumin. gelatin, or inuuunoglobulins: hydrophilic\n",
      "polymers such as polyvinylpyrrolidone, amino acids such as\n",
      "glyc&ne. glutamu&e. asparagine, lustidu&e, arg&n&ne, or lys&ne;\n",
      "monosaccharides. disaccharides. and other carbohydrates\n",
      "including glucose. mannosc, or dcxtrins, chelating agents\n",
      "such as L&DTA: sugars such as sucrose, mann&tol, trehalose or\n",
      "sorbitok salt-fern&ing counter-iona such as sodium; metal\n",
      "complexes (e.g.. Zn-prote&n complexes): and/or non-&on&c\n",
      "surfactants such as T)&/L&LN&», PLL&RONICS'u or polyeth-\n",
      "ylene lycol (PFG)\n",
      "\n",
      "Liposomes containing the PCSK9 antagon&st ant&body,\n",
      "pept&de, or aptamer are prepared by metliods lo&own in the am\n",
      "such as described iu Epsteu&. et al.. 1985, Proc Natl. Amid.\n",
      "Sc&. IJSA 82:3688; I hvang, et al.. 1980, Pmc. Natl. Aced. Sci.\n",
      "IJSA 77:4030. and IJ.S. Pat Nos 4.485,045 and 4.544.545.\n",
      "I.&posomes with enhanced circulat&on tnne are d&sclosed in\n",
      "I I S. Pat No. 5 013 556. Particularly useful liposomes can be\n",
      "gcneratedi by the reverse plxisc evaporat»m nwthod with a\n",
      "l&pid compos&t&on ci&mpnsu&g phiisphatidylchohne, chiiles-\n",
      "terol and VF,(i-dcrivatizcxI phosphatidylethanolaminc (PHJ-\n",
      "PF) I,iposomes are extruded through tiltcrc ol'defini:d pore\n",
      "size to yield liposomes with the desired d&ameter.\n",
      "\n",
      "The active ingr&xlicnts may nlso be entrapped in microcap-\n",
      "sules prepared. for example, by coacervat&on teclm&ques or by\n",
      "interfacial polymenzation. for example, hydroxymethylcel-\n",
      "lulosc or gelatin-microcapsules and poly-(methyhnethacry-\n",
      "late) microcapsules. respectively. &n collouk»1 drug dehvery\n",
      "systems (for example. Iiposomes. albumin microspheres,\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "19\n",
      "micrommds iims, nano-particles and nano capsules) or in mnc-\n",
      "roemulsinns. Such tecluiiques are disclosed in Remington,\n",
      "The Science and Pmicuce of Pharmacy. 20th Ld.. Mack Pub-\n",
      "lishmg (2000)\n",
      "\n",
      "Sllstan«XI\"IclcBSC pl'ipali&110&IS mal'li pl'i.\"Pitied Sultablc\n",
      "examples of sustained-release prepamtions include semiper-\n",
      "meable matnces of sohd hydmphobic polymers containing\n",
      "the antibody, winch matnces are in fiie form ol shaped\n",
      "articlcx e g.. film~. or microcapsules Fxamplcs of sustaiiwd-\n",
      "release niatrices include polyesters, hydrogels (for example,\n",
      "poly(2-hydroxyethyl-methacrylate), or 'poly(vinylalcohol)),\n",
      "polylamides\n",
      "\n",
      "3,77'3,919), copolvmers\n",
      "\n",
      "(IJ.S Pat No\n",
      "\n",
      "ol'-glutamicacid and 7 ethyl-L-glutanmte, non-degradable\n",
      "\n",
      "ethylene-vinyl acetate, degradable lactic acid-glycolic acid „\n",
      "copolymers such as the LIJPRON DFPOTI\" (uijectable\n",
      "microsplmrcs composed of lactic acid-glycolic acid copoly-\n",
      "mer and leupmlidc acetate), sue«isa acetate isobutyrate. Bnd\n",
      "poly-D-(-)-3-hydroxybutyric acid.\n",
      "\n",
      "\"\n",
      "\n",
      "o\n",
      "\n",
      "The fonuulations to be used lorin vivo administration must\n",
      "be stemle, This is readily accomptisticxt by. I'or example, fil-\n",
      "tration through sterile filtration membmnes. Therapeutic\n",
      "PCSK9 antagonist antibody, peptide. or aptamer compos&-\n",
      "tions are generally placed into a container having a sterile\n",
      "access port, for example, an intmvenous solution bag or vial\n",
      "havingsstopperpierceableby ahypoderm&c intecuonneedle.\n",
      "Suitable emulsions may be prepared using commercially\n",
      "Bvailiiblc fal clil&llsloilm such Bs IBIIBtlp&d™. I,lposynru.\n",
      "Infonutrol'\", Lipohuidinru and Llpiphysani\", The active\n",
      "ingredient may be cilhcr dissolved in a prc-mixed cmutsion io\n",
      "composition or alternatively ll may be dissolved &n an o&1\n",
      "(e.g.. soybean oil, saftloiver oil, cottonseed o&l. sesame oil,\n",
      "corn oil or almond oil) Bnd an emulsion fiirmcd upon mixing\n",
      "ivlth a phospholip&d (e.g.. egg phosphohp&ds, soybean phos-\n",
      "pholipids or soybean limithin) nnd water. It will bc appreci-\n",
      "atcdt that other ingredients may be aifdcd, for cxmuple glyc-\n",
      "lucose. to adlust fiie toiucity ofthe ennilslon. Suitable\n",
      "erol or\n",
      "ennilsions will lypically contain up to 20%v oil, for cxaniple,\n",
      "belween 5 and 20%. Thc I'at emulsion can cmnprise fat drop-\n",
      "lets between 0.1 and 1.0 um, particularly 0.l and 0.5 pm, and sr&\n",
      "luive a PH in tlm range of 5 5 to 8 0.\n",
      "\n",
      "\"»\n",
      "\n",
      "The emulsion compositions can be those prepared by mix-\n",
      "ing B P( SK9 antagonist antibody. peptide, or aptamer with\n",
      "Intralipidr\" or the componmils thereof (soybean oil, egg\n",
      "phospholipids. CPycerol and water).\n",
      "\n",
      "Cmmpositions for inhalation or insuffiation include solu-\n",
      "tions and suspensions ui pharmaceut&cally acceptable. aque-\n",
      "ous or organic solvent~. or mixtures thereof, and powders.\n",
      "Thc liquid or solid composit&mis may contain suitable phar-\n",
      "maceutlcally acceptable excipients as set out above. In some\n",
      "embodiments, the compositions are Bdmmistered by the oral\n",
      "or nasal respiratory route fiir local or systemic e fleet. Com-\n",
      "positions in prefembly stenle pharmaceut&cally acceptable\n",
      "solvent~ may be ncbuliscd by usc of gases Nebulised solu-\n",
      "tions may be breathed directly I'rom the nebulising device or\n",
      "the nebulising device may be attached to a face mask, twit or\n",
      "intcrmiltcnt positive pre«sure breathing machine. Solution.\n",
      "suspens«in or poivder compositions may be administered,\n",
      "prefembly orally or nasally, from devices which deliver the\n",
      "formulation in an appropriate manner\n",
      "IL PCSK9 Antagonists\n",
      "\n",
      "11m methods of the invention use a P('SK9 antag(mist\n",
      "antibody. peptide. or aptamer. w tuch refers to miy peptide or\n",
      "nucleic acid molecule tlmt blocks, suppres sea or reduces (in-\n",
      "cluding significantly reduces) P(.SK9 biologimil nctivity.\n",
      "&ncluduig doivnstream patt«vays mediated by PCSK9 signal-\n",
      "inc, such as elicitation of a cellular response to PCSK9.\n",
      "\n",
      "o\n",
      "\n",
      "1\n",
      "\n",
      "so\n",
      "\n",
      "(\n",
      "\n",
      "20\n",
      "A P('SK9 nntagonist antibody, PCS&tide, or aptmner should\n",
      "exlub&t Bny one or more of the folloiv&n clmractenstics: (a)\n",
      "bind to PCSK9; (b) block PCSK9 interaction with the LDLR;\n",
      "(c) block or decrease P( SK9-mcdiatcd doivn-regulation of\n",
      "the LDLR; (d) inlublt the PCSK9-mediated decrease ui LDL\n",
      "blood clearance, (e) increase LDL clearance in mcxfia by\n",
      "cultured hepalocytea, (0 increase blood I,DI. clearance by the\n",
      "liver ui v&vo, (\n",
      ") sensiuze to statins, and (ti) block PCSK9\n",
      "inhibi-\n",
      "in&cree&ion with other yei to bc identified ihctors.\n",
      "\n",
      "&o\n",
      "\n",
      "For purposes of llus nivent&on, the milibody. peptide. or\n",
      "\n",
      "aptamer preferably reacts with I'C'SK 9 in a maiuier that\n",
      "tss P(. SK9 signaling functmn and I,DI,R mtcraction In some\n",
      "embodiments. the PCSK9 antagomst antibody specitically\n",
      "recognizi:s prllnate P(.'SK9\n",
      "the\n",
      "PCSK9 uitagonist antibody binds primate and rodent\n",
      "I'CSKOJ.\n",
      "\n",
      "In sonw. embodiments.\n",
      "\n",
      "Thc antibodies useful in the present invention can encom-\n",
      "pass monoclonal md&bodies. polycloiml mtibodies, mitibody\n",
      "fragments (e.g., Fab, Fab', F(ab')„Fv, Fc. etc.), chimeric\n",
      "antibodies, bispccific mitibodics. hctcroconjugate antibodies,\n",
      "sm~JC chain (ScFv), nu&tants thereol'. i&sion proteins com-\n",
      "prising an antibody portion (e.g., a dnmain antibody), Inunan\n",
      "atuibodies, hunmn&zed antibodies, and any other modified\n",
      "config&umtion of the inmuinoglobulin molecule that com-\n",
      "prises an antigen recognition site of the required speciticity,\n",
      "uicludin glycosylat&on variants of antibodies. amino acid\n",
      "8'Ill&la&&Clog&call-\n",
      "sequence variants of antibodies. and covalently moditied\n",
      "a&uibodica. The uitibod&es may be murine, rat. hummi. or any\n",
      "other ofigtn (including ctumenc or humanized antibodies).\n",
      "\n",
      "In some embodiments. the P(.'SK9 antagonist antibody is a\n",
      "monoclonnl anubody The PCSK9 muagonist antibody can\n",
      "also be lnunanized. In other embodiments, the aimbody is\n",
      "human\n",
      "\n",
      "In some emboduuents, the antibody composes a moditied\n",
      "\n",
      "c oils tant ri'glori, sllcli Bs a cons&alit regin&1 &liat Is\n",
      "yally inert, that is, havulga reduced pomntia1 iiir provoking an\n",
      "uunnuie response. In some embodiments, the constant region\n",
      "is modified as described in I ur .1. Inummoi.. 1999. 29:2613-\n",
      "2(124, PC:T Publ. No WO99/58572: anti'or UK Pulent Appli-\n",
      "cation No. 98099S1.8. 'the I'c can be human lg()2 or hilluain\n",
      "IgCis The Fc can be human lgCi2 contain&flu thc nlillaltlol'I\n",
      "A330P331 to S330S331 (Idiom), in which the Bnuno acid\n",
      "residues are munbered with reference to the wild type IgCi2\n",
      "sequence Iiur J Inununol. 1999. 29 2613-2624. In some\n",
      "emboduuents. the antibody comprises B constant region of\n",
      "Ig(14 comprising the following nu&tations (Armour et al.,\n",
      "2003. Molemdar Inununology 40 585-s93): 0233F234L235\n",
      "to P233M234A23S (Igni«). in which the numbering &s with\n",
      "rel'erence to wild type tg(i4 In yet another embodiment. the\n",
      "is human IgCJ4 02331'234L235 to P233V234A235 with\n",
      "deletion C&236 (tgOB „,). In another embodiment the Fc is any\n",
      "lnunan IgC14 Fc (Ig(is. IgCI«s or Ig(i«,.) contaimng hinge\n",
      "stabihzuig mutation S228 to P228 (Aalberse et al., 2002,\n",
      "Immunology 105, 9-19) In anotlmr cmbodimmit. Iho Fc cmi\n",
      "be aglycosylnted I c\n",
      "\n",
      "the constant\n",
      "\n",
      "In some embodiments, the constant region is ag lycosyl ated\n",
      "by mutating lhc oligosaccharide attaclmmnt rcsiduc (such as\n",
      "Asn297) aod,'or itankuig residues tlrat are pan of the glyco-\n",
      "sylation recognition sequence in the constant region. In some\n",
      "region is aglycosylatcd Ior\n",
      "cmb&idimcnts.\n",
      "N-linked glycosylation enzymatically. The constant region\n",
      "may be aglycosylatixl for N-linked glycosylation cnzymati-\n",
      "cally or by expression in a glycosylat&on deficient host cell.\n",
      "The binding BSnity (Kol of a PCSK9 antagonist antibody\n",
      "to P(.SK&J (such as Inunmi P(.'SK9)) can be about 0 002 to\n",
      "about 200 BM. In some embodiments, the buiding affinity is\n",
      "any of about 200 nM. about 100 nM, about 50 nM, about 10\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "21\n",
      "nM, about I nlVL about 500 pM, about 100 pM, about 60 pM,\n",
      "about 50 pM, about 20 pM. about 15 pM, ubout 10 pM, about\n",
      "5 pM, or about 2 pM. In some embodiments, the binding\n",
      "affinity is less than any ofabout 250 nM. about 200 nM, about\n",
      "100 nM. about 50 nM, about 10 nM, about I nM, about 500 s\n",
      "pM, about 100 pM, about 50 pM. about 20 pM, about 10 pM.\n",
      "about 5 pM. or about 2 pM.\n",
      "\n",
      "a\n",
      "\n",
      "One way of deternuiung binding ailimty of antibodies to\n",
      "P('SK9 is by n&easunng. binding aginity ol'monofunctiwml\n",
      "Fab fmgments of the antibody. To obtain monofunct&otu&1 I'ab 8&\n",
      "fragments, an antibody (for example, IgCI) can be cleaved\n",
      "w&th papaii& i&r expressel recombu&ni&tlv Thc affit&ify of a\n",
      "PCSK9 I'ab fmyuent of an at&tibody can be deternuned by\n",
      "sari'ace plasmon resonance (Biacore3000™ surface plasmon\n",
      "resonance (SPR) svstcm. B&score, INC, P&scatav ay NI\n",
      ")\n",
      "equipped &vith pre-inunobilized streptavidin sensor chips\n",
      "(SA) using HBS-FP nmning buffi.r (0.01M HFPFS. pH 7 4,\n",
      "0.15 NaCI. 3 mM EDTA. 0,005% v/v Suriacxaut P20). Riot&-\n",
      "nylated luunan VCSK9 (or any other VCSK9) cm& be diluted\n",
      "into HBS-FP butferus a conccntmtion ol'less tlum 0.5 pg/mi\n",
      "and injected across the u&dividual clup channels usu&vg van-\n",
      "able contact times, to achieve tvvo ranges of m&tigen density,\n",
      "e&ther 50 200 response umts (RU) for data&led kmet&c studies\n",
      "or 800-1,000 RU for screenmg assay&. Regenerat&on studies\n",
      "have shown tlrat 25 mM NaOH in 25% v/v ethanol ctfi:ctively \"\n",
      "removes the bound I'ab wlule keep&ng the actwity of PCSK9\n",
      "on the clup for over 200 injections. Typically, serial d&lutions\n",
      "(spin&&ln&g conceal&i&t&(ii&s iif 0 I-10x est&mated Ko) ol'un-\n",
      "fied I'ab samples are injected for I min at 100 I&L/n&inute and\n",
      "dissociation times of up to 2 bo&lrs alc allo'wcvf. Thc c(incor. &(i\n",
      "&rations of the Fab prole&ns are determined by ELISA and/or\n",
      "SDS-PAUL elec trophores is using a Iinb of lo&own concentra-\n",
      "tion (ns dcti:rtnincd by amiw& acid analysis) as a standard\n",
      "K&netic assoc&anon rates (k,„) u&d d&ssociation rates (k,z) are\n",
      "obmined simultaimously by titting the data globally to a I: I\n",
      "I,angmuir bindin inodcl (Karla&a&n, R Roos, H Fagerstmn.\n",
      "L. Petersson. B, 1994 Methods Enzymology 6. 99-110)\n",
      "using tlm BL&.evaluation program. I;quilibrium dissociation\n",
      "constant (K„) vului:s are calculated i&s k.~'k„,. This protocol\n",
      "is suitable for use in detem&ining bind&ng affinity of an anti- sr&\n",
      "body to any PCSK9, including human Pt SK9. PCSK9 of\n",
      "another mammahan (such as mouse PCSK9. rat PCSK9,\n",
      "primate I&CSK9). as &veil as different forms of I&CSK9 (such\n",
      "as o and $& fom&) Binding nliinity of an antibody is gencmlly\n",
      "measured at 25\" C., but can also be measured at 37'.\n",
      "\n",
      "11&e V(:SK9 antagonist antibodies may be made by any\n",
      "method known in. the ait uicludu&g the method as prov&ded &n\n",
      "Example l. 'I'he rome and schedule of immun&zat&on of the\n",
      "host animal are generally in keeping with es&abi&shcxl and\n",
      "convennonal techmques for ant&body stimulat&on and pro-\n",
      "duct&on, as further described here&n. Oeneral techniques for\n",
      "product&on ol'human md mouse ant&bodies are known in thc\n",
      "ait and/or are described herein. A currently preferred method\n",
      "of n&ak&ng the antibodies con&prises tlm immuniwition of\n",
      "PCSK9 knockout (P('SK9-/-) annuals as disclosed herein\n",
      "It is contemplated that any manunalian subject including\n",
      "humnns or muibody pmducing cells thercl'rom can bc\n",
      "man&pulated to serve as the basis for producuon ol'mamnui-\n",
      "lian, including human. hybridoma cell lines Typically, the\n",
      "lliisi animal is inoculated intrapcritoneally, intra&miscularly,\n",
      "intraplantar, and/or u&tradennally\n",
      "orally, subcutaneously,\n",
      "with an amount of in&munogen, including as described herein\n",
      "Hybndomas cm& be prepared from the lymphocytes and\n",
      "inunortalized myeloma cells using the geneml somat&c cell\n",
      "hybridizatiw& technique of Kolder. B. m&d Milstcin, C . 1975.\n",
      "Nature 256:495-497 or as mod&fied by Buck, D. W.. et al..\n",
      "I&982, In Vitro. 18:377-381. Available myeloma lines, includ-\n",
      "\n",
      "u\n",
      "\n",
      "s\n",
      "\n",
      "R&\n",
      "\n",
      "r\n",
      "\n",
      "22\n",
      "ing but not lin&ited to X63-Agg 6&53 m&d those from the Salk\n",
      "Institute. ('ell 1)isuibution (Jcnter, San Diego. I alif.. i ISA,\n",
      "may be used in the hybrtd&zat&on. (Ienerally. the teclm&que\n",
      "involves fusing n&yeloma cells and lymphoid cells us&ng a\n",
      "fusogcn such as polyethylcnc glycol, or by elcmtrical means\n",
      "well knot&n to those skilled in the art. After the fiision. the\n",
      "cells are separated from the fus&on medium and gn&wn in a\n",
      "selective growth mednun, such rwv hypoxanth&ne-uninop-\n",
      "tcrin-thymidiim (HAT) medium, to eliminate unhybridized\n",
      "parent cells. Any of the media described herein. supple-\n",
      "mented w&th or &vithout serum, can be used for cultunnv\n",
      "hybridomas lira& secrete monoclonal untibodies. As miother\n",
      "altcmative to the cell fiision technique, EB&/ immortalized B\n",
      "cells may be used to produce the PCSK9 monoclonal anti-\n",
      "bod&es ofthe subject invention. The hybrtdomas are expanded\n",
      "and subcloned. if desired. and supcrnatants are assayed for\n",
      "af&t&.in&n&un(igen act&vlrt'lv'iinvcntun&al immunoassay pro-\n",
      "cedures (e.g., rad&oimmunoassay, enzyme inununoassay, or\n",
      "lluorescence &m&mmoassay)\n",
      "\n",
      "Hybridomas that may be used as a source of nnt&bodies\n",
      "encompass all derivatives, progeny cells of the parent hybri-\n",
      "domas tlmt produce nionoclonal ant&bodies specilic for\n",
      "I'C SK9. or a portion thereof.\n",
      "\n",
      "Hybrido mes that produce such antibodies may be grown in\n",
      "v&tro or in vwo usia known procedures. The monocku&al\n",
      "antibodies may be isolated from the culture media or body\n",
      "lluids. by coinvent&oral immunoglobului purilication proce-\n",
      "dures such as anunon&wn sulfate precipitation, gel electro-\n",
      "phorcsis, dialysis. chromatography. m&d ultrafiltration, if\n",
      "desired. IJndesired aciivity, &f present, can be rmnoved. for\n",
      "example, by rnm&u&g the preparation over adsorbent s made of\n",
      "the immunogcn attachedto asolidphascandclutingorrclcas-\n",
      "u&g the des&red m&tibodies off the immunogen. Inunumrtit&on\n",
      "of a host animal with a human PCSK9, or a fragment con-\n",
      "&ainuig the target amino acid scquencc conjugated to a protmn\n",
      "that &s &numu&o eric in the spec&es to be immumzed. e.g.,\n",
      "keyhole limpet lmmocyanin, serum albumin, bovine thyro-\n",
      "globulin, or soybean tryp sin inhibitor usu&g a b&li mctional or\n",
      "dertvat&z&ng agent, for example, maleinudobenzoyl sul fosu-\n",
      "ccinimi  ester (conjugation through cysmine residues), N-hy-\n",
      "droxysuccin&mide (thmugh lysine residues), glutaraldehyde,\n",
      "\n",
      "succinic anhydride, SOLq„or R'N I'R, where R and\n",
      "R're dilferent alk31 groups. can yield n population oi'anti-\n",
      "bod&es (e.g., monoclonal antibod&es).\n",
      "\n",
      "If desired, the V(.'SK9 antagonist antibody (monoclonal or\n",
      "polyclonal) ol interest may be sequenced and the polym&cle-\n",
      "ot&de sequence n&ay then be cloned u&to a vector fiir expres-\n",
      "\n",
      "sion or propagation Tbe sequence encoding tbe &mubodyol'&terestmay be mau&tau&ed u& vector &n a host eel I and the host\n",
      "\n",
      "cell can then be expanded and frozen for future use. Produc-\n",
      "t&on ofrecombu&mu n&wuiclonal antibod&es in cell culture can\n",
      "be cerned out tlu ough c luring ofant&body enes from B cells\n",
      "by means knmvn in thc art. See, e g., Tiller ct al.. 2008, .I.\n",
      "Imnuu&ol Methods 329. 112: US Pat. No 7,314,622.\n",
      "\n",
      "In an alten&ative. the polyoucleotide sequence may be used\n",
      "for genetic nianipulation to \"humanize\" tlm antibody or to\n",
      "improve the aiffimty. or other charactertst&cs of the antibody.\n",
      "For example, the constam rey'on may bc engineered to more\n",
      "nearly resemble human constant regions hi avoid immune\n",
      "response if the ant&body is used in cl&nical trtals and treat-\n",
      "ments in hunuins. It mny be desirable to genetically manipu-\n",
      "late the ant&body sequence to obtain greater aiiimty to PC SK9\n",
      "and greater efficacy u& inlubiting PCSK9). It will be apparent\n",
      "to one of skill\n",
      "in tlm art that one or more polynuchx&tide\n",
      "changes can be made to the PCSK9 antagonist ant&body and\n",
      "still maintain its binding ability to VCSK9.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "23\n",
      "'IJmre are filar general steps to humanize n n&onoclonal\n",
      "anubody. 'Ihese are: (I) determuung the nucleotide mid pre-\n",
      "d&cted amino acid sequence of the starting antibody li Jv&t and\n",
      "hcavy variable domains, (2) designing tlm Inimanizcd anti-\n",
      "body, i.e.. decidu&g v;hich mit&body frmnessork reg&on to use s\n",
      "during the humanizing process; (3) the actual luunanizing\n",
      "Illelllodologlesl tech&i&clues:\n",
      "tile trail&feet&(ill alltl\n",
      "iilltl\n",
      "expression ofthe humaruzed antibody. See. for example. U S.\n",
      "Pa( N(is. 4816,5C&7, 5.80771 3; 5,86C&692, 6331 415, 5„530,\n",
      "101: 5.693,761: 5.693.762; 5,585.08&J; and CI.180.370\n",
      "\n",
      "(4)\n",
      "\n",
      "ui\n",
      "\n",
      "iklmallls Sl:e,\n",
      "\n",
      "A number of\"humanized\" antibody molacu les compr&sing\n",
      "ml at&ligen-binding sile dcrivcd fret&& n i&on-1&im& nl itlunuilo-\n",
      "globul&n have been descnbed. &ncludin clumenc antibod&es\n",
      "having rodent or modified rodent V regions and their associ-\n",
      "ated CDRs fles&xi\n",
      "fol\n",
      "ttl hill&lail et&list&lilt\n",
      "example, Winter et al., IWI. Namre 349:293-299: Lobuglio\n",
      "ct al., 1989. Proc Nat Aced Sci. USA 86 4220-4224. Shat&\n",
      "ei al . 1987. 1 Immiu&ol 138 4534-4538, and Brown et al..\n",
      "1987. ('sneer Res. 47:3577-3583. Other references describe\n",
      "rodent C'DRs grnfted into a humm& supporting framcvork n\n",
      "re@'on (FR) prior to fissio with mi appropriate human ant&-\n",
      "body constant domain See, for example, Ricechmann et ai.,\n",
      "1988. Nature 332.323-327, Verhoeyen et al.. 1988. Sc&ence\n",
      "23&J&1534-153 G: and Jones et al.. 1986, Nature 321:522-52 S.\n",
      "Another refi:rcncc describes rodent\n",
      "recombinantly eng&neared rodent fmmework reg&ons. See,\n",
      "for example, European Patent Publ. No. OS1959G. These\n",
      "\"humalllzetf ill(ilecllles are designed ni mlllltlllli: nllwiillletl\n",
      "&mmunolog&cal response tou ard mdent anti-human ant&body\n",
      "molt:culcs which limits thc duration and efTcvtiivncss of lo\n",
      "therapeutic applm mons ol'hose moiet&es in hunuin rec&pi-\n",
      "cots. I'or example. the ant&body constant reg&on can be eng&-\n",
      ". docs not\n",
      "ncercd such that u is immunologically inert (e\n",
      "trigger complement lysis). See. e.g., PCT Publ. No WO99/\n",
      "&8572; I.&K I'atm&t Application No. 98099&1.8. Other meth-\n",
      "ods of In&manizing antibodies that may also be utilized arc\n",
      "d&sclosed by Dmigherty et al.. 1991. Nucl. Ac&ds Res.\n",
      "19.2471-2476 and in U S. Pat. Nos. 6,180377; Ci,054,297;\n",
      "5.997 867: & 866 692. 6 210 671: and 6 350 861: and in PC'\n",
      "Publ. No. WO 0 1i27160.\n",
      "\n",
      "( DRs supponcxl by \"\n",
      "\n",
      "st t\n",
      "\n",
      "\"»\n",
      "\n",
      "In yet another alternative. fully hill&la&& alltibodies mny bc\n",
      "obta&ned by us&ng commerc&ally available m&ce that have\n",
      "becca engineered to express specific human inununoglobulin\n",
      "proteins Transgonic m&imnls tlrat are designed to produce a\n",
      "more des&rable or more robust &nunune response may also be 4.\n",
      "used for generation of humanized or human antibodies.\n",
      "Ex unples of such technology are Xenomousel&'mm\n",
      "Abgen&x, lnc. (I'reniont, Calif.), lfuIVL&b-Mouseic and 'I'C\n",
      "Mouseru iron& Medarex,\n",
      "imd the\n",
      "Inc.\n",
      "Veloclnunune*'k mouse from Regeneron Phannaceuticals,\n",
      "Inc. Cfanytown. N.Y).\n",
      "\n",
      "(Princeton, N Jl),\n",
      "\n",
      "o\n",
      "\n",
      "s\n",
      "\n",
      "In nn nltcrimtivc. antibodies may be made rcwomb&nantly\n",
      "and expressed usuig any method known in the art. In another\n",
      "altcrnativc. antibodies may bc made rccombinantly by phage\n",
      "d&splay leclu&ology See, for example. U.S. Pnt. Nos. 5,565,\n",
      "332: 5,580.717; S,733,743; and t&,265,150: and Winter et al.,\n",
      "12 433-455 Alternativelv thc\n",
      "1994. Annu Rev lmmunol\n",
      "phage display teclmology (McCalTerty et al.. 1990, Nature\n",
      "348:552-553) can be used to produce human antibndics and\n",
      "ant&body frag&neat& in v&tro, I'rom immunoglobulin vnriable ai\n",
      "(V) dommn gene repertoires from un&mmunized donors.\n",
      "According to this tecluiique, mitibody V domain genes nre\n",
      "cloned in-frame into e&ther n major or conor coat prole&n gene\n",
      "of a filamentous bacteriophage. such as M13 or fd, and dis-\n",
      "plnycxl as fiinctional antibody fmgments on thc surface ofthe r\n",
      "phage particle. Because the filamentous part&cle contains a\n",
      "single-stranded DNA copy of the phage genome, selections\n",
      "\n",
      "24\n",
      "based on the functiimal prope&ties of thc m&tibody also result\n",
      "ui selection of the\n",
      "ene encoding the antibody exlub&un\n",
      "those properties. Thus, the plmge mimics some of the prop-\n",
      "cnies of thc B cell Phage display can bc pcrfornwd in n\n",
      "vanety of formats; see, e.g.. Joluison, Kevin S. and Cluswell,\n",
      "l&avid J., 1993, ('urrent Opinion in Stnicnira1 Bioloht) 3:5(i4-\n",
      "571. Several sources of V- ene segments can be used for\n",
      "phage display. Clackson et al., IWI. Nature 352;624-628\n",
      "isolated a diverse. array of nit&i-oxazt&lo&tc ant&bodies froin a\n",
      "small nsndom combuuttonal hbrary ofV enes derived from\n",
      "the spleens of umnunized mice. A repertoire ofV genes f'rom\n",
      "unimnnmi ted Iunuan dm&or, can bc constntctcxf and antibod-\n",
      "ies to a d&verse array of ant&gens (including self ant&gens) can\n",
      "be isolated cairn&tially follow:ing tlm teclmiqucs described by\n",
      "Mark et al.. 1991, I Mol B&ol 222:581-597, or Ciriffith et nl.,\n",
      "IW3. L'MBO J. 12:725-734. In a natural inunune response,\n",
      "antibody genes accuimilate mutations at a high rate (somntic\n",
      "hypenmnat&on). Some of the ch mges introduced w&ll confer\n",
      "higher afhnity, mid B cells displaying high-affmity surface\n",
      "immunoglobulin are prefercntially replicated and diffi:rm&ti-\n",
      "ated dunng subsequent antigen challenge. Tlus natural pro-\n",
      "cess can be mimicked by employing tl&e teclmique known as\n",
      "\"chain shufiiingy (Marks et al.. 1992, Bio/Teclmol. 10:779-\n",
      "783). In this method, the affinity of \"primary'* lmman anti-\n",
      "bodies ohtaiiwd by phage display can be improved by sequen-\n",
      "tially replac&ng the heavy and 1&ght chain V region enes w&th\n",
      "repertoires of naturally occu&ring variants (repertoires) of V\n",
      "domaui genes obtained from unimnnm&zed donors This lceeh-\n",
      "mque allow s the pmduction of ant&bodies nnd antibody frag-\n",
      "ments with affinities in the pM-nM ange A stmtcgy for\n",
      "maku& very large phage au&&body reperto&res (also knoivn as\n",
      "\"the mother-of-sll 1&branes\") has been described by Water-\n",
      "house et al, 1993, Nucl Acids Res 21.22C&5-2266. (ienc\n",
      "shulf1&ng can also be used to derive luuu m antibodies from\n",
      "mdent antibodies, where the human antibody has similar\n",
      "afiimtics aml spccilicities to tlm sinrting mdent antibody.\n",
      "Accorduig to tlus method, uluch is also referred to as\n",
      "\"epitopc imprinting\", the hcavy or fight chain V donmin cene\n",
      "of rodent muibodics obtuini:d by phage display technique is\n",
      "replaced v;ith a repertoire ofInunan V domain genes, creating\n",
      "rodent-human chimeras Selection on antigen results in iso-\n",
      "lat&on of human vanable regions capable of restoring a func-\n",
      "tional antigen-binding site. i.e, the epitope governs (im-\n",
      "prints) thc choice of panner Whmi thc process is repeated in\n",
      "order to replace the remaining rodent V domain, a luunan\n",
      "antibody is obtained (see PCT Publ. No. WO 93i06213).\n",
      "Unl&ke traditional hiunanizat&on of rodent antibodies by CDR\n",
      "gmfting. this tecluuque provides completely luunan antibod-\n",
      "&~es, uhich have no I'rameuork or C'DR residues of rodent\n",
      "0&I gill.\n",
      "\n",
      "ant \n",
      "\n",
      "It &s apparent that al thous+ the above discussion pertains to\n",
      "lnunau&zed nnubodies. the general principles d&scusssed ime\n",
      "nppl&cable to custom&zuig ant&bodies for use. ftir exmnple, &n\n",
      "dogs, cats, primate, equi&ms m&d bovines. It is furiher apparent\n",
      "that one or more aspects of human&zuig an\n",
      "&body des cn bed\n",
      "herein may be con&bine&I, e g.. ('DR grafting. framesvork\n",
      "nuitation and C'DR mutation\n",
      "\n",
      "Ant&bodies may be made recoinb&n u&tly by first &solauog\n",
      "the antibodies and antibody producing cells from host ani-\n",
      "mals, obtaining tlm gene sequence. and usia\n",
      "ihe gene\n",
      "sequence to express the antibody recombinantly in host cells\n",
      "(e g., ( HO cells) Another method which mny bc employcxl is\n",
      "lti express the antibody sequence &n plants (e.g.. tobacco) or\n",
      "trm&sgenic milk. Methods for expressing antibodies recombi-\n",
      "nantly in plams or milk lmvc been disclosed. Sox for\n",
      "example, Peeters, 2001. et al. Vaccine 19:2756: Lonberg, N.\n",
      "and D. Huszar, IW5, Int. Rev. Inununol 13:6S: and I'ollock,\n",
      "\n",
      "\f",
      "(js 8,080,243 B2\n",
      "\n",
      "25\n",
      "et al, 1999, I Immunol Merhods 231:147. Methods for mak-\n",
      "ing derivatives of antibodies. e g., humanized, single chain,\n",
      "etc. are known in the art.\n",
      "\n",
      "hnmunoassays m&d liow cytomctry sorting techniques such\n",
      "as fiuorcscencc acti&a&ed cell sorting (FA('8) can also bc\n",
      "employed to isolate antibodies that are specific for PCSK9.\n",
      "The antibod&es can be bound to many d&fferent camera.\n",
      "Carriers can be acnve and/or u&ert I.xamples of well-known\n",
      "carriers include polypropylcne, polystyrene, pe)yeti&')cue,\n",
      "dextran, nylon, amylases, glass, nan»al and modified cellu-\n",
      "loses, polyacrylmnides. Sgaroses and magnet&te. 'Il&e nature\n",
      "oithcc uriercanbeeitlmrsolubleoruisolublcforpurposesol'he\n",
      "\n",
      "invention. fhose skillcxI in the an will know of other\n",
      "suitable carriers for binding antibodies. or &vill be able to\n",
      "ascertain such, usu&g rounne experuuenlation.\n",
      "In some\n",
      "en&bodimcnts, tlm carrier comprises a moiety that targets the\n",
      "myocnrdnun\n",
      "\n",
      "Ia\n",
      "\n",
      "c\n",
      "\n",
      "DNA encoding the monoclonal ant&bodies is readily iso-\n",
      "la&ceil and sequenced using convent&onal procedures (e g.. by\n",
      "using oligonucleotide probes that are m&pable ol'bind&ng spe-\n",
      "ciiically to genes encoding the heavy and light chnins of the\n",
      "monoclonal m&tibodies). The hybndoma cells serve as a pre-\n",
      "ferred source of such DNA. Once isolated, the DNA may be\n",
      "placed u&to express&on vectors (such as expression vectors \"\n",
      "d&sclosed &n PCT Publ. No. WO 87/04462). v,hich are then\n",
      "transfected into host cells such as E. co/i cells, simian COS\n",
      "cells, (.hinese hains&er oven (CIIO) cells. or myeloma cells\n",
      "that do not otherwise produce immunoglobuhn protein, to\n",
      "obtain tlm syntlmsis oi'nxmoclonal antibodies in the rccmn- &a\n",
      "bn&anthost cells See.e.g.. PCTPubl No WO87/04462. The\n",
      "DNA also may be modified. for example. by substitut&ng the\n",
      "coding scqum&cc filr human heavv aml light ch&un constant\n",
      "domains in place ol'&he homologous murine sequences, Mor-\n",
      "rison ct al.. 1984, Proc Nat Aced. Sci. 81:6861, or by \"»\n",
      "covalently joining to the immunogkibubn wlding scxiucncc\n",
      "all or part of the coding sequence for a non-&nununoglobulin\n",
      "polypeptide. In that manner. \"chinmric\" or \"hybrid\" antibod-\n",
      "ies are prepared thut have the binding spec ifimty o I'a PCSK9\n",
      "monoclonal antibody herein.\n",
      "\n",
      "st &\n",
      "\n",
      "P( SK9 antagonist m&tibodies and polypcptides dcrivcd\n",
      "from m&tibodies can be Identifie or clmracterized us&ng\n",
      "methods known in the art. whereby reduction, amelioration,\n",
      "or ncutrali&ation of P('SK9 biologicnl nctivity is detected\n",
      "and/or measured. In some embodiments. a PCSK9 antagonist ss\n",
      "antibody or polypeptide is identificxI by incubating a cm&di-\n",
      "date agent w&th PCSK9 and mon&tonng bu&ding &&n&L'or atten-\n",
      "dm&t reduction or neutral&zation of a biological activity of\n",
      "P('SK9. The binding assay may be performed with puniied\n",
      "PCSK9 polypepude(s). or w&th cells naturally expressing, or\n",
      "I'CSK9 polypeptide(s).\n",
      "transfected to express,\n",
      "In one\n",
      "the binding assay is a compet&tive binding\n",
      "emb&xliment,\n",
      "assay, where the abihty of a cund&date ant&body to compete\n",
      "with a known P('SK9 antagonist for P('.SK9 binding is evalu-\n",
      "ated The aswiy may be performed in venous formats, inc iud-\n",
      "In other embodiments, a P('SK9\n",
      "ing the L'LISA fern&at.\n",
      "m&tagonist antibody is identified by incubating a mmdidatc\n",
      "agent w&th P( SK9 and nu&nitoru&g bn&du&g aud attendant\n",
      "inhibition of LDI,R expression and/or blood cholesterol\n",
      "clmirm&ce\n",
      "\n",
      "1\n",
      "\n",
      "sa\n",
      "\n",
      "c\n",
      "\n",
      "I&ollov, ing initial identificat&on. the activity of a candidate\n",
      "P('SK9 antagonist antibody can be further confinncxI and\n",
      "refined by b&oassays that are known to test the targeted b&o-\n",
      "logical activities. Alternatively. bioassays can be used to\n",
      "screen candidates directly Some of thc methods for identify-\n",
      "&ng and characterizing PCSK9 antagonist antibodies. pep-\n",
      "tides, or aptamers are descnbcxl in detail in the Examples.\n",
      "\n",
      "I\n",
      "\n",
      "26\n",
      "P( SK9 antagonist antibodies nu&y bc characterized using\n",
      "methods weil knovn u& the art. I or example, one method is to\n",
      "\n",
      "ident&fy the epitope to which it binds, or \"epitopemapping.*'lmrearc many methods known in thc a&t for mapping nnd\n",
      "\n",
      "charactenzu&g the location of epitopes on pmte&ns, includ&ng\n",
      "solving the crysta I structure of an m&tibody-antigen complex,\n",
      "con&pent&on assavs, gene fragulcirt cxprcsslon &&ss&&vs. &&&xi\n",
      "synthetic peptide-based assays, as descnbed, for example, &n\n",
      "('haptcr 11 ol'liar)on a&xi I,anc, Using Antibodies, a I.abo-\n",
      "mtory Manual, (Cold Sprmg Ilarbor Labomtory Pres~. Cold\n",
      "Spring I h&rbor N Y., 1999). In an add&tione 1 example, ep&tope\n",
      "mappuig cm& bc used to determine the sequence to wluch a\n",
      "erlands \n",
      "PCSK9 antago&ust ant&body b&nds. Ep&tope mappu&g is com-\n",
      "mercinlly avnilnblc from various sources, filr example, Pcp-\n",
      "scan Systems (Lie)her&wc 15. 8219 PH l,elystad, The Neth-\n",
      "). 'II&e epitope can be a linear epito pe, i e., contained in\n",
      "a single stretch of amino acids, or a confimnational epitopc\n",
      "fonncxl by a tinea-din&ensional interactmn of muino wids 01st\n",
      "may not necessarily be contained in a single stretch. Peptides\n",
      "of var) ing lengths (c.g, at least 4-(i mnino acids king) cm& bc\n",
      "isolated or synthesized (e... recombinantly) and used for\n",
      "binding essays with a P('SK9 antagonist antibody In another\n",
      "example. the epitope to wh&ch the PCSK9 ants onist m&t&-\n",
      "body bu&ds can be detem&ined in a systematic screening by\n",
      "using overlapping pcptides derived from the P('SK9\n",
      "sequence and detennu&u& binding by the PCSK9 antagon&st\n",
      "antibody. According to the gene fragment expression assays,\n",
      "the open reading frame encod&ng PCSK9 is fragmented either\n",
      "mndomly or by spec&fic genetic construct&ons and the reac-\n",
      "tivity of thc express&cd I'ragmcn&s ol'PCSK9 with tlm antibody\n",
      "to be tested &s detennu&ed. The gene ikagmen(s n&ay. for\n",
      "example, be produced by PCR and then tmnsc rib ed and trans-\n",
      "lated into protein in &'itro, in thc presence o fradioactivc amino\n",
      "acids. The bu&du& * ofthe u&tibody to the radioactively labeled\n",
      "PCSK9 fragments is then determined by inummoprecipita-\n",
      "tion and gel clectroplxlresi&. ('crtain epitopes can also be\n",
      "&dent&fied by using large 1&bm&nes of random pept&de\n",
      "sequences displayed on tlm surface of phage particles (phage\n",
      "hbraries) Alten&atively, a defined hbrary of overlapping pep-\n",
      "t&de frag&neo&a can be tested for binding to the test antibody in\n",
      "simple binding essays. In nn additional example. mutagenesis\n",
      "ofan ant&gen bu&d&ng domau&. domain swapp&ng experiments\n",
      "and alanine scaiufing nuitagenesis can be perfonucxI to iden-\n",
      "ti6 residues required, sufficient, and/or nocessary for cpitope\n",
      "binding. For exmnple, domain swapping expenments can be\n",
      "performed using a mutant P('SK9 in u hich various fragments\n",
      "of the PCSK9 polypept&de have been replaced (swapped)\n",
      "with sequences from VCSK9 from another species, or a\n",
      "closely related, but antigenicnlly distinct pmtein (such as\n",
      "another member of the proprote&n convertase fanuly). I)y\n",
      "assess&ng binding of the m&tibody to the mutant I'CSK9. the\n",
      "in&portance of tbe p aticular P(:SK9 I'ragment to antibody\n",
      "bindino can be assessed.\n",
      "\n",
      "Yet snot)mr nlcthod wl'lich can bc &ised to chamcterize a\n",
      "PCSK9 &Intagonist ant&body is &o use competit&ou essays with\n",
      "other nntibodies known to bind to the same antigen, i.e.,\n",
      "vtmlous hagnlcn(s on PCSK9, to dctcm&inc if thc P( SK9\n",
      "an&agoms& ant&body bu&ds to the same ep&tope as other mti-\n",
      "bodies. Competition essays are well known to those of sl ill in\n",
      "th&. art\n",
      "\n",
      "I'he crystal structure of the ant&body and antibody:ant&gen\n",
      "complex cm& also be nsed to chamacterize the m&tibody 'II&c\n",
      "residues are identiiied by calculating the d&fierence &n acces-\n",
      "sible surface area between the LI L3:I'('SK9 crystal strucnire\n",
      "and P(.SK9 stn&cturc alone. PCSK9 residues that show buried\n",
      "surface area upon complex formation w&th Li L3 ant&body are\n",
      "'I'he solvent accessible\n",
      "included as a part of the cpitope.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "27\n",
      "surf'ace of a protein is defined as tlm Incus of the emit re ul'\n",
      "probe sphere (represennng a solvent molecule of 1.4 A\n",
      "radius j as it rolls over the Van der Waafs surface ofthe protein.\n",
      "Thc solvent accessible surface area is calculated by gcncrat-\n",
      "uig surface points on an extended sphere about each atom (at\n",
      "equival-\n",
      "a distance from the atom centre equal to the smn of the atom\n",
      "and probe nldli). and eliminating those that he 11 ithin\n",
      "entt spheres associated with neighboring atoms as imple-\n",
      "mented in pnrgram ARBAIMOI (Brings, P J., 2000, CC'P4\n",
      "Newsletter No. 3R CCLRC, Daresbury).\n",
      "\n",
      "5\n",
      "\n",
      "1(1\n",
      "\n",
      "An expression vector can be used to direct expression of a\n",
      "PC'SK9 antagonist mitibody Oiw. skilled in the art is fmlihnr\n",
      "with administration of expression vectors to obtain expres-\n",
      "sionofmlexogenousprotcin invivo. Sec, e g,US Pat.Nos.\n",
      "6.436.908: 6,413,942, nnd 6,376.471 Administration ol'.\n",
      "expression vectors includes local or systemic administration,\n",
      "includino injoction, oral adtninistration. pnrticle gun or cath-\n",
      "eierized adnumstration, and topical admuuslration\n",
      "In\n",
      "miother embodiment, the expression vector is acbninistered\n",
      "directly to thc sympathetic tnmk or angfion. or into a coro-\n",
      "nary artery, atrium, ventrical, or pericardium.\n",
      "\n",
      "o\n",
      "\n",
      "\"\n",
      "\n",
      "Targeted delivery of therapeutic compositions containing\n",
      "an expression vector, or subgenomic polynucleotides c ui also\n",
      "be used. Receptor-mediated DNA dehvery techniques are\n",
      "described in, for exmnplc, I'indeis ct aln 1993, Trends Bio-\n",
      "il;202, Cluou et al., 1994. Gene liierapeutics:\n",
      "teclmol.\n",
      "Methods And Applications Of Direct (iene Transfer (J. A.\n",
      "Wolff.ed 8 Wuetal..1988..1 Biol C'hem. 263:621,Wuetal..\n",
      "1994, .f. Biol. Chem. 269:542; Zenke et ale 1990. Proc. Natl.\n",
      "Aced Sci. IJSA 873655; Wu cl al, 1991. I Biol Clmm so\n",
      "266:338. Therapeutic coinpositions containing a polynucle-\n",
      "otide are admiiu stered in a range of about 100 ng to about 200\n",
      "mg of DNA f'or local administration in a gene therapy proto-\n",
      "col Concentration ranges of about &00 ng to about &0 mg,\n",
      "about I pg to about 2 mg, about 5 pg to about &00 pg. and \"»\n",
      "about 20 pg lo about 100 pg of'DNA can also bc use&I during\n",
      "a gene thenspy protocol. The therapeutic polynucleotides and\n",
      "polypeptides can be dclivcrcd using gene delivery velgcles\n",
      "The gene delivery vducle cml bc ol'iral or non-viral ongin\n",
      "(see generally, Jolly, 1994, Cancer (rene Therapy I;Sl;\n",
      "Kimura, 1994, Hunmn (icne Therapy 5 845: ('onnellyi 1995,\n",
      "lhunan Gene 111erapy I:185; and Kaplitt, 1994, Nature\n",
      "(ieneti ca 6: 148j. L'xp ress i on of such coding sequences can be\n",
      "induced using endogenous mmmnalian or heterologous pro-\n",
      "moters. Lixpresslon of the coding sequence can be either 4.\n",
      "constitutive or regulated.\n",
      "\n",
      "so\n",
      "\n",
      "Viral-based veciors for delivery of a desired polynncle-\n",
      "otide mid expression in a desired cell are well know n in the art.\n",
      "Bxemplmy viral-based vehicles include bnl are nol limited\n",
      "to. recombuiant retroviruses (see. e.g. PCT Publ. Nos. WO o\n",
      "c90/07936; WO 94/03622; WO 93/256198; WO 93/25234: WO\n",
      "93/11230, WO 93/10218. WO 91/02805, US Pat. Nos\n",
      "5.219.740 and 4.777,127; CiB Patent No. 2.200.6Si: and L'P\n",
      "\n",
      "28\n",
      "Pntent No 0 345 242), alphavinis-bswsed vectors (e g., Sindbis\n",
      "virus vectors. Semhlo forest vinls (ATCC VR-67; ATCC\n",
      "(ATCVC VR-373: ATCC\n",
      "VR-1247), Ross River virus\n",
      "VR-1246) and Venerniclmi equine encephalitis vinis (ATCC\n",
      "VR-923; ATCC V R-1250: ATCIC VR 1249: ATCC VR-532)),\n",
      "and adeno-associated virus (AAV) vectors (see, e.g., PCT\n",
      "Publ. Nos. WO 94/12649, WO 93/03769; WO 93i'19191, WO\n",
      "94/2893K WO 95/11984 and WO 95/00655) Achniiustration\n",
      "ol'DNA linked to kifftxf adenovirus as dcscnbcd in C:uriel,\n",
      "1992. Ihun. Ciene liter. 3:147. can also be employed.\n",
      "\n",
      "Noll-viral delivery vehicles and methods can also be\n",
      "employed. includmg. bul not limited lo. polycationic con-\n",
      "densed DNA linked or unlinked to killed adenovirus alone\n",
      "(sce, c g., ('uriel, 1992, Hum. (iene Ther 3:147),\n",
      "ligand-\n",
      "lmked DNA (sep, eg, Wu..l.. 1989, Biol C'liam 264.16985),\n",
      "eukaryotic cell dehvery vehicles cells (see, e.g., U.S. I'at. No.\n",
      "5,814,482, PC:T Publ. Nos. WO 95/07994, WO 96/17072,\n",
      "WO 95/30763: mul WO 97/42338) and nucleic charge neu-\n",
      "tmiizmtion or fusion with cell membranes Naked DNA can\n",
      "also be employcdl Pxmnp fary naked DNA introduction ml th-\n",
      "ods are descnbed ln PCT Publ. No. WO 90/11092 and U.S.\n",
      "Pat. No. 5.580,859. Liposomes tliat cmi act as gene delivery\n",
      "velucles are described in U.S. Pat. No. 5,422,120; PCT Publ.\n",
      "Nos. WO 95/13796; WO 94/23(i97; WO 91/1444S: and BP\n",
      "0524968. Additional nppmaches are described in I'hilip,\n",
      "1994. Mol. Cell. Biol o 14. 2411, and in Wolfendin, 1994 Proc.\n",
      "Natl. Aced. Sci. 91:1&81.\n",
      "\n",
      "This invention encompasses compositions, lncludui phar-\n",
      "maceutical compositions. comprising antibodies descnbed\n",
      "iwrcin or made by lhc nwt bode and hnv ing the chmaclcri sties\n",
      "described hereui. As used herein, compositions comprise one\n",
      "or more antibodies, peptides, or aptamers that antagonize the\n",
      "inlernction of PCSK9 v,ith tlm I,DI.R, nnd/or onc or morc\n",
      "polynucleotldes composing sequences encoding one or more\n",
      "these antibodies or peptides Illese compositions may further\n",
      "suitable excipicnts. Such as phannaceutically\n",
      "comprise.\n",
      "lvluch are lvell\n",
      "acceptable excipients lncludin\n",
      "kl iowa lu thl'. Rift\n",
      "\n",
      "The PCSK9 antagonist antibodies and peptidcs ol'hc\n",
      "invention are cliaracterized by any (one or more) of the fol-\n",
      "lowing characteristics (a) bind to PCSK9: (b) block P('SK9\n",
      "uiteraction with the LDLR; (c) decrease PCSK9-mediated\n",
      "down-regulation of the Lf&LR: and (d) inhibit P('SK9-medi-\n",
      "ated inhibition of I.DI, blood clearance. Prcfi.rably. PCSK9\n",
      "antibodies have two or more of these features. More prefer-\n",
      "ably, the antibodies have three or more of the features. Most\n",
      "prefensbly, the antibodies have all four charactensucs.\n",
      "\n",
      "buffers,\n",
      "\n",
      "Accordingly, the invennon pmvides any of the follow ing,\n",
      "or compositions (ulcluding pharnulccuiical compositions)\n",
      "compnslng any antibody havurg a partial light chain sequence\n",
      "and a partial hery clmin sequence as found in 'Iable l. The\n",
      "underluicd sequences are CDR sequences according to Knbnl\n",
      "and in bold according to Chothia.\n",
      "\n",
      "TABLE I\n",
      "\n",
      "mAb Light Chatn Vattable Regton Heavy Chain Variable Regton\n",
      "\n",
      "SIS DIVI'ITQSQKPNSTSVGDRV\n",
      "\n",
      "EVQ'QQSGPELVKPGASVKISCKAS\n",
      "\n",
      "SVTCKASIINIIGTNVAICIQ\n",
      "\n",
      "GYTFTDYYININVKQSHGKSLRNIG\n",
      "\n",
      "QKPGQSPIGILIYSASYRYSG\n",
      "\n",
      "VPDRPTGSGSGTDPTLTISN\n",
      "\n",
      "YSTKCHELR LTSED A'1YYCARNL\n",
      "\n",
      "VLSEDLAEYPCQQFYSYPYT\n",
      "\n",
      "LPAYtIGQGTLVTVSA ISEQ ID\n",
      "\n",
      "PGGGTKLEIK lsEQ ID No\n",
      "\n",
      "I\n",
      "\n",
      "I\n",
      "\n",
      "No\n",
      "\n",
      "Ecl\n",
      "\n",
      "\f",
      "29\n",
      "\n",
      "TABLE I-continued\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "30\n",
      "\n",
      "WAb Light Claarn Variable Regron Heavy Chain Variable Pegion\n",
      "\n",
      "5AZO DIVI6TQSHKFNSTSVGDRVS\n",
      "\n",
      "QVQLQQPGAELVKPGASVKLSCKAS\n",
      "\n",
      "ITC~KAS DVSTAVAIvYQQK\n",
      "\n",
      "GYTPTSYWMHtmKQRPGQGLEWIG\n",
      "\n",
      "PGQSPKLLZYSASYRYTGVP\n",
      "\n",
      "EINPSNGRTNYNEKFKSKATLTVDKS\n",
      "\n",
      "DRPTGSGSGTDFTPTISSVQ\n",
      "\n",
      "S S TRY) )QL S 5 LT 5 5 D 5 AVYYCARER\n",
      "\n",
      "AEDLAVYYCQQRYSTPRTF\n",
      "\n",
      "PLYAMDY)GQGTSVTVSS\n",
      "\n",
      "GGGTKLEIK )SEQ ID No\n",
      "\n",
      "17)\n",
      "\n",
      ")SEQ ZD HO\n",
      "\n",
      "21)\n",
      "\n",
      "6P6 DIQHTQTTSSLSASLGDRVTZ\n",
      "\n",
      "EVQLQQSGPELl.'KPGASVKISCKAS\n",
      "\n",
      "SC~SAS\n",
      "\n",
      "ZSNYlbclYQQKP\n",
      "\n",
      "GYTFTDYYMNlh)KQSHGKSLKWIG\n",
      "\n",
      "DGTVFLLIYTrssLHsGVPs\n",
      "\n",
      "RFSGSGSGTDYSLTISNLEP\n",
      "\n",
      "SSSTAYMELPSLTSEDSAVYYCAGG\n",
      "\n",
      "EDIPTYYCQQYSKLPPTPGS\n",
      "\n",
      "GIYYRYDRNYPDYWGQGTTLTVSS\n",
      "\n",
      "GTKLEIK lsEQ ID No\n",
      "\n",
      "15)\n",
      "\n",
      ")SEQ ZD HO\n",
      "\n",
      "22l\n",
      "\n",
      "7D6 DIVI'ITQSHKPNSTSFGDRVS\n",
      "\n",
      "EVKLVESEGGLVQPGSSHKLSCTAS\n",
      "\n",
      "ITCHESDVSNALMiYQQK\n",
      "\n",
      "GFTPSDYYIDÃVRQVPEKGLEWVA\n",
      "\n",
      "PGHSPKLLI5'SASYRYTGVP\n",
      "\n",
      "NINYDGSMTSYLDSLKSRFIISRDNAK\n",
      "\n",
      "DRFTGSGSGTDPTFTISSVQ\n",
      "\n",
      "NILYLQMSSLKSEDTATYYCPPEKPA\n",
      "\n",
      "AEDLIVYYCQQHYSTPNTF\n",
      "\n",
      "AMD1WGQGTSVTVSS\n",
      "\n",
      "GGGTKLEIK lsEQ ID No\n",
      "\n",
      "19)\n",
      "\n",
      "ISEQ ZD NO\n",
      "\n",
      "23)\n",
      "\n",
      "LZL3 DIQHTQSPSSLSASVGDRVT\n",
      "\n",
      "QVQLVQSGAEVKKPGASVKVSCKAS\n",
      "\n",
      "ITC~RAS GZSSALAIvYQQKP\n",
      "\n",
      "GYTPTSYYMHtmRQAPGQGLEWM\n",
      "\n",
      "GKAPKLLIYSASYRYTGVPS\n",
      "\n",
      "GEISPPGGRTNYNEKFKSRVTHTRD\n",
      "\n",
      "RFSGSGSGTDFTFTISSLQP\n",
      "\n",
      "TSTSTVYHELSSLRSEDTAVYYCARE\n",
      "\n",
      "EDZATYYCQQRYSLWRTFG\n",
      "\n",
      "RPIYASDLWGQGTTVTVSS\n",
      "\n",
      "QGTKLEIK )SEQ ID No\n",
      "\n",
      "531\n",
      "\n",
      "(SEQ ID Ho 56)\n",
      "\n",
      "The unention aiso provides CDR portions of'lmtibodies to as\n",
      "\n",
      "V( SK9 (including I'.hothia and Kabat ('DRs). Dctcnnination\n",
      "ol'F.'DR reg«ms is lvell within thc skill of thc art It is under-\n",
      "stoodthatinsomeembodimonta( DRscanbeacombination\n",
      "ol'he Kabnt lmd Chothia CDR (also termed \"colnbined\n",
      "CDRs\" or \"extended CDRs\"). In some embodiments, the\n",
      "CDRs are the Ka bat CDRs. In other embodiments, the b 'DR s\n",
      "are the Chothia CDRs In other ~ords. ul embodiments la 1th\n",
      "more tlmn one CDIL the CDRS may be any ofKabat, Chotlua.\n",
      "conlbination CDRs, or combinations thereof\n",
      "\n",
      "5\n",
      "\n",
      "The ulventlon also prov)des methods of making mly ol'\n",
      "these antibodies or polypeptides. The antibodies ofthis inven-\n",
      "lion can bc made by procedures known in tlm ar) Thc\n",
      "polypeptides cml be produced by proteolytic or other degra-\n",
      "dation of the mltibodics, by rccombinmlt methods (i.e, sinoJe\n",
      "or fusion polypcplidcs) Rs described above or by chmnical N)\n",
      "synthesis. Volypeptides of the antibodies, especially shorter\n",
      "polypeptides up to about 50 amino acida are conveniently\n",
      "made by chenucal synthesis. 37lethods of chemical synthesis\n",
      "are known in the art and are commercially available. For\n",
      "example, an antibody could bc produced by an mltomated 6\n",
      "polypeptide synthesizer employing the sohd phase method.\n",
      "See also, U S. Vat. Nos. 5 g07 715; 4 g16 567: and 6 331,415.\n",
      "\n",
      "In another alternatilja the antibodies and peptides cml be\n",
      "made recombinantly using procedures tlmt are well known in\n",
      "the art. In one embodiment, a polynuclcotlde compnses a\n",
      "sequence encoding the heavy chain and/or the I)pit chain\n",
      "vmiablc regions of antibody 4A5, 5A10, 6F6. 7D4 or 1.11 3.\n",
      "The sequence encoding the antibody ofinterest may be main-\n",
      "tained in a vector in a host cell and the host cell can then be\n",
      "expanded and froyen for future use VLT)ors (including\n",
      "expression vectors) and host cells are fluther described\n",
      "herein.\n",
      "\n",
      "The im ention also encompasses scl'v of ant)bod)ca of this\n",
      "invcnnon Single chain vanablc region fragments al'6 njadc\n",
      "by linking light and)or heavy chain variable regions by using\n",
      "a short linking peptide. Bird et al.. 19gg, Science 242:423-\n",
      "426. An example of a lulking pcqltide is (Cifif)C)S), (SIIQ ID\n",
      "NO.24), which budges appmximately 3.5 nm bet~can the\n",
      "carboxy terminus of onc variable region and the amino ter-\n",
      "m)Due ofthe other variable region. L uikers ofother sequences\n",
      "have been designed and used. Bird et el., 193 g, supra. Linkers\n",
      "should be short, tlexible polypeptidcs and prcfbrably com-\n",
      "p)Ised of less than about 20 anuno acid residues. Llnkers can\n",
      "in turn be modified for additional functions. such as attach-\n",
      "\n",
      "\f",
      "(js 8,080,243 B2\n",
      "\n",
      "31\n",
      "ment of drugs or attachment to solid supports Tlm single\n",
      "chaui vanants can be produced either recombinantly or syn-\n",
      "thetically. For syntlietic production of scFv, an mitomated\n",
      "synthesizer can be used For rccombinmit production of scFv,\n",
      "a suitable plasnud contauungpolymicleotide that encodes the 1\n",
      "scpv can be introduced into a suitable host cell. either eukary-\n",
      "otic. such as yeast, plant. uisect or mammalian cells. or\n",
      "prokaryotic. such as Fd co/i. Polynucleotides encodmg the\n",
      "scF v o fintcrcst cnn be made by routine manipulations such as\n",
      "ligitionofpolynucleotides. Theresultantscl'vcanbeisolated lo\n",
      "using standard protein purification techniques known In the\n",
      "'irt\n",
      "\n",
      "Other forms of sin le chain antibodies. such as diabodies\n",
      "are also encompassed Dinbodics are bivalent. bispeci tie miti-\n",
      "bodicsinwhtchVIlandVl.domainsareexpressedonasin le\n",
      "polypeptide chain. but using a linker that is too short to allow\n",
      "for pairing bct(recon the two domains on the same chain,\n",
      "thereby Rircing the donuuns Io pnir (vith cmuplementary\n",
      "domains of another chain and creating nvo antigen binding\n",
      "sites (sce e g.. Holligcr. P. ct al . 1993, Proc Natl Acnd Sci\n",
      "USA ')0:6444-6448; Poljak, R..l., et al., 1994. Structure\n",
      "2:1121-1123).\n",
      "\n",
      "o\n",
      "\n",
      "For example, bispeciiic antibodies, monoclonal mttibodies\n",
      "that have binding specificities for at least t(vo different anti-\n",
      "gens, m n be prepmed using thc antibodies disclosed imrein\n",
      "Methods for nmkuig bi specific antibodies are known In the art\n",
      "(see, e.g., Suresh et al.. 198&x Methods in Enzymology 121:\n",
      "210). Traditnmnlly, the reeombuinnt production of bispemiic\n",
      "antibodies was based on the coexpression oftwo Inuuunoglo-\n",
      "bulin hcavy chain-light chain pairr, (1 ith the two hcavy chains io\n",
      "having dilperent specifimties (Millstein and Cuello. 1983,\n",
      "Nanire 305. 537-539).\n",
      "\n",
      "According to one npproach to mnking bispecilic SIItibod-\n",
      "Ies, antibody venable dom nns with the desired b uiding speci-\n",
      "iicities (mitibody-antigmi combining sites) are fused to \"»\n",
      "uumunoglobulin constant domaut scqumices. The liision\n",
      "preferably is with an immunoglobulut hery ch un constmtt\n",
      "domain, coniprising at least part of the hinge. CH2 and & H3\n",
      "regions It is prcfi.rrcd to have the iirst bca(T chaui amstmit\n",
      "region (&'H1), containing the site necessary for fight chain do\n",
      "bindino, present in at least onc oftlm fusions l&NAS encoding\n",
      "the inununoglobului heavy chain fusions and, if desired. the\n",
      "inuuunoglobulin light cliai, are insened into separate\n",
      "cxprcssion (mciors, mid are cotmnsfi.ctcd into a suitable host\n",
      "orgarusm. Iliis pro~ides for peat fiexibility in adjusting the d.\n",
      "mutual proportions of the three polypeptide fravgntents in\n",
      "embodiments when unequal ratios of the three polypeptide\n",
      "chains used in the construction provide the optinuuu yields. It\n",
      "Is, la(waver, possible to htscn tlm coding sequences for Iwo or\n",
      "all tluee polypeptide chains In one expression vector when tlie\n",
      "expression of at least two polypeptide chains in eqiml nitios\n",
      "results In hi h yields or when Ibc ratios are of mi particulnr\n",
      "sigiuiicance.\n",
      "\n",
      "o\n",
      "\n",
      "In one approach, tlm bi speci bc antibodies are composed of\n",
      "a hybrid immunoglobulin heavy chain with a tirst binding\n",
      "specificity in one ann, and a hybrid imnnmoglobulin heavy\n",
      "chain-light chain pair (providing a second binding. sp(wilic-\n",
      "Ity) In the otlier arm. Tlus asymmetnc structure, with an\n",
      "inuuunoglobulin light chain in only one half of the bispecific\n",
      "molecule. facilitates the separation of th(. desired bispecilic mi\n",
      "compound from unwanted immunoglobulin chain combina-\n",
      "'Iliis approach is described in P&'T Publ. No. WO\n",
      "tions.\n",
      "94/04690\n",
      "\n",
      "1\n",
      "\n",
      "Heteroconjugate antibodies. comprising two covalently\n",
      "joined antibodies, are also within the scope of thc invention\n",
      "Such antibodies have been used to target utunune system cells\n",
      "to unwanted cells (U.S. Pat. No. 4,676.980). and for treatment\n",
      "\n",
      "32\n",
      "of His/ infection (P& T Publ Nos WO 91/00360 and WO\n",
      "92i200373: EP 03089). Ileteroconjugate antibodies may be\n",
      "made using any convenient cross-linlong methods. Suitable\n",
      "cross-linking agents nnd tcwiutiques are well Ioutwn in the an,\n",
      "and are descnbed in U.S. Pat. No. 4,676.980.\n",
      "\n",
      "Chimeric or hybrid antibodies also may be prepared in\n",
      "vitro using kno(vn methods of synthetic protein chemistry,\n",
      "uicluding those involving cmss-linking agents. For example,\n",
      "intmunotoxins may bc constructed using d di sulfide cxchangc\n",
      "reaction or by fornung a tlucether bond. Examples of suitable\n",
      "reagents for tlfis purpose include iminotluolate mid methyl-\n",
      "4-nIercapiobutyrimidatc\n",
      "\n",
      "Iiumanized mtibody compnsuig one or more CDRs of\n",
      "antibodies 5A10 or 7D4 or one or nxire & DRs derived from\n",
      "antibodies 5A10 or 7D4 can be made. for example. using any\n",
      "metlmds know in the art. For example. four general steps may\n",
      "be used to humanize a monoclonal antibody Thcsc nre (1)\n",
      "determining the mmleotide md predicted amino ncid\n",
      "sequence of the starting antibody light and heavy variable\n",
      "ihchulniu11zLd dlltlbody. i.c, deciding\n",
      "d(lluallls, (2) ilcsigl1i!I\n",
      "which mitibody framework region ui use during the human-\n",
      "izing process; (3) using the acmal humanizing methodolo-\n",
      "giesitechniques; and (4)\n",
      "transfecting mid expressing the\n",
      "humanized antibody. See, for exaniple. U.S. Pat. Nos. 4.816,\n",
      "567, 5.807,715; 5,86&1,&i92; 6331,415; 5.530,101; 5,693,7&11,\n",
      "5,693,762; 5.585,089: uid 6.i 80,370.\n",
      "\n",
      "In the recombinant humanized antibodies, the Fc portion\n",
      "can be modilied to avoid interaction with Fc( receptor aud the\n",
      "complement and uumune systems. The tecluiiques for prepa-\n",
      "mtion of'such antibodies are dcscrib(xl in WO99/58572 For\n",
      "the cousIant region may be enguieered to more\n",
      "ex unple.\n",
      "resemble human constant regions to avoid immune response\n",
      "if thc antib(xly is uscxl in clinical trials and treatments in\n",
      "humans. See. for example, U.S. Pat. Nos. 5.997,867 and\n",
      "5,86&i,692.\n",
      "\n",
      "Huntanizedi antibody comprising the bght or hmivy clmin\n",
      "variable regions or one or more CDRs of mi antibody or Its\n",
      "variants shown in Table I, or oiw or more & DRs derived from\n",
      "tbc mitib(xly or its vananm sho(vn in Table 2 can be made\n",
      "using any methods known in the art.\n",
      "\n",
      "Hunmnizcxl antibodies indi'IL Inada by any nwtbod know n\n",
      "\n",
      "111 tile an.\n",
      "\n",
      "The invention encompasses modifications to the antibodies\n",
      "and polypeptidcs of the invention vmiams shown in Table 1,\n",
      "including functionally eqiuvalent antibodies which do not\n",
      "significmitly affect their propenies and variants which have\n",
      "enhanced or decreased activity andior afiinity, I'or example,\n",
      "the amino acid sequence may be mutated to obtain an anti-\n",
      "body with the desired buiding alIiuity to PCSK9 Modiiica-\n",
      "non ofpolypeptides is routine practice in the art and need not\n",
      "be described in detml herein. Modification of polypeptides is\n",
      "exempli lied in the Fxmnples Fxamp les of modilied polypep-\n",
      "tides include polypeptides (vith conservative substitutions of\n",
      "amino acid reaiducs. one or morc delctions or ndditions of\n",
      "amino acids which do not signilicantly deleteriouslv chmige\n",
      "the fiuictioim I activity. or wlfich mature (enhance) thc affinity\n",
      "of thc polypcptidc for im ligiuid. or u(c of chemical aimlogs.\n",
      "Alllillo IIcld scqucncc lllscltloIIs lllcludc alii(no- i(lid/ol\n",
      "carboxyl-mnninal fusions ranging in length from one rc»idue\n",
      "to polypcptides contnining a hundred or more r(si(hics. Sws\n",
      "well as intrasequence insertions of single or multiple amino\n",
      "acid residues. I:xamplcs of tenninnl insertions include mi\n",
      "amibody with an N-terminal metluonyl residue or the anti-\n",
      "body fused to an epitope tag. Other Insertional variants ofthe\n",
      "antibody molecule include the fusion to the N- or &'-terminus\n",
      "of the antibody of un enzyme or a polypepude wluch\n",
      "increases the half life ofthe antibody in the blood circulation.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "33\n",
      "Substitution varim&LS lmvc at 1m&st one amino acid residue\n",
      "in tlm m&tibody molecule removed and a different residue\n",
      "inserted in &ts place. 11&e sites of greatest &nterest for substi-\n",
      "tutio&u&l mutagencsis include the hypervariable regions, but\n",
      "FR alterations are also contcmplatcd C:onservative substitu-\n",
      "tions are shown in Table 2 under the heading of\"conservative\n",
      "substitutions\" If such substitunons result in a chan e &n bio-\n",
      "lo ical activity, then more substantial chm&ges, denonunated\n",
      "*'exemplary substitutions\" in Table 2, or as further described\n",
      "helot& In reference to amino acid classes. mny be introduced\n",
      "and the products screened.\n",
      "\n",
      "1ABLF 2\n",
      "\n",
      "Amu)o Acid So«su&nouns\n",
      "\n",
      "Co)uer,un e\n",
      "Suhs«&uuons\n",
      "\n",
      "Esca)plan\n",
      "Sub&&du«on)\n",
      "\n",
      "0«uuud\n",
      "lies&due\n",
      "\n",
      "A&a (A)\n",
      "i«)\n",
      "Asn (8)\n",
      "Asp (0(\n",
      "Cvs (C)\n",
      "(\n",
      "It& ( Q I\n",
      "mu! T)\n",
      "(GI\n",
      "Gl\n",
      "H)s IH)\n",
      "ne (Il\n",
      "I.eu I L I\n",
      "Lrs(K)\n",
      "Met (Ml\n",
      "The&pl\n",
      "Pro \\P)\n",
      "Se&(S)\n",
      "Iau (I'1\n",
      "Tsp iu')\n",
      "Tv) (Y)\n",
      "Vat (V)\n",
      "\n",
      "Val\n",
      "\n",
      "L s\n",
      "\n",
      "Oh)\n",
      "Ohl\n",
      "Scl\n",
      "Asn\n",
      "Asp\n",
      "Ma\n",
      "\n",
      "A&\n",
      "Leu\n",
      "He\n",
      "\n",
      "A&s\n",
      "Leu\n",
      "T)s\n",
      "Ala\n",
      "Thr\n",
      "S»l\n",
      "Ts\n",
      "\n",
      "I'h»\n",
      "\n",
      "I eu\n",
      "\n",
      "Va& Ia)L u*\n",
      "L)s. Oln Asn\n",
      "Oln. H)s. Asp Lss. A&S\n",
      "Glu. Asn\n",
      "Se&. Al,&\n",
      "\n",
      "&so. G&u\n",
      "A)P: r h)\n",
      "\n",
      "Asn. r'o. I\n",
      "1: As,\n",
      "Ieu.xal. VI\n",
      "& A(K Ph .Hcnennne\n",
      "«odeucwe. He.t)l, Me& Ala Phe\n",
      "A& & h),Asn\n",
      "Ieu. Phc, nc\n",
      "Leu. Val. I&e Ala. Tir\n",
      "Ala\n",
      "Th&\n",
      "\n",
      "se&\n",
      "T n Phe\n",
      "T)p Phe, Ths. See\n",
      "ne. Leu. Me&, Phe. &&s. Xodenca)e\n",
      "\n",
      "Substantial modifications in the biological properties ofthe\n",
      "antibody ue accon&phshed by sefectuig subsututions tlmt\n",
      "differ significantly u& their efl'ect on mmntauiing (a) the struc-\n",
      "ture of tlm polypeptide backbone in the area ol'lm substitu-\n",
      "tion, for example, as a sheet or helical conformation, (b) the\n",
      "char e or hydrophobicity of the molecule at the target site, or\n",
      "(c) tlm bulk of the side clmui Naturally occurring residues are\n",
      "divided into groups based on common side-chain pmperties:\n",
      "\n",
      "(11 Non-polar: Norleucine, Met, Ala, Val, Leu. He;\n",
      "(2) Polar without char e: Cys. Ser, Tlu„Asn. Gin:\n",
      "(3) Acidic (ncgati&mly charged) Asp. Cilu,\n",
      "(4) Basic (positively charged) I.ys, Arg,\n",
      "(5) Residues that influence clmin orientation: Crly) Pro; and\n",
      "(6) Aromauc Trp. Tyr, Phe, His.\n",
      "Non-Lonscrvativc substitutions are made by exchan ing a\n",
      "\n",
      "member of one of these classes for another class.\n",
      "\n",
      "Any cysteine residue not\n",
      "\n",
      "involved In mau&taining the\n",
      "proper conformauon of the sin&body also may be substituted,\n",
      "gcnernlly with scrinc, to impro«'. thc oxidnti&m stability of thc\n",
      "molecule and prevent aberrant cross-linking. Conversely.\n",
      "cyste&ne bond(s) may be added to the antibody to impmve its\n",
      "stability, particularlv where the antibody Ls u& antibody lrag-\n",
      "ment sucli as an Fv fcdgmenL\n",
      "\n",
      "Amino acid modifications can mnge from changing or\n",
      "n&odif& In one or more amino acids to complete redesign of a\n",
      "region, such as the variable region. Changes &n the venable\n",
      "rey'on can alter binding aflinity and/or specificit. In some\n",
      "cn&bodimcnts. no n&orc than one to live conwrvative amino\n",
      "acid substitutions nre made ssithin a CDR domain. In other\n",
      "embodiments, no more than one to three conservative amino\n",
      "\n",
      "34\n",
      "acid substitutions are n&ade within a CDR domain In still\n",
      "other embodiments. the C DR domain & s CDR 1 13 and/or CDIL\n",
      "L3.\n",
      "\n",
      "I\n",
      "\n",
      "Modificstions also inch&de glycosylated and nonglycosy-\n",
      "lated polypeptides. as well as polypeptides with other post-\n",
      "trnnslational modifications, such as. for example, glycosyla-\n",
      "tion v ith different sugars, acetyla(ion, m&d phosphorylation.\n",
      "Antibodies are glycosylated at conserved positions &n their\n",
      "constant regions (Iefli:ris dnd I und. 1997. (.hcm. Immunol.\n",
      "lo 65,H1-128, Wught and Morrison. 1997, T&bTFCH 15:26-\n",
      "32). The oligosacclmride side chains ofthe inununoglobulins\n",
      "affect thc protcm*s tinct«m (Boyd et al, 1996. Mol Inunu-\n",
      "nol 32:1311-1318: Wittwe and Howard. 1990, B&ochem.\n",
      "29 4175-4180) Slid the intrmnoleculnr interaction between\n",
      "portions of the glycoprotein. &vliich min sfli:ct Ihe conli)rma-\n",
      "tion and presented three-dimens ione I surface ofthe glycopro-\n",
      "toin (.Ietferis and I.&md, supra Wyss mid Wagner, 1996. C:ur-\n",
      "rent Opia. Biotech 7.409-416). Ohgosaccharides may also\n",
      "serve to target a given glycoprotein to certmn molecules based\n",
      "n i&pun spccilic recognition structures Cslycosylation of ai&ti-\n",
      "bod&es lms also been reported to affect antibody-dependent\n",
      "cellular cytotoxicity (AI&CC). In particular, C'HO cells with\n",
      "(3(1.4) N-scetylglu-\n",
      "tetracycline-regulated expression ol\n",
      "cosaminyltransferase Hl\n",
      "a glycosyltransferase\n",
      "(C/nTIH),\n",
      "catalyzing founation of bisecting CilcNAc, was reported to\n",
      "have &mproved ADCC activity (Umana et al.. 1999, Nature\n",
      "Biotech. 17:176-180).\n",
      "\n",
      "Glycosylation of antibodies &s typimilly either N-linked or\n",
      "0-linked. N-linked refers to the attaclm&ent of the carbohy-\n",
      "sn dmte moiety «) tlm side chain of an aspmdoi&m rcsi&hm Thc\n",
      "tupeptide sequences asparagme-X-senna. msparaguie-X-\n",
      "tlu eonine, and nsparaooine-X-cyste&ne, where X &s nny amino\n",
      "acid Lxccpt p«1bi&L) dr'L thc I ccogn&t&on scquc&iccs RII'u/s'\"\n",
      "metic attachment ol'he carbohydrate moiety to the aspar-\n",
      "\"» agine side chain. Thus, the presmicc of citlmr of these tripep-\n",
      "a potential\n",
      "t&de\n",
      "glycosylauon site. 0-linked glycosylation refers to the\n",
      "attaclnncnt of one of the sugnrs N-acctylgalactosamine,\n",
      "galactose, or xy lose to a hydro xyainu&o acid, most conunonly\n",
      "nn serine or tlueonine, although 5-hydroxyproline or 5-hydroxy-\n",
      "\n",
      "in a polypeptide crmdcs\n",
      "\n",
      "SL«Inc«con\n",
      "\n",
      "lysiim may also be used\n",
      "\n",
      "Addition of glycosylation sites to the antibody &s conve-\n",
      "niently accomplished by altering the amino acid sequence\n",
      "it conmins one or more of the above-described\n",
      "such that\n",
      "tripeptide sequences (f&ir N-linked glycosylation sites). The\n",
      "altemti on may also be made by the addition of, or substitution\n",
      "by, one or more senne or tlu eon&ac residues to the sequence of\n",
      "the onginal antibody (for 0-linked gfycosylation sites).\n",
      "\n",
      "Thc glycosylation pattern ofantibodies may also be altered\n",
      "u without alteung the underlying nucleotide sequence. Glyco-\n",
      "sylation largely depends on tlie host cell used to express the\n",
      "antibody Since the cell type used lor expression of recombi-\n",
      "nunt glycoproteins. e.g., antibodies, as potential therapeutics\n",
      "is rarely the native ccfl. variations in the glycosylat ion pattern\n",
      "I of the antibodies can be expected (s&m, e.g.. I lee et al.. 1997,\n",
      "\n",
      "I. Biol. Che&u. 272:9062-9070).\n",
      "\n",
      "In addition to tlm choice of host cells, I)nctors that aft'Lmt\n",
      "glycosylauon dunng recomb«rant producuon of nut&bodies\n",
      "include growth mode, media fom&ulation, culture density,\n",
      "ai oxygenation, pH. purilicati&m schcmcs and tlm like Various\n",
      "methods have been proposed to alter the glyco aylati on pattern\n",
      "achieved in a particular host organism including introducing\n",
      "or overexpressin cer(aui enzymes uivolved &n ofi osaccha-\n",
      "ride production (U.S. Pat. Nos. 5,047,335; 5,510,2C)l and\n",
      "5,278,299) Cilycosylation. or certain types of glycosylation,\n",
      "can be enzymnticully removed fmm the glycoprotein, for\n",
      "example. using endoglycosidase H (Fndo H). N-glycosidase\n",
      "\n",
      "s\n",
      "\n",
      "\f",
      "os\n",
      "\n",
      "yl at &on\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "35\n",
      "F, endoglycosidase F I, endoglycosidase F2, endoglycosidase\n",
      "F3.1n addit&on, the recomb&nant host cell can be enetically\n",
      "m&gineered to be defect&ve in process&ng certain types of\n",
      "I'hcsc and similar techniques arc well\n",
      "polysaccharidcs.\n",
      "known in the art.\n",
      "\n",
      "I\n",
      "\n",
      "\".o\n",
      "\n",
      "act &vste\n",
      "\n",
      "Other methods of moditication include using coupling\n",
      "techn&ques known in the arh including, but not h&uhed to.\n",
      "enzymat&c means. oxidative substin&tion and chelation.\n",
      "Modilications can be used.\n",
      "\n",
      "Iior cxmnplc. for attachmentol'abelsIi&r immunoassay. Modified polypept&des are made u&\n",
      "\n",
      "using established procedures in the an and can be screened\n",
      "using standard asm&ys kn&&wn ui the an, some ol uhich are\n",
      "descnbed below and &n the Examples.\n",
      "\n",
      "Immumil., 1999. 29 2613-2624. PC'T Publ No so\n",
      "\n",
      "In some en&bodinmnts of the invention, the antibody com-\n",
      "prises a modified constant region. such ns a &xmstm&t region i.\n",
      "that &s inununoloy'cally inert or partially inert. e.g., does not\n",
      "trigger complenmnt mcdiatcd lysis, docs not stimulate\n",
      "nucrogl ia: or have reduced activ&-\n",
      "ADCC, or does not\n",
      "ties (compared to the unmoditied antibody) in any one or\n",
      "more of the following triggering complacent n&cdiatcd lysis,\n",
      "stuuulating ADCC. or acuvaung micmglia. Different mod&-\n",
      "fications of the constant region may be used to achiswe opti-\n",
      "mal level and/or comb&nat&on of effector functions. See, for\n",
      "example, Morgan et al.. 199S. htununology 86:319-324;\n",
      "I.und et al., 1996, J. Imnninology 157'4963-9 IS7:4963-\n",
      "4969: Idusog&e et al.. 2000..1. Inuuunolo s 164:4178-4184;\n",
      "fao et al.. 1989, J. Immunology 143: 2595-2(&01; and Jefferis\n",
      "et al, 1998, Imnn&nological R&wicsvs 163.59-76. In some\n",
      "embodiments, the constant reg&on is modified as descnbed in\n",
      "Fur\n",
      "WO99!58572, and/or IJK Paten& Application No 9809951 8.\n",
      "the antibody compnses a luunan\n",
      "In other embodunents.\n",
      "hmivy chain IgG2 constm» region comprising the li&flowing\n",
      "nnitations: A330P331 to S330S331 ( unino ac&d munbenng\n",
      "wnhrcterencetothew&ldtypelg()2sequm&ce) Eur.J.lnumi- \"»\n",
      "nol. 1999, 29 2C&13-2624 In still other cinbodimm&ts, thc\n",
      "constant reg&on &s aglycosylated for N-l&nked glycosylation.\n",
      "In some embodiments, thc constant region is avlycosylatcd\n",
      "I'or N-linked\n",
      "lycosyla&ion by mutating the glycosylatcd\n",
      "anuno acid residue or flanking residues that are part of the so\n",
      "N-glycosylation recognition sequence in the constant region\n",
      "site N297 may be mutated to A,\n",
      "For example, N-glyc\n",
      "Q. K. or H. See. lao et al., 1989. J. Inummolony 143: 2595-\n",
      "2&&01. m&d.leff& ris ct al, 1998, Inununological kcvicsvs 163\n",
      "59-76. In some embodunents. the constant reg&on &s aglyco- s.\n",
      "sylatixI for N-linked glycosylation. fhe constant region may\n",
      "be aglycosylated lor N-hnked glycosylat&on enzymatically\n",
      "(such as removing carbohydmte by enzyme I'NC&ase), or by\n",
      "expression in a glycosyla&ion delicient host cefl\n",
      "\n",
      "I\n",
      "\n",
      "o\n",
      "\n",
      "Other antibody mod&iicntions include ant&bodies tlmt have\n",
      "been modified as described in PCT I'ubl. No. WO 99/SSS72,\n",
      "These nnt&bodies comprise. u& addition to a binding domnin\n",
      "d&rected at the target molecule. an elfector domo&n Imvu&g an\n",
      "amino acid sequence substantiafly homologous to all or part\n",
      "of a constant domain of a humnn uumunoglobuhn heavy\n",
      "chain These antibodies are capable of binding the target\n",
      "molecule without triggering signilicant complcmcnt dcpmi-\n",
      "dent lys&s, or cell-med&ated destruct&on of fite target In soine\n",
      "embodinmnts, the effector domain is capable of speciticafly\n",
      "buiding FcRn nnd/or Fc) Rllb. These arc typically ix&scd on a&\n",
      "chimeric domains derived from nvo or more lnuuan mmui-\n",
      "noglobuli n hcavy c1m in ('n2 domains. Antibodies n&odi tied in\n",
      "this mmu&er are particularly suitable for use ui cluo&uc ann-\n",
      "body therapy, to avoid intlammatory and other adverse reac-\n",
      "tions to conventional nntibody therapy.\n",
      "\n",
      "I\n",
      "\n",
      "6\n",
      "\n",
      "The Invent&on u&eludes affinity matiued emboduuents. I'or\n",
      "exmuple, aflinity n&aturisI antibodies can be produced by\n",
      "\n",
      "36\n",
      "pmcedures known in tlm art (Marks et al, 1992, Bio/Tech-\n",
      "nology. 10 779-783, Barbas ct al.. 1994, Proc Nau Acad. Sci,\n",
      "USA 91:38(8-3813; Scluer et al., 1995, Gene. 169;147-155;\n",
      "Yeiton e& al, 1995..1. hnmunol., 155 1994-2004, Jackson et\n",
      "al, 1995,.1 Immunol\n",
      ". 154(7):3310-9: Hawkins et al.. 1992,\n",
      "J. Mol. Biol., 226&88&9-896; and PCT Publ. No. WO2004/\n",
      "058184).\n",
      "\n",
      "The fo1 low u&g n&ethods may be used 1br ad) using the aflin-\n",
      "ity of an antibody and for characterizing a ('DR. One v,ay of\n",
      "charactenz&ng a CDR of an annbody anChor altering (such as\n",
      "unproving) the binding aflinity of a polypeptide, such as m&\n",
      "antibody. tanned *'libr ay scanmng mutagenesis\" Cienerafly,\n",
      "library scanninv nn&tagenesis works as foflosvs. One or more\n",
      "amino acid positions in the Cllk are replaced v;ith tuo or\n",
      "more (such as 3, 4, s, 6, 7. 8, 9, 10. 11, 12, 13. 14, 15. 16. 17,\n",
      "18. 19. or 20) amino ncids using art recognized nwthods. '11&is\n",
      "generates smail libraries ol'lones (in some embodiments,\n",
      "one for every mnino acid pos&tion that is analyzed) each with\n",
      "a complex&ty el'wo or more members (&f tu o or more amino\n",
      "acids are subst&tuted at e&'e&y pos&t&on). GeneIallv. &he hbla&1\n",
      "also includes a clone comprising the native (unsubstituted)\n",
      "amu&o ac&d A small number of cfones. e.g, about 20-80\n",
      "clones (depending on the complex&ty of the libmry), fmm\n",
      "each library arc screened for binding aftinity to tlm target\n",
      "polypeptide (or other bind&ng tar et), and c mdidates w&th\n",
      "increased, the same, decreased, or no binding are identified.\n",
      "Methods for determining b&nding nflin&ty are u all-knoss n ui\n",
      "the art. 1)u&ding alhmty may be deternuned us&n B&score\n",
      "surfncc pk&sirlo&'I rcsoflancc &i&'lalysis. which dc&oem difli.r-\n",
      "ecess u& binding aflinity ol'about 2-fold or greater. B&score is\n",
      "part&culnrly useful when the stoning ant&body already bu&ds\n",
      "v ith a relatively high alTinity, li&r cxamplc a K„ol'about 10\n",
      "nM or loss er. Screen&ng us&ng B&score surface plasmon reso-\n",
      "nance is described in tlm Examples, lmrein\n",
      "\n",
      "Binding aflimty may bc Ccterminnl using Kinexa Biocen-\n",
      "sor, scinnllation prox&muy essays. ELISA. ORIGEN &nunu-\n",
      "noa ssay (I CiI'), tluo re scen ca quenching, fluorescence trm&s-\n",
      "fer, and/or yeast display. Bindmg nlfinity may also bc\n",
      "screened using a suitable bioassay.\n",
      "\n",
      "In son&e em bc din&ants, every amino acid position in a ('DR\n",
      "is replaced (in some emboC&ments. one at a time) anth all 20\n",
      "natural amino acids using art recognized mutagenesis meth-\n",
      "ods (some of which are described herein) This generates\n",
      "small lib mries ofcl ones (in some embodunents. one for every\n",
      "amino acid position that is analyzed), each with a complexity\n",
      "of 20 members (&f all 20 amino acids are subsututed at every\n",
      "pos&&&on).\n",
      "\n",
      "In some embodmicn(s. the library tobe screened composes\n",
      "subst&tuuons &n two or more posit&ons, wluch may be &n the\n",
      "same ('Dk or in two or more CDks. 11&us. the library may\n",
      "compose substitut&ons in &uo or more posit&m&s u& one CDR.\n",
      "'I he library may compose substitut&on &n tv,o or more posi-\n",
      "tions in tuo or morc ( DRs. The librnry n&ay comprise sub-\n",
      "stitution in 3. 4, 5, or more pos&lions, smd posiuons f&&und in\n",
      "nvo. three, four, five or six (.'DRs. I'he substitution may be\n",
      "\n",
      "prcpnrcd using low redundancy codons. Swx c.g, Table 2ol'afiutet al . 1993. Ciene 137(l).109-18).\n",
      "\n",
      "The CDR may be ('IJRH3 and/or C'1)RI.3. The «)JR may\n",
      "bc onc or morc of C'DRI,I, C'DRI.2,\n",
      "( DRIuk C'DRHI,\n",
      "CDki12. and/or «DR113. 11&e CDR may be a Kabat ('Dk. a\n",
      "«hotl&ia ('DR, or m& extended ( DR.\n",
      "\n",
      "Cand&dates w&th improved bind&ng may be sequenced,\n",
      "thereby Identify&ng a CDR substinuion mutant which results\n",
      "in in&provixI aflinity (also termed an \"improved\" substitu-\n",
      "t&on). Catxhdates tlmt b&ud may also be sequenced, thereby\n",
      "ident&fying a CDR substitution which retains binding.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "37\n",
      "Multiple munds of screening may be conducted. For\n",
      "exmuple. candidates (each composing an anuno acid substi-\n",
      "tution at one or more position of one or more CDR) with\n",
      "improved binding are also usefiil for thc design of a second\n",
      "library containing at least the onginal and subsntuted anuno\n",
      "acid at each improved (.'DR position (i.e.. amino acid position\n",
      "ui the CDR at wluch a substitution mut mt ahois ed nuproved\n",
      "bindm ). Preparation, screenuig, and selection of this library\n",
      "is discussed I'artier bekiw\n",
      "\n",
      "Library sc uuung mutagenesis also provides a memis for\n",
      "cltamcterizing a CDR, in so far as the frequency of clones\n",
      "with improvexI binding. tfie same binding, decreased binding\n",
      "or no binding also provide information relating to the impor-\n",
      "tance of each amino acid position for the stability of the\n",
      "antibody-antigen complex For example, if a positioii of the\n",
      "C DR retains binding vvhen changed to all 20 nmino acids, that\n",
      "is unlikely to bc\n",
      "position is identified as a position that\n",
      "requirediiirantigenbinding Conversely,ifapositionofCDR\n",
      "retains binding in only a small percentage of substitutions.\n",
      "tliat position is identified xs a positimi tliat is important ui\n",
      "CDR fiuiction. '11tus. the library scanning mute enesis meth-\n",
      "ods generate information regarding positions in tlie CDRs\n",
      "that can be changed to many different amuio acids (includin\n",
      "all 20 amino acids), and positions in the CDRs which cannot\n",
      "be changcxl or which cmi only be changcdl to n fiw mnino\n",
      "acids.\n",
      "\n",
      "I'andidates ivith improved affinity may be combined in a\n",
      "second library, which mcludes the improvixI amino amd. the\n",
      "oriynal mmno acid, and may further include additional sub-\n",
      "stitutiolis at that positiiln. depending oil the complexity ill tlic\n",
      "library that is desired. or penm tted usia„ the desired screen-\n",
      "iilg iir selection method. In addition, if desired, and adjacent\n",
      "mnuui acid position can be mndomized to at li ast two or nuirc\n",
      "amuio acids. Randon»zation of ad)scent amuio acids may\n",
      "permit additional conformational tlexibility in the nuitant\n",
      "CDR. which inay. in turn, permit or Iiacilitatc the intr&iduciion\n",
      "of a larger number of uuproving mutations. The library may\n",
      "nlso comprise substitution at positions that did not show\n",
      "unproved alfinity in thc iirst round o I'screening\n",
      "\n",
      "'lite second I ibrary is screened or selected for library mem-\n",
      "bers with inipmvcd nnd/or altered binding affinity using miy\n",
      "method knov;n ui the art. including screening using 1)iacore\n",
      "surface plasmon resonance analysis, and selection using any\n",
      "method known in the art for scloction. including phage dis-\n",
      "play. yeast display, and nbosome display.\n",
      "\n",
      "Tiie invention also encompasses fiision proteins compris-\n",
      "uig one or more fragments or regions from the antibodies or\n",
      "polypeptides of this invention. In one embodinient, a fiision\n",
      "polypeptide is provided that mmiprises at lmist 10 contiguous\n",
      "anuno acids of a venable light cliain reyon shown ui SEQ ID\n",
      "NOs: 53. 16, 17. I g, or 19 and/or at least 10 amino acids of a\n",
      "variable heavy chaui region shoivn in SFQ ID NOs 54. 20.\n",
      "21. 22. or 23. In other embodiments, a fiision polypeptide is\n",
      "provided that comprises at least about 10, at least about 15, at\n",
      "least about 20, at least about 25, or at least about 30 contigu-\n",
      "ous amino acids of the variable light chain region and/or at\n",
      "least about 10, at least about 15, at least about 20, at least\n",
      "about 25, or at least nbout 30 ctintiguous amuio acids of the\n",
      "variable hcavy cltain region In another embodiment. the\n",
      "I'usmn polypeptide comprises a light chain vnriable region\n",
      "and/or a heavy chaui variable region, as shov;n in any of the\n",
      "sequence pairs selected from among SFQ ID NOs: 53 mid 54,\n",
      "16 and 20, 17 and 21. I g and 22, and 19 and 23. In another\n",
      "embodiment, tlie fusion polypeptide comprises one or more\n",
      "('DR(s) In still other embodimmitg tlic fusion polypeptide\n",
      "comprises CDI& 113 (VI I CDR3) and/or CDR L3 (VL CDI&3).\n",
      "For purposes of tlus invention, a fusion protein contains one\n",
      "\n",
      "38\n",
      "or more antibodies and another amino acid sequence to which\n",
      "it is not attached in the native molecule. for example. a het-\n",
      "erologous sequence or a homologous sequence from another\n",
      "region. Iixemplary hcterologous sequences include, but nre\n",
      "s not limited to a \"tag'* such as a FLACi tag or a 611 is tag. Tags\n",
      "\n",
      "are vvell known in the art\n",
      "\n",
      "A liision polypeptide can be created by methods knoivn ui\n",
      "the art. for example. synthetically or recombinantly. Typi-\n",
      "cally, thc fusion proteins ol'his invention are made by pre-\n",
      "t(1 paring an expressing a polymicleotide encoding them usin\n",
      "recombinant methods described herein. altlxiiigh they may\n",
      "also be prepared by other means knov, n in the nn, nicluiling,\n",
      "for example, chemical synthesis.\n",
      "\n",
      "This invention also provides compositions comprising\n",
      "antibodies or polypeptides con)ugated (fiir example, linked)\n",
      "to an agent tliat facilitate coupling to a solid support (such as\n",
      "biotin or avidin). I'or simplicity. refcrmice will bc made gen-\n",
      "erally to mtibodies with the understanding that these methods\n",
      "apply to any ofthe P(.: SK 9 binding mid/or antagonist embodi-\n",
      "o mmits described herein Conjugation gcni:rally rcli;rs to link-\n",
      "ing these components as described hereui. Tire linking (winch\n",
      "is generally fixing these components in proximate association\n",
      "at least for administration) cmi be achieved ui any number of\n",
      "ways. For example, a direct reaction between an agent and an\n",
      "antibody is possible whmi each possesses a substinient\n",
      "capable of reactin»vith the other. For example. a nucleo-\n",
      "philic youp, such as an amino or sulihydryl group. on one\n",
      "may be mipable of reacting is ith a carbonyl-conuunm griiup,\n",
      "such as an anhydnde or an acid halide, or auth an alkyl youp\n",
      "io containing a good leaving group (c.g, a halide) on tlie otlmr.\n",
      "An antibody or pohpep tide of tlus invention may be luiked\n",
      "to a labeling agent such as a ihiorescent molecule, a radioac-\n",
      "tive lliolccillc or'liv tithers labels knovvn in the art I,abcls arc\n",
      "known in the art wluch generally provide (either directly or\n",
      "\n",
      "\"» indirectly) a signal.\n",
      "\n",
      "Thc invmiiain also provides compositions (including phar-\n",
      "maceutical compositioas) and kits compnsing. as this disclo-\n",
      "sure makes clear, any or all of the antibodies and/or polypep-\n",
      "tides dcscnbcd herein\n",
      "\n",
      "4o\n",
      "\n",
      "The invention also provides isolated polynucfeotides\n",
      "micoding the mitibodies mid peptides of tlm invention, and\n",
      "vectors and host cells comprising the polynucleotide.\n",
      "\n",
      "Accordingly, the invention provides polynucleotides (or\n",
      "compositions,\n",
      "including pharmaceutical\n",
      "compositions),\n",
      "compnsuig polynucleotides encoduig any of the following;\n",
      "the antibodies 4A5, 5A10, 6FEi, 7D4. 1.11 3, or any fragment\n",
      "or part thereof havuig the ability to antagonize PCSK9.\n",
      "\n",
      "In another aspect. the invention provides polynucfeotides\n",
      "encoding any ol'he mitibodies (including mitibody I'rag-\n",
      "a ments) and polypeptides descnbed herein, such as antibodies\n",
      "and polypeptides lusving impaired eifector function. Poly-\n",
      "nucleotides can be madeand expressed by procedures Drown\n",
      "ui the art.\n",
      "\n",
      "5\n",
      "\n",
      "In another aspect, tlm invention provides compositions\n",
      "(such as phamiaceutical compositions) composing any of the\n",
      "polynucleotides of thc invention. In some embodiments. the\n",
      "composition euniprises an expression vector comprising a\n",
      "polynucleotide encoding the anubody as described hereui ln\n",
      "other embodiment, the composition comprises an expression\n",
      "ro imcuir comprising a polvnuclcotide encoding any of thi: miti-\n",
      "In still other\n",
      "bodies or polypeptides described herein.\n",
      "mnbodi ments, tlm composition comprises citlmr or both ofthe\n",
      "polynucleotides shown in SRQ ID NO.25 and SFQ ID\n",
      "NO:26. Expression vectors. and administration of polynucle-\n",
      "otidc compositions are furtlmr described herein.\n",
      "\n",
      "In another aspect, the invention provides a method ofmak-\n",
      "\n",
      "ing any of the polynucleotides described herein.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "39\n",
      "Polynucluotides complenmntary to any such sequences me\n",
      "also encompassed by the present invent&on. Polynucleotides\n",
      "may be single-stranded (coding or antisense) or double-\n",
      "s&tended, and may bc DNA (genomic, cDNA or synthetic) or\n",
      "RNA molecules. RNA molecules uiclude I lnRNA molecules,\n",
      "which contain introns and correspond to a DNA molecule in\n",
      "a one-to-one manner, md mRNA molecules, wluch do not\n",
      "contmn introns. Add&tional coding or non-codin sequences\n",
      "may, but ixmd mib bc present within a polynuclc&itide of the\n",
      "present u&vention, mui a polynucleotide may, but need not, be\n",
      "linked to other molecules und/or support matenals.\n",
      "\n",
      "Polynucleotides nuit'o&lip&lse a &&attic scxiuencc (& e . a&1\n",
      "endogenous sequence that encodes an ant&body or a port&on\n",
      "tlmreofl or may comprise a variant of such n sequence. Poly-\n",
      "nuclcioitide vanants contain one or more substitutions, add&-\n",
      "tions. deletions an&1'or insertions such that the inununoreac-\n",
      "tivi&y ofthe encoded polyp&7tidc is not diminished. relative to\n",
      "a native immunoreact&ve molecule. The elTect on the &mmu-\n",
      "noreactivity of the encoded polypeptide may generally be\n",
      "assessed ns describe&I herein Variants prefemblv cxlribit at\n",
      "least about 70% ident&ty. more preferably. at least about 80%\n",
      "identity, yet more preferably, at least about 90\"/a identity, and\n",
      "most preferably. at least about 95% &dent&ty to a polynucle-\n",
      "otide sequence that encodes a nat&ve antibody or a portion\n",
      "thereof\n",
      "\n",
      "Tivo polynucleot&de or polypepude sequences are sa&d to\n",
      "be \"identical\" ifthe sequence ofaucleoti des or emu&o acids in\n",
      "the tivo scx)ounces is the same when aligned for maxinnuu\n",
      "correspondence as descnbed beloiv. Compansons between\n",
      "two sequences arc typically pcrfonn&.d by cianparinv thc\n",
      "sequences over a companson windoiv to identify wid com-\n",
      "pare local reg&ons of sequence sundanty. A \"comparison\n",
      "w indov, *'& used herein, rcfi rs to a &ugnmnt oi'at least about\n",
      "20 conuguous posiuons, usually 30 to about 7 &, or 40 to about\n",
      "&0, in ivhich a sex)uence may be con&par&xi to a reference\n",
      "&mqucnce &ii'hc seine number ol'ontiguous posit&ons aficr\n",
      "the two sequences are opt&mally al&gned.\n",
      "\n",
      "Optimal alignment of sequences for comparison mny be\n",
      "conducted using the Megaligo progrmn in the l,asergenc suite\n",
      "of bioinformatics software (DNAS'IAR.\n",
      "Inc., Madison.\n",
      "Wis ), using default parwneters This progran& mnbodies scv-\n",
      "eml al&gnment schemes described in the follow&ng refer-\n",
      "ences: Dayhoff. M. O.. 1978, A model of evolutionary change\n",
      "in proteins Mntrices fiir detecting distant relationships. In\n",
      "Dayhoff. M. O. (ed.) Atlas of Pmte&n Sequence and Structure\n",
      "(National Biomedical Research Foundation. Washington\n",
      "D C.). Mol. 5. Suppl 3, pp. 345-358: Heu& J.. 1990. Un&tied\n",
      "Approach to Alig&ut&ent and Phylogenes pp. 626-645 Meth-\n",
      "183, (Academic Press. Inc, Sun\n",
      "ods u& Furymology vol\n",
      "D&ego. Calif.): H&gg&ns. D. Ci. w&d Sharp, P M., 1989,\n",
      "CABIOS 5:151-153: Myers. L'. W. and Muller W., 1988,\n",
      "CABIOS 4:11-17. Rob&nson. Pk D.. 1971, ('on&b. Theor\n",
      "11 10&: Santou, N., Nes. M.. 1987, Mol. Biol. Lvol. 4:406-\n",
      "425: Sneath. P. H. A and Sokal. R R.. 1973, Numerical\n",
      "Taxonomy the Princ&plea and Practice of Numencal Tax-\n",
      "onomy (Freeman Press, San Francisco. I'nlif.): Wilbur. W J.\n",
      "mid I ipmm&. D..i . 198'3. Proc Natl. Aced. Sci. USA 80 726-\n",
      "730.\n",
      "\n",
      "Preferably. the \"percentage of sequence identity's deter-\n",
      "mined by comparing two opt&mally aligncdi sequences over a\n",
      "w&ndow of comparison of at least 20 positions, wherein the\n",
      "portion of the polynuclmtide or polypeptide sequence in the\n",
      "comparison window may compose add&t&ons or deletions\n",
      "(i e., gaps) of20 percent or less, usually 5 to 15 percent, or 10\n",
      "to 12 percent, as compnrcd to thc refcrcnce sequences (w hich\n",
      "does not compose addiuons or deletions) for optimal ahgn-\n",
      "ment of the two s&xpiences. 'I'he percentage is calculated by\n",
      "\n",
      "40\n",
      "demrmining the number of positions at v,hich the identicnl\n",
      "nucle&c ac&d bases or anuno ac&d res&due occurs &n both\n",
      "sequences to yield the number of matched posit&ons. divi du&g\n",
      "tlm number of n&atchcd positions by tlm total nun&ber of\n",
      "(&.e. the wuidow size) and\n",
      "nniltiplying the results by 100 to yield the percentage of\n",
      "sequence ident&ty\n",
      "\n",
      "s positions in the reference sequence\n",
      "\n",
      "Vanants may also. or alternatively, be substantially\n",
      "lximologous to a nat&ve gcnc. or a portion or complmnm&t\n",
      "u& thereol. Such polynucleot&de vanants are capable of hybnd-\n",
      "izing under modemtely stnngent conditions to a naturally\n",
      "occurring DNA &cqumicc encoding a native antibody (or a\n",
      "complementary sequence).\n",
      "\n",
      "Suitable \"&miderately stringent conditions\" include pre-\n",
      "&&saltu& u»I soh&&ion of &xSSC, 0 5% SDS. 1.0 mM I:DTA\n",
      "(pH 8.0); hybridizing at 50\" ( .-(i5\" (.'., 5xSS('. overnight;\n",
      "fiilkiwed by washing twice ai 65\" C for 20 minutes with each\n",
      "of 2x. 0.5x and 0.2xSSC conuiining 0.1% SDS.\n",
      "\n",
      "As used herein, \"hivgly stringent conditions'r \"hikes\n",
      "o stringency conditions'* aro those lira& (I) employ low ionic\n",
      "strength and hi h temperature for wa slung. for example 0 01 &\n",
      "M sodium chloride/0.0015 M sodium citmte!0 I \"/a sodium\n",
      "dodecyl sulfate at 50's (2) employ dune hybndization a\n",
      "denaturing agent. such as formam&de, for example. 50/8 (v/v)\n",
      "formamidc with 0.1% bovine serum albumin/0.1\" k Ficoll/\n",
      "0.1% polyvinylpyrrol&dot&e/50 mM sodium phosphate buffer\n",
      "at pH 6&.5 with 750 mM sodium chloride, 75 mM sodium\n",
      "citrate at 42': or (3) employ 50'/& formamide. 5xSSC (0.75\n",
      "M NaCI. 0.075 M sod&um citmte), 50 mM sod&um phosplmte\n",
      "(pH 6 8), 0 1% sodium pyroplxisphatc, 5xDenhardt*s sulu-\n",
      "&&&1&1. son&cared saki&on spe»'11 DNA (50 iighnl). 0.1% SDS,\n",
      "and 105!a dextran sulfate at 42'., iv&th washes at 42'. &n\n",
      "0.2xSS('sod&um chloride/sodium ci&rate) and 50'/&& lonna-\n",
      "n»de a& 55'., followed by a high-stnngency wash cons&stu&g\n",
      "\"» of O.lxSSC containing RDIA at 55''. Thc skilled n&tissu\n",
      "&vill recognize how to adiust thc tempcniturc. ionic strength„\n",
      "etc. as necessary to ace onuno date factors such as probe length\n",
      "and thc like.\n",
      "\n",
      "&o\n",
      "\n",
      "It i&ill be appreciated by &hose ol'ordinary skill in the art\n",
      "that. as a result ofthe degeneracy ofthe genetic code, there are\n",
      "nmny nucleotide sequences that encode a polypeptide as\n",
      "described herein. Some of these polym&cleotides bear mim-\n",
      "ma1 homology to the nucleotide sequence of any native gene.\n",
      "Nonothcless. polynucleotidcs that vary due to differcnccs in\n",
      "codon usage are spec&ficaily contemplated by the present\n",
      "invention. Further, ageles of the genes comprising the poly-\n",
      "nucleot&de sequences prov&ded herein are w&thin the scope of\n",
      "the present invention. Alleles are endogenous genes that are\n",
      "altered m& a result o I'one or more mutnti oui. such as deleuo ns.\n",
      "u add&t&ons and/or subst&tut&ons of nuclco&tides. The result&ng\n",
      "mRNA and prote&n may, but need not, l&ave nn altered stnic-\n",
      "ture or function. Alfcles may bc identilied using stmidard\n",
      "techniques (such as hybri&h&mt&on. &unpl&iieet&on and/or data-\n",
      "base sequcncc comparison).\n",
      "\n",
      "s\n",
      "\n",
      "The polynucleotides of this invention can be obtauled\n",
      "using chemical synthesis, recombinant methods, or P('R.\n",
      "Methods of chemical polynuclwitide &yntlmsis arc well\n",
      "knoivn in the art wid need not be described in detad herem.\n",
      "Onc of skill in the art can use the sequences provided herein\n",
      "ro and a commercial DNA synthesizer to produce a desired\n",
      "\n",
      "DNA sequence.\n",
      "\n",
      "For preparing polym&clcotides using recombinant meth-\n",
      "ods. a polynucleot&de compnsuig a des&red sequence can be\n",
      "inserted into a suitable vector, and the vector in turn can be\n",
      "introduced into a suitable host cell fiir replication and ampli-\n",
      "ficauon. as further discussed here&n. Polym&cleot&des muy be\n",
      "inserted into host cells by any means known in the a&t ('ella\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "41\n",
      "are transformed by introducing an exogenous polynucleotide\n",
      "by direct uptake. endocitosis, tmnsfection, Ixmaung or elec-\n",
      "troporat&on. Once u&troduced, the exogenous polynucleotide\n",
      "can bc maintained witldn the cell ms a non-intcgratcd v&xtor\n",
      "(such as a plasm&d) or &a&earn&ed into the host cell genome.\n",
      "fhe pclynu ciao tide so amplified can be isolated from the host\n",
      "cell by methods well knov,n w&thui the art. See. e.g, Sam-\n",
      "brook et al., 1989, supra.\n",
      "\n",
      "Allcmativelv,\n",
      "\n",
      "PC'R allows\n",
      "\n",
      "reprixlnclion\n",
      "\n",
      "of DNA\n",
      "\n",
      "1\n",
      "\n",
      "sequences. PCR teclmology &s well into&vn ui the art and ls lo\n",
      "described in U.S. Pat. Nos. 4,683,195. 4,800.159, 4.754,065\n",
      "'i&id 4,683.202. Cs well cs PC'R The Polymcrase C'hain Reac-\n",
      "tion, Mullis et al., 1994, eds. (Birkauswer Press. Boston,\n",
      "Mass ).\n",
      "\n",
      "RNA cau bc obta»ied by using lhe isolated DNA in an\n",
      "appropriate vector and inserting it into a suitable host cell.\n",
      "When the cell replica&as and the DNA is transcribed into\n",
      "RNA. &he RNA m&n that& be isolaled using nielhods well\n",
      "known to those of skill in the art, as set forth in Sambrook et\n",
      "al, 1989, supm, I'or cxaluplc.\n",
      "\n",
      "\"v\n",
      "\n",
      "Suitable cion&ng vectors may be constructed according to\n",
      "standard teclmiques, or may be selected from a large number\n",
      "of clonuig vectors evadable in the art. Wlule the clo&un\n",
      "vector selected nmy vary according to the host cell intended to\n",
      "be used, useful cloning vectors will generally have the ability \"\n",
      "to self-replicate. may possess a s&ngle tar et for a part&euler\n",
      "restriction endo nuc lease. and/or may carry genes fora marker\n",
      "that can be used &n selecting clones contamin the vector.\n",
      "Su&table examples uiclude plasnuds and bactenal v&ruses,\n",
      "c g. pUC'l8, pU('19, Blucscript (c g.. pBS SK+) and its &v\n",
      "derivatives, inp lb, mp 19. pBR322. pMB9, Coll',I. pCR),\n",
      "RP4. phage DNAs, and shuttle vectors such as pSA3 and\n",
      "pAT28 Tlmse nnd many othir clmung vectors are avnilablc\n",
      "from conunerc&al vendors such as B&oRad. Strategene, and\n",
      "I llv& t fr& get'1\n",
      "\n",
      "Expression vectors generally are replicablc polynucleotidc\n",
      "constructs that contain a polymicleot&de according to tile\n",
      "invm&tion. It is implied that an expression vector must be\n",
      "replicable in the Ix&st cells e&ther as CT&iso&ucs or cs an integral\n",
      "part of the chron&oson&al DNA. Suitable expression vectors sv\n",
      "include but arc not limimd to plasmids, viral vectorz includ-\n",
      "ing adenov&ruses. adeno-associated v&ruses,\n",
      "retrov&ruses,\n",
      "cosmids, and expression vector(s) disclosed in P('T Publ. No.\n",
      "WO 87/04462. & bc&or components may generally include.\n",
      "but are not limited to, one or more of the follow ing: a signal 4.\n",
      "sequence: m& origin of replication; one or more marker genes;\n",
      "su&table transcnpt&onal contml l&ng elements (such as promot-\n",
      "ers, enhancers and termu&ator). I&or expression (&.e., transla-\n",
      "tion), one or nmre translatu&nal controlluig elemcnm are also\n",
      "usually required. such as nbosome b&nduig sites. translation\n",
      "initiation sites. and stop codons.\n",
      "\n",
      "c\n",
      "\n",
      "The vectors containing the polynuclex&t&des of u&terest can\n",
      "be uitroduced into the host ceil by any of a number of appro-\n",
      "priate nmanw including clectroporation, transfection employ-\n",
      "ing calmum chloride, nibid&um chloride, cele&um phosphate,\n",
      "DL'AE-dextran. or other substances; microprojectile bom-\n",
      "bmdment, lipofixtion, mxl in 1'ection (c g, v'lmre the vector is\n",
      "an infect&ous agent such as vaccin&a &in&s). The choice of\n",
      "introducing vectors or polynucleotides will often depm&d on\n",
      "I'eatures of limbos'ell\n",
      "\n",
      "s\n",
      "\n",
      "sa\n",
      "\n",
      "'lite invention also prov&des host cells comprising any of\n",
      "the polynuclcotides described herein Any la&st cells capable\n",
      "of over-express&n hetemlogous DNAs cmi be used for tile\n",
      "purpose of isolating the genes encoding the antibody,\n",
      "polypeptide or protein of interest. Non-limiting exmnples of (\n",
      "manuualian host cells uiclude but are not l&mited to COS.\n",
      "HeL1. NSO. and CHO cells. See also PCT Ih&bl. No. WO\n",
      "\n",
      "42\n",
      "\n",
      "87/04462. Suitable non-n&anunalim& host cells\n",
      "include\n",
      "pmkaryotes (such as E co /i or R sub/i i/is) and yeast (such as\n",
      "5'. Cerevisve, R pv&abc: or K. lvc/is). Preferably the host cells\n",
      "express the cDNAs at a level of about 5 fold higher, more\n",
      "preferably, 10 fold lugher. even more preferably, 20 fold\n",
      "higlier tinn that oftile corresponding endogenous antibody or\n",
      "pmte&n of interest, if present, m the host cells. Screen&ng the\n",
      "host cells for a specific binduig to PCS K9 or a lxCSK9 dome&n\n",
      "is cl'll:ctcd by an immunoassay or FACS. A cell overcxpress-\n",
      "uig the antibody or proteui of interest can be &denuiied.\n",
      "C. Ciimpositions\n",
      "\n",
      "The composiiions used m the methods of tlm invention\n",
      "compnse an effective amount of a PCSK9 ant&1 onist ant&-\n",
      "body. a PCSK9 antagonist m&tibody dcrivcd polypeptide. or\n",
      "other PC'SK9 mitagon&sts describexI herein, Iixamples of such\n",
      "compositions, as well as how to formulate them, are also\n",
      "described in mi oarlier sccction and below. In one embodiment,\n",
      "the compos&t&on lhrther compnses a PCSK9 antagonist\n",
      "In\n",
      "another embodiment, the composition comprises one or more\n",
      "PC'SK9 antagonist m&libodics\n",
      "In other embodimen(S lhc\n",
      "PCSK9 antagon&st antibody recoy&izes lnunan PCSK9. In\n",
      "still other embodiments, the P(.'SK9 antagonist antibody is\n",
      "human&zed. In yet other embodiments, the PCSK9 antagonist\n",
      "antibody compnses a constant region that does not trigger an\n",
      "unwanted or undesirable imnumc response, such as antibody-\n",
      "med&ated lysis or ADCC. In other emboduuents, the PCSK9\n",
      "antagoiust antibody compnses one or more ('DR(s) of the\n",
      "a&uibody (such as one. u&o.\n",
      "I'our, live, or. m some\n",
      "ln some emboduuents. the\n",
      "embod&ments. all\n",
      "P('SK9 m&tagonist nntibody is bim&an\n",
      "\n",
      "s&x CDRs),\n",
      "\n",
      "three.\n",
      "\n",
      "Il &s understood that lhe composit&ous mui comprise more\n",
      "than one PCSK9 antagonist antibody (e.g.. a mixnire of\n",
      "PC'SK9 antagonist antibodies\n",
      "recognize dilfcrm&l\n",
      "ep&topes of PCSK9) Other exemplary compos&uons com-\n",
      "prise more than one P('SK9 antagonist antibodies tlmt recog-\n",
      "nize lhc same CT&itope(s). Cr dilfcrenl spec&es ol'C'SK9\n",
      "amagoiust antibod&es that bind to different ep&topes of\n",
      "P()SK9\n",
      "\n",
      "that\n",
      "\n",
      "The composit&on used in lhe pres&ait invention can lurther\n",
      "comprise phannaceut&cally acceptable carriers, excipients, or\n",
      "stabilizers (Rcmington: The Science and Practice of Phar-\n",
      "macy 20th Ed., 2000, Lippincott W&lliams and W&lkins. Ed.\n",
      "K. E. Hoover), in the form of lyophilized formulations or\n",
      "aqueous solutions Acceptable carriers. excipienis. or stabi-\n",
      "1&zers are nontox&c to recip&ents at the dosages and concen-\n",
      "uations, and may comprise buffers such as phosphate, citrate,\n",
      "and other organic ac&ds: ant&ox&dents &nclud&ng ascorb&c ac&d\n",
      "and metluon&ne: preseivatives (such as octadecyldunethyl-\n",
      "bm&zyl mnim&niun& chlonde, hexmnellmminn chloride, ben-\n",
      "zalkoiuum cldonde. benzethoiumn cldonde; phenol. butyl or\n",
      "benzyl alcohol, allyl parabens such as methyl or propyl para-\n",
      "ben. catechol, resorcinol, cyclohexano1„3-pentanol, nnd\n",
      "m-cresolk low molecular we& ht (less than about 10 res&dues)\n",
      "polypeptides, proteinz such ns senun albun&in. gelntin, or\n",
      "&mn&uuogobulins: hydrophil&c polymers such as polyvi-\n",
      "nylpyrrolidone; amino acids such as glycine, glutamine,\n",
      "aspalagi»c, lustidinc. Cn ininc, or lysinm monosaccharidcs,\n",
      "d&saccharides. aud other carbohydrates u&clud&ng glucose,\n",
      "mannosc, or dextrm&s; chelating agents such as Vl) I'A: sugars\n",
      "such ns sucrose. mannitol, trclmlosm or sorbilol, salt-fonnmg\n",
      "counter-iona such as sodium; metal complexes (e.g., Zn-pro-\n",
      "tein complexes); and/or non-ionic surfnctm&ts\n",
      "such as\n",
      "TWEENPC, PLURONICS™ or polyethylene glycol (PECi).\n",
      "Plmnuaceutically acceptable excipients are further descnbed\n",
      "herein.\n",
      "\n",
      "In one embodiment. the antibody &s achnimstered ui a for-\n",
      "nui lation as a sterile aqueous solution Imv ing a pH t1&at ranges\n",
      "\n",
      "\f",
      "(js 8,080,243 B2\n",
      "\n",
      "43\n",
      "from about 5.0 to about 6 5 and comprising from about\n",
      "I\n",
      "m /ml to about 200 mg/ml of antibody. from about I milli-\n",
      "molar to about 100 mtllimolar of histidine buffer, from about\n",
      "0 01 mg&ml to about 10 mg/ml of polysorbatc80, from nbout\n",
      "100millimolarto about400millimolaroftrehalose,and from 1\n",
      "about 0.01 millimolar to about 1.0 millimolar of disodium\n",
      "I,DTA dihydrate.\n",
      "\n",
      "The PCSK9 antagonist antibody Und compositions thereof\n",
      "can olso be used ui ConjunCuon with other agents tlmt serve tO\n",
      "enhance and'or complement the efiectiveness of the &gents.\n",
      "D. Kits\n",
      "\n",
      "Thc invention also provides kits liir use in the instant meth-\n",
      "ods. Kits of the invention include one or more contauiers\n",
      "comprising a P( SK9 antagonist antibody (such as n human-\n",
      "Ired mitibody) or peptide descnbed hereul alai ulstructimis\n",
      "for use in accordance w ith any of the methods ofthe invention\n",
      "dcscribcd hcrcin Cicncrally, thcsc instnictions comprise a\n",
      "descnptmn of administratmn of the PC'SK9 ant ig&mist uiti-\n",
      "body. peptide, or aptamer for tlm above described therapeutic\n",
      "lrcauucllni\n",
      "\n",
      "Ui\n",
      "\n",
      "\"o\n",
      "\n",
      "In some embodiments, the anubody is a humamzed anti-\n",
      "body In some embodiments, the antibody is lnunan In other\n",
      "embodiments. the antibody Is a monoclonal antibody. The\n",
      "instructions relating to the use of a I'CSK9 antagonist anti-\n",
      "body generally include inf&imiation as to dosage, dosing \"\n",
      "schedule, Und route of adnuiustration for the intended treat-\n",
      "ment. The containers may be unit doses. bulk packages (e.g..\n",
      "nndti-dose packages) or sub-&uut doses Instructions supplied\n",
      "ill tile kIts of thc 1llvcitt1oil Bl'c typic all'&'\n",
      "ll(tell l its tinct lolls oil\n",
      "a label or package insert (c g.. a paper sheet includ&.d in Ihc so\n",
      "kit), but machine-readable instructions (e... uistructious cer-\n",
      "ned on a magnetic or optical stomge disk) are also acceptable.\n",
      "The kits of this invent«m arc in suitabl&. packaging Suit-\n",
      "able packaging ulcludes. but is not linuted to, vials. bottles,\n",
      "jars. flexiblc packaging (e g., sealed Mylar or plastic bags),\n",
      "Bud Ihc like Also coIUPJupl&11&xl itrc pack&&gas liir usc in com-\n",
      "buiation v'ith a specific device. such as an inhaler. nasal\n",
      "ndministrafiondks ice(P g,anatomixer)ormlinfusiondevice\n",
      "such ms a niinipump A kit may have a stenle access port (I'or\n",
      "example the container may be an intravenous solution bag or So\n",
      "a vial having a stopper picrccnblc by a hypodermic injection\n",
      "needle). The container may also have a stenle access port (for\n",
      "exmnple the contniner may be an intravmious solution bag or\n",
      "a vial having a stopper picrccablc by a hypodermic injection\n",
      "needle). At least one actne agent in the composition is a ss\n",
      "P('SK9 antagonist antibody. The container (e.g., pri-tilled\n",
      "syniige or autointector) may further compose a second phar-\n",
      "maceutically active agent.\n",
      "\n",
      "\"»\n",
      "\n",
      "Kits may optionally provide additnmal componenms such\n",
      "as buffers and interpretive information. Normally, the kit\n",
      "comprises a contmner and a label or package insert(s) on or\n",
      "Bssocuucd with the contmner.\n",
      "Mutations and Modificauons\n",
      "\n",
      "U\n",
      "\n",
      "1\n",
      "\n",
      "To express tlm P( SK9 antibodies of tlm present invention,\n",
      "DNA fragments encoding V» and V, regions can first be\n",
      "obtained using any of the methods described abnvc Various\n",
      "modifications, c g . nuitat iona, dclctions, tind/or additions can\n",
      "also be intr&xluced into the DNA sequences using standard\n",
      "methods known to those of skill in die art. For example,\n",
      "&UUtagcllcs&s call bc cart'lcd UUI uslllg staudal'0 lac(linda. such ui\n",
      "as I'CR-mediated mutagenesis, in wluch the mutated nucle-\n",
      "otidcs nre incorporated into tlm P('R primem such tluit the\n",
      "PCR product contmns the desired mutations or site-directed\n",
      "mutagenesis.\n",
      "\n",
      "One type of substitution, fiir example. tlmt may bc made is /\n",
      "\n",
      "to change one or more cysteines in the antibody, which may\n",
      "be cliemically reactive, to another residue. such as, without\n",
      "\n",
      "44\n",
      "limitation, alaninc or serine. For exanlplc, there can be a\n",
      "substitution of a non-canonical cysteine. The substitution cmi\n",
      "be made in U CDR or fmmew ork region of a variable domaui\n",
      "or in the constmlt domain ol'n antibody. In some embodi-\n",
      "nlents, the cvsteinc is canonical\n",
      "\n",
      "The antibodies may also be modified, e.g., in the variable\n",
      "domauis of the heavy and/or light chains. e... to alter a\n",
      "binding property of the anubody I or ex unple, a mutation\n",
      "nlay bc maCk in onc or morc of tlm C'DR regions to increase\n",
      "or decrense the K» of thc mitibody I'or PCSK9. to increase or\n",
      "decrease k,C or to alter tile binding specificity ofthe antibody.\n",
      "Techniques~in site-direcmd mutageiwsis nre v;cll-known in\n",
      "the art. See. e.g., Sambrook et al, and Ausubel et al., supra.\n",
      "A modification or mutation may also be made in a frame-\n",
      "work region or constmlt domaul to increase the half-fife of a\n",
      "I'C SK9 antibody. See, e.g., PCT Pub l. No. WO 00/09560. A\n",
      "nnimtion in a framewnrk region or constant domain can also\n",
      "be made to alter the unnulnogemcity of the antibody, to\n",
      "provide a site for covalent or ixm-covalent binding to another\n",
      "molecule. or to alter such properties as cmnplement lixntion,\n",
      "PCR bmdin and anubody-dependent cell-mediated cytotox-\n",
      "icity. According to the uivention. a single antibody may have\n",
      "mutations in any one or more of the CDRs or frammvork\n",
      "regions of the venable domain or in the constant domain.\n",
      "\n",
      "In a process kno&vn as \"germ lining\", certain mnino acids in\n",
      "the VII and Vi scqUPllccs cUll be mutated to match those iinuxl\n",
      "naturally in germline V,& and Vs sequences. In particular, the\n",
      "amino acid sopmnces o I'tlm I'rmnew ork rcgmns in the V» and\n",
      "sequences can be nnitated to niatch Ihe germline\n",
      "V,\n",
      "sequences tn reduce the risk of inmumogenicity when the\n",
      "antibody is adnnnistered Ciennline DNA Sequences Ior\n",
      "human V» and Vc genes are known in the art (see e.g.. the\n",
      "'Vbase'* human gernlline sequence database, siv. also Kabat,\n",
      "lk A., et al. (1991) Sequences of Proteins of Immunolo Ical\n",
      "interest, Fifth Hdition, H S. Deportment of Health and Hummi\n",
      "Services, NIH Publ No 91-3242, Tomlinson ct al.. 1992, .1.\n",
      "Mol. Biol. 227:776-798: Und Cox et al., 1994. Bur, J. Inunu-\n",
      "nol 24:827-83ti.\n",
      "\n",
      "Another type of amino acid substinluon tlrat may be made\n",
      "is to remove potential proteolytic sites In the antibody. Such\n",
      "sites may occur in a ('DR or franwwork region of n vtmiablc\n",
      "domaui or In the constanl dom Un of an antibody. Subslitution\n",
      "of cysteine residues and removal of proteolytic sites may\n",
      "divroase thc risk ofheterogeneity in the antibody product and\n",
      "tluls increase its homogeneity. Another type of amulo acid\n",
      "substitution eliminates a~sparaginc-giycinc pairs, which form\n",
      "potential deanudation sites. by altering one or both of the\n",
      "residues. In miother example. thc (utenninal lysins of the\n",
      "hcavy chain of a P( SK9 antibody of tlm invention call bc\n",
      "clem ed. In vanous embodiments of the ulvention. the hea&0\n",
      "and light clu&ins of the I&CSK9 antibodies nlay optionally\n",
      "ulclude a signal sequence.\n",
      "\n",
      "Once DNA fragtuents encoding the V» and Vc segtuents of\n",
      "th&. prcsmlt in&mntion are obtainixi, these»DNA fragnwnts cnn\n",
      "be further manipulated by standard recombinant DNA tech-\n",
      "niques, for example to mmvert the variable region genes ro\n",
      "Ihll-length mlt&body chain gcncs, to Fnb fra ment genes. or to\n",
      "a scfv gene. In these manipulations. a Vc- or Vr»encodutg\n",
      "DNA fragment is opemtivcly linked to arixitber DNA fnsg-\n",
      "ment encoding another protein, such as an antibody constant\n",
      "region or a flexible linker. The tenn \"operatively linked*', as\n",
      "used in Ibis contexk is illtelldcd Io &nevi&i tfmt the tv 0 DNA\n",
      "fbagments are )oined such that the mnino acid sequences\n",
      "mlcodcd by tlm t&vo DNA I'ragnmnts rcnlain in-I'rmnc\n",
      "\n",
      "Tile isolatcd DNA encoding the V» regimi cnn be c&mvcrted\n",
      "to a full-length heavy chmn gene by operatively linking the\n",
      "VI/ encoding DNA to another DNA nmlecule encodmg\n",
      "heavy chain constant regions (CIII, CH2 and CI13). The\n",
      "sequences of human heavy chain constant region genes are\n",
      "\n",
      "\f",
      "(js 8,080,243 B2\n",
      "\n",
      "45\n",
      "known in the art (scca ge Kabat, I..A., et al . 1991, Sequences\n",
      "of Proteins of Inununological Interest, I'ifth I.dition, U S.\n",
      "Deparunent of I lealth and Human Services, Nil I I'ubl. No.\n",
      "91-3242) and DNA frag&cents encompassing these regions\n",
      "can be obtained by standard PC R an&plifhcatiim The hcavy\n",
      "chain constant region can be an IgCi l. Igf)2, IgCi3, Igti4. IgA,\n",
      "Igp.. IgM or I D constant re &on, but most preferably is an\n",
      "igCII or 180i2 constant region. The Ig(i const&lnt\n",
      "leg&on\n",
      "sequence can be any ofthe various all el as or a I1otypes known\n",
      "to occur among differm&t individual a\n",
      "such as Cim(1). h im(2)\n",
      "Cim(3). and Gn&(17) These allotypes represent naturally\n",
      "occurring amino acid substitution in the igtil constant\n",
      "regions. Fora I'ab fragment heaiy chau& ene. the VI I-encod-\n",
      "&n DNA cm& be opemt&vely linked to another DNA molecule\n",
      "encoding only the hcavy clmin I HI constant region. The I H I\n",
      "heavy chain const u&t reg&on may be denved from any of the\n",
      "heavy chain genes.\n",
      "\n",
      "The isola&cd DNA encoding thc Vr region inn bc converted\n",
      "to a full-lenegth light chain gene (us well as a 1&ab light cha&n\n",
      "gene) by operatively linking the Vr-encoding DNA to m&other\n",
      "DNA molecule encodu&g the l&ght ch nn constant region, Cr .\".n\n",
      "I'he sequences ofluunun fight cl&mn constant region scenes are\n",
      "knoivu in the art (aei e g . KabaL F.. A . ct al . 1991, Sequences\n",
      "of Prote&ns of Immunolo ical InteresL I'ifth Bdit&on, U S.\n",
      "Department of Health and Ilunmn Serv&ces, NIH Publ. No.\n",
      "91-3242) and DNA frag&name encompassing these regions \"\n",
      "can be obtained by standard PCR unpliiicat&on. The 1&ght\n",
      "chain consmnt region can be a kappa or lambda cimstant\n",
      "region. The kappa constant region mav bc any ol'the vari&ms\n",
      "alleles known to occur among different individuals, such as\n",
      "Inv(l). Inv(2), and inn(3). The lmnbda constant rcgim& nmy bc Tn\n",
      "derived from any of the tinea lambda ence.\n",
      "\n",
      "To create a scl'v gene, the V~ and Vr-encoding DNA\n",
      "I'ragmcnts are operatively linked i(& dnothc&'&ugn&cnt cncoll-\n",
      "&ng a fiexible 1&nker, e.g.. encoding the mnino acid sequence\n",
      "(Cily4-Ser),, such that the Vu and Vi seqtmnces cm& be \"»\n",
      "expressed as a cont& uous su&gle-chau& prote&n, with the Ve\n",
      "and Vav regions joined by the flexible linker (See e g., Bird et\n",
      "al, 1988, Science 242.423-42t&, Huston et al, 1988, Proc\n",
      "Natl. Acad. Sci. USA 85; 5879-5883: McCafferty et al., 1990,\n",
      "Namre 348:552-554. The single chain antibody may be nn\n",
      "monovalenL if only a single Vu and Vn are used. b&valent, &f\n",
      "tw 0 V» and V, are used, or polyvalent, &f more than nvo V„\n",
      "m&d Vn are used. BisP&x:itic or Polyvalent anfibodics &nay bc\n",
      "generated that bu&d specdically to PCSK9 and to another\n",
      "molecule.\n",
      "\n",
      "4.\n",
      "\n",
      "u\n",
      "\n",
      "In m&otlmr einbodimint, a fusion antibody or immunoad-\n",
      "hesin may be made tluit compmses all or a portion oi a PCSK9\n",
      "m&tibody of the invention linkcxl to another polypeptide In\n",
      "another embodimenL only the vmiable domains ol'he\n",
      "PCSK9 antibody are linked to the polypeptide. In another\n",
      "cmbodinmnt,theVTudon&ainofaPC'SK9antibody islinkedto\n",
      "afirstpolypeptidi.whilethcV, dmnainofaPCSK9antibody\n",
      "is linked to a second polypeptide that associates with the first\n",
      "polypeptide in a mannersuch that the VuandVr domains can\n",
      "interact ivith one another to form an ant&gen bind&ng s&te. In\n",
      "another preferred embodiment, the VH domain is separated\n",
      "I'rom the Vr domain by a linker such that tlm VH mul VI,\n",
      "domains can interact with one another. The V„-hnker-'e',\n",
      "antibody is then linked to the polypeptide of interest. In\n",
      "add&t&on, fiis&on anubodkes can be created in wh&ch tivo (or m&\n",
      "more) single-chain antibodies are linked to one another. 'IKis\n",
      "&s useihl il'one wanLs u& create a divalent or polyvalent ant&-\n",
      "body on a su&gle polypeptide cha&n. or if one wants to create\n",
      "a bispecific antibody.\n",
      "\n",
      "6\n",
      "\n",
      "In other ambi&dimenta other umd&lied m&tibodies may be 6\n",
      "\n",
      "prepared us&ng PCSK9 anubody encoding nucleic ac&d mol-\n",
      "cculcs For instance, \"Kappa bodies\" (ill ct ale 1997, Pmtcin\n",
      "\n",
      "46\n",
      "I'ng, 10:949-57).\"Minibodies\" (Mnrtinctel..1994, FMBO I.\n",
      "13 5303-9), \"Diabodies'Holliger et al, 1993, Proc. Natl.\n",
      "Acad. Sc&. (ISA 90: 6444-6448), or \"Janu sins\" (Trm&necker et\n",
      "al., 1991. L'MBO J. 10:3655-3659 and 'Iraunecker et al.,\n",
      "1992. Int Ji. Cancer (Suppl.) 7 51-52) nuiy be prepared usu&g\n",
      "follow&ng the\n",
      "standard molecular biolog&cal\n",
      "teachings ol'he speciiimitmn.\n",
      "\n",
      "techn&ques\n",
      "\n",
      "B&spec&iic antibod&es or ant&gen-b&nding fragments can be\n",
      "produced by a vanety of methods including fus&on of hybri-\n",
      "dumas or linking of Fab'ragments. See, e.g, Songsivilai k\n",
      "Laclm&mu&. 1990, C1&n. Bxp. Inununol. 79: 315-321„Kostelny\n",
      "ct al, 1 992. J. hnnnmol. 148 1547-1553. In addition, bispc-\n",
      "cilic anubodies may be formed as \"d&ab&&dice\" or '*Jmiusins '*\n",
      "In some embodiments. the bispieciiic antibody binds to two\n",
      "diffi:rent epitopes of PC.SK&J\n",
      "In some mnbodiments. the\n",
      "modified ant&bodies duse&&bed above are prepared using one\n",
      "or more of the variable domains or C'DR regions from a\n",
      "inunan PC'SK9 antibodv provided herein.\n",
      "Cienerauon of Antigen-Specific Annbodies\n",
      "\n",
      "recomb&nant\n",
      "\n",
      "More than 500 polyclonal and monoclonal antibodies\n",
      "cused against\n",
      "full-length human PCSK9,\n",
      "recombinm&t full length mouse PCSK9, and various synthet&c\n",
      "pi7 tides w ere evaluated for their ability to down regulate tots I\n",
      "LDLR protein u& cultured Huh7 human liver cells. Amon\n",
      "these antibodies were a set of antibodies raised to and reactive\n",
      "with a set of 12-20 mnim& amd rcs&due polypc7uides that,\n",
      "based on the structure of PCSK9, were predicted to cover\n",
      "&up&ority of the protein simfacc At thc highest conccntmtion,\n",
      "the best antibodies exhib&ted only about 60% block&ng activ-\n",
      "ity.\n",
      "\n",
      "Thus, an alternntive aml hercu&fi&re unexplored approach\n",
      "u&t&-\n",
      "\n",
      "was employed, nmnely. the geneuu&on of monoclonal\n",
      "bodies by inununizing PC'SK9 null mice with riccombinant\n",
      "fuII-long&h PC'SK9 protein This mannir of antibody pri7a-\n",
      "muon y&aided antagorust anubodies that show complete\n",
      "blocking of PC'SK9 binding to I.DI,R, mhmpletc blocking of\n",
      "PCSK90&ixfiatnxiloweringol1 DI R levelsinlluh7cells,and\n",
      "loitering of LDLc in vivo including in mice to levels compa-\n",
      "mble to tlmt seen in PCSK9-/- mice, as shown in Fxample 7.\n",
      "Representative ant&bodies (hybridomas) of the present\n",
      "invention were deposited in the American fype I'ulture Col-\n",
      "lection (ATC'C') on Feb 28, 200K and were assigned tlm\n",
      "access&on numbers u& Table 3. Hybridomas were depos&ted\n",
      "for antibodies 4AS, 5A10. 61'Ci and 7D4.\n",
      "\n",
      "TABLL'\n",
      "\n",
      "i,n& bnd Re&&&ence\n",
      "\n",
      "ATCC *iccesunn inn\n",
      "\n",
      "4A\n",
      "\n",
      "A&(&\n",
      "\n",
      "6&6\n",
      "&un\n",
      "\n",
      "P&'Admns\n",
      "&n&A4066\n",
      "PTA-SS64\n",
      "PTA Scent\n",
      "\n",
      "LXAMPI.DS\n",
      "\n",
      "Fxmuplc I\n",
      "\n",
      "Cicnerating and Screening PC'SK9 Antagonist\n",
      "Antibodies\n",
      "\n",
      "Cieneral Procedures for Immunization ofAnimals fihr Ciener-\n",
      "atu&g Monoclonal Antibodies:\n",
      "\n",
      "Balb/c or 12971&16 pcsk9-/- mice were injected 5 times on\n",
      "a 13 day schedule with 100 pg antigen PC:SK9-/- (tlmt is,\n",
      "nul I or lu&ock out auca) can be obtained fmm. or as des cubed\n",
      "by, Rashid et al.. 2005. I'mc Natl Acad Sci USA 102: 5374.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "47\n",
      "See also H.S Pat. No. 7.300,754. For the tirst 4 injections,\n",
      "an«gen was prepared by nuxing the recombinant proteins\n",
      "with adjuvant. Inununogen was given via injection to the\n",
      "scruff of thc nnvk.\n",
      "the fiiot pads and intraperitoncafly,\n",
      "approximately every 3 days over the course of 11 (hnys. Ivith\n",
      "the last boost administered i.v., without adjuvmit. On Day 13.\n",
      "ihc roice uci'c cufliiliiizcd Iiiil ilmir splccus werc I'cI(iovcil.\n",
      "Lymphocytes were inunortalized by fusion with an estab-\n",
      "lished cell liim «I make hybridoma clonimx using siimdard\n",
      "hybridoma technology. distnbuted uito 96 well plates. Clones\n",
      "were allowed to gross. then selected by ELISA screenuig\n",
      "using the immimixing mitigen. as behuv.\n",
      "ELISA Screemng ot Antibodies:\n",
      "\n",
      "Supernatant medin from growing hybrid(mia cloncs were\n",
      "screwnnxt separately for their ability to bind the recombuinnt\n",
      "luunan P('SK9 or recombinant mouse VCSK9. The assays\n",
      "werc performed with i)6-well plates coated overnight with\n",
      "100 pl of a I Vg/ml solution of ime of the an«gens Fxcess\n",
      "reagents were washed from the wells be«veen each step with\n",
      "PBS containing 0 05% Twnmn-20. Pintos werc then blocked\n",
      "with PBS containing 0.5% BSA. Supernatant was added to\n",
      "the plates and incubated at room temperature for 2 hours.\n",
      "Horse radish peroxidase (IIRP) conlugnted goat-anti mouse\n",
      "Fc wos added to bind to the mouse antibodies bound to the\n",
      "antigen. Tetrmncthyl beozidine was then ndded as substrate\n",
      "for HRP to detect the unount ofmouse antibody present in the\n",
      "supeniatant. The reaction uas stopped and the relative\n",
      "amount of uiu body was quonti lied by reading the absorbance\n",
      "at 450 nm. I lybndoma clones that secreted antibodies that are\n",
      "capable of binding to ciihcr mouse or lnmian PCSK9 werc\n",
      "selected for furflier onnlysis.\n",
      "PCSK9-Mediated LDLR Down-Reg(«lotion in 1luh7 Cells:\n",
      "\n",
      "Hybridoma cloncs secreting human or mouse PC'SK9\n",
      "binduig antibodies were expmided and supematants were\n",
      "harvcstcd 'Iotai IgCis were purihed from approximately 10\n",
      "ml of ihc supernatant using protein A bead~. diolyzedt uito\n",
      "PBS buffer, and the tinal voliune reduced to yield solutions\n",
      "with 0 7-1 mg/mt ofantibodies. I'uri tied antibodies u crc then\n",
      "used to test their ability to mhibit the ability ol'CSK9 to\n",
      "mediate LDLR dovin-regulation in Huh7 cells. Huh7 cells\n",
      "were plated and aflou cd to grow to SO'Ao coirflu( (Icy in RPMI\n",
      "media contauiing 10% IIBS. 4 mM glutomine, and penicdlin\n",
      "and streptavidin in 96 well plates. 1he mediiun vvos chanoed\n",
      "to onc containing 10%v dc-1 ipidatnxt F BS fiir 3-16 hra to induce\n",
      "LDLR expression. Cells were then incubated for g-16 hours\n",
      "with 40 pl/well of 293 expression media supplementixt with C(\n",
      "pg/ml of Inunan (preferably) or mouse PCSK9. u 3th or with-\n",
      "out 70-100 ug/nil oftest antibodies. The PCS K9 and antibody\n",
      "contmning midin were removed at ihe cnd of incubntion, and\n",
      "cells were lysed with 17 gl lysis buffer by shakuig at 4 C for\n",
      "an hour. 11ie lysis buffer consisted of 50 mM glycerol phos-\n",
      "phate. 10 mM HFPES pH 7.4. 1% Tn«m X-IOO, 20 mM\n",
      "NaCI, mid a cocktail of protease intubitors (Roche). Cell\n",
      "lysates were cottcctnxt and analvzcd fiir I,DI R protein levels\n",
      "via staining o I'Western blots folloii ing SDS pclyacryl anode\n",
      "gel electrophoresis Hybridoma clones producing antibodies\n",
      "that can partially or Iiully rose«c I,DI R level wcn. selected fiir\n",
      "further mudysis By '*I,DLR down regt(lotion assay\" is memit\n",
      "the above assay using Huh7 cells.\n",
      "\n",
      "FICi\n",
      "\n",
      "I iflustratcs thc CITcct ol'nti-PC'SK9 antagonistic\n",
      "monoclonal antibodies 7D4.4, 4AS.C73. 6F6.(i10.3 mid\n",
      "5AI 0.BS on the ability of In(mon and mouse V( SK9 to down\n",
      "regulate LDLR ui cultured I iuh7 cells. 100 CM of n«Ouse or\n",
      "luunon recombinant I'CSK9, and a serial dilution of 25-300\n",
      "nM of antibodies werc used. A) mouse P('SK9 B) lniman\n",
      "PCSK9. 11ie figures are Western blots shomng that the anti-\n",
      "bodies are in general more effective in blocking the function\n",
      "\n",
      "48\n",
      "of hi(itin(i P('Ski) than mouse P('SK9 I'he several nntibodies\n",
      "haivgenerally similoroffinities forhumanP('SK9but vary in\n",
      "their affiiuty for munne PCS K 9.\n",
      "\n",
      "5\n",
      "\n",
      "Fxample 2\n",
      "\n",
      "Determining Antibody Binding Athnity\n",
      "\n",
      "I'he affinities of V(.:SK9 antibodies to VCSKI9 were mea-\n",
      "'\" sured on a surface plasmon resonmice Biacore 3000 biosen-\n",
      "sor cquippcd with a research-ornde sensor chip using HBS-\n",
      "nou GF.\n",
      "FP runnuig buller (BuicorcAB, Uppsala, Siveden\n",
      "Healthcare). Rabbit polyclonal anti-Ms Ig(is vvere amine-\n",
      "couplod at saturating levels onto dm chip using a stmidard\n",
      "\" N-lndroxysuccininude/etlnldimethylmninopropyl carbodi-\n",
      "imide (NHS/1113(') chemistry. I'he buffer was sv;itched to\n",
      "IIBS-EP+I mg,'mL BSA+I mg/mL CM-dextmn Full-length\n",
      "PCS K 9 IgCis were diluted to about 15 Vno/niL and capnired for\n",
      "I min at 5 ttt /min to give levels of about 500RII per flou cell,\n",
      "leavuig one bl udi io serve as a reference chmuiel, 3.73-302\n",
      "nM hl'C'SK9 or 2.54-206 nM ml'CSK9 mere injected as a\n",
      "5-membcrnxt 3-fold series for I min at 100 VI /niin.\n",
      "\n",
      "\"-\"\n",
      "\n",
      "Dissociation was monitored for 5 min. The chip was re en-\n",
      "emted afler the last injection of each titmtion tvith tu o 30 sec\n",
      "-\"'ulses ol'100 mM phosphoric amd Buffi:r cycles provided\n",
      "blanks for double-referencuig the data. v, luch Ivere then tit\n",
      "globnlly to a simple binding nmdcl using Biacvaluation sofi-\n",
      "u are v 4.1. Atiimties were de«laced from the quotieoi of the\n",
      "kinetic rate constants (Ko=k„Fkox). The results of Example 2\n",
      "'\" arishowninTablc4. Tficscdatashou tluitihemiubodies have\n",
      "excellent athmty for nninne PCSK9 or human PCSK9. as\n",
      "indicated\n",
      "\n",
      "TABLL'\n",
      "\n",
      "inh(bi«on(t\n",
      "7 DI K Pi SK9\n",
      "bmrbng(K'v)\n",
      "\n",
      "K,„ror\n",
      "PPSK9\n",
      "ii Mi)\n",
      "\n",
      "Kiiini\n",
      "Pr'SK9\n",
      "(3 Sl\n",
      "\n",
      "Knrni\n",
      "PC~SK9\n",
      "\n",
      "(nMI\n",
      "\n",
      "I gnni\n",
      "\n",
      "SUUIUU\n",
      "\n",
      "7111(I(i(l\n",
      "\n",
      "h(n non\n",
      "\n",
      "hnn(UU\n",
      "\n",
      "',4 IIM\n",
      "\n",
      "0,4 UM\n",
      "(.5 n Mi\n",
      "\n",
      "(UMI\n",
      "\n",
      "I\n",
      "\n",
      "Ulnas('(OUUO\n",
      "\n",
      "n(OUU\n",
      "\n",
      "n(UUU\n",
      "\n",
      "3 UM\n",
      "\n",
      "1 UM\n",
      "i« UM\n",
      "I nvt\n",
      "\n",
      "io\n",
      "6.66\n",
      "in\n",
      "8.47\n",
      "9 Isx in\n",
      "(2 x(0\n",
      "I 4( x io\n",
      "7 x ino\n",
      "I\n",
      "I ii x IO\n",
      "3 97 x IU\n",
      "\n",
      "(.89\n",
      "\n",
      "in\n",
      "\n",
      "in\n",
      "\n",
      "'55 io\n",
      ".84\n",
      "7 94 x I 0 \"\n",
      "x in\n",
      "4 S9 x 10 '\n",
      "7\n",
      "77 x io\n",
      "in\n",
      "\n",
      "'.. 8\n",
      "\n",
      "6.4\n",
      "64\n",
      "I I\n",
      "\n",
      "177\n",
      "\n",
      "I 3\n",
      "\n",
      "nn\n",
      "\n",
      "mib\n",
      "\n",
      "445\n",
      "3(0\n",
      "\n",
      "67'6\n",
      "7D4\n",
      "\n",
      "5.4(n\n",
      "6I16\n",
      "\n",
      "7D4\n",
      "\n",
      "L'xample 3\n",
      "\n",
      "0\n",
      "\n",
      "Ai«slys(s of the Effect of PCSK9 Antibodies on\n",
      "PCSK9-LDLR interaction\n",
      "\n",
      "PCSK9 hos been shou n to bind LDLR with un aflinity of\n",
      "130 nM under neutral pH ((.unningham ct al. 2007, Nat\n",
      "5 Struct Mol Biol. 14(57413-9). Recombinant mouse orhuman\n",
      "VCSK9 protein was biotinylated using the Pierce reagents\n",
      "following tfm manul'UC«ire'S inatructiOns. F/EISA platea\n",
      "(Corning Mixisorb) were coated u ith a solution of I t(g'mt\n",
      "recombinant LDI,R extracellular domain (Rdrt) Systems) in\n",
      "60 each v cll at 4 C oveniighi. blocked with 2% BSA+PBS liir2\n",
      "hrs at room tempemture, and then iva shed 5 times with wash-\n",
      "ing buffer (I xVBS+0.05%v Tween-20). Wells were incubated\n",
      "u 3th 50 pl of indicated concentrations of bionnylated PC SK9\n",
      "protein for I hr Kf. LDLR-PCSKD) binding can be stabilized\n",
      "by adding 50 td of 4% FDH+4% sucrose+PBS solution and\n",
      "incubate for 5 min. Wells were wushed 5 tunes with wosiung\n",
      "butTer. incubated with I:2000 dilution of HRV conjugated\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "49\n",
      "Strepavidin (Invitrogen) I'or I hr at RT. wasJ&i&J 5 tinm& v ith\n",
      "washing buffer TMB substrate &has added to the v,ella. the\n",
      "solut&on v;ls incubated 20 to 30 min at RT, and the reaction\n",
      "was tern&inated using I M phosphoric acid. Signals were read\n",
      "at 450 mu.\n",
      "\n",
      "mxl mouse P( SK9 HiRorno bi lixed\n",
      "\n",
      "FIO. 2 illustmtes the dose-response of ant&-PCSK9 antago-\n",
      "nist monoclonal m&tibodies 6F6Ci103. 7D4.4. 4A5(i3,\n",
      "5A I 0 Bg, negat&ve control antibody 42117. and PB S on block-\n",
      "ing the b&nding of recombinant biotinylated lnunan PCSK9\n",
      "rceeombi&umt I DI R extra-\n",
      "cellular dom un u& v&tro. Part A) shov;s humm& PCSK9 bu&d-\n",
      "ing, to human I.DI R extracellular domain and that 7D4, 4A5.\n",
      "5A10. m&d 6F/1 are cll'ective in blocking binding, ulmreas\n",
      "42H7 and I'BS are not. Part B) shov, s mouse PCSK9 binding\n",
      "to human I.DI,R exrracellular domain\n",
      "\n",
      "The interaci&on cm& also be evalun&ed ul free soluuon at\n",
      "neutral pH. FJO. 3 illustrates the dose-response of anti-\n",
      "P( SK9 monoclonal antagonist antibodies 6F6.(i 10 3, 7D4 4,\n",
      "4A5.63 and 5AI0.B8 on blocking binding of recombinant\n",
      "biotinylated human P('SK9 (30 nM) to liuropium labeled\n",
      "recombinant LDLR extracellular dom un (10 i&I) u& soluuon\n",
      "at neutml pH in vitro. 'Ilus assay measures b&nding &n free\n",
      "solution at neutml pH.\n",
      "\n",
      "50\n",
      "injecting human-P( SK9 at 50 nM for I min at 10 pl /min (ro\n",
      "tether it via tlm Ig(i on the clup) and then binding an army of\n",
      "I C&s (final 500 nM each) for 2 mine each. The &mmobil&zed\n",
      "lg(is were regenerated with 0 mild acid (Pierce gentle elution\n",
      "bufl'sr+I M NaCJ) Antibodies dirovted to known dilfercnt\n",
      "epitopes were used as controls for positive sandhvich forma-\n",
      "tion in th&s assay\n",
      "\n",
      "c. Siructure-guided muta enesis to map antibody b&nd&n\n",
      "cpitopes. Ha&cd on the crystal stn&cture of P(.SK9 m&d thc\n",
      "1&kely u&volvement of D374 in LDLR binding (Cunningham\n",
      "et 01., 2007. Nat Struct Mol Biol. 14(5): 413-419), nu&eteen\n",
      "PCSK9 siaface-r&widue mutunts (F379A. 1369A, R194A,\n",
      "l&374Y, D238R. T377R, K222A. R199A, F216A, R218A,\n",
      "R237A Dl 92R l&367R R165 k R167 4 A443T A53V\n",
      "I 474&r, 11449A) near or far from the posiuon of D374 were\n",
      "chosen fbr nnitation to map the antibody binding epitopes.\n",
      "\n",
      "&0\n",
      "\n",
      "„-\n",
      "\n",
      "d Mutant and antibody production The 19 single point\n",
      "mutants &here generated I'rom the prev&ously describe&I hh ikl-\n",
      "type DNA construct ((loaning&L7&n et al., 2007, supra) using\n",
      "standard DNA techniques. Thc mutant proteins werc\n",
      "transient tronsfowt&on &n HIJK293T coils and\n",
      "expressed usus\n",
      "secreted into the cell media. 'I he mutant proteins were puri-\n",
      "licd v ith thc high-throughput AKTA Xprcss system ((iF,\n",
      "llealthcare) by Ni'nd size-exclusion chromatography\n",
      "steps, using conditions similar to those described earlier Pro-\n",
      "teu& concentrations were detenmned usu&g the LabClup\n",
      "instrument (Bio-Rad). The PCSK9-blocking murine antibod-\n",
      "ies 4A5, 7D4. 5A10 and fiF6 uvre expressed with transient\n",
      "10 transfect&on &n IIL&K2931 cells and purilied &Pith 0 pn&te&n (1\n",
      "column eluted w&th 0.1 M (ilycine buffer at pH 2.8 and\n",
      "neutralized into 1.0 M Tns at pl I 9.0.\n",
      "\n",
      "antibodies 5A 10 and 7D4 (preparation describe&I\n",
      "\n",
      "e. The reg&ons of PCSK9 that are contacted by monoclonal\n",
      "later herein)\n",
      ";; were determined by proteus tomography (Sidec A B, Stock-\n",
      "holm. Sweden). The loops at positions 186-200, 371-379,\n",
      "176-181, 278-283. 449-45'3. 402-406. and 236-245 of P('SK9\n",
      "were prox&mal to uuino ac&d residues of the ant&body. The\n",
      "sequm&ces corresponding to tlm loops arc shown in Table 5,\n",
      "and in a prcferrcd embodi men&„ the antagonis(h ol'he inven-\n",
      "txul bind to one or more of these sequences in PS('K9.\n",
      "\n",
      "TABLE 5\n",
      "\n",
      "PCSK9 Loop\"\n",
      "\n",
      "Sequence\n",
      "\n",
      "SEQ ID »0\n",
      "\n",
      "186-200\n",
      "\n",
      "236-245\n",
      "\n",
      "DTSIQSDHREIEGRV\n",
      "\n",
      "GPDAGVAKGA\n",
      "\n",
      "0\n",
      "\n",
      "371-379\n",
      "\n",
      "rssDcsTcp\n",
      "\n",
      "176-181\n",
      "\n",
      "GGSLVE\n",
      "\n",
      "278-283\n",
      "\n",
      "449-453\n",
      "\n",
      "402-406\n",
      "\n",
      "QPVGPL\n",
      "\n",
      "HGAGI&\n",
      "\n",
      "REPEL\n",
      "\n",
      "f. Biacore bu&du&g of the nu&tents to &mmobihzed I,DI R.\n",
      "Recombinant LDLR extracellular domain protein was immo-\n",
      "R& bili/cd onto 0 Biacore SA chip Fach nnitant protein uas\n",
      "inlected to the Biacore-3000 M) in duplicates at 25 mM to\n",
      "0.012 mM at five concontmtions (from I'\n",
      ". v, ith a running\n",
      "bufl'er of 50 mM Tns pil 7.5, 2 mM CaCls. 200 mM NaCJ,\n",
      "0 02A01 20 and I tng/ml BS 3 All the results fit nicel)'o 0 I: I\n",
      "binding kinetics model As expected, nuitation at residues in\n",
      "direct contact with the L&(ilAA domau& (I'379A. R194A,\n",
      "1369M 'I'377R. 0238R) significantly weakens (by 10-100\n",
      "\n",
      "I')&ample 4\n",
      "\n",
      "J.'p&tope Mapping/Binding of Ant&bodies using the\n",
      "Crystal Structure of the LI I,3 P('SK9 Complex,\n",
      "Biacore, and Mutagenes&s\n",
      "\n",
      "a Crystal structure ol the 1.11,3.P('SK9 complex. The res&-\n",
      "dues were &dent&fied by calculatu&g the difference &n acces-\n",
      "sible surl'ace arcs bctwccn tlm1,113:P('SK9 crystal stnicturc\n",
      "and PCSK9 structure alone. PCSK9 res&dues that shov. buned\n",
      "surface area upon complex fonuation v,ith I,IL3 antibody\n",
      "Wore u&Cluded as apart GI'thi: Lpilopc Thc solvent accessible\n",
      "surface of a proteu& he as delined as the locus ol the centre of a\n",
      "probe sphere (representing a solvmu molecule of I 4 A\n",
      "radius) as it rolls over the%ender W»RJS surlhccofthe protein\n",
      "fhe solvent accessible surface area was calculated by gener-\n",
      "ating surface poif&ts on an cxtcndc&J sphcrc about each R&onl\n",
      "(at a distance from the atom centre equal to the s&uu of the\n",
      "atom and probe radii), and eliminating those that lie witlfin\n",
      "cquivalcnt sphorcs associand with neighboring atoms as\n",
      "unplemented &n proc+'an& ARBAIMOL (Bnggs, P..i., 2000,\n",
      "C(.:P4 Newsletter No. 38, C('I.R('. Daresbury).\n",
      "\n",
      "The result of the crystal structure analys&s are shown &n\n",
      "FICi. 23. I'JO. 23A shou s the crystal structure of the PCSK9\n",
      "(light gray surface ILT&reseutafion) bound io the 111,3 mlti-\n",
      "body (black cartoon representat&on). The epitope for L 1L3\n",
      "binding to PCSK9 involves residues 1 &3-155, 194, 197, 237-\n",
      "239. 367, 369, 374e&79 and 381 of thc P('SK9 amino acid\n",
      "sequence (SLQ ID NO:53). By companson, the epitope for\n",
      "the I DI.R HOF domain binding to P('SK9 involves residues\n",
      "15:)-1«, 194, 238, 367, 369, 372, 374-375, and 377-381\n",
      "(Khvon et al.. 2008, PNAS 10&: 1820-1825).\n",
      "\n",
      "b (iroup antib&alice and epitopcs based mi competition in\n",
      "P('SK9 buuling. I'ull-length Jg(is were unine-coupled to a\n",
      "CM5 sensorchip(three per chip at about 7000RU final), using\n",
      "a standard FDC/NHS-mcd&etc&I aminc-coupling chemistry\n",
      "One flow cell uas left umnodified to pmvide a reference\n",
      "channel Htunm&-P(.'SK9 (J00 nM) &has premixed with an\n",
      "array of IgGs (final 500 RM) and these complexes were\n",
      "injected over the clup using I min injections at 10 PL/min.\n",
      "Antibodies that bind to competing cpitope& will block the\n",
      "b&nding of PCSK9 to the antibody inunob&lized on the chip.\n",
      "Alternatively. a c la as icn I sandhv ich approach was used by tirst\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "51\n",
      "fold) 1.171 R binding Moreover, tinea nnirants not in contact\n",
      "with E(IF-A fR199A, R218A, K222A) showed weaker bind-\n",
      "they are\n",
      "in\n",
      "involved in hindu&8 other donuiins ol' DI,R Overall, Iheae\n",
      "experiments vahdatc thc mtcgrity and activity ol'thc mutants\n",
      "for subsequent epitope mapping experiments.\n",
      "\n",
      "85-15 fold). Tins new finding suggests that\n",
      "\n",
      "g. Buiding oi the mutants to immobilized 4A5, 7D4„5A10\n",
      "and 6F6 uiubodies Biotuiylated uit&-PCSK9 antibodies\n",
      "were immobilized on SA chips using standard methods\n",
      "Mutant buiding experiments &vere perfonued using Biacore\n",
      "3000 at 25'. with a running buffer of 50 mM Tn s-I ICI pl I\n",
      "7 5, 1&0 mM Na('I and 0.02'A P20 Mutm»s were tested at\n",
      "333 nlVI or 111 nM concentmtions in duplicates, with the ones\n",
      "giving weakened hindi»su compared to the wild-type as the\n",
      "residues uivolved ui nugb binding /listed belov,).\n",
      "\n",
      "mwd\n",
      "\n",
      "4e«,\n",
      "\n",
      "6.3&u\n",
      "696\n",
      "134\n",
      "\n",
      "»u&dw Res&duce u& Dcs eudu&e 0&dc& I Mu&.ua I:ircc&s\n",
      "\n",
      "RZ17 F379;6&7 R&94 RI99 4 D 36\n",
      "R&94, »337, 1369 D'9&, RI 99\n",
      "IL&37, a&94, F379 D336. 1369. I\" 77. x&99\n",
      "IL'I.R&94, F379 1369. R&99\n",
      "\n",
      "Example &\n",
      "\n",
      "Cloning and Sequencing of Antibodies\n",
      "\n",
      "One million hybridoma cells were hmnogcnircd usia tbu\n",
      "QIAshrcddcr spin columns uml\n",
      "total RNA was cxtractcd\n",
      "according to RNAeasy Micro kit from QIA(JL'N. cDNA was\n",
      "synthesized using SuperScript III RT lot from Invitrogen.\n",
      "Mauable ruegions from the PCSK9 antibodies were cloned\n",
      "using the mouse Ig(i-Primer Sets froni Novagen. which con-\n",
      "sist of degenerate pruners for clonin mouse igC& heavy chain\n",
      "genes and the mouse kappa or lambda hght chains. PCR\n",
      "cycluig conditions werc the liilkrwuigs I cycle ai 92 ('ior 2\n",
      "\n",
      "min: two cycles at 94 ('or 30 sec. 44 (.'or 30 sec mid 72('or2 min: two cycles at 94 C for 30 sec. 46 C for 30 sec and\n",
      "\n",
      "72 C for 2 min: two cycles at 94 C lor 30 sec, 48 C for 30 sec\n",
      "and 72 (. for 2 ni in, tw o cycles ai 94 (.'or 30 scc. 50 C fir 30\n",
      "secand72( for2min;twocyclcsat94C for30scc,52( for\n",
      "30 sec and 72 C for 2 min; follo&ved by 35 cycles at 9)4 C fbr\n",
      "30 sec. 54 C for 30 sec uid 72 C for 45 scc. The resulung PCR\n",
      "producw& were cloned into Topo-TA clem ng veck&r I'rom lnvit-\n",
      "rogen and sequenced. Jhe clo&&cxl antibody sequences were\n",
      "coniimied by ¹ennuial sequencin of the tirst 10 anuno\n",
      "acids of the onginal antibodies pmduced from ascites.\n",
      "\n",
      "I',xample 6\n",
      "\n",
      "C&cneration of Aniigcns Iior Immunization\n",
      "\n",
      "Recombinant human I'CSK9 protein was pmduced as\n",
      "reported (.unningham ei al., 2007. Net Struct Mo I Biol, 14(5).\n",
      "413-9. To produce recombinant mouse PCSK9 protein, the\n",
      "cDNA of mouse P('SK9 was clone&I into mammalian expres-\n",
      "sion vector PRK& with the addition of a 6-His tag at the\n",
      "( -temiinus by methods knov;n in the art. transiently trans-\n",
      "fected and expressed in IIBK293 cells. Recombinant pmtein\n",
      "was purified from conditioned media using a Ni colunm.\n",
      "\n",
      "Surface peptides of human and mouse P( SK9 were\n",
      "selected based on PCSK9 protein structure, and synthesized\n",
      "by Elim Biopharmaceuticals.\n",
      "\n",
      "Fxaf«'pic 7\n",
      "\n",
      "PCSK9-Specific Antibodies as PCSK9 A»taco»tats\n",
      "\n",
      "Identification of P('SK9-Specific Antagonist Antibodies\n",
      "\n",
      "I\n",
      "a. Identification of PCSK9-Blocking Antibodies\n",
      "\n",
      "Murine antibodies to human and/or mouse PCSK9 were\n",
      "generated by uumumzing mice with 1»uuan-PCSK9 and\n",
      "niousc-PCSK9 synthetic pcptidcs as prepared in I'xaniple 6\n",
      "1» or recombinant proteins. and screening antibodies by ELISA\n",
      "assay usinug human and'or mouse PCSK9 recombinant pro-\n",
      "tein us Ilm untigens as de&cubed in Fxmnple I mid other\n",
      "standard hybridoma procedures. Over 500 positive clones\n",
      "'&9& fe oh&ainu&I and allowed to gros& to confiuency in 6 well\n",
      "plates with 10 ml media. Media supernatant were collected\n",
      "and ton&1 IgG& in tlm conditioned media were purified using\n",
      "n&Ab Selccct (Pierce) The ability ofpurifmd and concentrated\n",
      "mouse ig(is to inhibit nuiuse and human PCSK93 function was\n",
      "6 tested in lluh7 cells using the methods descubed in Iixample\n",
      "1. Hybridoma clones expressing Ig(is that she&cad some\n",
      "degrees of blocking v ere expanded and retested. 60 promis-\n",
      "uig clones were subcloned. expanded, and injected into either\n",
      "Balb/c or nude nuce to produce sac&tea. Antibodies puniied\n",
      "thorn dsmtes fiuid werc rctestcd for their ability to inhibit thc\n",
      "do&un rcuulation of I DI,R by human or mouso PCSK9 in\n",
      "Huh7 cells. I&our hybridoma clones. 4A5, &A10. 6F6, and\n",
      "7D4. were identified as being able to completely inlub&t\n",
      "lnunan PCSK9 I'unction, and at least partially udiibit mouse\n",
      "PCSK9 function. To determiiw IC39 of each of tlmse b loci ing\n",
      "untibodies, a senal dilution of lg(is i&ere used in the assay.\n",
      "stamng from 100 ugml to 3.125 ug/ml, with human and\n",
      "mouse P('SK9 c&mc&.ntration being comstant at 6 pg&ml\n",
      "b. Effect of PCSK9 Antagonists on P('SK9-LDLR Binding\n",
      "PCSK9 has been sluiwn to be co-localized with LDLR in\n",
      "cellular compartments fl agdce et al.. 2006, .I ('lui lnv, 116\n",
      "(11):2995-3005 Recombinant P(.SK9 protein also binds ro\n",
      "I.DI R extrnccllular domain in vitm (Fislmr ct el., 2007, JBC,\n",
      "46 282/28):20502-12. To determine the relationslup betv,een\n",
      "inlubiiimi ofP('SK9 mcuirdted do&un-regulation of I,DI.R nnd\n",
      "inlubiti&m of P('SK9-I,DI R bindmg by mitibodies, we tested\n",
      "the P(.'SK9 antibodies tliat partially or completely blocked\n",
      "PCSK9 function on I,I)I R and representative& of antibodies\n",
      "that do not block. All partial antagonistic antibodies also\n",
      "partially inhibited LDI,R extmcellular domain binding to\n",
      "PCSK9. except one. Antagonisuc antibodies that can com-\n",
      "pletely block PCSK9 function, namely 4A5, 5A10, 6i&6 and\n",
      "7D4 also completely inhibited LDLR cxtmcellular domam\n",
      "u buidin to PCSK9 /fable 5). 1050 values of these four wit&-\n",
      "\n",
      "\"o\n",
      "\n",
      "bodies correlates with their binding affinity ui PCSK9.\n",
      "c. Fpitope Dctenuination of the Blockuig Antibodies\n",
      "\n",
      "FI(i. 4 illustrates the epitope bi»ning of anti-PCSK9 anti-\n",
      "bodies. Part A) shows cpitopc infornmtion ol'nti-P('SK9\n",
      "3 mAbs, deternuned by binduig to synthetic 13-18-mer pep-\n",
      "tides or epitopc binding via Biacore Part B) shows the ability\n",
      "of immobilized antibodies 6F6, 5A10 and 4A5 to bind to\n",
      "human PCSK9 premixed with the mAbs mdicated on the y\n",
      "axis by Biacore assay\n",
      "\n",
      "Mi\n",
      "\n",
      "Another monoclmufi miti-P('SK9 mitibody, tcrnwd 6Ci7,\n",
      "binds to recombinant nuiuse I'CSK9 but not human PCSK9.\n",
      "Scuo Table t&. 6(i7, 4A5. &A10, 61'Ii, and 7D4 mutually exclude\n",
      "each other's buiding to mouse PCSK9. Chimem analysis\n",
      "benveen mouse and human PCSK9 reveals that 6(17 binding\n",
      "to P('SK9 require& the catalytic domain. Scc Table 6. Thus the\n",
      "binding sites of 4A5, 5A10, 6F6, und 7D4 overlup the cata-\n",
      "lytic site and/or the epitope bound by 6(17.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "53\n",
      "\n",
      "TABLLI 6\n",
      "\n",
      "Recoiilbmslii pi'oieili\n",
      "\n",
      "607 t\n",
      "\n",
      "iimiix\n",
      "\n",
      "Hunt:ui Pt:5K9\n",
      "Hunmn pm 4 ffufffm estab ti 4 inousc C-temi\n",
      "liurncn um 4 mouse catalvtic 4 mouse C-term\n",
      "Is(oint pro + )fllfnm t ilill ifii + liiiiiiilii I ft'i'iii\n",
      "Ivlouse Pro+ inonse estab trc + hutnsn C tenn\n",
      "tv(mise PCSK9\n",
      "\n",
      "ho\n",
      "ho\n",
      "1'cs\n",
      "So\n",
      "Yes\n",
      "'es\n",
      "\n",
      "d. Deternuning Sequences Species Specificity of Anti-\n",
      "P('SK9 Antibodies\n",
      "\n",
      "To determine the species sperilicity of the anti-PCSK9\n",
      "antibodies. antibodies were incubated with plasnta from dif-\n",
      "I'crcnt species and the result mt complexes were purified and\n",
      "probed by an independent anti PCSK9 anubody on Western\n",
      "blots. The mltibodies 4 tt5, 5A10, 6F(i, mtd 7D4 recognized\n",
      "hummt. cynmnolgus monkey. ntouse. Snd rat PCSK9. See\n",
      "FI( L 5. Antibody 6(17 recogiu zed only murine PCS K9 and an\n",
      "unrelated control antibody 42H7 did not recognize any tostcd\n",
      "P('SK9. Id.\n",
      "e. Determining Stxfttences of Antagonist P(.'SK9 Antibodies\n",
      "Tfm mnino acid stx)ucnccs of the variable douuiins of\n",
      "P('SK9 antibodies 4A5. 5A10, 61'6. and 7D4 were deter-\n",
      "mined using the method described in I',xample 5. The\n",
      "scqucncca indicate that the mtt if udice are related but different\n",
      "from each other. Table I shows the amino acid sequences of\n",
      "the variable regions of each antibody Table 7 shows thc CI&K\n",
      "sequences of the 11 ht chains und heavy chuuts of Table I as\n",
      "identified by the Kabat and Dhotis methods.\n",
      "\n",
      "TABLE 7\n",
      "\n",
      "Anti-P('SK91g(is 4A5, 5A 10 and 6 F6 were am inc coupled\n",
      "to the Biacore chip. hl'(.'SK9 f100 nM) was mixed with 500\n",
      "nM of 4A5, 5A10, 6F6 or 7D4 in vanous ratios and ut)ected\n",
      "Iior I min at 10 pl'min The fmu anubodimv nuitually blocked\n",
      "one another irrespective of the Rvmiy oriemation tested. sug-\n",
      "gesting that they all bind to competing epitopes. In contrast,\n",
      "they are able to form sandwich complexes tvith other non-\n",
      "fully-bloclung antibodies that were mapped to specific\n",
      "regions using syntlmtic pcptides.\n",
      "2. Effect of PCSK9 Specific Antibodies as PCSK9 Antagonist\n",
      "lll Mlvo\n",
      "a. PCSK9AE(agonis(Antibodiesl owcrSemmC'holevterolin\n",
      "Mice\n",
      "\n",
      ")0\n",
      "\n",
      "To determine if PCSKQ) antagonist monoclonal antibodies\n",
      "can all act cholesterol levels ut vivo by inhibit utg the l unction\n",
      "of extmcellular P('SK9, the effect of 7D4 tvas tested against\n",
      "mouse PCSK9 ut vitro. on serum cholesterol tvhen inlcc(ed\n",
      "ulto mice. 6 to 7 week old male C57/bl6 nuce were kept on a\n",
      "12 hr light/dnrk cycle, blcdl to colltmt approximately 70 pl\n",
      "serum ou day -7 Antagonist PCSK9 anubody 7D4, nnd 0\n",
      "control isotype matching monoclonal antibody were injected\n",
      "into mule 7 wcck old ('57/bl6 mice via i p injections on days\n",
      "0, l. 2, and 5 Mice v,ere saculiced on day 4 without fasting,\n",
      "„, and senun samples were collected. All frozen sentm samples\n",
      "werc vun( to IDFXX laboratoues for totnl cholesterol, Irig-\n",
      "lyceride, HDL clxllesterol and LDL cholesterol measure-\n",
      "ments. FI(i. 6 shou s Chat 7194 lowered serum cholfSterol by\n",
      "4S%r v.bile the contml antibody did not have any sigmlicant\n",
      "affect. Both the amount and percentage ofreduction are simi-\n",
      "\n",
      "SlocXtng PCSK9 Antlbodlen and Anttgen-binding CDR Sequence:\n",
      "\n",
      "according t.o rabat\n",
      "\n",
      "iundetlfnedl and chotia (bold)\n",
      "\n",
      "VL CDRZ\n",
      "\n",
      "VL CDR2\n",
      "\n",
      "VL CDR3\n",
      "\n",
      "4A5\n",
      "\n",
      "RASQNVGTNVA\n",
      "(SEQ ID NQ. 27)\n",
      "\n",
      "5AIQ K~AS DVSTAVA\n",
      "\n",
      "(SEQ ID No\n",
      "\n",
      "30)\n",
      "\n",
      "SASYRYS\n",
      "(SEQ ID NQ\n",
      "\n",
      "SASYRYT\n",
      "(SEQ ID No\n",
      "\n",
      "28l\n",
      "\n",
      "12)\n",
      "\n",
      "6P6\n",
      "\n",
      "7D4\n",
      "\n",
      "SASizGISNYLN\n",
      "(SEQ ID No\n",
      "\n",
      "32i\n",
      "\n",
      "YTSSLHS\n",
      "(SEQ ZD No. 33)\n",
      "\n",
      "K~AS DVSNALA\n",
      "(SEQ ID 110\n",
      "\n",
      "LZL3 RASQGISSALA\n",
      "\n",
      "(SEQ ID No\n",
      "\n",
      "34l\n",
      "\n",
      "ill\n",
      "\n",
      "aASYRYT\n",
      "ISEQ ID Nor 12)\n",
      "\n",
      "SASYRYT\n",
      "(SEQ ID No\n",
      "\n",
      "12)\n",
      "\n",
      "QQFYSYFYT\n",
      "(SEQ ID NO\n",
      "\n",
      "QQRYSTPRT\n",
      "(SEQ ID No\n",
      "\n",
      "~YSKLPPT\n",
      "(SEQ ID IIO\n",
      "\n",
      "QQRYSTFWT\n",
      "!SEQ ID No\n",
      "\n",
      "QQRYSLWRT\n",
      "(SEQ ID NO\n",
      "\n",
      "29l\n",
      "\n",
      "31)\n",
      "\n",
      "55)\n",
      "\n",
      "35)\n",
      "\n",
      "13)\n",
      "\n",
      "VH CDRZ\n",
      "\n",
      "VH CDR2\n",
      "\n",
      "VH CDR3\n",
      "\n",
      "4A5\n",
      "\n",
      "GYTFTDYYNN\n",
      "(SEQ ID Non\n",
      "56(vhole), 36 and 37i\n",
      "\n",
      "5AIQ GYTPTSYWNH\n",
      "(SEQ ID Nos\n",
      "57(Whole), 41 and 42l\n",
      "\n",
      "6F6 GYTPTDYPHtl\n",
      "(SEQ ID Nos\n",
      "56(vholet, 36 and 37)\n",
      "\n",
      "7D4\n",
      "\n",
      "GFTPSOYYI'IA\n",
      "(SEQ ID uos\n",
      "50(vholel, 48 and 49l\n",
      "\n",
      "LIL3 GYTPTSYYIIH\n",
      "\n",
      "SEQ ZD No\n",
      "59(whole), 60, and 8\n",
      "\n",
      "(SEQ ZD No\n",
      "\n",
      "38 and 39)\n",
      "\n",
      "WLLPAY\n",
      "iSEQ ZD No\n",
      "\n",
      "40)\n",
      "\n",
      "E IMP SNGRT NINE KF KS\n",
      "(SEQ ID NQ. 43 and 44)\n",
      "\n",
      "ERPLYANDY\n",
      "(SEQ ID NQ\n",
      "\n",
      "45)\n",
      "\n",
      "(SEQ ZD No\n",
      "\n",
      "38 and 4\n",
      "\n",
      "GGIYYRYDRNYPDY\n",
      "47)\n",
      "(SEQ ID IIO\n",
      "\n",
      "IIINYDGSNTSYLDSLKS\n",
      "(SEQ ID NO\n",
      "\n",
      "50 and 51)\n",
      "\n",
      "SKFAIiNOY\n",
      "(SEQ ID No\n",
      "\n",
      "52)\n",
      "\n",
      "EI SP PGGRTNYNE KF KS\n",
      "(SEQ ZD NO.\n",
      "\n",
      "9 ard 61)\n",
      "\n",
      "ERPLYASDL\n",
      "iSEQ ZD Iio\n",
      "\n",
      "10)\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "55\n",
      "lnr to what was reported for P( SK9-!- mice (PC'SK9) knock-\n",
      "out mice). suggesting that one can actueve complete or near\n",
      "complete inhibition of I'C'SK9 fiuiction tluough blocking\n",
      "extracellular PCS K 9 only. and that intrace it u lar\n",
      "PCS K 9 p lays\n",
      "little or no role ui down-regulating LDLR under normal\n",
      "liver LDLR levels\n",
      "physiological conditions. As expected.\n",
      "were uiduced ui mimals treated uith 7D4 compared to tlxise\n",
      "treated with a control antibody (FIG. 6).\n",
      "b A P utially Blocking Antibody lied No FITiut on Blood\n",
      "Cholesterol Levels\n",
      "\n",
      "FI(i. 7 illustrates tlmt a partial antagonist polyclonal anti-\n",
      "PC'SK9 mAb C'RN6 docs not alTect cholesterol Icvcls in mice\n",
      "Tuo groups of S week old C57/b16 mice (n 10 ance/youp)\n",
      "were blixl mid tcstixi for cholesterol levels on day -7, dosed\n",
      "with 15 nty&kg/day ol'CRN6 or a comtrol antibody by &.v.\n",
      "acbninistration on days 0, l. 2 and 3: and then bled and tested\n",
      "for cholesterol levels 24 Iux after the tinal dose. FIG 7A\n",
      "shows that CRN6 an1ibody partially blocks PCS K9 inc din&cd\n",
      "dovvn regulation of LI&LR in Huh7 cells in vitro. I'l(r 7B\n",
      "shoes that administration of C'RNti antibody does not alTi.ct\n",
      "serum cholesterol levels in mice.\n",
      "c. Prolonged I.ffect on Senun ('holesterol by Antagonist\n",
      "PCSK9 mAb ui Mice.\n",
      "\n",
      "s\n",
      "\n",
      "&a\n",
      "\n",
      "o\n",
      "\n",
      "A time course study was performed to determine the time\n",
      "of onset and duration of thc cholesterol lovmring effect of \"\n",
      "PCSK9 ants omst antibodies in mice. IvLAb 7D4 or salute\n",
      "control &vere each injected i.v. at 10 ms&kg or 3 mV1 g iu 48\n",
      "6-week-old C57/bl6 mice Eight mice froiu each treatment\n",
      "roup were sacrificed on days I, 2, 4. 7. 14 und 21 after\n",
      "injection. A single injection of 704 producod a fast and pro-\n",
      "lmi ed lov cong etTect on senun cholesterol. A 25% reduc-\n",
      "tion in senuu cholesterol vias seen at 24 lus after injection.\n",
      "Scc FICi. 8 Maximum drop of serum cholesterol uas\n",
      "observed at the 7 day tune point. At 21 days. the reduction in\n",
      "cholesterol is no longer statistically significant. Pau B) shows \"»\n",
      "HDI choh:sterol I.DI, cholesterol levels were very low\n",
      "\n",
      "so\n",
      "\n",
      "FIG. 9 illusimtes that the anti-PCSK9 ants omst mAb 7D4\n",
      "dose dcpcndcntly reduces scn&m total cholesterol, HDI.. and\n",
      "LDI. in mice Six groups ol'8 week old C'57!bl6 mice (n 8/\n",
      "group) werebledandtestedforbatmlcholesteroHevelsonday so\n",
      "-7 and administered with the indicat cat doses ofantibodies or\n",
      "saline on days 0, l. 2, and 3 by i. p. bolus in)ection. Senun\n",
      "levels 24 lus\n",
      "samples were collected and tested for cho les tern l\n",
      "atlcr tlm Inst dose FICi. 9A shows total cholesterol levels.\n",
      "wluch decreased to less tlmn 60'!!o of control after administra- s.\n",
      "tion of 3 to 30 mJokg/chsy. The maximal effect on total cho-\n",
      "lesteml was seen at 10 mg'kg, and statist&cally signdicant\n",
      "I nioo/kg. Iihi. 9B shows HDL levels, uluch\n",
      "reduction at\n",
      "dix:reused &o less &lain 70'fio al'ter &dian&latm&ion el'\n",
      "ui 30\n",
      "mg!kg/day. FIG. 9C shows LDL levels, wluch decreased to\n",
      "nearly zero at all tested doses of 0.3 my&'kg/day and above.\n",
      "d Dose Response of Antagonist Antibodies Spccilic to\n",
      "PCSK9 ut Mice\n",
      "\n",
      "u\n",
      "\n",
      "1\n",
      "\n",
      "FRi 10 illustrates that anti-PCSK9 mitagonist antibody\n",
      "5A10 dose dependently lowers cholesterol levels in nues\n",
      "FIC). 10A shows six groups of 8 vveek old ('57/bl(i mice\n",
      "(n—8/group) to which werc administimcd the indicated doses\n",
      "ofantibodies or salute daily ou days 0. I, 2, and 3 by 1 v. bolus\n",
      "injection. Senim samples were collected and tested for cho-\n",
      "lesterol levels 24 hrs after the last dose and shov,ed a gradu- ai\n",
      "ated decrease with increasing dose of antibody. PIC&. 10B\n",
      "shovvs five groups of 8 week old ( 57/b16 mice (n=g!y&mp) to\n",
      "wluch were administered the uidicated doses of antibodies or\n",
      "saline on day 0 by i. p. bolus injection. Senun samples were\n",
      "collected mid tcstcd fiir cholesmrol levels on day 7 and also (\n",
      "showed a graduated decrease with increasing doses of anti-\n",
      "body\n",
      "\n",
      "FI(i. 11 illustrates tlmt anti-PC'SK9) mitagonist antibodies\n",
      "4A5 and 61'ti lower cholesterol levels in mice in a dose-\n",
      "dependent fashion. Eight week old C57'b16 mice(n 8/group)\n",
      "were administered &bc indicated doses ol';m&ibodies or saline\n",
      "on uay 0 by i.p bolus injcciion Scnmi samples &vere col-\n",
      "lected and tested for cholesterol le~ala on day 7. In FIC). I I A,\n",
      "the mttibody 4A5 showed a raduated decrease in total serum\n",
      "cholesterol withincreasingdoseol'antibody In I'ICi. IIB, the\n",
      "antibody 6F6 shinned decrcasc in toml serum cholesterol at 10\n",
      "mg/kg/day.\n",
      "\n",
      "Anti-PCSK9 antagonist antibodies 4A5. 5A10, 6116 and\n",
      "7D4 increase liver I.DI,R levels in mice as I'ound by Western\n",
      "blot analysis. See FICi. 12. For 4A5, 5A10 and 6F6. 8 week\n",
      "old C57&b16 mice were administercxt with 10 ms+8 of anti-\n",
      "bodies or saline on day 0 by i.v, bolus us)ection. animals were\n",
      "sacrihccd on day 7, and whole liver lysate of 3 individual\n",
      "aninud s uvre analyzcxt fitr I DI.R and (IAPDH pmtain levels\n",
      "by Western. I!or 7D4. 8 week old B16/c57 nuce were admin-\n",
      "istered u 1&h 10 m !kg of antibodies on days 0. I, 2, and 3 vu&\n",
      "i p bolus injection, animals were sncrificed on day 4. and\n",
      "whole liver lysate of 3 individual mr&mals were mialyzcxl tiir\n",
      "LDLR and CiAPDI I proteui levels by Westeni blot. All miti-\n",
      "body-treated nuce showed lu h levels of LDLR as compared\n",
      "to tile I BS c&1&ltl'ol alice.\n",
      "\n",
      "FICi. 13 illustrates that miti-PCSK9 antagonist antibody\n",
      "in the LDLR-!- mouse, L'1 ht week old\n",
      "has no effect\n",
      "[,DI.R-/- mice (I,DI R KO mice) were administered 10\n",
      "mg/kg 4A5 or sahne on day 0 by &.p. bolus in) ecuon. Serum\n",
      "smnples (from n 9-10 nuce) were collected mid tested for\n",
      "cholesterol le&mls mi day 7. Administration ol'he antibody\n",
      "did not appreciably alter the levels of total serum cholesterol„\n",
      "HI&L, or LI&I ..\n",
      "\n",
      "FICi. 14 illustrates that multiple treaunen(s of anti-PC'SK9\n",
      "antagoiust aimbodies ui nues can substantially decrease total\n",
      "serum cholesteml. I',ight u eek old ('57/blfi mice were admin-\n",
      "is&eredt the indicated doses ol'antibodies or PBS on days 0, 7.\n",
      "14 and 21 by i.v. bolus injection. Serum samples (n— 5-11\n",
      "niicc) uvre collected and tcstcd for cholesterol levels on dny\n",
      "28.\n",
      "\n",
      "L'xampfe S\n",
      "\n",
      "PCSK9Antagonist Antibodies lower Serum I,DI. in\n",
      "Non-luunan Primates\n",
      "\n",
      "To test the in vivo eIIect of antibodies to PCSK9. annbody\n",
      "7D4 was tested in cynomolgus monkeys. I'our 3-4 year old\n",
      "cynomo l gus ni on key is ere injected u it h vehicle (PB8 s0 01%o\n",
      "Tu een 20) on day 0, and 10 my kg 7D4 on day 7. Plasma lipid\n",
      "profiles were analyzed on days 0. 2, 7, 9, 11, 14. 21 and 28\n",
      "fastin . A single injection of 10 mg/kg\n",
      "folkming overnight\n",
      "7D4 Produced a drmnatic reduction in Plasma LDL (60'!!o)\n",
      "(FI(i 15A) and I,DI paiticle numbers (FI(i. 15D) in all 4\n",
      "aiumals, wlufe having muiimal sfl'ect on their HDI\n",
      "levels\n",
      "(FIG. 15B) and HDI, particle numbers (Fl(i. 15E). Iiital\n",
      "cholcstcrol (FICi 15C:) &vas also rcdiucmd following 7D4 treat-\n",
      "ment. wlule tngfyceride level (PIC& 151') was uot signifi-\n",
      "cantly affected. Total 7D4 ((I), and total PCSK9) levels (H)\n",
      "were also measured.\n",
      "\n",
      "PIC&. 16 illustrates the dose-response of miti-PCSK9 anti-\n",
      "body 7D4 on serum cholesterol levels in the cynomolous\n",
      "monkey. Two male and two female cynomolgus monkeys 3-5\n",
      "yearn of age in each group st ere given the indicated dose of\n",
      "7D4 on day 7 and an equal volume of saline on oay 0 by i v.\n",
      "bolus uiiecuon. Plasma samples were taken at indicated tune\n",
      "points and plasma LDL levels v;ere measured.\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "57\n",
      "I'if) 17 illustrates a con&parison of anti-PCSK9 nntibodies\n",
      "4A«, A10. 6F6 and 7D4 (&n scnun clx)lc&terol levels in thc\n",
      "cynomolgu& monkey Tvvo male and two female cynomolgus\n",
      "monkeys 3-6 years of age in each gn&up werc gii cn I mg/kg\n",
      "of the indicated antibody on day 0 by i.v bolus i»)ection\n",
      "Plasnui 6 unplcs narc taken at indicated tnne points, plasma\n",
      "IiDI. levels wcm measured and noi&haling to tlmt on day -2\n",
      "FICi 18 illustmtes thc eifect ol'nti-PC'SK9 nntngonist\n",
      "antibody 7D4 nn plasma cholesrerol levels of cynomolgus\n",
      "monkeys fed a 33 4% kcnl Iat dict suppicn&en&vedi w&th 0.1%\n",
      "cholesterol. Six 3-5 yenr old cynonu&lgus monkeys (vere put\n",
      "on high-Iht dict I'or 16 wacke Three monkeys werc tres)cd\n",
      "with 10 mg/kg 7D4 and three with saline on thc indicated\n",
      "levels of individunl moid(eys were measured and\n",
      "date I.DI\n",
      "nonnahzed to tlmt of the treatment day.\n",
      "\n",
      "Fxan&pie 9\n",
      "\n",
      "Humanized Anti-PC'SK9 Antibody\n",
      "\n",
      "11&e murine monoclonal antibody 5A10 was humanized\n",
      "'itld affinity matured to provide the I 113 antibody LI I 3 has\n",
      "\n",
      "6\n",
      "\n",
      "week old 057/b16 &nice w ere do seal with 10 n&g/kg I. I I 3 or m&\n",
      "equal volume of aalu&e by i. p, iniect&on on day 0, Serum\n",
      "smnples werc 00&llcctcd and nssayed for cholesterol levels on\n",
      "days 2. 4 and 7. LIL3 decreased total serum cholesterol by\n",
      "about 40% at days 2 and 4 In another study, when 10 mg/kg\n",
      "of1,113 was affininistered as a single intrapcritonenl (IP) dose\n",
      "to I 57BI /6 mice feed a normal dict (n=10), scn&m cholesterol\n",
      "levels v ere reduced by 47%0 compared to safu&e treated con-\n",
      "n& trois. 4 days post treatment. When LIL3 was a(hnuustered as\n",
      "a s&ogle IP dose at 0„0.1, 1„10 and 80 mg('kg (n 6/youp) u&\n",
      "a dose-response experiment in male Spra gue-Daw ley rats fed\n",
      "a normal diet, serum cholesterol levels were dose-depen-\n",
      "dently reduccxI. n ith nmximum effect of 50% seen at 10 and\n",
      "80 mg/kg. 48 hours post dosinc. The dumtion of the choles-\n",
      "terol repression vms also dose dependent, rm&gu&g fron& I\n",
      "tn\n",
      "21 days\n",
      "\n",
      "The un&no acid sequence of 1,11.3 fully hu&danired hea(y\n",
      "chain (SL'Q ID NO'15) is shown in Table 8. 'H&e sequence of\n",
      "the variable region is underlined (SFQ ID NO. 54).\n",
      "\n",
      "TABLE B\n",
      "\n",
      "~v&v s ae ~vkk\n",
      "\n",
      "asv&v scka~cf(tft ~sheer a ~&evm e ~&s\n",
      "\n",
      "f\n",
      "\n",
      "rtn\n",
      "\n",
      "nekfksrvtv, trdtststvy melsslrsed (tea&a(carer ~1 asdlv\n",
      "\n",
      "gttvtvssas\n",
      "\n",
      "tkgps(fpla pcsrstsest aalgclvkdy fpep (tvsvn sgaltsgvht fpavlqasgl\n",
      "\n",
      "y 1 svvtvp\n",
      "\n",
      "nfgtqtyt cnvdhkp nt kvdktverkc cvecppcpap pvagpsvflf\n",
      "\n",
      "pp)pkdtlmi srtpevtcvv vdvshedpev qfn(yvdgve vhnakt)pre eqfn tfrvv 30o\n",
      "\n",
      "svltvvhqdv lngkeykckv snkglpss&e kt&.sktkgqp repq(yt&pp sreemtknqv 360\n",
      "\n",
      "a&tel(kgfy psd&aveses ngqpennykt.\n",
      "\n",
      "tppmldsdgs fflyskltvd ksrwqqgn(f\n",
      "\n",
      "620\n",
      "\n",
      "rcsvmhealh nhytqksl 1 spgk\n",
      "\n",
      "an affi&uty for munne PCSK9 of 200 pM and an affin&ty for\n",
      "hummi PCSK9 ol'100 pM when mmisured by Biacorc 1.113\n",
      "completely u&h&b&ts the PCSK9-med&ated down reyilat&on of\n",
      "\n",
      "The am&no ac&d sequence of LIL3 fi&lly humanized light\n",
      "chain (SFQ ID N(yl4) is six)wn in Table 9 Thc variable\n",
      "reyon &s underl&ned (SBQ ID NO: 53).\n",
      "\n",
      "TABLE 9\n",
      "i- ~ala&.\n",
      "\n",
      "~di\n",
      "\n",
      "t s\n",
      "\n",
      "I asvcidtvt ~xtcza-\n",
      "\n",
      "i: ~ka alii . ~a. r t\n",
      "\n",
      ".\n",
      "\n",
      "~rfs 0 s td ~ftft&ssl\n",
      "\n",
      "~edict\n",
      "\n",
      "c\n",
      "\n",
      "~rs&vrtf\n",
      "\n",
      "gtkle&krtv aapsvf&fpp\n",
      "\n",
      "sdeqlksgta svvcllnnfy preakvqvkv dnalq gnsq esvteqdskd styslsstlt\n",
      "\n",
      "1 kadyekhk (yacevthqg lsspvtksfn rgec\n",
      "\n",
      "LDLR &n cultured Huh7 cells when incubated w&th 100 nM\n",
      "luunan or murine PCSK9 ant&body. See FIO. 19.\n",
      "\n",
      "I'ICi. 20 illustrates the dose-response of I I L3, mouse pre-\n",
      "musor 5A10. and ncSative control mti body 42117 to block the\n",
      "bindins of recnmbinant biotinylated human P(.'SK9 and\n",
      "mouse PCSK9 to inm&ob&iized recombinant LDLR extracel-\n",
      "lular domain in v&tro. I'ICI. 20A shows ln&man PCSK9 b&nd&ng\n",
      "to human I,DI.R extracellular domain at pH 7 5 FICI 20B\n",
      "shows human PCSK9 binding to Imnmn LDLR extmcellular\n",
      "domain at pl I 53. 1&ICi. ZU('hou s mouse P(:SK9 binding to\n",
      "hum m I,DI,R extracellular domau& at pH 7.5.\n",
      "I'ICL 20D\n",
      "shows uu&use PC SK9 lund&ng to hiuntu& I,DI,R extracellular\n",
      "dona&in at pH 5 3.\n",
      "\n",
      "I'IO. 21 shows the effect on serum cholesterol of treatment\n",
      "with 10 mg/kg LIL3 in mice. Two groups (n—8/group) of 8\n",
      "\n",
      "11O. ZZ shows the effect of mtravenous admimstmtion of\n",
      "an effect&ve dose (3 n&cc/kg) of antibody 5A10 (solid circles)\n",
      "or m&tibody L I IB (solid sqimres) to each ol'our cynonuil us\n",
      "6 monkeys at day zero. 'I he change in senm& HDI (FICI. 22A)\n",
      "and senun LDI. (VI(i. ZZB) was n&easurcxI from -2 to +28\n",
      "days Both antibodies resulted in greater than about 70%0\n",
      "decrease in sen&m I,DL levels by about seven days, an effect\n",
      "that substantially persistcxI for about six more days in the\n",
      "u& animals admmistcred I,H 3 All thc animal& slmwed nom&nl\n",
      "1&ver and kidney function and near-normal hematocrits.\n",
      "\n",
      "I,H 3 dose dependently rcduccd I DI.-CL with a max innun\n",
      "effiect observed &othe mg/k group. wh&ch mau&tained a 70%0\n",
      "reduction u& LDL-I'evels uun I day 21 post-dosing. and fully\n",
      "recovered by day 31. HDIc('evels werc not affcected by\n",
      "L I L3 treaunent in all dose groups. The aiumals u& the 3 mg'kg\n",
      "dose youp (n—4) were also given nvo add&tional IM doses nf\n",
      "\n",
      "60\n",
      "\n",
      "120\n",
      "\n",
      "100\n",
      "\n",
      "260\n",
      "\n",
      "60\n",
      "\n",
      "120\n",
      "\n",
      "lsc\n",
      "\n",
      "216\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "59\n",
      "3 mg/ko I 11 3 on study days 42 mid 56 (2 wucks npart). These\n",
      "nvo additional doses again lowered LDL-C mid maintauied\n",
      "LDL-('evels belovi 50% for 4 weeks. LDL-('evels remnied\n",
      "to normnl two weeks later Senmi HDI.-C lcvcls remained\n",
      "unchanged tlmiupout the study.\n",
      "\n",
      "'lite efficacy of LI L3 in non-human primates with hyper-\n",
      "clxilesterolemia and pluimiacodynanuc interactions between\n",
      "L I L3 and I IMO-CoA reductase inhibituioo statins were inves-\n",
      "tigated Priortothcinitiationofihcstudy,thcl,DI.-C'Iuvclsol'\n",
      "cohort of cynomolgus monkeys (n 12) were elevated to an\n",
      "average of 120 nig/dL. compared to the normal average levels\n",
      "ol 50 mg/dl„by fcehng with a dict contaiimi\n",
      "35%o I'at\n",
      "(wtiwt) and 600 ppm cholesterol lor over I g months. Surpris-\n",
      "ingly, no effect was observed on senun total cholesterol or\n",
      "I.DI -C'levels afier the daily admutist ration ol'a medium-dose\n",
      "(10 myo'animal) of Crestorag (msuvastatin calcium) for 6\n",
      "weeks, and after a subsequent dnily administcition ofhigh-\n",
      "dose (20 mg,'k ) for 2 weeks A single administration of 3\n",
      "mgil 0 I,I L3 with Crestorii'r vehicle treatment for 2 weeks.\n",
      "olfivtivcly lowered scntm [,DI.-C 1st'i.ls by 56i'o bv dny 5\n",
      "\n",
      "60\n",
      "post treatment, and gradually recovered in 2.5 to 3 wrecks\n",
      "while not afi'ectmg IIDL-C levels. Upon switclun the ani-\n",
      "mals to daily administration of 50 mg/kg Zocotot (simvasta-\n",
      "tin), their I DI,-(. Icvcls reach' maximal reduction of 43%\n",
      "at day 5, and stabilized thereafter. After 3 weeks of 50 mg/kgi\n",
      "day!ocor(tt administration, these miima Is were treated with a\n",
      "suigle dose ol 3 mg~kg I,11.3 ii bile still receiving 50 mg/kg/\n",
      "day Zocorg, Administration of LIL3 resulted in another\n",
      "additional 65% rahictimi m I DIe(., ui addition ui the 43%\n",
      "i(i reduction by Zocorg. by day 5. and returned to pre-dosin\n",
      "\n",
      "I\n",
      "\n",
      "levels within 2 ii eeks.\n",
      "\n",
      "Other CDR amino acid substitutions welf.''iilr'. 113 5A10 in\n",
      "thr coUise iif lliiillailiEtititlil tiild afiinity maturation and to\n",
      "achieve particulnr properties. The sequences of tlm moditied\n",
      "CDRs and the PCSKQ buiding abiliucs ol'he nntibodies\n",
      "containing these modifiixt ('DRs are listed in Fq(IS. 24 A-Ci.\n",
      "Tlm numbers following each sequence in FICIS. 24 A-(i rep-\n",
      "resent the SRQ ID NO for that sequence.\n",
      "\n",
      "fhe disclosures of ail references cited herein are hereby\n",
      "\n",
      "incotporatuxf by rcfi:rcncc herein\n",
      "\n",
      "SEQUEtiCE LISTING\n",
      "\n",
      "160 NUNBER OP SEQ ID NOS\n",
      "\n",
      "167\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "\n",
      "SEQ ID No I\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "PRT\n",
      "\n",
      "15\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "I\n",
      "\n",
      "a213 ORGPNISH Homo\n",
      "\n",
      "aPren\n",
      "\n",
      "asp Thr Ser Ile Gln Ser asp His Erg Glu Ile Glu Gly Rrg Val\n",
      "I\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "SEQ ID No 2\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "PRT\n",
      "213 ORGIUIISii Homo sapiens\n",
      "\n",
      "10\n",
      "\n",
      "400\n",
      "\n",
      "SEQUEIICE\n",
      "\n",
      "2\n",
      "\n",
      "Gly arg asp ala Gly Val Rla Lys Gly ala\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "SEQ ID No\n",
      "211\n",
      "IENGTH 0\n",
      "212\n",
      "PRT\n",
      "TYPE\n",
      "213 ORGmiISN Homo saprens\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "3\n",
      "\n",
      "ala Ser Ser ifsp Cys Ser Thr Cys Phe\n",
      "I\n",
      "5\n",
      "\n",
      "SEQ ID NO\n",
      "LENGTH 6\n",
      "PRT\n",
      "TYPE\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213 ORGSIIISii Homo\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "4\n",
      "\n",
      "apreno\n",
      "\n",
      "Gly Gly Ser Leu\n",
      "I\n",
      "\n",
      "Val Glu\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID No\n",
      "LEIIGTH\n",
      "6\n",
      "TYPE\n",
      "PRT\n",
      "ORGBNISH Homo\n",
      "\n",
      "apren\n",
      "\n",
      "\f",
      "61\n",
      "\n",
      "62\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "5\n",
      "\n",
      "Gln Pro Val Gly Pro Leu\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "s210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 4\n",
      "LEI'GTH 5\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Homo sapzens\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "Hzs Gly Ala Gly Trp\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "SEQ ID NO 7\n",
      "LENGTH\n",
      "\n",
      "5\n",
      "PRT\n",
      "\n",
      "210\n",
      "211\n",
      "212s T'ZPE\n",
      "213\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "7\n",
      "\n",
      "Ala Glu Pzo Glu Leu\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "ORGANISE Homo sapzens\n",
      "\n",
      "5\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 8\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213 ORMEISH Artzfzc\n",
      "220\n",
      "223\n",
      "\n",
      "FEATURE\n",
      "OTHER INFORFLATION\n",
      "\n",
      "zal\n",
      "\n",
      "s400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "8\n",
      "\n",
      "Ser Tyr Tyr Net Hrs\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 9\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISH Artzfzc\n",
      "FEATURE.\n",
      "OTHER INFORHATION\n",
      "\n",
      "lal\n",
      "\n",
      "400. SEQUENCE\n",
      "\n",
      "9\n",
      "\n",
      "5\n",
      "\n",
      "Ser\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID EO 10\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzfrc\n",
      "FEATURE.\n",
      "OTHER INFORHATION\n",
      "\n",
      "zal\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "10\n",
      "\n",
      "VARIABLE HEPNY CHAIN CDR\n",
      "\n",
      "VARIABLE HEAVY CHAIN CDP.\n",
      "\n",
      "Glu Ile Ser Pro Phe Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "\n",
      "10\n",
      "\n",
      "15\n",
      "\n",
      "VARIABLE HEAVY CHAIN CDR\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ser Asp Leu\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "11\n",
      "\n",
      "SEQ ID I'10 11\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzftc\n",
      "FEZTURE\n",
      "OTHER INFORSZATION\n",
      "\n",
      "zal\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "11\n",
      "\n",
      "Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala\n",
      "I\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "VARIABLE LIGHT CHAIN CDR\n",
      "\n",
      "\f",
      "63\n",
      "\n",
      "64\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "V..RIABLE LIGHT CHAIN CDR\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "c213\n",
      "c220\n",
      "223\n",
      "\n",
      "SEQ ID NO 12\n",
      "LENGTH\n",
      "7\n",
      "PRT\n",
      "TYPE\n",
      "ORG.SHSN AZtzfzC\n",
      "FEATURE:\n",
      "OTHER 11'IFORNATION\n",
      "\n",
      "ral\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "12\n",
      "\n",
      "Ser Ala Ser Tyr Arg Tyr Thr\n",
      "I\n",
      "\n",
      "SEQ ID NO 13\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGWIISN Artzfzc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220. FEATURE.\n",
      "223\n",
      "\n",
      "OTHER INFORN'ZION\n",
      "\n",
      "lal\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "13\n",
      "\n",
      "VARIABLE LIGHT CHAIN CDR\n",
      "\n",
      "Gln Gln Azg Tyr Ser Leu Trp Azg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 14\n",
      "LENGTH 214\n",
      "PRT\n",
      "TYPE\n",
      "ORG621ISH Artzfzc\n",
      "FEATURE\n",
      "OTHER INFORFZATION\n",
      "\n",
      "zal\n",
      "\n",
      "c400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "14\n",
      "\n",
      "HUHZUZIEED LZL3 LIGHT CHTIN\n",
      "\n",
      "Asp Ile Gln Het Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Leu Ala Trp Tyr Gln Gln Lys Pro Gly L. Ala Pro Lys Leu Leu Ile\n",
      "\n",
      "35\n",
      "\n",
      "40\n",
      "\n",
      "45\n",
      "\n",
      "Tyr Ser Ala 6'er Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "60\n",
      "\n",
      "Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro\n",
      "65\n",
      "80\n",
      "\n",
      "\". 5\n",
      "\n",
      "70\n",
      "\n",
      "Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Ser Leu Trp Arg\n",
      "\n",
      "85\n",
      "\n",
      "90\n",
      "\n",
      "95\n",
      "\n",
      "Thr Phe Gly Gln Gly Thr Ly. Leu Glu Ile Lys Arg Thr Val Ala Ala\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "110\n",
      "\n",
      "Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly\n",
      "\n",
      "115\n",
      "\n",
      "12 0\n",
      "\n",
      "125\n",
      "\n",
      "Thr Ala Ser Val Val Cys\n",
      "\n",
      "130\n",
      "\n",
      "Leu Leu Asn Asn\n",
      "135\n",
      "\n",
      "140\n",
      "\n",
      "Phe Tyr Pro Arg Glu Ala\n",
      "\n",
      "Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln\n",
      "145\n",
      "160\n",
      "asp Ser Thr Tyr Ser 'u Ser\n",
      "\n",
      "Glu Ser Val Thr Glu Gln A p Ser Ly\n",
      "165\n",
      "\n",
      "170\n",
      "\n",
      "155\n",
      "\n",
      "150\n",
      "\n",
      "1. 7 5\n",
      "\n",
      "Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys Hzs Lys Val Tyr\n",
      "\n",
      "180\n",
      "\n",
      "185\n",
      "\n",
      "190\n",
      "\n",
      "Ala Cys Glu Val Thr Hzs Gln Gly Leu Ser Ser Pro Val Thr Lys Ser\n",
      "\n",
      "195\n",
      "\n",
      "200\n",
      "\n",
      "205\n",
      "\n",
      "Phe Asn Azg Gly Glu Cy-\n",
      "\n",
      "210\n",
      "\n",
      "\f",
      "65\n",
      "\n",
      "66\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "a223\n",
      "\n",
      "444\n",
      "\n",
      "SEQ ID NO 15\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzftc\n",
      "FEATURE\n",
      "OTHER INFORHATION\n",
      "\n",
      "tal\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "15\n",
      "\n",
      "HUI131IZED LIL3 HEAVY CHAIN\n",
      "\n",
      "Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Tyr Het Hzs Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Het\n",
      "\n",
      "35\n",
      "\n",
      "40\n",
      "\n",
      "45\n",
      "\n",
      "Gly Glu Ile Ser Pro Phe Gly Gly Arg Thr Asn Tyr Asn Glu Ly- Phe\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "0\n",
      "\n",
      "Lys Ser Irg Val Thr Het Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr\n",
      "80\n",
      "\n",
      "75\n",
      "\n",
      "70\n",
      "\n",
      "Het Glu Leu Ser Ser Leu Arg Ser Glu Asp Tht Ala Val Tyr Tyz Cys\n",
      "\n",
      "85\n",
      "\n",
      "90\n",
      "\n",
      "95\n",
      "\n",
      "Ala Arg Glu Arg Pro Leu Tyr Ala Ser Asp Leu Trp Gly Gln Gly Thr\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "110\n",
      "\n",
      "Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro\n",
      "\n",
      "115\n",
      "\n",
      "12 0\n",
      "\n",
      "125\n",
      "\n",
      "Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly\n",
      "\n",
      "13 0\n",
      "\n",
      "135\n",
      "\n",
      "140\n",
      "\n",
      "Cys Leu Val Ly Arp Tyr Phe Pzo Glu Pro Val Thr Val Ser Trp Asn\n",
      "145\n",
      "160\n",
      "\n",
      "155\n",
      "\n",
      "150\n",
      "\n",
      "Ser Gly Ala Leu Thr Ser Gly Val Hzs Thr Phe Pro Ala Val Leu Gln\n",
      "\n",
      "165\n",
      "\n",
      "170\n",
      "\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser\n",
      "\n",
      "180\n",
      "\n",
      "185\n",
      "\n",
      "190\n",
      "\n",
      "Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp Hzs Lys Pro Ser\n",
      "\n",
      "195\n",
      "\n",
      "200\n",
      "\n",
      "205\n",
      "\n",
      "4 n Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys\n",
      "\n",
      "210\n",
      "\n",
      "215\n",
      "\n",
      "220\n",
      "\n",
      "Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe\n",
      "240\n",
      "225\n",
      "\n",
      "230\n",
      "\n",
      "235\n",
      "\n",
      "Pro Pro Lys Pro Lys Asp Thr Leu Het Ile Ser Arg Thr Pro Glu Val\n",
      "\n",
      "245\n",
      "\n",
      "250\n",
      "\n",
      "255\n",
      "\n",
      "Thr Cy. Val Val Val Asp Val Ser Mzs Glu Asp Pro Glu Val Gln Phe\n",
      "\n",
      "260\n",
      "\n",
      "265\n",
      "\n",
      "270\n",
      "\n",
      "Asn Trp Tyr Val Asp Gly Val Glu Val Hts Asn Ala Lys Thr Lys Pro\n",
      "\n",
      "275\n",
      "\n",
      "280\n",
      "\n",
      "285\n",
      "\n",
      "Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr\n",
      "\n",
      "290\n",
      "\n",
      "295\n",
      "\n",
      "300\n",
      "\n",
      "Val Val Hr ~ Gln Aap Trp Leu Ann Gly Ly- Glu Tyr lys Cy. Lya Val\n",
      "320\n",
      "305\n",
      "\n",
      "310\n",
      "\n",
      "315\n",
      "\n",
      "Ser Asn Ly- Gly Leu Pro Ser Ser Ile Glu Ly Thr Ile Ser Ly- Thr\n",
      "\n",
      "325\n",
      "\n",
      "330\n",
      "\n",
      "335\n",
      "\n",
      "Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg\n",
      "\n",
      "340\n",
      "\n",
      "345\n",
      "\n",
      "350\n",
      "\n",
      "Glu Glu Het Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly\n",
      "\n",
      "355\n",
      "\n",
      "360\n",
      "\n",
      "365\n",
      "\n",
      "Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pzo\n",
      "\n",
      "370\n",
      "\n",
      "375\n",
      "\n",
      "380\n",
      "\n",
      "\f",
      "67\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser\n",
      "400\n",
      "385\n",
      "\n",
      "395\n",
      "\n",
      "390\n",
      "\n",
      "Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln\n",
      "\n",
      "405\n",
      "\n",
      "410\n",
      "\n",
      "415\n",
      "\n",
      "Gly Asn Val Phe Ser Cys Ser Val Met Mrs Glu Ala Leu Hrs Asn His\n",
      "\n",
      "420\n",
      "\n",
      "425\n",
      "\n",
      "430\n",
      "\n",
      "Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys\n",
      "\n",
      "435\n",
      "\n",
      "440\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 16\n",
      "LEIIGTH\n",
      "TYPE\n",
      "ORGANISM Mu mu culus\n",
      "\n",
      "108\n",
      "\n",
      "PRT\n",
      "\n",
      "400. SEQUENCE\n",
      "\n",
      "16\n",
      "\n",
      "Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "15\n",
      "\n",
      "Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thz Asn\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Set Pro Ly. Ala Leu Ile\n",
      "\n",
      "35\n",
      "\n",
      "40\n",
      "\n",
      "45\n",
      "\n",
      "Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "60\n",
      "\n",
      "Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Leu Ser\n",
      "65\n",
      "80\n",
      "\n",
      "70\n",
      "\n",
      "75\n",
      "\n",
      "Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Phe Tyr Ser Tyr Pro Tyz\n",
      "\n",
      "85\n",
      "\n",
      "90\n",
      "\n",
      "95\n",
      "\n",
      "Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 17\n",
      "LEIIGTH\n",
      "TYPE\n",
      "ORGANIS'N Mus mus«ulu\n",
      "\n",
      "108\n",
      "\n",
      "PRT\n",
      "\n",
      "400. SEQUENCE\n",
      "\n",
      "17\n",
      "\n",
      "Asp Ile Val liat Thr Gln Ser His Lys Phe Met. Ser Thr Ser Val Gly\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "15\n",
      "\n",
      "Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Set Pro Ly. Leu Leu Ile\n",
      "\n",
      "35\n",
      "\n",
      "40\n",
      "\n",
      "45\n",
      "\n",
      "Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "60\n",
      "\n",
      "Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala\n",
      "65\n",
      "80\n",
      "\n",
      "70\n",
      "\n",
      "75\n",
      "\n",
      "Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Arg Tyr Ser Thr Pro Arg\n",
      "\n",
      "85\n",
      "\n",
      "90\n",
      "\n",
      "95\n",
      "\n",
      "Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 18\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANIS'N Mus musculu\n",
      "\n",
      "107\n",
      "\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "6'EQUENCE\n",
      "\n",
      "18\n",
      "\n",
      "!\\sp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser .Ala Ser Leu Gly\n",
      "\n",
      "\f",
      "69\n",
      "\n",
      "70\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "10\n",
      "\n",
      "15\n",
      "\n",
      "Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Leu A n Tzp Tyr Gln Gln Lys Pzo .'. p Gly Thr Val Ly- Leu Leu Ile\n",
      "\n",
      "35\n",
      "\n",
      "60\n",
      "\n",
      "65\n",
      "\n",
      "Tyr Tyr Thr Ser Ser Leu Hts Ser Gly Val Pro Ser Arg Phe Ser Gly\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "60\n",
      "\n",
      "Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro\n",
      "65\n",
      "80\n",
      "\n",
      "70\n",
      "\n",
      "75\n",
      "\n",
      "Glu Acp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Phe\n",
      "\n",
      "85\n",
      "\n",
      "90\n",
      "\n",
      "95\n",
      "\n",
      "Thr Phe Gly Ser Gly Thr Ly- Leu Glu Ile Ly\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 19\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISN Nu- tsusculus\n",
      "\n",
      "108\n",
      "\n",
      "PRT\n",
      "\n",
      "600\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "19\n",
      "\n",
      "Asp Ile Val Met Thr Gln Ser His Lys Phe Net Ser Thr Ser Pits Gly\n",
      "\n",
      "1\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "15\n",
      "\n",
      "Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Asn Ala\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Leu Ala Trp Tyr Gln Gln Lys Pro Gly Hzs Ser Pro Lys Leu Leu Ile\n",
      "\n",
      "35\n",
      "\n",
      "60\n",
      "\n",
      "65\n",
      "\n",
      "Phe Ser Ala Ser Tyr Azg Tyr Thr Gly Val Pro Asp Azg Phe Thr Gly\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "60\n",
      "\n",
      "Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala\n",
      "65\n",
      "80\n",
      "\n",
      "75\n",
      "\n",
      "70\n",
      "\n",
      "Glu Acp Leu Ala Val Tyr Tyr Cys Gln Gln Hz Tyr Ser Thr Pro Trp\n",
      "\n",
      "85\n",
      "\n",
      "90\n",
      "\n",
      "95\n",
      "\n",
      "Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Ly Arg\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID 110 20\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISE Nus musculus\n",
      "\n",
      "115\n",
      "\n",
      "PRT\n",
      "\n",
      "600\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "20\n",
      "\n",
      "Glu Val Gln Leu Gln Gln Sez Gly Pro Glu Leu Val Ly- Pro Gly Ala\n",
      "1\n",
      "\n",
      "5\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "Ser Val Lys Ile Ser Cys Lys I\\la Ser Gly Tyr Thr Phe Thr I\\sp Tyr\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Tyr Net Asn Trp Val Lys Gln Ser Hzs Gly Lys Ser Leu Glu Trp Ile\n",
      "\n",
      "35\n",
      "\n",
      "40\n",
      "\n",
      "65\n",
      "\n",
      "Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "60\n",
      "\n",
      "Ly. Gly Ly Ala Thr Leu Thr Val Asp Ly- Ser Tyr Ser Thr Ala Tyr\n",
      "65\n",
      "80\n",
      "\n",
      "75\n",
      "\n",
      "70\n",
      "\n",
      "Net Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys\n",
      "\n",
      "85\n",
      "\n",
      "9Q\n",
      "\n",
      "95\n",
      "\n",
      "Ala Arg Trp Leu Leu Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "110\n",
      "\n",
      "Val Ser Ala\n",
      "115\n",
      "\n",
      "\f",
      "71\n",
      "\n",
      "72\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "a213\n",
      "\n",
      "SEQ ID NO 21\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANIISN Nu- musculus\n",
      "\n",
      "118\n",
      "\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "21\n",
      "\n",
      "Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Trp Net Hzs Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ils\n",
      "\n",
      "35\n",
      "\n",
      "40\n",
      "\n",
      "45\n",
      "\n",
      "Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Aan Tyr Asn Glu Ly- Phe\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "0\n",
      "\n",
      "Lys Ser Lys Tla Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr\n",
      "80\n",
      "\n",
      "75\n",
      "\n",
      "70\n",
      "\n",
      "Net Gln Leu Ser Ser Leu Thz Ser Glu Asp Set Ala Val Tyr Tyz Cys\n",
      "\n",
      "85\n",
      "\n",
      "90\n",
      "\n",
      "95\n",
      "\n",
      "Ala Arg Glu Arg Pro Leu Tyr Ala Net Asp Tyt Trp Gly Gln Gly Thr\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "110\n",
      "\n",
      "Ser Val Thr Val Ser Ser\n",
      "\n",
      "115\n",
      "\n",
      "210\n",
      "a211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 22\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANIISN Nu mu culus\n",
      "\n",
      "PRT\n",
      "\n",
      "123\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "22\n",
      "\n",
      "Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arp Tyr\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Tyr Net Asn Trp Val Lys Gln Ser Hza Gly Lys Ser Leu Glu Trp Ile\n",
      "\n",
      "35\n",
      "\n",
      "40\n",
      "\n",
      "45\n",
      "\n",
      "Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "60\n",
      "\n",
      "Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ssr Ser Ser Thr Ala Tyr\n",
      "65\n",
      "80\n",
      "\n",
      "75\n",
      "\n",
      "70\n",
      "\n",
      "tact Glu Leu Arg Ser Leu Thr Ser Glu Asp Set Ala Val Tyr Tyr Cys\n",
      "\n",
      "85\n",
      "\n",
      "90\n",
      "\n",
      "95\n",
      "\n",
      "Ala Gly Gly Gly Ile Tyr Tyr Arg Tyr Asp Arg Asn Tyr Phe Asp Tyr\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "110\n",
      "\n",
      "Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser\n",
      "\n",
      "115\n",
      "\n",
      "12 0\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 23\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISE Mu mu culus\n",
      "\n",
      "117\n",
      "\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "23\n",
      "\n",
      "Glu Val Lys Leu Val Glu Ser Glu Gly Gly Leu Val Gln Pro Gly Ser\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Ser Net Lys Leu Ser Cy- Thz Ala Ser Gly Phe Thr Phe Ser Asp Tyr\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Tyr Het Ala Trp Val Arg Gln Val Pro Glu Lys Gly Leu Glu Trp Val\n",
      "\n",
      "\f",
      "73\n",
      "\n",
      "74\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "35\n",
      "\n",
      "40\n",
      "\n",
      "Ala Asn Ile Asn Tyr Asp Gly Ser Asn Tfsr Ser Tyr Leu Asp Ser Leu\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "60\n",
      "\n",
      "Ly. Ser Arg Pfse Ile Ile Ser Arg .'. p A n Ala Ly- Asn Ile Leu Tyr\n",
      "65\n",
      "80\n",
      "\n",
      "70\n",
      "\n",
      "75\n",
      "\n",
      "Leu Gln Het Ser Ser Leu Lys Ser Glu Asp Tnr Ala Tnr Tyr Tyr Cys\n",
      "\n",
      "85\n",
      "\n",
      "90\n",
      "\n",
      "95\n",
      "\n",
      "Ala Arg Glu Lys Pfre Ala Ala Net Asp Tyr Trp Gly Gln Gly Tnr Ser\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "110\n",
      "\n",
      "ON\n",
      "\n",
      "LINKING PEPTIDE\n",
      "\n",
      "Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Val Thr Val Ser Ser\n",
      "115\n",
      "\n",
      "15\n",
      "\n",
      "SEQ ID NO 24\n",
      "\n",
      "210\n",
      "211s LENGTH\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artrf\n",
      "FEPTUPE\n",
      "OTHER INFORNTTI\n",
      "\n",
      "rcral\n",
      "\n",
      "400\n",
      "\n",
      "6'EQUENCE\n",
      "\n",
      "24\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "s220\n",
      "223\n",
      "\n",
      "642\n",
      "\n",
      "SEQ ID NO 25\n",
      "LENGTH\n",
      "TYPE\n",
      "DNA\n",
      "ORGAEISN Artrf\n",
      "FEATURE:\n",
      "OTHER 11'IFORHATI\n",
      "\n",
      "rcral\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "25\n",
      "\n",
      "ON\n",
      "\n",
      "HUILANIZED LIGHT CH..II'1 NUCLEOTIDE SEQUENCE\n",
      "\n",
      "gatatacaaa tgacacaatc tccatcctct ctttccgcat cagtcggcga ccgcgtaacc\n",
      "\n",
      "at.cacatgta gagcttctca aggcatctcc tccgccctcg catggtacca acaaaaacca\n",
      "\n",
      "ggtaaagccc caaaactcct catatactca gcttcataca gatacaccgg cgtaccctca\n",
      "agattctcag gttcaggctc tggaacagac tttactttca ccatttcatc actccaaccc\n",
      "\n",
      "gaagacatag ctacatatta ctgccaacaa agatacagcc t.ctggagaac att.tggccaa\n",
      "\n",
      "ggaacaaaac tcgagatcaa acgtacggtg gctgcaccat. ctgtcttcat ctt.cccgcca\n",
      "\n",
      "tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat\n",
      "\n",
      "cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag\n",
      "\n",
      "gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg\n",
      "\n",
      "ctgagca\n",
      "\n",
      "g\n",
      "\n",
      "g\n",
      "\n",
      "g\n",
      "\n",
      "g\n",
      "\n",
      "t\n",
      "\n",
      "gt t\n",
      "\n",
      "g ct gcgaagtcac c.cat.c.agggc\n",
      "\n",
      "ctgagctcnc ccgtcacaaa gagcttcaac aggggagagt gt\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 26\n",
      "1332\n",
      "LENGTH\n",
      "TYPE\n",
      "DNA\n",
      "ORGANHSH Artrf\n",
      "FEATURE.\n",
      "OTHER INFORf4ATI\n",
      "\n",
      "rcral\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "26\n",
      "\n",
      "ON\n",
      "\n",
      "HUSUUIIZED HEAV'I CHAIN NUCLEOTIDE SEQUENCE\n",
      "\n",
      "caagttcaac tcgttcaatc tggagcagaa gtaaaaaaac ctggcgcctc tgttaaagta\n",
      "\n",
      "agttgtaaag catccggtta cacattcaca tcatattaca tgcattgggt aagacaagcc\n",
      "\n",
      "cctcgacaag cactcgaatg gatgggtgaa atctctcctt ttggcggccg aacaaactat\n",
      "\n",
      "aatgaaaaat ttaaatcccg cgtaactatg acccgagaca catccacatc tactgtttat\n",
      "\n",
      "60\n",
      "\n",
      "120\n",
      "\n",
      "180\n",
      "\n",
      "240\n",
      "\n",
      "300\n",
      "\n",
      "3 0\n",
      "\n",
      "420\n",
      "\n",
      "480\n",
      "\n",
      "540\n",
      "\n",
      "600\n",
      "\n",
      "60\n",
      "\n",
      "120\n",
      "\n",
      "180\n",
      "\n",
      "240\n",
      "\n",
      "\f",
      "75\n",
      "\n",
      "76\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "atggaacttt cctcactgcg ttctgaagac actgctgttt attactgtgc acgcgaaaga\n",
      "\n",
      "cctctctacg cttccgatct ctggggccaa ggaacaacgg tcaccgtctc ctcagcctcc\n",
      "\n",
      "accaagggcc catctgtctt cccactggcc ccatgctccc gcagcacctc cgagagcaca\n",
      "\n",
      "gccgccctgg gctgcctggt caaggactac ttcccagaac ctgtgaccgt. gtcctggaac\n",
      "\n",
      "tctggcgctc tgaccagcgg cgtgcacacc ttcccagctg tcctgcagtc ctc.aggtctc\n",
      "\n",
      "tactccctca gcagcgtggt gaccgtgcca tccagcaact tcggcaccca gacctacacc\n",
      "\n",
      "tgcaacgtag atcacaagcc aagcaacacc aaggtagata agaccgtgga gagaaagtgt\n",
      "\n",
      "tgtgtggagt gtccaccttg tccagcccct ccagtggccg gaccatccgt gttcctgttc\n",
      "\n",
      "cctccaaagc caaaggacac cctgatgatc tccagaaccc cagaggtgac ctgtgtggtg\n",
      "\n",
      "gtggacgtgt cccacgagga cccagaggtg cagttcaact. ggtatgtgga cggagtggag\n",
      "\n",
      "gtgcacaacg ccaagaccaa gccaagagag gagcagttca actccacctt cagagtggtg\n",
      "\n",
      "agcgtgctua ccgtggtgca ccaggactgg ctgaacggaa aggagtataa gtgtaaggtg\n",
      "\n",
      "tccaacaagg cactcccatc cagcatcgag aacaccatct ccaagaccaa gggacagcca\n",
      "\n",
      "agagaqccac agctgtatac cctgccccca tccaqagacg acatgaccaa gaaccaggtg\n",
      "\n",
      "tccctgacct gtctggtgaa gggattctat ccatccgaca t.cgccgtgga gtgggagtcc\n",
      "\n",
      "aacggacagc cagagaacaa ctataagacc acccctccaa tgctggactc cgacggatcc\n",
      "\n",
      "ttcttcctgt attccaagct gaccgtggac aagtccagat ggcagcaggg aaacgtgttc\n",
      "\n",
      "tcttgttccg tgatgcacga ggccctgcac aaccactata cccagaagag cctgtccctg\n",
      "\n",
      "300\n",
      "\n",
      "360\n",
      "\n",
      "420\n",
      "\n",
      "480\n",
      "\n",
      "540\n",
      "\n",
      "600\n",
      "\n",
      "660\n",
      "\n",
      "720\n",
      "\n",
      "780\n",
      "\n",
      "840\n",
      "\n",
      "900\n",
      "\n",
      "960\n",
      "\n",
      "1020\n",
      "\n",
      "1080\n",
      "\n",
      "1140\n",
      "\n",
      "1200\n",
      "\n",
      "1260\n",
      "\n",
      "1320\n",
      "\n",
      "1332\n",
      "\n",
      "Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala\n",
      "1\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "tctccaggaa ag\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 27\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISE Hus musculus\n",
      "\n",
      "PRT\n",
      "\n",
      "11\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "27\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 28\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISE Nus musculus\n",
      "\n",
      "7\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "28\n",
      "\n",
      "Ser Ala Ser Tyr Arg Tyr Ser\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 29\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGAEISN Nus musculus\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "29\n",
      "\n",
      "Gln Gln Phe Tyr Ser Tyr Prc Tyr Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 30\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANIB'N Mus musculu\n",
      "\n",
      "PRT\n",
      "\n",
      "11\n",
      "\n",
      "400\n",
      "\n",
      "6'EQUENCE\n",
      "\n",
      "30\n",
      "\n",
      "Lys Ala Ser Gln Asp Val Ser Thr Ala Val Ala\n",
      "\n",
      "\f",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "78\n",
      "\n",
      "77\n",
      "\n",
      "10\n",
      "\n",
      "SEQ ID NO 31\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "210\n",
      "211\n",
      "s212\n",
      "s213 ORG.NIS14 Nu\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "31\n",
      "\n",
      "tAll culu\n",
      "\n",
      "Gln Gln Erg Tyr Ser Thr Pro Rrg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 32\n",
      "LEIIGTH\n",
      "TYPE\n",
      "ORGRNISII Mu mu culus\n",
      "\n",
      "PRT\n",
      "\n",
      "11\n",
      "\n",
      "400. SEQUENCE\n",
      "\n",
      "32\n",
      "\n",
      "Ser Rla Ser Gln Gly Ile Ser Rsn Tyr Leu Isn\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "5'EQ ID NO 33\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGRNISM Mus musculus\n",
      "\n",
      "7\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "33\n",
      "\n",
      "Tyr Thr Ser Ser Leu Hrs Ser\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID I'10 34\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGRNISM Mus musculus\n",
      "\n",
      "PRT\n",
      "\n",
      "11\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "34\n",
      "\n",
      "Ly Rla Ser Gln Rsp Val Ser R n Rla Leu Rla\n",
      "I\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "210m SEQ ID NO 35\n",
      "211m LENGTH\n",
      "212\n",
      "213\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "TYPE\n",
      "ORGRNISbt Mus mttscullts\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "35\n",
      "\n",
      "Gln Gln Hrs Tyr Ser Thr Pro Trp Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 36\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGRNISN Mus musculus\n",
      "\n",
      "7\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "36\n",
      "\n",
      "Gly Tyr Thr Phe Thr Rsp Tyr\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID I'10 37\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGRNISM Mus musculus\n",
      "\n",
      "5\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "37\n",
      "\n",
      "Rsp Tyr Tvr Met Rsn\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "\f",
      "79\n",
      "\n",
      "80\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "4 p Ile Aan Pro Aan Aan Gly Gly Thr Thr Tyr Aan Gln Lya Phe Ly-\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 39\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISN Mus musculus\n",
      "\n",
      "PRT\n",
      "\n",
      "c400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "39\n",
      "\n",
      "Aan Pro Asn Aan Gly Gly\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 39\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISN Mus musculu\n",
      "\n",
      "PRT\n",
      "\n",
      "17\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "39\n",
      "\n",
      "Gly\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 40\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGPAHSN Mu musculu\n",
      "\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "40\n",
      "\n",
      "Trp Leu Leu Phe Als Tyr\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "c210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO\n",
      "LEI'GTH 7\n",
      "PRT\n",
      "TYPE\n",
      "ORGPIIISM Mu mu culua\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "41\n",
      "\n",
      "Gly Tyr Thr Phe Thr Ser Tyr\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "SEQ ID NO 42\n",
      "\n",
      "210\n",
      "211m LENGTH\n",
      "212m T'IPE\n",
      "213\n",
      "\n",
      "5\n",
      "PRT\n",
      "\n",
      "ORGANISM Mus musculus\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "42\n",
      "\n",
      "Ser Tyr Trp Met Hts\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 43\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISM Mus musculus\n",
      "\n",
      "6\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "43\n",
      "\n",
      "A n Pro Ser Asn Gly Arg\n",
      "\n",
      "5\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEO ID NO 44\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISM Mus musculus\n",
      "\n",
      "PRT\n",
      "\n",
      "17\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "44\n",
      "\n",
      "Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Lya Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Ser\n",
      "\n",
      "\f",
      "81\n",
      "\n",
      "82\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "4 p Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Gly Gly Ile Tyr Tyr Arg Tyr Asp Arg Asn Tyr Phe Asp Tyr\n",
      "I\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID No 45\n",
      "LEItGTH 9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Mus musculus\n",
      "\n",
      "ssoo\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "45\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala tset Asp Tyr\n",
      "I\n",
      "5\n",
      "\n",
      "SEQ ID No 46\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGAEISM Mus musculus\n",
      "\n",
      "PRT\n",
      "\n",
      "17\n",
      "\n",
      "sEQUENCE\n",
      "\n",
      "46\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "soo\n",
      "\n",
      "Gly\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "6'EQ ID No 47\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISM Mus musculus\n",
      "\n",
      "PRT\n",
      "\n",
      "14\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "47\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID I'io 48\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISM Mus musculus\n",
      "\n",
      "7\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "48\n",
      "\n",
      "Gly Phe Thr Phe Ser Asp Tyr\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "210m SEQ ID No 49\n",
      "211m LENGTH\n",
      "212\n",
      "213\n",
      "\n",
      "5\n",
      "PRT\n",
      "\n",
      "TYPE\n",
      "ORGANISbi Mus musculus\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "49\n",
      "\n",
      "Asp Tyr Tyr Met Ala\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID No 50\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISN Mus musculus\n",
      "\n",
      "6\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "50\n",
      "\n",
      "Asn Tyr Asp Gly Ser Asn\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID I'io 51\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISM Mus musculus\n",
      "\n",
      "PRT\n",
      "\n",
      "16\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "51\n",
      "\n",
      "Asn Ile Asn Tyr Asp Gly Ser Asn Thr Ser Tyt Leu Asp Ser Leu Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "\f",
      "83\n",
      "\n",
      "84\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 52\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGAEISN Mus musculua\n",
      "\n",
      "8\n",
      "PRT\n",
      "\n",
      "s400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "52\n",
      "\n",
      "Glu Ly. Phe Ala Ala Net A p Tyz\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 53\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISN homo aapzen\n",
      "\n",
      "107\n",
      "\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "53\n",
      "\n",
      "4 p Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly\n",
      "\n",
      "1\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "15\n",
      "\n",
      "Asp Arg Val Thr Zle Thr Cys Arg Ala Ser Gln Gly Zle Ser Ser Ala\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Leu Ala Tzp Tyr Gln Gln Lya Pzo Gly Lys Ala Pro Ly- Leu Leu Ile\n",
      "\n",
      "35\n",
      "\n",
      "40\n",
      "\n",
      "45\n",
      "\n",
      "Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "60\n",
      "\n",
      "Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro\n",
      "65\n",
      "80\n",
      "\n",
      "75\n",
      "\n",
      "70\n",
      "\n",
      "Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Ser Leu Trp Arg\n",
      "\n",
      "85\n",
      "\n",
      "90\n",
      "\n",
      "95\n",
      "\n",
      "Thr Phe Gly Gln Gly Thr Lye Leu Glu Ile Ly\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 54\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISN homo sapzen\n",
      "\n",
      "118\n",
      "\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "54\n",
      "\n",
      "Gln Val Gln Leu Val Gln ser Gly Ala Glu Val Lys Lys Pro Gly Ala\n",
      "1\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "15\n",
      "\n",
      "Ser Val Ly\" Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr\n",
      "\n",
      "20\n",
      "\n",
      "25\n",
      "\n",
      "30\n",
      "\n",
      "Tyr Net Hzs Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net\n",
      "\n",
      "35\n",
      "\n",
      "40\n",
      "\n",
      "45\n",
      "\n",
      "Gly Glu Ile Ser Pro Phe Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe\n",
      "\n",
      "50\n",
      "\n",
      "55\n",
      "\n",
      "60\n",
      "\n",
      "Lys Ser Arg Val Thr Net Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr\n",
      "65\n",
      "\n",
      "75\n",
      "\n",
      "80\n",
      "\n",
      "70\n",
      "\n",
      "Net Glu Leu Ser Ser Leu Arg Ser Glu Psp Thr Ala Val Tyr Tyr Cys\n",
      "\n",
      "85\n",
      "\n",
      "90\n",
      "\n",
      "95\n",
      "\n",
      "Ala Arg Glu Arg Pro Leu Tyr Ala Ser Asp Leu Trp Gly Gln Gly Thr\n",
      "\n",
      "100\n",
      "\n",
      "105\n",
      "\n",
      "110\n",
      "\n",
      "Thr Val Thr Val Ser Ser\n",
      "\n",
      "115\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 55\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANIS'N Artzfzczal Sequence\n",
      "FEATURE:\n",
      "OTHER INPORNATIOE Synthetzc\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "55\n",
      "\n",
      "\f",
      "85\n",
      "\n",
      "86\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "Gln Gln Tyr Ser Lys Leu Pro Phe Thr\n",
      "5\n",
      "\n",
      "c210\n",
      "c211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "10\n",
      "\n",
      "SEQ ID NO 56\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artific\n",
      "FEATURE\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "56\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gly Tyr Thr Phe Thr Asp Tyr Tyr Net F.cn\n",
      "1\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "SEQ ID NO 57\n",
      "\n",
      "210\n",
      "211s LENGTH\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artific\n",
      "FEATUPE\n",
      "OTHER INFORNITION\n",
      "\n",
      "400\n",
      "\n",
      "6'EQUENCE\n",
      "\n",
      "57\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gly Tyr Thr Phe Thr Ser Tyr Trp Net Mi\n",
      "I\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "c220\n",
      "223\n",
      "\n",
      "10\n",
      "\n",
      "SEQ ID NO 58\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Artific\n",
      "FEATURE:\n",
      "OTHER Il'IFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "58\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gly Phe Thr Phe Ser Asp Tyr Tyr Net Ala\n",
      "I\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "SEQ ID NO 59\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213s ORGWIISN ArtifiC\n",
      "220. FEATURE.\n",
      "223\n",
      "\n",
      "OTHER INFORNATION\n",
      "\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "59\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Syntlietic\n",
      "\n",
      "Gly Tyr Thr Phe Thr Ser Tyr Tyr Net His\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 60\n",
      "LENGTH\n",
      "7\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artific\n",
      "FEATURE\n",
      "OTHER INPORKATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "60\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gly Tyr Thr Phe Thr Ser Tyr\n",
      "1\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 61\n",
      "LENGTH\n",
      "6\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artific\n",
      "FEATURE.\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "6'EQUENCE\n",
      "\n",
      "61\n",
      "\n",
      "Ser Pro Phe Gly Gly Arg\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "\f",
      "87\n",
      "\n",
      "88\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "210\n",
      "211\n",
      ".212\n",
      ".213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 62\n",
      "LENGTH\n",
      "0\n",
      "PRT\n",
      "TYPE\n",
      "ORGANIS14 Artrfrc\n",
      "FEATURE:\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "62\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Gln Asp Val Ser Thr Ala Val Ala\n",
      "5\n",
      "\n",
      "11\n",
      "\n",
      "SEQ ID NO 63\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213 s ORGMIISN ArtrftC\n",
      "220\n",
      "223\n",
      "\n",
      "FEATURE\n",
      "OTHER INPORKATION\n",
      "\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "3\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Gly Gly Thr Arg Val Val Ser Thr Ala Val Ala\n",
      "1\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "4\n",
      "\n",
      "10\n",
      "\n",
      "SEQ ID NO\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artrfrc\n",
      "FEATURE\n",
      "OTHER INPORKATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "64\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Arg Gly Asp Phe Val Ser Thr Ala Val Ala\n",
      "10\n",
      "1\n",
      "\n",
      "5\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 65\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artrfrc\n",
      "FEATURE:\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223. OTHER INPOPNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "5\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "1\n",
      "\n",
      "Ser\n",
      "\n",
      "1\n",
      "\n",
      "Ser\n",
      "\n",
      "5\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 66\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artrfrc\n",
      "FEATURE\n",
      "OTHER INPORKATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "66\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "7\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANIS'N Artrfrc\n",
      "FEATURE:\n",
      "OTHER INPORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "67\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Glu Ile Asn Pro Ser Gly Gly Arq Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "\n",
      "10\n",
      "\n",
      "15\n",
      "\n",
      "Glu Ile Aen Pro Ser Ser Gly Arg Thr Aen Tyr Aen Glu Ly. Phe Lya\n",
      "\n",
      "10\n",
      "\n",
      "15\n",
      "\n",
      "\f",
      "89\n",
      "\n",
      "90\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "Glu Ile Asn Pro Ser Thr Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "Glu Ile Asn Pro Ser Ile Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Glu Ile Asn Pzo Ser Asp Ser Azg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Glu Ile Asn Pzo Ser Gly Asn Azg Thz Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Glu Ile Asn Pro Ser Ser Ser Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID I'10 68\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISM Artzfzc\n",
      "FEATURE\n",
      "OTHER INFORMATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "68\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 69\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213 ORnaNISM Aztzfrc\n",
      "220\n",
      "223\n",
      "\n",
      "FEATURE:\n",
      "OTHER IEFORMATION\n",
      "\n",
      "PRT\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "9\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 70\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artzftc\n",
      "FEATURE\n",
      "OTHER INFORMATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "70\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "I\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Aztzfrc\n",
      "FEATURE:\n",
      "OTHER INFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "71\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Ser\n",
      "\n",
      "Sez\n",
      "\n",
      "Ser\n",
      "\n",
      "Sez\n",
      "\n",
      "Ser\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 72\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artrfrc\n",
      "FEATURE\n",
      "OTHER INFORMATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "72\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pzo Leu Tyr Ala Met Asp Tyz\n",
      "I\n",
      "5\n",
      "\n",
      "\f",
      "91\n",
      "\n",
      "92\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "r223\n",
      "\n",
      "SEQ ID NO 73\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Artzfrc\n",
      "FEATURE\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "73\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ala Asp Tyr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 74\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artrftc\n",
      "PEATURE:\n",
      "OTHER INPORI6ATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "74\n",
      "\n",
      "ral sequence\n",
      "\n",
      "synthetrc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ile Asp Tyr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "400\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 75\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Arttftc\n",
      "FEATURE.\n",
      "OTHER INFORH'TION\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "5\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu 'rg Pro Leu Tyr Ala Azg A p Tyr\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 76\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISE\n",
      "FEATURE.\n",
      "OTHER INFORHATION\n",
      "\n",
      ".Artrftc\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "76\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Gly Asp Tyr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "7\n",
      "\n",
      "SEQ ID NO\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artzfrc\n",
      "FEATURE:\n",
      "OTHER INFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "77\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Lys Asp Tyr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 78\n",
      "LEI'GTH 9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artrftc\n",
      "PEATURE:\n",
      "OTHER INFORHATIOE\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "78\n",
      "\n",
      "ral sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Pro Asp Tyr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "\n",
      "SEQ ID NO 79\n",
      "LENGTH\n",
      "\n",
      "9\n",
      "\n",
      "\f",
      "93\n",
      "\n",
      "94\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "PRT\n",
      "\n",
      "TYPE\n",
      "ORGANISM Artificial Sequence\n",
      "FEATURE\n",
      "OTHER INFORHPTION Synthetic\n",
      "\n",
      "s400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "79\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ser 8 p Tyr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 80\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISN Artificial Sequence\n",
      "FEATURE.\n",
      "OTHER INFORMATION Synthetic\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "80\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Leu Asp Tyr\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 81\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGPSHSN Artificial Sequence\n",
      "FEATURE.\n",
      "OTHER INPORHATION Synthetic\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "81\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Val Asp Tyr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 82\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISN Artificial Sequence\n",
      "FEATURE\n",
      "OTHER INFORMATION Synthetic\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "82\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Trp Asp Tyr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 83\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISM Artificial Sequence\n",
      "FEATURE\n",
      "OTHER INFORMATION Synthetic\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "83\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala His Asp Tyr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 84\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANIISH Artificial Sequence\n",
      "FEATURE.\n",
      "OTHER INFORMATION Synthetic\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "84\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Phe Asp Tyr\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "\n",
      "SEQ ID NO 85\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISM Artificial Sequence\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "\f",
      "95\n",
      "\n",
      "96\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "220\n",
      "223\n",
      "\n",
      "PEATURR.\n",
      "OTHER INFORN\"ZION Synthetzc\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "85\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Thr .. p Tyr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 86\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artzfzc\n",
      "FEATURE\n",
      "OTHER INPORFLATZON\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "86\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Phe Ser Thr Pro Arg Thr\n",
      "5\n",
      "1\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 87\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213 DRONISH Aztzfzc\n",
      "220\n",
      "223\n",
      "\n",
      "FEATURE:\n",
      "OTHER IEFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "87\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Prg Tyr Ser Aep Trp Azg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "e210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 88\n",
      "LEZ'GTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAIIISH Artzftc\n",
      "FEATURE.\n",
      "OTHER INFORKATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "88\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Ser Trp Arg Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210a SEQ ID NO 89\n",
      "211\n",
      "LENGTH\n",
      "9\n",
      "212\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artzftc\n",
      "213\n",
      "220\n",
      "FEATURE\n",
      "OTHER INFORH'TION\n",
      "223\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "89\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Thr Ala Azg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 90\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artzfzc\n",
      "FEATURE\n",
      "OTHER INPORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEOUENCE\n",
      "\n",
      "90\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "synt.hetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Leu Tyr Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 91\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Aztzfzc\n",
      "FEATURE.\n",
      "OTHER INFORMATION\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "\f",
      "97\n",
      "\n",
      "98\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "91\n",
      "\n",
      "Gln Gln Arg Tyr Ser Phe Trp Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID I'10 92\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Arttftc\n",
      "FEATURE\n",
      "OTHER INFORIAATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "92\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthettc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Prc Trp Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 93\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Arttftc\n",
      "FEATURE:\n",
      "OTHER INPORINATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "93\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthettc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Gly Trp Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "c212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 94\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANIISN Arttfrc\n",
      "FEATURE:\n",
      "OTHER INFORNATZON\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "94\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synt hat rc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Ile Trp Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "SEQ ID NO 95\n",
      "\n",
      "210\n",
      "211e LENGTH\n",
      "212a T'IPE\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "9\n",
      "PRT\n",
      "ORGANISE Arttftc\n",
      "FEATURE:\n",
      "OTHER INFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "95\n",
      "\n",
      "tal sequence\n",
      "\n",
      "Synthettc\n",
      "\n",
      "Gln Gln rrg Tyr Ser Ala Trp Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 96\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artrfrc\n",
      "FEATURE\n",
      "OTHER INFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "96\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthettc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Leu Phe Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 97\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANIS'N Artrfrc\n",
      "FEATURE:\n",
      "OTHER INPORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "97\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthettc\n",
      "\n",
      "\f",
      "99\n",
      "\n",
      "100\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "Gln Gln Arg Tyr Ser Thr Arg Arg Thr\n",
      "5\n",
      "\n",
      "r210\n",
      "r211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 98\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artific\n",
      "FEATURE\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "98\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gln Gln Arg Tyr Ser Thr Leu Tyr Thr\n",
      "5\n",
      "1\n",
      "\n",
      "SEQ ID NO 99\n",
      "\n",
      "210\n",
      "211e LENGTH\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artific\n",
      "FEATUPE\n",
      "OTHER INFORNITION\n",
      "\n",
      "400\n",
      "\n",
      "5'EQUENCE\n",
      "\n",
      "99\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gln Gln Arg Tyr Ser Thr Trp Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "r220\n",
      "223\n",
      "\n",
      "SEQ ID NO 100\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Artific\n",
      "FEATURE:\n",
      "OTHER Il'IFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "100\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gln Gln Arg Tyr Ser Leu Ala Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 101\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213a ORGWIISN ArtifiC\n",
      "220. FEATURE.\n",
      "223\n",
      "\n",
      "OTHER INFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "101\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Syntlietic\n",
      "\n",
      "Gln Gln Arg Tyr Ser Ser Glu Arg Thr\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 102\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artific\n",
      "FEATURE\n",
      "OTHER INPORKATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "102\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gln Gln Arg Tyr Gly Thr Ala Arg Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 103\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artific\n",
      "FEATURE.\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "5'EQUENCE\n",
      "\n",
      "103\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gln Gln Arg Tyr Ser Gln !\\la !\\rg Thr\n",
      "\n",
      "\f",
      "101\n",
      "\n",
      "102\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "210\n",
      "211\n",
      ".212\n",
      ".213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 104\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANIS14 Aztzfzc\n",
      "FEATURE:\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "104\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Azg Tyr Ser Leu Hza Azg Thr\n",
      "5\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 105\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213 a ORGM4ISN ArtzfzC\n",
      "220\n",
      "223\n",
      "\n",
      "FEATURE\n",
      "OTHER INPORKATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "105\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Azg Tyz Ser Gly Val Azg Thz\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 106\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Artzfzc\n",
      "FEATURE\n",
      "OTHER INPORKATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "106\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Gln Ser .'. g Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 107\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Aztzfzc\n",
      "FEATURE:\n",
      "OTHER INPOPNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "107\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Prg Tyr Ser Ala Glu Arg Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 108\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzfzc\n",
      "FEATURE.\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "108\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Azg Tyr Ser Gln Phe Azg Thr\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEO ID NO 109\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISE\n",
      "FEATURE\n",
      "OTHER INPORKATION\n",
      "\n",
      ".Artzfzc\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "109\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Azg Tyz Ser Sez Azg Azg Thz\n",
      "5\n",
      "1\n",
      "\n",
      "\f",
      "103\n",
      "\n",
      "104\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "a220\n",
      "a223\n",
      "\n",
      "SEQ ID NO 110\n",
      "LElzGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAMISN Artzfzc\n",
      "FEATURE;\n",
      "OTI'ER INPORIMATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "110\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Svnthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Cye Ser Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "SEQ ID NO 111\n",
      "LEIIGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISM Artzfzc\n",
      "PEATURE:\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223. OTHER INFORMATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "111\n",
      "\n",
      "zal sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Thr Aen Arg Arg\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID EO 112\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISFI Artzfzc\n",
      "FEATURE\n",
      "OTHER INFORMITION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "112\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Zzg Tyr Ser Arg Trp Azg Thz\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 113\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAMISN Artzfzc\n",
      "FEATURE.\n",
      "OTI'ER INFORFIATION\n",
      "\n",
      "400. SEQUENCE\n",
      "\n",
      "113\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Prc Tyz Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 114\n",
      "LElzGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGPIIISH Artzfzc\n",
      "FEATURE;\n",
      "OTHER INPORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "114\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Tyr Trp Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 115\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISM Artzfzc\n",
      "FEATURE\n",
      "OTHER INFORMATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "115\n",
      "\n",
      "zal sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Gly Phe Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "\n",
      "SEQ ID NO 11\n",
      "\n",
      "\f",
      "105\n",
      "\n",
      "106\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "LENGTH\n",
      "9\n",
      "PPT\n",
      "TYPE\n",
      "ORG62IISN Artrfrc\n",
      "FEATURE\n",
      "OTHER INFORFZATZON\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "c400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "116\n",
      "\n",
      "Gln Gln Arg Tyr Ser Tyr Trp I\\rg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 117\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Artrfrc\n",
      "FEATURE:\n",
      "OTHER INPORHATION\n",
      "\n",
      "400. SEQUENCE\n",
      "\n",
      "117\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Gln Gln frg Tyr Ser Phe Lye Arg Thr\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "6'EQ ID NO 115\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artrfrc\n",
      "PEATURR.\n",
      "OTHER INFORFZATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "119\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Ala Arg Arg Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 119\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artrfrc\n",
      "FEATURE\n",
      "OTHER INPORFZATZON\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "119\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Syntretrc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Arg Tyr Arg Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 120\n",
      "LENGTH\n",
      "9\n",
      "PPT\n",
      "TYPE\n",
      "ORGIUIISN Artrfrc\n",
      "FEATURE:\n",
      "OTHER IEFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "120\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Leu Gln I\\rg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 121\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGPIIISN Artrfrc\n",
      "FEATURE:\n",
      "OTHER INPORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "121\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Gln Gln frg Tyr Ser Thr Ser Arg Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "\n",
      "6'EQ ID NO 122\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "\f",
      "107\n",
      "\n",
      "108\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "ORGANISM Arttftc\n",
      "FEATURE\n",
      "OTHER INFORM'TION\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "122\n",
      "\n",
      "Gln Gln Arg Tyr Ser Hz\n",
      "1\n",
      "\n",
      "5\n",
      "\n",
      "6;la Arg Thr\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 123\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Artzfzc\n",
      "FEATURE.\n",
      "OTHER INFORMATION\n",
      "\n",
      "600\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "123\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr ser Lye Tyr Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 124\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artzfzc\n",
      "FEATURE:\n",
      "OTHER IMFOPMATIOM\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "124\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthettc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Gln Ser Arg Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID I'10 125\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISM Artrftc\n",
      "FEATURE\n",
      "OTIIER INFORNFTIOM\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "125\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Thr Ala Phe Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 126\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artzfrc\n",
      "FEATURE\n",
      "OTHER INFORM'TION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "126\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Thr Cya Cya Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 127\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Artzfzc\n",
      "PEATURE:\n",
      "OTHER INFORNATZON\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "127\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "aynt hat zc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Thr !\\ep !\\rg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 128\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGAMISN Artzfzcral Sequence\n",
      "FEATURE\n",
      "\n",
      "\f",
      "109\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "223\n",
      "\n",
      "OTHER INPORNATION Synthetic\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "128\n",
      "\n",
      "Gln Gln Arg Tyr Ser Glu Aep Azg Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 129\n",
      "LENGTH\n",
      "8\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artific\n",
      "FEATURE\n",
      "OTHER INFORHPTION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "129\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gln Gln Arg Iiz Val Gly Arg Thr\n",
      "5\n",
      "\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 130\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artific\n",
      "FEATURE:\n",
      "OTHER INPORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "130\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gln Gln Arg Tyr Ser Leu Ser Arg Thr\n",
      "5\n",
      "\n",
      "210\n",
      "e211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 131\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANIISN Artific\n",
      "FEATURE.\n",
      "OTHER INFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "131\n",
      "\n",
      "ial sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gln Gln Arg Tyr Ser Leu Gly Azg Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210a SEQ ID NO 132\n",
      "211a LENGTH\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISbl Artific\n",
      "FEATUPE\n",
      "OTHER INPORNTTION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "132\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gln Gln Arg Tyr Ser Arg Ala Arg Thr\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 133\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Artific\n",
      "FEATURE\n",
      "OTHER INFORNPTION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "133\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Gln Gln Arg Tyz Ser Hi. Ala I.rg Thz\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 134\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artific\n",
      "FEATURE:\n",
      "OTHER INFORNATION\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "\f",
      "111\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "Glu Ile Gln Val Ser Gly Gly Arg Thr Asn Tyr Asn Glu Lys Plae Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "134\n",
      "\n",
      "Gln Gln Arg Tyr Ser Thr Pro Asp Thr\n",
      "I\n",
      "5\n",
      "\n",
      "s210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 135\n",
      "LEI'GTH 9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzfzc\n",
      "FEATURE.\n",
      "OTHER INFORSIATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "135\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Gln Gln Arg Tyr Gln Gln Pro Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "17\n",
      "\n",
      "210s SEQ ID NO 136\n",
      "211\n",
      "LEHGTH\n",
      "212\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artrfzc\n",
      "213\n",
      "220\n",
      "FEATURE\n",
      "223\n",
      "OTHER INFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "136\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 137\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANIISN Artzfzc\n",
      "FEATURE.\n",
      "OTHER INFORHATION\n",
      "\n",
      "Ial sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "137\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 138\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artrfzc\n",
      "FEATURE\n",
      "OTHER INFORH'TION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "138\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 139\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGAIIISH Artzfzc\n",
      "FEATURE:\n",
      "OTHER INPORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "139\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Ser\n",
      "\n",
      "210\n",
      "s211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "Ser\n",
      "\n",
      "Ser\n",
      "\n",
      "Ser\n",
      "\n",
      "210\n",
      "\n",
      "SEQ ID NO 140\n",
      "\n",
      "Glu Ile Asn Pro Trp Gln Gly Arg Thr F.cn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Glu Ile Asn Pro Val Gln Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Glu Ile Ser Pro Tyr Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "\f",
      "113\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "Glu Ile Gln Glu Ser Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "17\n",
      "\n",
      "PPT\n",
      "\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "211\n",
      "212\n",
      "213 DEREISM Artrfrc\n",
      "220\n",
      "223\n",
      "\n",
      "FEATURE\n",
      "OTHER INFORFLATION\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "s400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "140\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 141\n",
      "LEIIGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISM Artrfrc\n",
      "PEATURE:\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223. OTHER INFORMATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "141\n",
      "\n",
      "ral sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 142\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Artrfrc\n",
      "FEATURE\n",
      "OTHER INPORKATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "142\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213 s\n",
      "220.\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 143\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGWIISM Artrfrc\n",
      "FEATURE.\n",
      "OTHER INFORMATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "143\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Syntlsetrc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 144\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artrfrc\n",
      "FEATURE\n",
      "OTHER INFORMATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "144\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Ser\n",
      "\n",
      "Ser\n",
      "\n",
      "Ser\n",
      "\n",
      "Ser\n",
      "\n",
      "Ser\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 145\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISM Artrfrc\n",
      "FEATURE.\n",
      "OTHER INFORMATION\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetrc\n",
      "\n",
      "Glu Ile Ser Pro Ile Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Glu Ile Asn Pro Glu Hr Gly .'. g Tlr ann Tyr Asn Glu Ly\n",
      "I\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Phe '\n",
      "15\n",
      "\n",
      "Glu Ile Asn Pro Ser Glu Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "Glu Ile Asn Pro Trp Met Gly Arg Thr A n Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "\f",
      "115\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "145\n",
      "\n",
      "Glu Ile Asn Pro Gln Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Glu Ile Aan Pro Val Lys Gly Arg Thr aan Tyr Asn Glu Lys Phe Ly-\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Glu Ile Gly Pro Trp Gly Gly Arg Thr Psn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Glu Ile Asn Pro lie Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Ser\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "400\n",
      "\n",
      "Ser\n",
      "\n",
      "Ser\n",
      "\n",
      "Ser\n",
      "\n",
      "Ser\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 14\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Artzfrc\n",
      "FEATURE\n",
      "OTHER INPORFZATION\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "146\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 147\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGPIIISH Artrfzc\n",
      "FEATURE.\n",
      "OTHER INPORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "147\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthettc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 148\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGIZNISH .Artzftc\n",
      "FEATURE.\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "148\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 149\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORG.AIISN AZtrfrC\n",
      "PEATURR.\n",
      "OTHER INFORSIATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "149\n",
      "\n",
      "ral Sequence\n",
      "\n",
      "Synthettc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID I'10 150\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzftc\n",
      "FEITURE\n",
      "OTHER INFORFIATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "150\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Ile Gln Ile Ser Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "Glu Ile Asn Pro Gln Gly Thr Arg Thr F.cn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "\f",
      "117\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "Ser\n",
      "\n",
      "210\n",
      "e211\n",
      "e212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 151\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANNSN Artzfzc\n",
      "FEATURE.\n",
      "OTHER INFORMATION\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "151\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ser Asp Ser\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212e T'ZPE\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID I'10 152\n",
      "LENGTH\n",
      "\n",
      "9\n",
      "PRT\n",
      "ORGANISE Artzfzc\n",
      "FEZTURE\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "152\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ser 5 p Arg\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "e223\n",
      "\n",
      "SEQ ID NO 153\n",
      "LEI'GTH 9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artzfzc\n",
      "FEATURE\n",
      "OTHER INPORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "153\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Het Asp Arg\n",
      "I\n",
      "5\n",
      "\n",
      "SEQ ID NO 154\n",
      "9\n",
      "LEIZGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANIS'N Artzfzc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220. PEATURE.\n",
      "223. OTHER INFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQURNCE\n",
      "\n",
      "154\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Asn Asp Ala\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID EO 155\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzfzc\n",
      "FEATURE.\n",
      "OTHER INPORHATI014\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "155\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Asn Asp Val\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID I'10 156\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzfzc\n",
      "FEZTURE\n",
      "OTHER INFORFIATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "156\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyz Ala Hzs A p Val\n",
      "I\n",
      "5\n",
      "\n",
      "\f",
      "119\n",
      "\n",
      "120\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "s213\n",
      "s220\n",
      "223\n",
      "\n",
      "SEQ ID NO 157\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORG.OIISN AZtzfzC\n",
      "FEATURE:\n",
      "OTHER 11'IFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "157\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ser Asp Tyr\n",
      "I\n",
      "\n",
      "SEQ ID NO 158\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGWIISN Artzfzc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220. FEATURE.\n",
      "223\n",
      "\n",
      "OTHER INFORN'ZION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "158\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ser Asp Val\n",
      "I\n",
      "5\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 159\n",
      "LENGTH\n",
      "TYPE\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213 ORnaIIISH Artzftc\n",
      "220\n",
      "223\n",
      "\n",
      "FEATURE\n",
      "OTHER INFORteATION\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "s400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "159\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ser A p Ala\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 160\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISH Artzfzc\n",
      "FEATURE.\n",
      "OTHER INFORHATION\n",
      "\n",
      "400. SEQUENCE\n",
      "\n",
      "160\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Asn Asp Ser\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 161\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORG.OIISN AZtzfzC\n",
      "PEATURR.\n",
      "OTHER INFORtZATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "161\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Thr Asp Leu\n",
      "I\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 162\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Arttftc\n",
      "FEATURE\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "162\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ser Asp Ser\n",
      "I\n",
      "5\n",
      "\n",
      "\f",
      "121\n",
      "\n",
      "122\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "a223\n",
      "\n",
      "SEQ ID NO 163\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISN Artzfzc\n",
      "FEATURE\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "163\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Asn Asp Net\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 164\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzftc\n",
      "PEATURE:\n",
      "OTHER INPORI4ATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "164\n",
      "\n",
      "zal sequence\n",
      "\n",
      "synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Hts Asp Leu\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 165\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzfzc\n",
      "FEATURE.\n",
      "OTHER INFORH'TION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "165\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu 'rg Pro Leu Tyr Ala Hzs A p Ile\n",
      "I\n",
      "\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "9\n",
      "PRT\n",
      "\n",
      "SEQ ID NO 166\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGANISE\n",
      "FEATURE.\n",
      "OTHER INFORHATION\n",
      "\n",
      ".Artzfzc\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "166\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Asn Asp Val\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO I 7\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artzfzc\n",
      "FEATURE:\n",
      "OTHER INFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "167\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ser Asp Tyr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 168\n",
      "LEI'GTH 9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzftc\n",
      "PEATURE:\n",
      "OTHER INFORHATIOE\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "168\n",
      "\n",
      "zal sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ser Asp Arg\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "\n",
      "SEQ ID NO 169\n",
      "LENGTH\n",
      "\n",
      "9\n",
      "\n",
      "\f",
      "123\n",
      "\n",
      "124\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISM Artific\n",
      "FEATURE\n",
      "OTHER INFORHPTION\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "s400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "169\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Ser 5 p Val\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 170\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artific\n",
      "FEATURE.\n",
      "OTHER INFORffATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "170\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Hls Asp Val\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 171\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGPIIISH Artific\n",
      "FEATURE.\n",
      "OTHER INPORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "171\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala Asn Asp Net\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 172\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artific\n",
      "FEATURE\n",
      "OTHER INFORMATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "172\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Glu Arg Pro Leu Tyr Ala His Asp Leu\n",
      "5\n",
      "1\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 173\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISM Artific\n",
      "FEATURE\n",
      "OTHER INFORMATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "173\n",
      "\n",
      "ial Sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 174\n",
      "LEI'GTH 17\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISM Artific\n",
      "PEATURE:\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "174\n",
      "\n",
      "ial sequence\n",
      "\n",
      "Synthetic\n",
      "\n",
      "Ser\n",
      "\n",
      "1\n",
      "\n",
      "Ser\n",
      "\n",
      "Glu Ile Asn Pro Trp Gln Gly Arg Thr Asn Tyr Asn Glu Lys Phe Ly\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Glu Ile Asn Pro Val Gln Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "15\n",
      "\n",
      "\f",
      "125\n",
      "\n",
      "126\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "Glu Ile Ser Pro Tyr Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Glu Ile Gly Pro Trp Gly Gly Arg Thr Asn Tyr Asn Glu Zys Phe Ly-\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "5\n",
      "\n",
      "Ser\n",
      "\n",
      "Ser\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "r223\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "r223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 175\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artzfzc\n",
      "FEATURE\n",
      "OTHER INFORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "175\n",
      "\n",
      "tal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 174\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORGWIISN Artzfzc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220. FEATURE.\n",
      "223\n",
      "\n",
      "OTHER INFORN'TION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "17\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "SEQ ID NO 177\n",
      "LEI'GTH 9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISN Artzfzc\n",
      "FEATURE\n",
      "OTHER INPORNATION\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "177\n",
      "\n",
      "Gln Gln Arg Tyr Ser Asp Trp Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "SEQ ID NO 178\n",
      "LEIIGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANIS'N Artzfzc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220. PEATURE.\n",
      "223. OTHER INFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQURNCE\n",
      "\n",
      "178\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Ser Trp Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID EO 179\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzfzc\n",
      "FEATURE.\n",
      "OTHER INPORHATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "179\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Ala Glu Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID I'10 180\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzftc\n",
      "FEITURE\n",
      "OTHER INFORFIATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "180\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Leu Hzs Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "\f",
      "127\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "c213\n",
      "c220\n",
      "223\n",
      "\n",
      "SEQ ID NO 181\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORG.SIISN AZtzfzC\n",
      "FEATURE:\n",
      "OTHER 11'ZFORNATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "181\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Ser Glu Arg Thr\n",
      "I\n",
      "\n",
      "SEQ ID NO 182\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGWIISN Artzfzc\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220. FEATURE.\n",
      "223\n",
      "\n",
      "OTHER INFORN'ZION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "182\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Azg Tyr Ser Leu Gln Azg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 183\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORG431ISH Artzfzc\n",
      "FEATURE\n",
      "OTHER INFORFZATION\n",
      "\n",
      "c400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "183\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Thr Zlzg Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID NO 184\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGAEISH Artzfzc\n",
      "FEATURE.\n",
      "OTHER INFORHATION\n",
      "\n",
      "400. SEQUENCE\n",
      "\n",
      "184\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Azg Tyr Ser Asp Trp Zlrg Thr\n",
      "5\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "17\n",
      "\n",
      "SEQ ID NO 185\n",
      "LENGTH\n",
      "PRT\n",
      "TYPE\n",
      "ORG.SIISN AZtzfzC\n",
      "PEATURR.\n",
      "OTHER INFORBZATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "185\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Ser\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "213\n",
      "220\n",
      "223\n",
      "\n",
      "SEQ ID I'10 186\n",
      "LENGTH\n",
      "9\n",
      "PRT\n",
      "TYPE\n",
      "ORGANISE Artzfzc\n",
      "FEITURE\n",
      "OTHER INFORFIATION\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "186\n",
      "\n",
      "zal Sequence\n",
      "\n",
      "Synthetzc\n",
      "\n",
      "Gln Gln Arg Tyr Ser Arg Ser Arg Thr\n",
      "I\n",
      "5\n",
      "\n",
      "Glu Ile Ser Prc Tyr Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys\n",
      "I\n",
      "\n",
      "15\n",
      "\n",
      "10\n",
      "\n",
      "\f",
      "129\n",
      "\n",
      "130\n",
      "\n",
      "US 8,080,243 B2\n",
      "\n",
      "-continued\n",
      "\n",
      "210\n",
      "211\n",
      "212\n",
      "a213\n",
      "a220\n",
      "223\n",
      "\n",
      "7\n",
      "PRT\n",
      "\n",
      "SEQ ID No 187\n",
      "LENGTH\n",
      "TYPE\n",
      "ORGAN11SN ArtrfrCral SequenCe\n",
      "FEATURE:\n",
      "OTHER INFORNATION svntuetrc\n",
      "\n",
      "400\n",
      "\n",
      "SEQUENCE\n",
      "\n",
      "187\n",
      "\n",
      "Asp Ala Ser rsn Arg Ala Tar\n",
      "1\n",
      "\n",
      "It is claimed:\n",
      "l. An Lso lated antibody which specifically binds to PCSK9\n",
      "and comprises a heavy clmtn venable regton (VII) comple-\n",
      "mentary determining region one (CORI) lmving the amino\n",
      "amd sequence shnw n in SI'Q ID NO g. 59. or 60, 0 Vl I CDR2\n",
      "having the tuntno actd sequence sho~n in SFQ ID NO;9 or\n",
      "61, 0 VH ('DR3 havins the anlino acid sequence shown in\n",
      "Sl'.Q ID NO 10. a light chain varinble region (VL) ('DR I\n",
      "having the amino acid sequence shown in SL'Q ID NO:11, 0\n",
      "Vl, ('DR2 having tlm amino acid scqtmncc shown in SFQ ID\n",
      "NO 12. Snd a VI, CDR3 havulg the untno acid sequence\n",
      "shown in SFQ 117 NO:13.\n",
      "\n",
      "2. An Isolated antibody comprising a heavy clmin variable\n",
      "region (VI I) mid a light chain variable region (Vl h tvberein\n",
      "the VI I region comprises the unulo actd sequence of SLQ ID\n",
      "NO: 54 and the VL region comprises the amino acid sequence\n",
      "\n",
      "„„of SFQ ID NO 53.\n",
      "\n",
      "3. A humalured anttbody compnstn a hatt chatn havtn\n",
      "thc amino acid sequence of SFQ ID NO 14 and a hcaty clmin\n",
      "havtng the amino acid sequence of SI',Q ID NO:15. wtth or\n",
      "without the (utenninal lysine of the amino acid sequence of\n",
      "SFQ ID NO 15\n",
      "\n",
      "\f",
      "\n"
     ]
    }
   ],
   "source": [
    "print(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "square-relaxation",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
